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Canine adenovirus type 1 (CAV-1) causes severe, and often fatal, disease in 
domestic dogs and red foxes (Vulpes vulpes). It has also been reported to infect 
ursids, mustelids and other free-ranging canids. The disease caused by CAV-1 was 
first reported as ‘fox encephalitis’ and came to prominence when it caused major 
losses in farmed silver foxes, a colour variant of the red fox, in North America in the 
early 20th century. The disease caused by CAV-1 soon appeared to ‘spillover’ into 
the domestic dog population and was described independently as ‘infectious canine 
hepatitis’ (ICH), by which it is mainly known in all species. ICH became a serious 
problem among unvaccinated and susceptible pets, along with distemper and other 
‘rife’ infectious diseases at the time. Canine adenovirus (in the form of canine 
adenovirus type 2; CAV-2) is now included in the recommended vaccination 
schedule of all pet dogs in the UK and, more recently, CAV-1 has been fully 
sequenced and annotated. 
 
This PhD re-investigates the pathology caused by CAV-1 in red foxes compared to 
domestic dogs. There is a suggestion that neurological disease in foxes may 
predominate and be the cause of high mortality rates and a rapid course of disease. 
Outbreaks of ICH in wildlife rehabilitation centres were investigated, and novel 
immunohistochemical techniques employed, to investigate this possibility. It was 
shown that CAV-1 causes severe systemic pathology in many animals. In the dog, it 
was noted that, although central nervous system (CNS) pathology exists, hepatic 
pathology was often severe and may predominate. Vascular endothelial cells in the 
red fox CNS were more heavily infected with CAV-1 than in dogs, and lysis of these 
cells is likely to be the direct cause of the multifocal haemorrhages observed 
histologically, and possibly a major contributor to the cause of death. New cell types, 
previously not reported to be permissible for CAV-1 infection, were detected to be 
positive for CAV-1. It is hypothesised that there are multiple manifestations of the 
disease caused by CAV-1, which is evident interspecifically. It is recommended that 
these manifestations are taken into account when describing disease because CAV-1 
does not only cause a ‘hepatitis’ and does not infect only canine species. 
 
The current epidemiological state of CAV-1 was also investigated using a large 
sample of red foxes from across the UK. It was found that a large proportion of free-
ranging foxes had been exposed to the virus and a proportion of animals remain 
infected, in multiple tissues and in the absence of disease; these may represent 
persistent infections. For the first time, some red foxes were demonstrated to shed 
CAV-1 in high titres, as quantified by quantitative polymerase chain reaction 
(qPCR). This suggested that red foxes are likely to be a wildlife reservoir of CAV-1 
in the UK, and could be a source of infection for dogs. 
 
The ‘persistence of infection’ is also a characteristic of human adenoviruses (HAds) 
and it was hypothesised that these related viruses share common mechanisms to 
persist in infected tissues. It was also hypothesised that British mustelid species may 
also be a source of CAV-1 infection and that species is also persistently infected 
with adenoviruses. New adenoviruses were detected in British pine martens and 
otters, which also demonstrated persistent infections, as suggested by detection by 
the polymerase chain reaction (PCR). One adenovirus, tentatively named marten 
adenovirus type 1 (MAdV-1), partially sequenced by high throughput sequencing 
(HTS), appeared to be an Aviadenovirus, which is an unusual finding. It is 
hypothesised that this could be evidence of a host switch from an infected avian prey 
to a new mammalian host. This raises new questions on the capability of 
adenoviruses, usually regarded as very host specific, to opportunistically switch 
hosts. 
 
The molecular mechanisms employed by adenoviruses to persist in their hosts have 
been poorly studied to date. Therefore, a final aim of the project was to investigate 
the cell types in red foxes which could be capable of maintaining a persistent 
infection with CAV-1, and to investigate the dynamics of CAV-1 infection in cell 
cultures and clinically affected tissues by utilising reverse transcriptase qPCR (RT-
qPCR). Overall, the study and the techniques developed could provide a basis for 
future research to investigate how HAds, which persistently infect some human 
tissues, can re-activate under a state of immunosuppression and cause severe, 






Canine adenovirus type 1 (CAV-1) causes severe, and often fatal, disease in 
domestic dogs and red foxes (Vulpes vulpes). The disease ‘fox encephalitis’ first 
came to prominence when it was noted to cause high mortality rates in farmed silver 
foxes, a colour variant of the red fox, in North America in the early 20th century. 
The disease caused by CAV-1 soon appeared to ‘spill over’ into the domestic dog 
population and was described as ‘infectious canine hepatitis’ (ICH), by which it is 
now known. ICH became a serious problem among unvaccinated and susceptible 
pets, along with distemper and other ‘rife’ infectious diseases at the time. Canine 
adenovirus is now included in the recommended vaccination schedule of all pet dogs 
in the UK and, more recently, the virus itself has been genetically characterised. This 
PhD re-investigates the pathology caused by CAV-1 in red foxes compared to 
domestic dog. There is a suggestion that neurological disease in foxes may 
predominate and be the cause of high mortality rates and a rapid course of disease. In 
the dog, although central nervous system (CNS) pathology exists, there appears to be 
a broader range of clinical signs and a less rapid course of disease in some animals. 
It is hypothesised that there are multiple manifestations of the disease caused by 
CAV-1. Therefore, there is a requirement for ‘ICH’ to be re-‘defined’ because it 
does not only cause a ‘hepatitis’ and does not infect only ‘canines’. The prevalence 
of CAV-1 was also investigated using a large sample of red foxes from across the 
UK. It was found that a large proportion have been exposed to CAV-1 and a 
proportion of animals remain persistently infected, in multiple tissues, in the absence 
of overt disease. This suggests that red foxes are likely to be the main wildlife 
reservoir of CAV-1 in the UK and could be a source of infection for dogs. The 
‘persistence of infection’ is also a characteristic of human adenoviruses (HAds) and 
it is hypothesised that these related viruses share common mechanisms to persist in 
infected tissues. New adenoviruses were also detected in British pine martens and 
otters, which also demonstrate likely persistent infections. However, the molecular 
mechanisms employed by adenoviruses to persist in their hosts has been poorly 
studied to date. A final aim of the project was to investigate the cell types in red 
foxes which are capable of maintaining a persistent infection with CAV-1, and to 
investigate the dynamics of a viral infection in cell cultures and clinically affected 
tissues. The study could provide a basis for future studies to investigate how HAds, 
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Infectious canine hepatitis (ICH), a disease primarily of canids, is caused by the 
adenovirus, canine adenovirus type 1 (CAV-1). ICH is a severe and systemic disease, 
and is often fatal. The disease caused by CAV-1 was initially widely reported as an 
encephalitis in farmed silver foxes, a melanistic mutant of the red fox (Vulpes 
vulpes), in North America by Green et al. (1930). The first reported outbreak is 
unclear, since it may have also coincided with outbreaks of canine distemper (caused 
by canine distemper virus; CDV) in the same populations in the 1920s (Green, 1925; 
Green and Dewey, 1929). However, the series of experimental infections by Green et 
al. (1930), concluded it was likely that there was a distinct disease. Thus, due to the 
predominance of ‘encephalitis-like’ clinical signs, the disease gained the descriptive 
term “epizootic fox encephalitis” (Green et al., 1930), which is no longer used in 
contemporary texts. The disease was then later described in domestic dogs (Canis 
lupus familiaris), but as one which predominately caused severe hepatic lesions (and 
lesions in many other tissues): “hepatitis contagiosa canis” (Rubarth, 1947; Parry, 
1950), or ICH, by which the disease is currently widely known 
 
Experimental infections with CAV-1 were commonly performed in the first half of 
the 20th century in captive red foxes (Vulpes vulpes) when outbreaks were a 
relatively common occurrence on vulpid farms (Kummeneje, 1971). Rubarth (1947) 
showed how the disease which manifested in the fox and the dog were comparable, 
which later proved to be a result of pathological processes caused by the same 
infectious agent. The “filterable virus” agent was found to create a state of viraemia 
in the infected individuals, which subsequently progressed to localisation of the virus 
to target tissues (Green et al., 1930; Rubarth 1947). This early work led to the 
discovery of the infectious agent, the adenovirus CAV-1 (Kapsenberg, 1959; Davies 
et al., 1961). 
 
The development of effective vaccines in the second half of the 20th century 
(Cabasso et al., 1958; Bass et al., 1980), to protect pet dogs against CAV-1, has 
caused ICH to be an uncommon infectious disease in countries in which dogs are 
 




routinely vaccinated. Since then, research on CAV-1 and adenoviruses has seemingly 
been neglected. However, disease caused by CAV-1 is still occasionally reported in 
free-ranging canids, such as red foxes (Thompson et al., 2010) and in domestic dogs 
(Wong et al., 2012; Duarte et al., 2014). There is some evidence to suggest that red 
foxes may be a source of infection for pet dogs (Thompson et al., 2010; Balboni et 
al., 2013). Furthermore, early studies on adenoviruses suggests that they are capable 
of establishing persistent infections in host tissues (Huebner et al., 1954; Enders et 
al., 1956); this has not been fully explored in free-ranging canids infected with CAV-
1 and its significance in the emergence of infectious disease in susceptible host 
species has not been adequately considered.  
 
This thesis has re-explored the role of CAV-1 in a free-ranging canid, the red fox, 
and considered this species as a wildlife reservoir of CAV-1 in the UK. It has also 
focussed on the pathology caused by CAV-1 and how adenoviruses can persist in 
host tissues, which is a poorly explored area of research. The persistence of 
adenoviruses has become increasingly recognised as a problem in 
immunosuppressed human beings (Walls et al., 2003; Ison, 2006). Therefore, this 
thesis has also considered CAV-1 as a suitable and novel model to help study the 
dynamics, and the underlying molecular pathogenesis, of adenovirus infections in 
human beings. 
 
The introductory chapter has provided a discussion on the current knowledge of the 
molecular pathogenesis of adenoviruses, the pathology caused by CAV-1 and the 
research which has been conducted on CAV-1 epidemiology. The aims of the current 
research has been outlined. 
  
 




1.2 Origins of adenoviruses 
 
CAV-1 is now known to be a member of the Adenoviridae family, which infect a 
wide-range of vertebrate hosts (Davison et al., 2003). Adenoviruses are responsible 
for a large number of well characterised diseases in humans, non-human primates 
and other animals. The characterised diseases caused by adenoviruses in veterinary 
species tend to have wide-ranging systemic effects and are usually severe. Many 
human adenoviral diseases are respiratory or gastrointestinal in nature (Schmitz et 
al., 1983; Gray et al., 2000); in immunocompetent adults, disease is usually not 
severe or systemic and is self-limiting (Hayashi and Hogg, 2007; Kunz and Ottolini, 
2010). However, disseminated disease in immunocompromised human patients is 
increasingly recognised (Munoz et al., 1998; Lion 2014). Of the more recently 
detected adenoviruses (in a wide-range of host species), many are not well 
characterised and are often detected in the absence of disease (i.e. as an ‘inapparent 
infection’; e.g. Nkogue et al., 2016; Han et al., 2017) during molecular surveys. This 
suggests that adenoviruses may establish persistent infections or become ‘latent’ in 
the infected host (see section 1.6 Persistence of adenovirus infections). 
 
Adenoviruses (in humans) were first described by Huebner et al. (1954) as 
“adenoidal-pharyngeal-conjunctival agents”, a term to describe the “adenoid-
degenerating” pathogens (based on the observation of their proliferation in primary 
human adenoid tissue cultures), which were thought to cause a number of 
uncharacterised respiratory diseases of varying severity (Rowe et al., 1953). 
Hilleman et al. (1955) independently described the “respiratory illness viruses”. The 
‘agents’ were initially classified into ‘serotypes’ based on their immunological 
classification, determined by cross-reactivity with antisera (Huebner et al., 1954; 
Rowe et al., 1955). The term “adenovirus” was first coined by Enders et al. (1956), 
based on the common tissue of experimental isolation, adenoids. Even at this early 
stage of research the characteristic acute respiratory disease, caused by some of the 
human adenoviruses, and the possible persistence of infections in lymphoid tissue 
was well reported (Huebner et al., 1954; Enders et al., 1956). 
 




Despite its earlier discovery, it was not until 1959 that Kapsenberg first described the 
serological relationship of “infectious canine hepatitis virus” (ICHV, later CAV-1) to 
the human adenoviruses (e.g. based on common complement-fixing (CF) antigen; 
Kapsenberg 1959). The confirmation of ICHV as an adenovirus came from detailed 
electron microscopic study by Davies et al. (1961). A potentially distinct canine 
adenovirus, ‘Toronto A 26/61’ strain (later to be named canine adenovirus type 2; 
CAV-2), a cause of infectious tracheobronchitis (ITB) in dogs, was discovered by 
Ditchfield et al. (1961; see section 1.8 Canine adenovirus type 2). However, during 
this ‘period of discovery’ the relationship of adenoviruses to one another was 
unclear. There was increased recognition of the inadequacy of the distinction of 
adenoviruses by serotypes (based on serological diagnostics); an individual serotype 
was known to cause different diseases and characteristically similar diseases could 
be caused by supposedly unrelated serotypes (Enders et al., 1956). 
 
It was not until the advancement of molecular tools and techniques, which allowed 
adequate phylogenetic studies to be conducted, that the phylogenetic relationships of 




1.3 Phylogenetics of adenoviruses 
 
The current phylogenetic relationships of example adenoviruses from each genera 
are summarised in Figure 1.1. At the 1975 meeting of the International Committee 
on Taxonomy of Viruses (ICTV) the Adenoviridae family was created and 
adenoviruses were grouped among genera (Fenner, 1975). Adenoviruses in the 
earliest two genera, Mastadenovirus and Aviadenovirus, were classified by host 
origin. They were thought to be distinct based on the immunological properties of the 
known adenoviruses at the time, whereby there was generally an absence of cross-
reactivity of the structural proteins between the viruses from mammalian and avian 
hosts (Norrby et al., 1976). 
 
 




Subsequent phylogenetic studies revealed the distinction of additional proposed 
genera, based on the combination of the annotation of genomes (and partial 
genomes) and serological cross-reactivity (see section 1.4. Genomic structure of 
adenoviruses). Full genome analysis revealed that some bovine adenovirus 
subgroups, for example, did not adhere to the properties of the two genera within the 
Adenoviridae family at the time (Benkö and Harrach, 1998). The atadenoviruses 
(Figure 1.1), which appeared to have an ancestral reptilian host, was so called due to 
the relatively high adenine-thymine (AT) content in the genomes studied (Farkas et 
al., 2008). The atadenoviruses were proposed to have three independent host 
switches to marsupial, avian, and ruminant hosts, based on the discovery of 
adenoviruses possessing the properties of atadenoviruses in possums, ducks and 
ruminant hosts (Benkö and Harrach, 1998; Davison et al., 2003). 
 
The siadenoviruses (Figure 1.1) are thought to be amphibian in origin, with a 
hypothesised host switch to include additional avian hosts (Benkö and Harrach, 
2003). A fifth genus, Ichtadenovirus, was most recently identified, which contains 




















The phylogenetic relationship of hexon genes from selected members of each genera 
(indicated by different colours) of the family Adenoviridae. The distance tree is 
rooted with sturgeon adenovirus type 1 (Ichtadenovirus), which is considered to be 
the most divergent adenovirus. Phylogenetic reconstruction was performed using the 
Maximum Likelihood method (Le and Gascuel, 1993), computed using MEGA6 
(Tamura et al., 2013). The GenBank reference for each sequence is indicated next to 





















1.4 Physical and genomic structure of adenoviruses 
 




1.4 Physical and genomic structure of adenoviruses 
 
The members of Adenoviridae are non-enveloped, double stranded (ds) DNA 
viruses. They are icosahedral in structure and have a genome of ‘medium size’ 
(approximately 26,000 to 45,000 base pairs [bp]; Davison et al., 2003). CAV-1 itself 
contains the typical dsDNA genome of the adenoviruses, amounting to 
approximately 30.5 kbp. (Morrison et al., 1997; Davison et al., 2003; Williams and 
Barker, 2008). The annotated genome of CAV-1 was first outlined by Morrison et al. 
(1997), following the publication of the first complete DNA sequence of a CAV-1 
strain and exemplifies the typical genomic structure of mastadenoviruses (Figure 
1.2); There are 16 conserved genes common among the adenoviruses, thought to be 
from the ‘ancestral adenovirus’ (Davison et al., 2003). 
 
The common orthologous genes have important functions including DNA replication 
(e.g. the genes pol, pTP and DNA binding protein [DBP]) and involvement in 
encapsidation (e.g. IVa2 and 52K). The genome encodes for structural proteins and 
those involved with formation of progeny virions (e.g. hexon, fiber2, protease, pIII 
(and pIIIa), pVI-VIII, pX, 33K and 100K; Davison et al., 2003; Figure 1.2). The 
hexon protein comprises the 20-sides of the formed virion (Rux and Burnett, 2004). 
The fiber protein product forms a projection at each vertex and is bound to a penton 
base structure. The knob domain at the distal extremity of each fiber protein is shown 
to function as the primary site to of attachment to adenovirus host cell receptors 









2 American English stylisation of ‘fibre’. Referred to as ‘fiber’ hereafter to standardise the 
terminology. 
 




Figure 1.2  
Morrison et al. (1997) annotated the CAV-1 (field strain RI261) genome and created 
a schematic of the genomic structure, which is homologous amongst most 
mastadenoviruses. Open reading frames (ORFs) are numbered and the gene products 
named (underlined); this is indicated by arrows in the direction of transcription. A 1 
kbp scale to indicate genomic position is shown below the ORFs (Figure based on 











The external structure of adenoviruses has been established by crystallography of the 
capsid proteins (Roberts et al., 1986; van Raaij et al., 1999) and by electron 
microscopy of infected cells (Furcinitti et al., 1989; Stewart et al., 1993; Zhang and 
Bergelson, 2005). CAV-1 itself was first imaged by Davies et al. (1961). The 
dsDNA adenovirus genome is enclosed by the core proteins, a major structural 
element (consisting of proteins V, VII, X and terminal protein [TP]; Stewart and 
Burnett, 1993; Smith et al., 2010). This central structure is surrounded by the capsid 
proteins, consisting of proteins II (hexon), III (penton base), IIIa, IV (fiber), VI, VII 
and IX (Stewart and Burnett, 1993; Figure 1.3). 
 
Despite the annotation of full adenovirus genomes and the predicted open reading 
frames (ORFs), the exact function of many of the gene products is unclear; many 


























Stylisation of an adenovirus particle. Key structural and capsid proteins are labelled. 
The core consists of dsDNA and associated proteins (Image from Stewart and 
Burnett, 1993; reproduced with permission from The Japan Society of Applied 


















1.5 Molecular pathogenesis 
 
The entry and replication cycle of adenoviruses is well described in HAds 
(Maclachlan et al., 2011). However, the detailed molecular pathogenesis of CAV-1, 
and other veterinary adenoviruses, has not been explored. Therefore, inferences are 
made from studies on HAds on the basis of predicted homologous proteins among 
adenoviruses of other host species (see section 1.4 Physical and genomic structure of 
adenoviruses). The multiple functions of the transcribed gene products of HAds are 
still to be fully elucidated. However, the key events in the replication of a ‘typical’ 
Mastadenovirus are summarised below. 
 
The DNA replication and assembly of proteins to form progeny virions occurs in the 
nucleus of the infected host cells. Briefly, upon targeting of the host cell, the fiber 
knob of the viruses interact with one of several identified receptors, of which the 
coxsackievirus and adenovirus receptor (CAR) is most well characterised (Bergelson 
et al., 1997; Maclachlan and Dubovi, 2011). The fiber knob domain of many HAd 
types interact with CAR (Bewley et al., 1999). Other HAds have been shown to 
interact with the complement regulatory protein ‘cluster of differentiation 46’ 
(CD46; Gaggar et al., 2003) and some use sialic acid as a cell receptor (Amberg et 
al., 2002). 
 
Cellular invasion ensues by internalisation of virions in clathrin-coated pits (Soudais 
et al., 2000), aided by interaction of penton bases with integrins, which may also act 
as receptors (Zhang and Bergelson, 2005; Maclachlan and Dubovi, 2011). Virus is 
released from endosomes in the cytosol and subsets of viral capsid proteins shed 
sequentially. The exact nature of the factors leading to ‘uncoating’ of adenovirus and 
penetration of the endosome are unclear, but there is some evidence that 
adenoviruses encode a specific protease (23K cysteine protease) and that the pH 
(which is acidic) of the endosome may trigger uncoating (Webster et al., 1989; 
Greber et al., 1993; Smith et al., 2010). The viral genome is transported to the host-
cell nucleus via microtubule retrograde transport, assisted by cytoplasmic dynein 
(Kelkar et al., 2004; Gastaldelli et al., 2008; Maclachlan and Dubovi, 2011). 
 




The replication cycle of adenoviruses are split into two phases of transcription and 
gene expression. The ‘early’ transcriptional units (E) of the mastadenoviruses (E1A, 
E1B and E2-E4) are controlled by distinct promoters (Maclachlan and Dubovi, 
2011). Proteins from these units are primarily non-structural and are involved with 
regulation of host cell transcription, regulation of cell cycle, ‘immunosurveillance’ 
and apoptosis (Wold and Gooding, 1991; Tollefson et al., 1996; Täuber and Dobner, 
2001). In addition to the early transcriptional units there are two intermediate units 
(IVa2 and IX), and a single ‘late’ transcribed unit (L) which encodes multiple 
proteins and is under the control of one major late promoter (MLP; Farley et al., 
2004; Maclachlan and Dubovi, 2011). The L products are involved in processes such 
as adenovirus-induced cell lysis, recruitment of other packaging proteins and 
production of mature virions (Wu et al., 2012). 
 
On relocation of the viral genome to the cell nucleus, E1A is expressed, which also 
activates the other E genes (Wu et al., 2012). The proteins of the E1A and E1B units 
are thought to induce dysregulation in the cell cycle, through suppression of p53, 
preventing the degradation of host and viral DNA (Martin and Berk, 1998; Berk, 
2005). E3, although not required for successful viral replication in cell cultures, is 
one of the most well studied transcriptional units and is mostly involved with 
immunosurveillance and manipulating the virus and host cell interactions (Wold and 
Gooding, 1991). The proteins of the E3 region also interfere with host immunity. For 
example, E3 19 kDa inhibition of MHC class I antigen transport prevents ‘attack’ of 
host cells by cytotoxic T lymphocytes (Andersson et al., 1985). Furthermore, in 
human adenovirus type 2 (HAd2), apoptotic mechanisms of the host cell can be 
blocked by E1B 19 kDa and E3 14.7 kDa (Gooding et al., 1998; Gooding et al., 
1991). Apoptosis is also prevented by internalisation of tumour necrosis factor (TNF) 
receptor I (Maclachlan and Dubovi, 2011). As replication ensues, the transcription 
systems of the infected host cell are ‘hijacked’ by the virus (Davison et al., 2003; 








IVa2 and L4 22 kDa are involved with packaging of viral DNA into new viral 
particles (Ostapchuk and Hearing, 2008; Wu et al., 2012). Other proteins such as L4 
33 kDa (in human adenovirus type 5, HAd5) are involved with the promotion of 
early-to-late switching of gene expression (Farley et al., 2004). The L4 100 kDa 
protein is involved with multiple processes such as chaperoning hexon polypeptides 
and assembly of the hexon trimer (Cepko and Sharp, 1982). Capsids are likely to be 
produced in the nucleus of the infected cell, and interact with the newly synthesised 
adenovirus genome in combination with the packaging proteins, to form a 
‘procapsid’, which is completed by a putative packaging ‘motor’ protein (Ostapchuk 
and Hearing, 2005). 
 
Cytopathology in adenovirus infections usually occurs after a duration of 24 to 48 h, 
as adenoviruses cause the margination and condensation of the nuclear chromatin. 
Histopathologically, this can be visualised as the classical intranuclear inclusion 
bodies (Maclachlan and Dubovi, 2011); specifically, Cowdry type A (Cowdry et al., 
1935). The eventual lysis of the host cell and release of new adenovirus particles is 
thought to be aided by E3 11.6 kDa protein, the adenovirus death protein (ADP), in 
HAd2 and HAd5 (Wold et al., 1984; Doronin et al., 2003). 
 
The tropism of different adenoviruses towards cells is assumed to correspond to the 
sites displaying clinical signs as a result of cytopathic effect (CPE), but this has not 
been well studied (Soudais et al., 2000). The marked difference in tropism 








1.6 Persistence of adenovirus infections 
 
In the early studies by Huebner et al. (1954) it was recognised that, although several 
HAd serotypes were capable of causing acute clinical disease, the spontaneous 
degeneration of otherwise healthy adenoid tissues could be a result of persistently 
infectious adenoviruses, which had been supressed by some host or viral driven 
mechanism. It was hypothesised that persistent HAd infections could be responsible 
for chronic disease in the respiratory tracts of humans including the adenoids and 
tonsils, following recovery from the acute stages of adenoviral diseases (Huebner et 
al., 1954). 
 
It is important to define the meaning of a ‘persistent infection’. In this thesis, a 
persistent viral infection is defined as a duration of infection which lasts longer than 
expected, regardless of whether disease is present or not (Maclachlan and Dubovi, 
2011). Thus, by definition a ‘latent infection’ is also a persistent infection; it is 
mediated by specific host-viral mechanisms which allow the virus to persist within a 
cell (which may include integration into host DNA). The virus may not detectably 
transcribe genes, or only produce a subset of gene products, but will not produce new 
infectious virus particles unless ‘stimulated’ (Maclachlan and Dubovi, 2011). The 
use of the term ‘inapparent infection’ in this thesis refers to a canid infected with 
CAV-1 that does not show overt clinical signs of the disease. A canid with an 
inapparent infection is assumed to be persistently infected. However, subclinical 
disease of normal duration cannot be ruled out due to the lack of clinical history or 
time-course controlled infection. 
 
The suggestion of persistence of CAV-1 in renal cells in dogs (Poppensiek and 
Baker, 1951) preceded suggestion of HAd persistence (Evans, 1958), although CAV-
1 was not known to be an adenovirus at the time. Poppensiek and Baker (1951) 
demonstrated that CAV-1 could be detected in the urine of infected dogs from three 
days post inoculation up until “at least” 161 days post inoculation. In dogs which 
persistently shed CAV-1 in the urine, it is thought that renal tubular epithelial cells 
 




remain can be infected for several weeks post infection (Wright et al., 1971); 
although the site of persistence beyond this time scale has not been demonstrated.  
 
Research in HAds was popular and widespread in the 1980s due to the realisation 
that HAds were capable of ‘re-activation’ and causing severe, systemic disease in 
immunocompromised patients (Zahradnik et al., 1980; Shields et al., 1985). 
However, despite the early recognition that adenoviruses may have mechanisms 
which halt a lytic replication cycle, the mechanisms behind seemingly persistent 
infections are poorly studied. Only a handful of more recent studies have reported 
possible, contributory pathways which could aid establishment of a persistent 
infection. 
 
Possible mechanisms of persistence, for example, may include the proteins of E3 
which may interfere with pathways including the expression of the histocompatibility 
class I antigens (HLA) on the cell surface and the function of TNFα (Körner et al., 
1992). Furthermore, Bruder et al. (1997) have indicated that gp19K gene products 
could be involved with the persistence of expression of adenovirus vector in infected 
cells (by sequestering of MHC class I proteins). A more recent study in primary 
human bronchial epithelial cell and immortalised human diploid fibroblast cell 
cultures demonstrate that interferon(IFN)α and IFNγ can bind the E1A enhancer 
region (at the E2F binding site) and subsequently suppress the expression of E1A 
and replication of HAd5 (Zheng et al., 2016). Cells maintained HAd5 for over 100 
days and this has been the only model of adenovirus persistence to date (Zheng et al., 
2016). 
 
Studies on HAds (types 1, 2, 5 and 6) have found that persistence of adenovirus may 
be mainly limited to lymphocytes in lymphoid tissue, and this is likely to be T 
lymphocytes (Garnett et al., 2002). Garnett et al. (2002) also found that although 
HAd-PCR positive T-lymphocytes were frequent among tissue donors, but only one 
of 16 (6%) samples, in which lymphocytes were co-cultured with ME180 (epithelial; 
carcinoma derived) cells, produced infectious virus. Garnett et al. (2002) 
 




hypothesised that this may be demonstrative of adenovirus quiescence in human 
lymphocytes. 
 
However, B lymphocytes have subsequently been shown to be infected 
experimentally (Zhang et al., 2010). Zhang et al. (2010) also demonstrate that both B 
and T cells (immortalised cell lines) can maintain HAd for over 100 days, which is 
somewhat contradictory to the findings of Garnett et al. (2002). Further, as 
previously discussed, renal tubular epithelial cells may maintain CAV-1 for some 
time post infection (Poppensiek and Baker, 1951; Wright et al., 1971; see section 
1.7.1 Pathogenesis of ICH for more detail). Therefore, there is little corroborating 
research among studies (and adenoviruses of different host species) on which cells 
can maintain adenoviruses in the long-term, and very little research on specific 
mechanisms of persistence. 
 
It is also unclear how the adenovirus genome is maintained within the infected cells. 
Viral genomes can be maintained in host cells through integration with the host 
genome, for example, as demonstrated by human herpesvirus 6 (HHV-6) which 
integrates into the human chromosome (Strausbaugh et al., 2001). However, Zhang 
et al. (2010) effectively demonstrated that HAd2 and HAd5 DNA was not integrated 
within Burkett’s lymphoma (BJAB) cells though digestion with restriction 
endonucleases and Southern blot analysis of fragments. Therefore, Zhang et al. 
(2010) suggested that the HAd2 and HAd5 genomes exist as monomeric episomes 
within the infected cells. 
 
Figure 1.2 outlined the genomic structure of mastadenoviruses and highlighted the 
homologous gene families shared amongst them. Given the suggestion that CAV-1 
may persist in renal tissues (Poppensiek and Baker, 1951), there may be common 
mechanisms shared amongst adenoviruses which allow them to establish persistent 
infections in their hosts. Because of the realisation that immunosuppressed human 
beings can suffer from systemic disease caused by‘ re-activated’ adenoviruses 
(Zahradnik et al., 1980; Shields et al., 1985), CAV-1 may offer a suitable model to 
 




further investigate the molecular mechanisms underlying this process. This will be 




1.7 Infectious Canine Hepatitis (ICH) 
 
1.7.1 Pathogenesis of ICH 
 
Infection of an animal with CAV-1 is considered to occur primarily through contact 
with infected material via the oro-nasal route. Transmission of CAV-1 is via 
excretions, such as saliva, faeces and urine of infected individuals (Decaro et al., 
2012; Williams and Barker, 2008). The incubation period for CAV-1 is 
approximately four to six days; the virus is thought to first infect the tonsillar tissue, 
before seeding other tissues in the host via haematogenous spread (Decaro et al., 
2012) 
 
The primary ‘target’ cell of CAV-1 is considered to be hepatocytes (although other 
cells in the liver, such as Kupffer cells are also infected; Decaro et al., 2012). Many 
other cell types are also permissive; renal tubular epithelial cells and glomerular 
cells, vascular endothelial cells in the central nervous system (CNS) and in other 
organs are known to have been infected (Wright et al., 1981; Wright and Cornwell, 
1983; Thompson et al., 2010). Disease is largely enacted through cytopathology as a 
result of CAV-1 replication, progressing to large areas of cellular necrosis, 
particularly in the liver parenchyma (Rubarth, 1947). The influx of immunological 
cells allows progression of inflammation. The haemorrhages often characteristic of a 
CAV-1 infection are a result of vascular endothelial cell disruption and lysis from 
viral CPE (Greene, 2013). 
 
Due to the often widespread insults, a thrombocytopaenic state and ultimately 
disseminated intravascular coagulation (DIC) may result (Decaro et al., 2012; 
Greene, 2013). Wigton et al. (1976) characterised additional haemostatic 
abnormalities induced by CAV-1 infection, such as retarded platelet function, 
 




increased prothrombin times and an increase in the degradation products of fibrin-
fibrinogen. As a consequence, ICH has been suggested as an appropriate animal 
model for the investigation of therapy for DIC in human patients, however, this has 
not been readily adopted (Wigton et al., 1976; Berthelsen et al., 2011). 
 
Following an effective immune response, the increase in circulating neutralising 
antibody may permit the deposition of immune complexes in renal glomeruli, leading 
to glomerular injury and subsequent proteinuria. However, direct viral cytolysis may 
precede this if CAV-1 is deposited in renal endothelial cells and glomeruli (Wright et 
al., 1981; Wright and Cornwell, 1983; see section 1.7.2 Clinical signs of ICH). Type 
III hypersensitivity also results in ocular lesions, leading to the classic ‘blue eye’ 
appearance one to three weeks post-recovery (see section 1.7.2 Clinical signs of 
ICH). 
 
It is suggested that CAV-1 infection can persist in the renal tubular epithelial cells in 
a number of individuals, and this may cause an on-going focal interstitial nephritis 
(Poppensiek and Baker, 1951), which peaks at 15 to 25 days post infection (Wright 
et al., 1971); for at least this long this is a direct result of CPE (Wright et al., 1971). 
As a result, CAV-1 can be detected to be shed in the urine for approximately six 
months post infection in the absence of overt disease in the live animal (Poppensiek 
and Baker, 1951; Baker et al., 1954). There is no reported mechanism to explain why 
these particular cells appear to permit persistence of infection, and whether virus 
persists or enters a state of persistence (or latency) in other cells or organs (see 
section 1.6 Persistence of adenovirus infections). The number of infected animals in 
which CAV-1 establishes a persistent infection is also not known. 
  
 




1.7.2 Clinical signs of ICH 
 
Despite the name ‘infectious canine hepatitis’, the clinical signs of the disease are 
diverse and individual dogs and foxes may only demonstrate a subset of the 
documented associated clinical features. In some dogs and foxes which develop ICH 
the clinical signs during the clinical course of disease may be vague or peracutely 
fatal, and therefore may go unnoticed even under good standards of observations and 
veterinary care. In both species, overt symptoms generally have a duration of two to 
four days, following the initial incubation period (Innes and Saunders, 1962; Decaro 
et al., 2012). 
 
Individuals with ICH may demonstrate an apathetic demeanour, progressing to a 
state of depression and lethargy in some cases. The animal may become 
hyporexic/anorexic and polydipsic (Innes and Saunders, 1962). In dogs, neurological 
symptoms in surviving animals usually last less than a day, but can last for up to 
three days (Cabasso, 1962). Affected dogs are usually pyrexic, however hypothermia 
is sometimes noted, particularly in smaller individuals with marked loss of fluids 
(Cabasso, 1962; Duarte et al., 2014). In both red foxes and dogs, fluid loss 
progresses as a result of diarrhoea (which may be haemorrhagic) and emesis 
(Ettinger et al. 2017). 
 
Infected canids may cough frequently, particularly in cases with pneumonic 
involvement; on thoracic auscultation, coughing, stridor and wheezes may be 
audible. There may be excessive lacrimation and serous discharge at the nares (Innes 
and Saunders, 1962; Decaro et al., 2012). 
 
Serious neurological signs in affected dogs and foxes may continue from apathy to 
restlessness or hyperexcitability. Nystagmus may be present. Seizuring, a comatose 
state or paralysis can ensue (Figure 1.4; Innes and Saunders, 1962; Cabasso, 1981; 
Williams and Barker, 2008; Decaro et al., 2012). The neurological symptoms may 
show similarity to those seen in canine distemper (Parry et al., 1951; Innes and 
Saunders, 1962), and should be differentiated, although differences may be subtle in 
 




some cases. Neurological symptoms in canine distemper may only occur following a 
longer course of disease, whereas CNS lesions may cause the first symptoms in ICH. 
Other clinical symptoms may also be present in canine distemper, such as a 
mucopurulent ocular and nasal discharge and secondary bacterial infections (Green, 
1925; Greene, 2013), which help to differentiate the diseases. 
 
Clinical accounts suggest the disease is often fatal following the onset of more severe 
neurological signs (Green et al., 1930; Sompolinsky, 1949; Thompson et al., 2010). 
Early experiments and clinical texts suggest that, although common in the red fox, 









Experimental inoculations of red foxes (Green et al., 1930) resulting in: a) weakness 
and marked paralysis in a group of red foxes; b) hindlimb spastic paralysis in a red 











The mortality rate of ICH may be variable and dependent on various factors such as 
the signalment of the animal, whether treatment is undertaken and at what stage in 
the clinical course of ICH treatment is initiated. Experimental inoculations in dogs 
resulted in a mortality rate of ten to 30% (Cabasso, 1963). Historical mortality rates 
on Danish fox farms estimated that mortality rates in silver foxes was 36.4%, but was 
16.4% in blue foxes (a colour variant of the arctic fox (Vulpes lagopus; 
Sompolinsky, 1949). In many accounts it is not possible to assess whether animals 
were treated appropriately or if any intervention was attempted. There are no modern 
accounts of mortality rates in the dog using a metadata approach, using data from 
surveys of veterinary practices worldwide. There is also no data available on the 
annual number of cases diagnosed or suspected by veterinarians in the UK or 
elsewhere. Although small outbreaks in dogs tend to show a high mortality (e.g. 
Müller et al., 2010), the literature does not present isolated ICH cases with a 
successful outcome. It is suspected by the author that such cases are not presented for 
publication in the first place because of the lack of novelty. Therefore, the true 
mortality in dogs is hard to ascertain. 
 
Where mortality is described, there is a suggestion that mortality rates are higher in 
those with primary neurological symptoms and in juveniles (Green et al., 1930; 
Caudell et al., 2005; Decaro et al., 2007). However, others describe only non-
specific symptoms in acutely fatal cases (Müller et al., 2010). Since the early studies 
on fox fur farms, there are no accounts of foxes presenting to veterinarians which 
survive the disease (originating from natural infections); others report death in free-
ranging animals (e.g. Gerhold et al., 2007) and fatal outbreaks in wildlife 
rehabilitation centres (e.g. Walker et al., 2016a), where CNS signs predominate. 
 
There are several sequelae of ICH; animals may present with corneal clouding and 
opacity, colloquially called “blue eye”, which is considered a ‘classic’ feature of ICH 
in both red foxes and dogs. This is a result of immune complex deposition in the 
cornea. However, this tends to be a sequela in some survivors rather than a 
pathognomonic clinical sign (Curtis and Barnett, 1973; Gerhold et al., 2007; Ettinger 
et al., 2017). Interstitial nephritis can also occur in some dogs several weeks after 
 




infection (see section 1.7.1 Pathogenesis of ICH; Wright et al., 1971), although it is 
unlikely to be attributed to overt clinical signs. Sequelae have not been described in 
free-ranging red foxes. 
 
Despite the wide range of possible clinical signs, there is some evidence to suggest 
that there are species differences, between red foxes and domestic dogs, in the 
likelihood of particular clinical signs exhibited. For example, naturally infected red 
foxes may be more likely to exhibit CNS signs alone and may die rapidly (Cabasso, 
1962; Decaro et al., 2012). This is partly demonstrated by the fact the disease was 
first discovered as a ‘fox encephalitis’ and was considered by some to be a 
manifestation of distemper (Green, 1925; Green et al., 1930; Sompolinsky 1949). 
 
The disease was later described by Rubarth (1947) and Parry (1950); who identified 
various manifestations of the disease in dogs, based on the severity and course of 
disease. These four scenarios were outlined as i) an acutely fatal ‘fulminating’ form, 
in which the dog dies within hours from ‘circulatory collapse’; ii) a severe (‘less’ 
fatal) form in which dogs will show a wide variety of signs including haemorrhagic 
diarrhoea, pyrexia, neurological disturbances and abdominal pain iii) a mild form 
with slight pyrexia and mild neurological disturbances; iv) no clinical signs, and 
immunity demonstrated by serology (Rubarth 1947; Innes and Sunders, 1962; 
Decero et al., 2012). It is noted that severe neurological symptoms are not the 
predominating feature in some outbreaks in dogs, although they do occur and can be 
fatal (e.g. Caudell et al. 2005). No studies have been conducted to demonstrate the 
frequency of particular clinical signs or systematically demonstrate that foxes are 
more likely to suffer from severe CNS lesions (described in 1.7.4 Histopathology of 
ICH) than other lesions. Interspecific differences of ICH will be discussed further in 











1.7.3 Gross pathology of ICH 
 
Pathology may be extensive, or only localised, depending on the clinical course of 
disease and sites of viral proliferation. Red foxes and dogs that have died peracutely 
or acutely from ICH can have a good body condition score (BCS) and show limited 
gross pathology upon post-mortem examination (Decaro et al., 2012). However, in 
other cases, and in both species, the described gross pathological features of ICH are 
varied. 
 
In some canids, sub-cutaneous oedema, in addition to abdominal expansion, may be 
present; the latter is due to the occupation of the peritoneal cavity with sanguineous 
transudate. Icterus may be seen, but may not be present in acutely fatal cases and 
unless liver disease is extensive enough to impair hepatic function (Figure 1.5); in 
dogs, biochemical parameters can quantify the degree of hepatic damage (Innes and 
Saunders, 1962; Greene, 2012). Lymph node enlargement is evident in some cases, 
but the degree of enlargement varies among sites and is not consistent. Tonsillitis can 
occasionally be observed (as red and enlarged tonsils; Innes and Saunders, 1962). 
Petechial or ecchymotic haemorrhages may be seen on mucous membranes (Decaro 
et al., 2012). 
 
Within the thoracic cavity subpleural haemorrhages may be observed (Innes and 
Saunders 1962). In some cases with pneumonic involvement, lung lobes can show 
multiple patches of consolidation and may be hyperaemic. In younger dogs, when the 
thymus is evident, it has been described that thymic haemorrhage or congestion may 
be present (Innes and Saunders 1962; Decaro et al. 2012). 
 
In the abdomen, hepatomegaly and splenomegaly are often present in both species. 
The liver may be friable and have a fibrinous surface, and there may be ascites 
(Williams and Barker 2008; Greene, 2013; Figure 1.5). Sub-serous oedema of the 
gall bladder can be a feature in some cases (Appel, 1987; Oliveira et al., 2011; 
Greene, 2013). Oedema may also be evident and extensive in the gastro-intestinal 
tract. Petechial haemorrhages are frequently observed on the gastric and intestinal 
 




mucosa (Innes and Saunders, 1962). The intestinal tract may be filled with 
haemorrhagic contents (Figure 1.5). There may also be multifocal renal infarction or 
evidence of glomerulonephritis, which can be particularly evident grossly in both 
species (Greene, 2013; Figure 1.5).  
 
On gross examination, the brain may appear hyperaemic and meninges congested; 
haemorrhage can be present as punctate or multifocal haemorrhages on the cut 
surface (Innes and Saunders, 1962; Caudell et al., 2005; Walker et al., 2016a). 
 
The eyes of infected animals may demonstrate anterior uveitis with corneal opacity 
(‘blue eye’); these lesions may be a result of type III hypersensitivity, so this is less 
likely to be seen in acutely fatal cases (Carmichael, 1965). A serous or mucoid, 
ocular discharge may be observed (Gerhold et al., 2007; Greene, 2013). In free-
ranging wildlife there are no documented descriptions of the immune-mediated 
sequelae of ICH. However, experimentally inoculated captive red foxes may 
demonstrate a corneal oedema (blue eye) and an interstitial nephritis (Green et al., 






















Typical gross lesions observed during post-mortem examination of a fox or dog with 
ICH. However, some, all or none of the lesions may be observed depending on 
clinical signs, severity of disease and course of disease. a) Fox liver; enlarged and 
friable; b) Fox kidney; pale streaks within cortical tissue; c) Fox intestine; 
haemorrhagic contents; d) Fox oral mucosa; demonstrating icterus. (Photographs 
















1.7.4 Histopathology of ICH 
 
The replication of CAV-1 in a host is cytopathogenic and lesions are widespread 
(Appel, 1987); as a consequence, much is presented to the pathologist which is 
visible microscopically (using standard haematoxylin and eosin (H&E) staining) as a 
result of direct cytopathic processes and insult to the target cells. The main findings 
include vascular haemorrhages which can be evident in many infected tissues on 
microscopic examination; this is caused by direct vascular endothelial cell damage 
and the subsequent extravasation of blood cells (Appel, 1987). 
 
The dominant pathological change of ICH (in dogs particularly) is hepatic. Skulski 
(1958) showed the relationship between the appearance of icterus and the degree of 
hepatic damage. It was shown that of the cases which presented with icterus, a more 
severe and widespread necrosis of hepatocytes was identified histologically (Skulski, 
1958; Innes and Saunders, 1962). The classic finding in the liver is a pattern of 
centrilobular necrosis (Decaro et al., 2012). Ectasia of sinusoids may additionally be 
evident (Innes and Saunders, 1962). Hepatocytes may appear necrotic and 
dissociated; intranuclear inclusion bodies are readily found in hepatocytes (Figure 
1.6), but are not restricted to these cells; they may be evident in Kupffer cells and 
vascular endothelial cells in the liver (Innes and Saunders 1962; Williams and 
Barker, 2008; Thompson et al., 2010). Intranuclear inclusion bodies are typically 
pathognomonic for a viral infection, and, if available, historical and other clinical 
findings provide a good base of evidence for ICH diagnosis in the absence of other 
diagnostic data. Within the periportal hepatic areas there may also be an 
accompanying infiltrate of inflammatory cells, neutrophils and mononuclear cells 
(Williams and Barker, 2008). 
 
Histological findings in the kidney during acute ICH typically include a focal 
interstitial nephritis and intranuclear inclusion bodies may be evident in glomerular 
cells and in renal tubular epithelial cells. There may also be associated tubular 
necrosis (Figure 1.5; Wright et al., 1983; Thompson et al., 2010). 
 
 




Pathological examination of lungs may reveal patches of consolidation with 
erythrocytes and fibrinous exudate, and alveolar walls may be thickened (Greene, 
2013). There may be rare intranuclear inclusion bodies in vascular endothelial cells. 
 
In the cases that show CNS insult, various findings are evident. Intranuclear 
inclusion bodies may be seen in the vascular endothelial cells of the CNS and there 
may be perivascular cuffing of infected vessels with inflammatory infiltrating cells 
(e.g. Green et al. 1930). In the brain, there may be congestion of blood vessels and 
multifocal haemorrhages may be evident in the neuropil or associated with larger 
blood vessels. The nuclei of scattered neurons may appear pyknotic (Caudell et al., 
2005). Within the brainstem, there may be petechial haemorrhage and lymphocytic 
perivascular cuffing (Figure 1.5; Innes and Saunders, 1962). Based on historical 
descriptions and more recent evidence (Green et al., 1930; Sompolinsky 1949; 
Thompson et al., 2010), there is suggestion that CNS lesions may predominate in 
non-domestic canids. However, outwith the CNS, widespread lesions are also 
evident even in cases in foxes with severe neurological insult (Thompson et al., 
2010). In addition, fatal CNS lesions as a result of CAV-1 infection, are not 
exclusive to red foxes because neurological dominant cases have been reported in 
domestic dog puppies (Caudell et al., 2005). There is no evidence to suggest that the 
degree of cerebral and hepatic damage is correlated. The frequency of CNS clinical 
signs and lesions compared between red foxes and dogs has not been formally 
studied, and is largely anecdotal.  
 
There are likely to be separate pathogenic mechanisms for the ocular lesions 
observed during acute and chronic ICH (or recovering animals). A severe 
iridocyclitis, which may be evident histopathologically, could be a direct result of 
proliferation of CAV-1 in vascular endothelial cells and in uveal reticuloendothelial 
cells. The corneal oedema and opacity (also evident grossly) along with iridocyclitis 
which is present in recovering/recovered dogs is more likely to be due to the 
accumulation antigen-antibody immune complexes, forming a type III 
hypersensitivity (Carmichael, 1965). 
 
 





Micrographs highlighting typical features of ICH. a) Fox liver; intranuclear inclusion 
body in a hepatocyte (solid arrow); b) fox kidney; renal tubular epithelial cell 
necrosis (Reproduced from Thompson et al. (2010) with permission from BMJ 













c) fox brain; perivascular round cell infiltration; d) fox brain; experimental infection; 
temporal lobe with haemorrhage. (Images from Green et al. (1930); reproduced by 















1.7.5 Diagnosis of ICH 
 
Pathological findings and the associated clinical history of the animal may provide a 
high degree of suspicion, leading to a tentative diagnosis of ICH. However, 
molecular diagnosis by the polymerase chain reaction (PCR), and subsequent 
sequencing, is required for a definitive diagnosis (Gerhold et al., 2007; Choi et al., 
2014). PCR protocols have been successfully developed which allow specific 
detection of CAV-1 and CAV-2 (e.g. Hu et al., 2001) in relevant swabs or samples 
(e.g. urine, mucopurulent sections etc.), or in affected tissue samples taken during 
post-mortem examination. 
 
However, in a typical veterinary general practice, methods for objective detection 
and diagnosis are often not available as an ‘in-house’ diagnostic method and so an 
informed clinical judgement, or the use of commercial external laboratories, for 
diagnosis is often utilised. Attempted treatment (including euthanasia if considered 
appropriate) should be initiated before the confirmation of CAV-1 infection due to 
the rapid course of disease. The need for such objective molecular diagnoses within a 
practice may be considered to be low due to the large scale uptake of routine 
vaccination procedures worldwide, rendering the apparent prevalence of ICH in pet 
dogs rare (see section 1.7.6 Prevention of ICH). However, the introduction of the 
European Union (EU) Pet Travel Scheme (PETS), which allows movement of pets 
among European member countries (currently with no absolute requirement of ‘up to 
date’ vaccination status for diseases other than rabies), and client lapses or non-
compliance with vaccination recommendations for their pet dogs (see section 1.7.6 
Prevention of ICH), means that there is the occasional report of previously ‘rife’ 
disease in the EU ‘re-emerging’, indeed, including ICH (Decaro et al., 2007; Müller 
et al., 2010) and distemper (Walker et al., 2014). Furthermore, the possibility of 
wildlife reservoirs of diseases such as ICH should be considered (Thompson et al., 
2010) given the relatively high density of the fox population in the UK (Webbon and 
Harris, 2004). Therefore, due to the highly infectious nature and severity of the 
disease, veterinarians should have access or means to a rapid diagnosis of ICH and, 
 




at least, be able to be suspicious of ICH in relevant cases and be prepared to 
disseminate findings to relevant members of the veterinary community. 
 
In addition, some semi-objective (binary) commercial immunoassays are now 
available to veterinary practices, which can detect antigen in animals which are 
actively shedding virus. However, these are not capable of distinguishing between 
CAV-1 and CAV-2. Haemagglutination and haemagglutination inhibition (HI) tests, 
can also detect CAV and antibodies to CAV, although these are not commonly 
performed commercially (Marusyk and Yamamoto, 1971; Whetstone et al., 1988). 
 
Although there are no pathognomonic haematological or biochemical derangements 
for ICH, biochemical parameters may alter during the course of disease and may aid 
diagnosis and guide treatment for a better prognosis. Typical of acute viral infection, 
a leukopenia may occur in early ICH, which can progress to leucocytosis (Ettinger et 
al., 2017). Coagulopathies may be identified with a thrombocytopenia or an increase 
in partial thromboplastin time (PTT) and activated PTT (APTT), as a result of 
retarded hepatic synthetic function and as also occurs during the state of DIC (Innes 
and Saunders, 1962; Appel 1987; Greene 2012; Ettinger et al., 2017). The enzymes 
alkaline phosphatase (ALKP) and alanine aminotransferase (ALT) may elevate 
depending on the amount of hepatic necrosis (Müller et al., 2010; Ettinger et al., 
2017). Urinalysis with, for example, the commonly available Urinalysis Test Strips 
(Siemens, Surrey, UK) may reveal proteinuria and albuminuria, due to direct acute 
glomerular damage from viral cell lysis, or due to later immune complex deposition 
(Wright et al., 1974; Wright and Cornwell, 1983; Ettinger et al., 2017). Bilirubinuria 
may be present in cases with hepatocellular damage (Innes and Saunders, 1962). 












1.7.6 Prevention of ICH 
 
The ‘first line’ defence against ICH is vaccination. The first bivalent vaccines to 
provide protection against ICH and canine distemper were developed in the 1950s 
(Cabasso et al., 1958; Burgher et al., 1958). These vaccines were based on live 
modified strains of CAV-1. However, post-vaccination complications were relatively 
high with the live attenuated CAV-1 vaccines (Wright, 1976). A common side-effect 
of administration was the high prevalence of corneal oedema and anterior uveitis as a 
result of type III hypersensitivity (as per ‘blue eye’ as a sequela of naturally 
occurring ICH). It has been reported that some cases of kerato-uveitis as a result of 
vaccination with CAV-1 do not resolve (Curtis and Barnett, 1983). 
 
The frequency of side-effects after administration of vaccine preparations containing 
CAV-1 resulted in the development of vaccinations based on CAV-2, which 
provided a relatively safe vaccination option due to the less severe disease caused by 
CAV-2 (see section 1.8 Canine adenovirus type 2; Bass et al., 1980). The 
considerable serological cross-reactivity between CAV-1 and CAV-2 meant that an 
animal exposed to CAV-2 was immune to CAV-1. This lead to the development of 
vaccines preparations containing CAV-2 as an alternative. These vaccines were 
hugely successful, resulted in minimal side effects and were protective for both 
CAV-1 and CAV-2 (Bass et al., 1980; Curtis and Barnett, 1983). 
 
Vaccination to prevent ICH is now considered part of the core (recommended) 
vaccine schedule of pet dogs by the World Small Animal Veterinary Association 
(WSAVA; Day et al., 2016). Vaccination is now generally performed using 
combined, multivalent vaccines (MLV), which include a preparation containing 
CAV-2, along with canine distemper virus (CDV), canine parvovirus (CPV) and 
canine parainfluenza virus (CPiV), colloquially referred to by manufacturers and 
veterinarians as the ‘DHPPi’ (i.e. distemper, hepatitis, parvovirus and parainfluenza) 
vaccine (Abdelmagid et al., 2004). Immunocompetence is generally accepted to 
occur at around six to 12 weeks in puppies and kittens (Day, 2007), so it is important 
to consider this in vaccination regimes. WSAVA recommends that dogs receive the 
 




first dose of the core vaccination at the age of six to eight weeks, and then every two 
to four weeks until the age of 16 weeks (Day et al., 2016). 
 
Antibodies to CAV are transferred in utero, from dam to foetus, and are present in 
neonates which nurse (Winters, 1981). Therefore, a combination of maternal 
immunity and a properly initiated and continued vaccination regime should protect 
an immunocompetent puppy for its life. However, immunisation of free-ranging red 
foxes does not occur, so juvenile red foxes may become vulnerable to CAV-1 when 
maternal immunity wanes (Appel et al., 1975). 
 
Historically, booster vaccinations have been administered annually to pet dogs, 
usually because this is a convenient interval for veterinarians and their clients. 
Additionally, this allows for an annual health check of the animal when pet dogs do 
not present for disease in the intervening period. However, it is now recognised that 
vaccinations may provide a duration of vaccinal immunity (DOI) for three years or 
longer in vaccines produced by North American manufacturers (Schultz, 2006). 
Therefore, annual vaccination for CAV-1 may not necessarily be required in every 
animal. The ‘non-core’ parainfluenza vaccine (which is part of the DHPPi vaccine) 
can be administered separately on an annual basis if required (Day et al., 2016). 
During the last decade this has contributed to a rise in the availability of commercial 
‘in-house’ serological kits for veterinarians to detect antibodies against CAV and 
other viral agents, to indicate if animals require a ‘booster’ vaccine dose, and is 
particularly useful for dogs being admitted to shelters (Gray et al., 2012; Litster et al. 
2012). 
 
A trait shared by CAV-1 with other adenoviruses is environmental and chemical 
resistance (Zimmermann et al., 2011). CAV-1 has been demonstrated to be a heat 
stable virus up to a temperature of 56 °C, but is quickly inactivated at temperatures in 
excess of 60 °C. The virus persists in the environment for several months at 
temperatures below 4 °C, and can remain infective during this time. This is also true 
for adenoviruses having been kept at ambient temperature for three months (Ochi et 
al., 1956; Cabasso, 1962; Decaro et al., 2012). In addition, repeated episodes of 
 




freeze-thawing and freeze-drying still allows detection of CAV-1 particles (Innes and 
Saunders, 1962). The implication of this in management of relatively dense 
populations of susceptible animals in captivity is that rigorous cleaning and 
vaccination regimens should be instated and enforced to prevent the spread of 
disease. 
 
1.7.7 Treatment of ICH 
 
There is no specific anti-viral therapy for CAV-1 in dogs; any intervention or 
administration of medication is generally supportive. Upon diagnosis of ICH, or 
suspected diagnosis, supportive treatment should be initiated quickly due to the rapid 
course of disease (Decaro et al., 2012). Therefore, if ICH is suspected, the 
veterinarian should not wait for a definitive diagnosis ante-mortem by molecular 
methods (which are usually not available ‘in-house’) since the animal may die before 
confirmation of infection with CAV-1. 
 
Supportive treatment should focus on the management of the effects caused by the 
CPE of the virus, such as widespread haemorrhages and the resultant fluid losses 
which ensue, which also include additional losses from diarrhoea, vomiting and 
failure to meet daily fluid intake requirements (Ettinger et al., 2017). Administration 
of intravenous (IV) fluids should be initiated in most cases. A fluid rate to counteract 
high fluid losses should be calculated in addition to canine maintenance fluid rates. 
An isotonic fluid such as Ringer’s solution is an appropriate choice (Greene, 2013). 
It is recommended that if there is a state of hypoglycaemia, which can contribute to a 
comatose state in the affected animal, then a glucose bolus should be administered 
intravenously (50% glucose; 0.5 mL/kg) (Greene, 2013). Severe haemorrhage 
(determined by packed cell volume (PCV) and mucous membrane observations) may 
result in a clinical decision to replace blood by transfusion (whole blood, or plasma if 
whole blood is not available) when this is financially and practically available. 
 
Broad-spectrum antibiotics may be considered for prophylactic administration to 
protect against secondary bacterial infections as a result of compromised epithelial 
 




barriers, particularly in the gastrointestinal tract. If DIC is diagnosed then treatment 
is most likely to be instigated by replacement of clotting factors by blood transfusion 
(Ettinger et al., 2017). 
 
Specific treatment regimens for CNS derangements, such as seizuring, are not 
published, but should follow general veterinary procedures for the control or 
palliation of seizure patterns. Acute CNS clinical signs in canids with ICH are likely 
to be a result of multifocal haemorrhage in the CNS vasculature (Green et al., 1930; 
Thompson et al. 2010) and treatment at this stage may be futile. Euthanasia (e.g. by 
barbiturate administration or other humane methods) should be considered in all 
severe cases on humane grounds, particularly where prognosis is grave or hopeless. 
 
Systemic prednisolone treatment during the acute stages of ICH exacerbates disease 
and is contraindicated (Wong et al., 2012). Treatment of corneal oedema with 
corticosteroids is contraindicated because administration of these too early in 
recovery may result in suppression of immune response and proliferation of viral 
growth in the eye. In the rabbit model for HAd5, topical corticosteroids with limited 
potency enhanced viral growth compared to control animals (Romanowski et al., 
2002). This can result in permanent ocular damage and blindness (Carmichael, 
1965).  
 
Very limited studies have been carried out in regards to specific treatment for ICH. 
An IFN inducer, polyinosinic-polycytidylic acid, has been experimentally used by 
Wooley et al. (1974) to increase survival times of dogs which were intravenously 
administered CAV-1. Treatment was initiated 24 h prior to exposure to virus and 
mean survival was only 3.8 days. In practice, such treatment is likely to be both 
impractical and expensive, offer little advantage to supportive therapies and may 










1.8 Canine adenovirus type 2 (CAV-2) 
 
CAV-2 was first detected as part of an outbreak of laryngotracheitis in Toronto, 
Canada in 1961 (Ditchfield et al., 1962). Clinical signs in animals affected during the 
case study by Ditchfield et al. (1962) demonstrated that the disease was highly 
infectious, affecting 11 of 13 dogs (84.6%) and that the dogs developed a dry and 
‘hacking cough’, associated with mild pyrexia (38.9-39.4 °C). Hyporexia was also 
noted in the affected dogs, in addition to oedema of the upper respiratory tract, but 
there was no pulmonary involvement in these cases (Ditchfield et al., 1962). A throat 
swab from one of the affected dogs produced CPE in cell cultures after three days 
post-infection, and this was designated as a canine adenovirus (strain Toronto 
A26/61), on the basis of its serological cross reactivity and its appearance on 
histological preparations and electron micrographs (Ditchfield et al., 1962). 
 
Later experiments showed specificity of ‘fiber-specific’ antisera directed towards 
fiber proteins of CAV-1 and CAV-2 in HI tests (Marusyk, 1972). Based on these 
data, and clinical findings, it was suggested that the CAV-2 was distinct from CAV-
1. The development of molecular techniques allowed definitive differentiation of the 
two virus types. 
 
CAV-2 is now implicated in the ‘kennel cough complex’ (KC) or ‘infectious 
tracheobronchitis’ (ITB), along with other pathogens such as Bordetella 
bronchiseptica, CPiV, Mycoplasma spp. (Appel and Bemis, 1978) and more recently 
characterised viruses, such as canine respiratory coronavirus (CRCoV; Erles and 
Brownlie, 2008). These pathogens may be isolated alone or in combination in dogs 
with ITB, but cause similar clinical signs. 
 
There is some limited evidence that CAV-2 also targets intestinal epithelial cells. For 
example, CAV-2 has been isolated from the intestinal tract of a puppy with 
haemorrhagic diarrhoea, in addition to groups of dogs with diarrhoea (Hamelin et al., 
1985; Macartney et al., 1988). CAV-2 has also been isolated from the brains of 
several juvenile domestic dogs with respiratory and neurological signs (Benetka et 
 




al., 2006). There is no research to explain this apparent expansion of tropism of 
CAV-2 from the respiratory tract in dogs, but immunosuppression (including stress-
induced) could theoretically play a role. 
 
ITB or disease caused by CAV-2 has not been described in non-domestic canids, 
including red foxes. However, Balboni et al. (2013) detected CAV-2 in the faeces of 
a single red fox, but this was not associated with any disease. 
 
1.9 Current epidemiology of CAV-1 
 
The current distribution of CAV-1 is widespread, with serological evidence of 
exposure to the canine adenoviruses spanning the globe. In addition to domestic dogs 
and red foxes, serological surveys show that antibodies reactive to CAV exist in 
mustelid (Philippa et al., 2008) and ursid populations (Zarnke and Evans, 1989) in 
addition to other fox species (Garcelon et al., 1992) and wolves (Canis lupus; 
Choquete and Kuyt 1974). However, given the degree of cross-reactivity of 
adenovirus antibodies, there is a degree of uncertainty on whether the detected 
antibodies were formed against a challenge of CAV (either CAV-1 or CAV-2) or 
another Mastadenovirus. 
 
There are varying estimates of the serological prevalence of un-typed canine 
adenoviruses in free-ranging red foxes in Europe, ranging from 3.5% in Germany 
(Truyen et al., 1998) to 59.6% in Norway (Åkerstedt et al., 2010). Detected antibody 
prevalence can be particularly high in some populations of species, such as the island 
fox (Urocyon littoralis) in the Californian Channel Islands, USA where 97% of the 
sampled population were seropositive (Garcelon et al., 1992). A high seroprevalence 
of 94.7% was also estimated in wolves in Alaska, USA (Stephenson et al., 1982). 
 
Given the fact that the virus appears to be highly prevalent, based on serological 
surveys, and severe disease is sporadically described in veterinary literature and 
anecdotally, CAV-1 should be of high interest to the wildlife sector. There are 
concerns raised that wildlife populations, particularly the red fox, which is highly 
 




adapted to urban environments (see section 1.10 Red foxes in the UK), may be a 
wildlife reservoir for CAV-1 creating the chances of disease ‘spillover’ into domestic 
dogs (Thompson et al., 2010; Balboni et al. 2013). 
 
It is important to define what a ‘reservoir’ is in the context of CAV-1. It is noted that 
CAV-1 can infect more than one host species. In the UK, the suggested terminology 
outlined by Haydon et al. (2002) suggests that the ‘target’ population are domestic 
dogs. It is hypothesised that in countries which routinely vaccinate pet dogs against 
ICH that this species is unlikely to maintain CAV-1 in the absence of an additional 
source of disease, that is, a wildlife reservoir. The majority of pet dogs in the UK are 
vaccinated (PDSA and Yougov, 2016) and thus it is possible that there is a herd 
immunity effect to protect unvaccinated dogs. Infectious canine hepatitis is now 
rarely reported in dogs in Western Europe (Horzinek, 2006). Given the evidence 
presented by Thompson et al. (2010) that free-ranging foxes in the UK have been 
infected ‘in the wild’ with CAV-1 (see Chapter 2), then red foxes in the UK may be a 
reservoir of disease. However, the dynamics of infectious between red foxes requires 
further study to investigate this possibility. 
 
Despite the array of serological studies, the true impact of the disease in free-ranging 
species is difficult to ascertain. Firstly, this is due to the fact that CAV-1 shares 
approximately 75% genetic identity with CAV-2, resulting in high-cross reactivity of 
antibodies (as is exploited with CAV-2 vaccines; Decaro et al., 2012). This is only 
occasionally taken into account or considered in serological studies, but is a 
significant oversight due to the differing nature of the viruses, the clinical signs and 
severity of the diseases they cause (see section 1.7.3. Gross pathology of ICH), and 
their reported host-range and host-pathogenicity (Greene, 2013). 
 
Secondly, the number of animals sampled for antibodies to the viruses often fall 
short of a suitable sample size to make powerful, population-level inferences. 
Moreover, it is also hard to predict and model the impact of potential spillover of 
disease from wildlife populations to the domestic dog population and whether, in 
fact, domestic animals pose a reverse threat to the wildlife population, particularly in 
 




cases where stray or feral populations are high, as in some other countries (e.g. 
Belsare et al., 2014). Given that, in the UK, the red fox is becoming increasingly 
urbanised and is very common, it is important to determine the prevalence of CAV-1 
in free-ranging populations, and determine whether they are likely to maintain CAV-
1 (i.e. red foxes are a reservoir of infection; Haydon et al., 2002). 
 
1.10 Red foxes in the UK 
 
The red fox is generally hard to study from a behavioural and ecological point of 
view. The biology of the animal dictates that many individuals will not be observed 
due to their nocturnal activity. Those that will be seen are often because of the 
encroachment of human settlements into the natural habitat of the fox, or the fox 
adapting to man-made environments and becoming urbanised (Sadlier et al. 2004). 
Studies have found that some ‘carnivorous wildlife’ populations achieve a higher 
population density in ‘urban sprawl’ than is possible in rural or natural environments 
(Bateman and Fleming, 2012). This possible ‘conflict’ between urban and suburban 
human populations and wildlife extends to other medium to large carnivores 
including raccoons (Procyon lotor; e.g. Schubert et al., 1998), badgers (Meles meles; 
e.g. Harris, 1984) and bears (e.g. Ursus americanus; Don Carlos et al., 2009), and is 
largely a consequence of an increase in anthropogenic food sources and shelter 
(Harris 1981; Bateman and Fleming, 2012).  
 
The red fox is considered to be one of the iconic species of the urbanisation process 
of wildlife and has been heavily documented in cities in the UK, including Bristol, 
London and Edinburgh (Harris, 1981a; Harris, 1981b; Kolb, 1984). There have been 
many accounts of the increase in suburban and urban populations of red foxes across 
Europe (e.g. Hofer et al., 1999; Duduś et al., 2014), North America (e.g. Lewis et al., 
1999) and Australia (e.g. Marks and Bloomfield, 1999). However, this encroachment 
of wildlife into the man-made, human occupied environments has raised questions 
regarding the role of the red fox as a wildlife reservoir of disease (Hofer et al., 1999; 
Brochier et al., 2007) for both humans and domesticated animals, including pet dogs. 
 
 




Due to the large number of red foxes in the UK (Webbon and Harris, 2004), they 
have been considered as a sentinel species for some diseases (Meredith et al., 2015). 
Although the capture of wild foxes in humane traps is legalised, the sedation and/or 
blood sampling of a live animal for purely scientific purposes is not permitted 
without Home Office (UK Government) approval. This, in addition to the practical 
limitations and labour required to capture-recapture (‘resight’) a fox, makes targeted 
sampling of live individuals, in an adequately sized sample population, an inefficient 
method for monitoring (Sadlier et al. 2004). However, there are a large number of 
farmers and game keepers in the UK, who will legally shoot (i.e. possess firearms 
certificates and kill humanely) red foxes for game and land management purposes 
(see Chapter 2). This provides a large resource for sampling for disease surveillance 
(e.g. rabies; Harris and Rayner, 1986, Trichinella spp.; Zimmer et al., 2008, and 










1.11 Aims of the study 
 
The study and thesis is divided into three interlinking topics, split over several 
chapters: 
i) Pathology of ICH 
ii) Epidemiology of CAV-1 and novel adenoviruses in free-ranging wildlife 
in the UK 
iii) Pathogenesis of CAV-1 
 
i) Pathology of ICH in red foxes and domestic dogs 
 
This division addressed the pathology of the disease caused by CAV-1 in canids. 
In Chapter 2, the pathology of CAV-1 infections in red foxes in wildlife 
rehabilitation centres was considered following outbreaks of ICH in juvenile red 
foxes. It was concluded that disease in red foxes may be more likely to target the 
CNS than in domestic dogs using a comparative pathology approach. This 
possibility was considered further in Chapter 3 using immunohistochemistry to 
better define ICH in red foxes compared to domestic dogs. The need to re-define 
the pathology of ‘ICH’ in the two species was considered. Veterinarians should 
be aware of the wide range of clinical signs and possible manifestations 
(including subtle signs) of ICH. 
 
ii) Epidemiology of CAV-1 in free-ranging red foxes and 
mustelids in the UK 
 
In Chapter 4 the role that CAV-1 plays in red foxes in the UK was considered. 
This followed a suggestion in Chapter 2 that CAV-1 may be prevalent in free-
ranging red foxes in the UK and that some individuals may become persistently 
infected. Thus, the prevalence of CAV-1 in free-ranging red foxes in the UK was 
estimated. The development and implementation of improved molecular 
detection methods was discussed, specifically a nested PCR and quantitative real-
time PCR (qPCR), which permitted the detection of very low copy numbers of 
 




viral particles in tissue and fluid samples from foxes and dogs. The prospect of a 
‘wildlife reservoir’ of CAV-1 was considered. The purpose of this was to 
evaluate the risk that wildlife pose to domestic dogs, and whether preventative 
controls should be implemented. 
 
Because there is some evidence that non-canid species can develop ICH, the role 
of mustelids was considered as an additional reservoir of CAV-1 in the UK 
(Chapter 6). Tissues from mustelids in Scotland were screened using PCR and 
high throughput sequencing was employed to detect novel adenoviruses. The 
development of a novel serological assay, capable of distinguishing between 
antibodies against CAV-1 and CAV-2, was explored in Chapter 6. 
 
iii) Pathogenesis of CAV-1 
 
Chapter 7 addressed the molecular pathogenesis of CAV-1 and investigated 
which cells remain infected in persistently infected red foxes, and whether such 
tissues demonstrated residual pathology. A CAV-1 in situ hybridisation (ISH) 
detection method was established to detect CAV-1-infected cells in tissue 
sections, in addition to a reverse transcriptase qPCR (RT-qPCR) to monitor 
CAV-1 infection dynamics in cell cultures. A framework was provided to address 
the mechanisms employed by CAV-1 to persistently infect tissues in future 
studies. 
 
The thesis is concluded by a discussion of the implications of the findings for 
adenoviral disease in veterinary species and in humans. Overall, it is suggested that 
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2.1 Chapter introduction 
 
Historically, disease caused by CAV-1 (‘ICH’) has often been described as part of 
experimental infections in red foxes (Green et al., 1930), in domestic dogs in 
veterinary practices (Headley et al., 2013; Duarte et al., 2014) and in dogs in shelters 
with a low-level of biosecurity (Pratelli et al., 2001). In addition, as has been 
introduced in Chapter 1, ICH is occasionally reported in other species, which are 
captive in zoological collections (Park et al., 2007), in individual free-ranging 
animals found already deceased (grey fox; Urocyon cinereoargenteus; Gerhold et al., 
2007) and in free-ranging species which are temporarily captive and under veterinary 
care for other reasons (black bears; Ursus americanus, timber wolves; Canis 
occidentalis; Pursell et al., 1983). 
 
Cases of ICH are occasionally and anecdotally reported in red foxes in wildlife 
hospitals in the UK (Thompson et al., 2010); however, many are not usually formally 
reported. Additionally, studies in free-ranging species rarely investigate or identify 
the original source of infection for the diseased animal. Thompson et al. (2010) 
highlighted a case of ICH in one free-ranging red fox submitted to a wildlife hospital 
in 1995. A pair of foxes with ICH, submitted to a veterinary surgery in 2000, were 
also described. These cases were seemingly isolated and disease was already present 
in the red foxes on presentation to the veterinarians (Thompson et al., 2010), 
therefore they are likely to have been infected ‘in the wild’. 
 
In this chapter, a published manuscript (Walker et al., 2016a) is presented, which 
describes rapidly fatal outbreaks of ICH in multiple groups of juvenile red foxes at 
two wildlife hospitals in Scotland, UK. The manuscript presents findings which 
demonstrate that multiple red foxes had become infected and diseased whilst already 
present in the wildlife hospitals (‘resident animals’), which has not been previously 
reported. The foxes were present for other reasons and were not previously suffering 
from infection with CAV-1. It is hypothesised that a persistently infected fox, not 
showing overt signs of infectious disease, was the source of infection for resident 
foxes at one wildlife hospital. 
 




Furthermore, histopathological examinations were conducted on tissues from the 
CNS of affected animals, which have not been examined in previous studies in free-
ranging foxes from the UK. The resulting pathological descriptions highlight that 
neurological disease caused by CAV-1 may be frequent in red foxes. The manuscript 
also emphasises the importance of biosecurity considerations for wildlife and 












Reproduced from [Infectious canine hepatitis in red foxes (Vulpes vulpes) in wildlife 
rescue centres in the United Kingdom, D. Walker, E. Abbondati, A. L. Cox, G. B. B. 
Mitchell, R. Pizzi, C. P. Sharp, A. W. Philbey, Veterinary Record, 178, 421, 2016] 
with permission from BMJ Publishing Group Ltd. Adapted with permission from 
BMJ Publishing Group Ltd. 
 
Publication contributions – DW wrote the draft manuscript, contributed to 
histopathological interpretations, DNA extractions and molecular analyses. The 
post-mortem examinations, which preceded DW’s scholarship, were performed by 
EA, ALC, GBBM and RP, who also provided the specimens and access to the 
original clinical notes (2011-2013). Slides were prepared by the histopathology 
section, Royal (Dick) School of Veterinary Studies (RDSVS). DW is grateful to AWP 
and CPS for assistance with histopathological interpretations and molecular 
work/primer development respectively. 
 
 




2.2 “Infectious canine hepatitis in red foxes (Vulpes 





Outbreaks of infectious canine hepatitis (ICH) are described in red foxes (Vulpes 
vulpes) at two wildlife rescue centres in the United Kingdom. Disease occurred in 2 
to 4 month old juvenile foxes, which were held in small enclosures in groups of three 
to eight animals. The foxes died or were euthanased after a short clinical course, 
sometimes including neurological signs and jaundice, with a high case fatality rate. 
Four red foxes submitted for post-mortem examination had enlarged, congested 
livers, with rounded borders and mild accentuation of the lobular pattern. On 
histological examination, there was random, multifocal to massive hepatic necrosis, 
along with multifocal vasculitis in the central nervous system (CNS) and mild, 
multifocal glomerulonephritis. Intranuclear inclusion bodies, typical of canine 
adenovirus type 1 (CAV-1) infection, were present in hepatocytes, vascular 
endothelial cells in the CNS, renal glomeruli and renal tubular epithelial cells. CAV-
1 was detected in tissues from affected foxes by the polymerase chain reaction and 
sequencing. Congregation of juvenile foxes in wildlife rescue centres is likely to be a 
risk factor for transmission of CAV-1. Preventative measures in wildlife centres 
should be implemented to prevent the spread of the virus among conspecifics and to 
other susceptible species. 
 






Early laboratory studies showed that red foxes (Vulpes vulpes) are susceptible to 
experimental infection with canine adenovirus type 1 (CAV-1), the cause of 
infectious canine hepatitis (ICH) (Green et al., 1930). However, the pathology and 
clinical signs of ICH in naturally infected, free-ranging canids are not well 
characterised. Red foxes in the United Kingdom (Thompson et al., 2010) and Italy 
(Balboni et al., 2013) appear to be a wildlife reservoir of CAV-1. Serological 
exposure to untyped CAV in several free-ranging carnivore species has been 
reported worldwide (Amundson and Yuill, 1981; Truyen et al., 1998; Thompson et 
al., 2010), suggesting that CAV-1 may be sustained in wild canid populations. 
However, there are only a few reports of the occurrence of spontaneous ICH in free-
ranging foxes (Woods, 2001), limited to descriptions of isolated cases in a grey fox 
(Urocyon cinereoargenteus) (Gerhold et al., 2007) and three red foxes (Thompson et 
al., 2010). 
 
It has been hypothesised that sporadic transmission of CAV-1 from infected red 
foxes to susceptible (unvaccinated) domestic dogs may occur through contact with 
infected excretions, such as urine and faeces (Thompson et al., 2010). Widespread 
vaccination of dogs in the United Kingdom, in combination with responsible dog 
ownership and effective control of stray dogs, is likely to have reduced the incidence 
of transmission of CAV-1 amongst dogs to a low, and probably unsustainable, level. 
However, the possibility of infection through direct or indirect contact with 
susceptible wildlife, or unvaccinated dogs, may be a mechanism allowing the 
occasional presentation of ICH in dogs to veterinary surgeons in general practice. 
Furthermore, concern has been expressed about the emergence of infectious diseases, 
such as canine distemper (Walker et al., 2014), rabies and Echinococcus 
multilocularis (Bourne et al., 2015), in the United Kingdom as a consequence of both 
legal and illicit animal movements. Therefore, veterinary surgeons should be aware 
of the clinical signs and diagnoses of such diseases, and also be conscious that 
wildlife, such as foxes, which occasionally are presented for veterinary intervention, 
are also susceptible to many diseases of the domestic dog. 
 





In the Mediterranean, ICH has been reported as an ‘old’ disease which is re-
emerging (Decaro et al., 2007). Other cases of ICH in dogs and foxes have been 
reported in the past decade in Europe (Gleich et al., 2009; Müller et al., 2010, 
Thompson et al., 2010), Asia (Wen et al., 2009; Cheema et al., 2012), North 
America (Wong et al., 2012; Headley et al., 2013) and South America (Inkelmann et 
al., 2007; Oliveira et al., 2011). However, this published evidence suggests that the 
frequency of occurrence of ICH has not necessarily changed substantially in the last 
25 years. Despite this, in conjunction with evidence of serological exposure in 
wildlife, such reports support the hypothesis that there is on-going exposure and 
transmission of CAV-1 to susceptible species. There is no current evidence to 
suggest that the incidence of ICH in dogs is higher in areas with a greater wildlife 
disease burden. However, in principal, there is potential for disease ‘spill over’ 
events from red foxes to unvaccinated dogs. 
 
In this paper, the clinical and pathological findings in juvenile red foxes that died 
during outbreaks of ICH at two wildlife rescue centres in Scotland are described. To 
the authors’ knowledge, this is the first detailed report of ICH in multiple red foxes 
affected during disease outbreaks in wildlife rescue centres, whereas previously ICH 
was reported in free-ranging red foxes in the United Kingdom (Thompson et al., 
2010). Furthermore, the present study confirms the presence of CAV-1 in the United 
Kingdom by the polymerase chain reaction (PCR) and sequencing. These findings 
provide further evidence that CAV-1 is present in red foxes in the United Kingdom, 














2.4 Materials and methods 
 
2.4.1 Clinical histories 
 
Foxes 1, 2 and 3 were juvenile red foxes from different litters that had been orphaned 
and were admitted to the Scottish Society for the Prevention of Cruelty to Animals 
(SSPCA) National Wildlife Rescue Centre, Fishcross, Scotland, in May 2013 to be 
reared with the aim to release them back to the wild. In early June 2013, fox 1 died 
and fox 2 was euthanased due to collapse and seizures. Subsequently, fox 3, from the 
same group of animals, died suddenly overnight. In the same month, a further three 
associated foxes were found dead and a further three foxes were euthanased after 
exhibiting seizures. 
 
Fox 4 died at Hessilhead Wildlife Rescue Centre, Beith, Scotland in June 2011. It 
was one of four red foxes that had died at the centre within 2 weeks. The cub was 
enclosed in outdoor pens with five others, one of which exhibited convulsions prior 
to death. Fox 4 appeared to be normal when inspected by the staff at the centre on the 
day prior to death. The only other notable finding in the history of this group of 
animals was evidence of diarrhoea on the floor of the enclosure. 
 
2.4.2 Post-mortem examination and histopathology 
 
Foxes 1, 2 and 3 were submitted to the Royal (Dick) School of Veterinary Studies, 
Edinburgh, Scotland, for post-mortem examination in June 2013. Samples of liver 
(foxes 2 and 3), brain (fox 2) and lung (foxes 1 and 3) were collected into viral 
transport medium (10% phosphate buffered glycerol saline) and stored at -20 °C. Fox 
4 was submitted to Scotland’s Rural College (SRUC), Auchincruive, Scotland, for 
post-mortem examination. A range of tissues, including brain, spleen, heart, 
mesenteric lymph node, liver, kidney and small intestine, were fixed in formalin, 








2.4.3 Polymerase chain reaction and sequencing 
 
DNA was extracted from tissue samples from foxes 1, 2 and 3 using the AllPrep 
DNA/RNA Mini kit (Qiagen, Hilden, Germany). DNA was extracted from ~20 µm 
thick sections of formalin-fixed paraffin-embedded (FFPE) tissues from fox 4 using 
the QIAamp FFPE DNA Tissue kit (Qiagen). 
 
The PCR for adenoviral DNA polymerase sequences was performed using a nested 
protocol adapted from Wellehan et al. (2004). The PCR reaction mixture contained 2 
µL DNA, 36.5 µL H2O, 10 µL 5x GoTaq reaction buffer (Promega, Madison, WI, 
USA), 0.5 µL ‘polFouter’ forward primer (100 µM), 0.5 µL ‘polRouter’ reverse 
primer (100 µM), 0.3 µL deoxynucleotide triphosphates (10 mM) and 0.2 µL (1 U) 
GoTaq G2 DNA polymerase (Promega). The samples underwent two rounds of 
conventional nested PCR (94 °C for 5 minutes, 45 cycles of 94 °C for 30 seconds, 46 
°C for 1 minute and 72 °C for 1 minute, followed by a final extension at 72 °C for 5 
minutes); then, 2 µL PCR product from the first round was used as a template for the 
second round, under the same conditions, using the internal primers ‘polFinner’ and 
‘polRinner’, described by Wellehan et al. (2004). The expected amplicon size for 
CAV-1 is 321 base pairs (bp). The resulting amplicons were visualised using the 
G:BOX gel imaging system (Syngene, Cambridge, UK) following separation by gel 
electrophoresis in agarose containing SYBR Safe DNA Gel Stain (Invitrogen, 
Paisley, UK). Sanger sequencing was performed using the internal primers 

















2.5.1 Gross pathology 
 
Fox 1 
Fox 1 was a juvenile male red fox with a moderate degree of autolysis. The liver was 
moderately enlarged, friable and brown, with mild accentuation of the lobular 
pattern. There was mild congestion of the meninges. 
 
Fox 2 
In fox 2, a male juvenile red fox, the liver was mildly enlarged and dark red, with 
multifocal, irregular areas of brown discolouration. The intestinal mucosa had 
multifocal patches of red discolouration. There was mild, diffuse, congestion of the 
meninges. 
 
Fox 3  
Fox 3 was a juvenile red fox of unknown sex in poor body condition and with 
jaundice. The liver was mildly enlarged and dark brown, with poorly defined pale 
patches. The spleen and mesenteric lymph nodes were mildly enlarged. The lumen of 
the stomach, small intestines and proximal large intestines contained dark red, 
haemorrhagic fluid. 
 
Fox 4  
Fox 4 was a female juvenile red fox weighing 2 kg. The liver and kidneys were 





Histopathology of the liver of fox 1 revealed moderate to severe, random, multifocal 
to massive necrosis of hepatocytes. Amphophilic intranuclear inclusion bodies, 
including many classical Cowdry type A inclusion bodies, were present within 
 




numerous hepatocytes. There was dissociation and vacuolation of hepatocytes. Blood 
vessels and hepatic sinusoids contained fibrin thrombi. In the lungs, there were mild 
interstitial infiltrates of lymphocytes and macrophages in alveolar walls, along with 
mild interstitial oedema and formation of fibrin thrombi within blood vessels. Small 
numbers of intra-alveolar macrophages were present. In random, small blood vessels 
within the cerebral cortex, there was segmental swelling of vascular endothelial cells, 
mild perivascular oedema, occasional individual cell degeneration and rare 
intranuclear inclusion bodies. 
 
Fox 2 
The liver of fox 2 exhibited moderate to severe, random, multifocal to massive 
necrosis of hepatocytes, along with dissociation and vacuolation of hepatocytes, and 
expansion of the spaces of Disse. Numerous intranuclear inclusion bodies were 
present in hepatocytes (Figure 2.1A). In the kidney, there were occasional 
intranuclear inclusion bodies in probable mesangial cells in glomeruli and in 
epithelial cells lining the proximal convoluted tubules. Occasional degeneration of 
individual cells, probably mesangial cells, was evident in glomeruli. There was mild 
vacuolation of epithelial cells, mainly in the proximal convoluted tubules, along with 
small amounts of proteinaceous and sometimes cellular material in tubule lumina. 
There were no significant findings in the brain. 
 
Fox 3 
In the liver of fox 3, there was severe, massive, hepatic necrosis, with dissociation, 
vacuolation and fragmentation of hepatocytes, and numerous intranuclear inclusion 
bodies. There was a mild increase in the number of neutrophils within hepatic 
sinusoids. In the lung, there were increased numbers of macrophages and 
lymphocytes in alveolar walls, along with individual cell degeneration, probably of 











The liver of fox 4 exhibited moderate, random, multifocal hepatic necrosis, with 
occasional intranuclear inclusions. In the kidney, rare intranuclear inclusion bodies 
were present in probable mesangial cells in glomeruli (Figure 2.1B) and there was 
occasional individual degeneration of epithelial cells lining proximal convoluted 
tubules. There was moderate lymphocytolysis within lymphoid follicles in the white 
pulp of the spleen and in the cortex of the mesenteric lymph node. Moderate 
numbers of intranuclear inclusion bodies were present in endothelial cells of blood 
vessels apparently scattered at random throughout the brain (Figure 2.1C), often 
associated with perivascular haemorrhage and occasionally with mild, focal 
degeneration and necrosis of neurones (Figure 2.1D). 
 
2.5.3 Polymerase chain reaction and sequencing 
 
Adenoviral sequences were detected by PCR in frozen tissues processed from foxes 
1 (lung), 2 (brain and liver) and 3 (lung and liver), as well as in FFPE brain and 
pooled spleen, mesenteric lymph node and cardiac muscle from fox 4. The primers 
amplified a 272 bp segment of the adenoviral DNA polymerase gene in foxes 1, 2 
and 3 when the primer sequences are excluded (Wellehan et al., 2004). Shorter 
fragments were sequenced from the FFPE samples (fox 4). The sequences from all 
foxes had a 100% match to CAV-1 (GenBank AC_000003.1), excluding the 

















Photomicrographs of histological sections from foxes with infectious canine 
hepatitis. Haematoxylin and eosin staining. Scale bars = 50 μm. 
 































d) Brain from fox 4, showing perivascular oedema and haemorrhage, along with 













In this study, four cases of spontaneous ICH were confirmed by clinical and 
pathological examination, supported by PCR and confirmation of CAV-1 by 
sequencing, in juvenile red foxes that died at two wildlife rescue centres in Scotland. 
Several other foxes died within a period of weeks during the outbreaks of ICH at 
both wildlife rescue centres. The clinical histories suggested that the disease was 
peracute to acute and appears to have followed a similar course to the classical 
“fulminating form” of ICH (Parry, 1950). In ICH, clinical signs develop after an 
incubation period of two to six days (Cabasso, 1962). 
 
The gross and histopathological findings in affected red foxes in the present study 
were consistent with ICH. The most frequent gross changes were enlargement and 
altered colour of the liver. Jaundice was prominent in one fox. Oedema of the wall of 
the gall bladder may be observed in dogs with ICH (Decaro et al., 2012), but was not 
evident in the red foxes in the present study. Similarly, there was no evidence of 
corneal opacity (“blue eye”) in the red foxes included in this investigation. On 
histological examination of the liver, intranuclear inclusion bodies were evident in 
hepatocytes, along with hepatocyte necrosis. Inclusion bodies were also seen within 
glomeruli and occasionally in renal tubular epithelial cells in the kidneys. A notable 
feature in the present cases was the presence of vasculitis and intranuclear inclusion 
bodies in vascular endothelial cells in the brain. Central nervous system lesions were 
not described in a previous study of ICH in free-ranging red foxes, since brain was 
not available from these cases (Thompson et al., 2010). 
 
Wildlife rescue centres in the United Kingdom receive numerous juvenile foxes in 
spring and early summer, usually as orphans due to misadventure or disease in the 
vixens. Congregation of juvenile foxes in pen groups is likely to provide an 
opportunity for transmission of infectious disease. The juvenile foxes in the current 
study had a rapid onset and short duration of disease, with a high case fatality rate. 
Juvenile red foxes are likely to be susceptible to infection and at risk of severe ICH if 
they have not received maternal antibodies against CAV-1 or if maternal immunity 
 




has waned. It is also possible that other diseases, such as parasitism, emaciation or 
captivity-induced stress, may have affected the susceptibility of fox cubs to ICH. 
 
Further investigation into the origin of the outbreak at one of the wildlife centres 
revealed that the usual quarantine procedures for new admissions had not been 
followed. In particular, a newly introduced fox cub was allowed to have direct 
contact with a group of juvenile foxes that had been at the centre for several weeks. 
Congregation of susceptible juvenile foxes with conspecifics in captivity is likely to 
be a risk factor for the spread of CAV-1 and the occurrence of outbreaks of ICH. 
Transmission of CAV-1 occurs through direct exposure to infected animals, or 
indirect contact via contaminated urine, faeces or ocular or nasal secretions (Decaro 
et al., 2012; Woods, 2001). The duration of persistence of CAV-1 in the environment 
in such excretions is uncertain, although the virus has been shown to persist and 
remain infective for several months at temperatures below 4 °C (Decaro et al., 2012). 
The course of the disease outbreak at the second wildlife centre and the underlying 
factors are unknown. 
 
It is clear that ICH is frequently manifested as a fatal disease in both red foxes and 
dogs. The majority of the literature reporting disease due to ICH in red foxes is based 
on experimental infections (Green et al., 1930) or as reports of isolated cases of 
naturally acquired disease (Thompson et al., 2010). However, there is serological 
evidence of untyped CAV antibodies in free-ranging red foxes in Europe (Truyen et 
al., 1998; Thompson et al., 2010), as well as other parts of the world, suggesting that 
a proportion of free-ranging red foxes are exposed to the virus and will survive 
without fatal disease. 
 
Infectious diseases, such as ICH, should be considered when undertaking veterinary 
assessment of sick red foxes submitted to wildlife rescue centres. It is also important 
to note that CAV-1 will be excreted by red foxes with ICH, as well as by animals 
incubating the disease and possibly by clinically healthy foxes. Moreover, since 
domestic dogs are susceptible to ICH, the possibility of transmission of CAV-1 from 
red foxes to dogs (and vice versa), either directly or through fomites, should be 
 




considered. There is some evidence that CAV-1 can be shed in the urine of 
apparently recovered dogs for up to 9 months following experimental infection with 
CAV-1 (Baker et al., 1954). 
 
Continued vaccination of domestic dogs against CAV-1 (with CAV-2-based 
vaccines) is recommended, whereas vaccination of foxes in the wild is unlikely to be 
practically or economically feasible. Reasonable precautions should be taken in 
wildlife rescue centres and veterinary hospitals to reduce the risk and to prevent the 
spread of CAV-1 amongst susceptible species, including red foxes, dogs, other 
canids, as well as some mustelids. A suitable level of infectious disease control 
should be implemented in well managed animal rescue centres and veterinary 
hospitals.  
 
In one of the wildlife rescue centres in the current investigation, it is likely that a fox 
with inapparent infection had been introduced and presumably was the source of 
CAV-1 for other foxes in the same or nearby pens. Therefore, quarantine and close 
observation of wildlife entering rescue centres and veterinary hospitals is 
recommended. Considering that the incubation period for ICH may be up to 1 week 
following exposure to CAV-1 (Cabasso, 1962), this length of quarantine should be 
considered. 
 
Vaccination of foxes on entry to wildlife rehabilitation centres could be considered, 
but may only be effective if a quarantine period of 1 to 2 weeks is also applied, to 
allow sufficient time for vaccinated animals to produce protective neutralising 
antibodies. Foxes can be vaccinated with live attenuated vaccines, licensed for use in 
dogs, which contain the cross-protective virus CAV-2; most vaccines available 
routinely will also contain canine parvovirus, canine distemper virus and canine 
parainfluenza virus. The number of vaccinations will depend on the age of the animal 
being vaccinated. Long-term ‘residents’ of wildlife rehabilitation centres should be 
routinely vaccinated, at the manufacturer’s published intervals, to provide immunity 
to these individuals if the quarantine of new arrivals is not possible. 
 
 




In conclusion, multiple cases of spontaneous ICH were identified in juvenile red 
foxes at two wildlife rescue centres in Scotland. CAV-1 appears to have spread 
amongst susceptible animals, either directly or indirectly, resulting in a high case 
fatality rate after a short clinical course. Disease management protocols should be 
adopted in wildlife rescue centres and veterinary hospitals which regularly receive 
red foxes, in order to prevent the spread of CAV-1 among susceptible animals. 
Infectious diseases, such as ICH, which are encountered infrequently in domestic 
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2.6 Chapter conclusion 
 
This article has described fatal disease caused by infection with CAV-1 in multiple 
juvenile red foxes, which were temporarily captive in wildlife rescue centres. A red 
fox at one of the centres, which was apparently free of CAV-1, was the likely source 
of infection for susceptible, ‘resident’, juvenile foxes. This was found to be the result 
of inadvertent mismanagement of an incoming patient at the wildlife centre. There 
was not enough clinical history available at the second wildlife centre to investigate 
the cause of the outbreak. Thus, the manuscript highlights, in a non-experimental 
setting, an important and underexplored aspect of adenovirus pathobiology: the 
possibility of persistence of infection in ‘recovered’ or subclinically affected 
animals. 
 
The manuscript suggests that a seemingly clinically normal red fox was the source of 
infection for other red foxes. However, a limitation of the study was that urine and 
faeces (as an indirect source of the infection) from the incoming animal at this 
wildlife rehabilitation centre were not sampled and screened by PCR to prove this 
link. Therefore, it is important to investigate further how prevalent CAV-1 is among 
red foxes in the UK, whether they become persistently infected with CAV-1 and 
whether inapparently infected individuals also shed virus into the environment via 
urine and/or faeces. 
 
Determining the serological and molecular prevalence of CAV-1 could provide the 
evidence that foxes are a possible ‘wildlife reservoir’ of CAV-1. It is also important 
to find out how prevalent CAV-1 is among red foxes in the UK, because they may be 
a source of CAV-1 infection for owned domestic dogs. It could aid veterinary care 
and prevention by the validation of implemented biosecurity measures. Based on the 
current evidence, red foxes should be vaccinated (if feasible) following the WSAVA 
recommended protocol for dogs (Day et al., 2016). They should also be subject to 
quarantine and monitoring on admission to wildlife centres or veterinary practices; 
foxes are likely to come into contact with other free-ranging conspecifics (or 
unvaccinated dogs). 
 




From the evidence presented in this study, the disease was rapidly fatal, with some 
animals possessing few notable, preceding clinical signs. The number of deaths 
occurring at the wildlife centres in the short time period could be a result of the close 
contact of the contained groups of foxes, and is reminiscent of the large losses 
encountered in fox fur farms (Green et al., 1930; Sompolisnky, 1949). Due to the 
‘busy nature’ of work at wildlife centres, and presumption that there was no reason 
to monitor the groups of red foxes more regularly at the time, some subtle clinical 
signs of ICH may not have been recorded in the groups (e.g. apathy, anorexia, 
nystagmus and other CNS signs). As a result, veterinarians should be aware of the 
rapid course of ICH when managing red foxes, and that clinical signs may be vague. 
 
It is rationally hypothesised that disease in the juvenile foxes could have been 
exacerbated, and the course of disease accelerated, by other stressors in the wildlife 
rehabilitation centres, such as immunosuppression from psychological stress at being 
held temporarily captive, or some other disease process such as physical injury. 
Immunosuppression has been suggested to be a predisposing factor for ICH in a 
puppy which died in Yukon, Canada (Wong et al., 2012) and is commonly reported 
in immunosuppressed humans which die from systemic adenoviral disease, which is 
not normally expected in immunocompetent patients (Walls et al., 2003; Ison, 2006). 
 
Finally, the manuscript has also importantly highlighted the CNS pathology that 
results from infection of red foxes with CAV-1, which has not been fully explored in 
the free-ranging red foxes studied previously in the UK, where brains were not 
examined (Thompson et al., 2010). It is re-emphasised that Green et al. (1930) first 
described the disease caused by CAV-1 in foxes as “epizootic fox encephalitis” (due 
to severe CNS disease) which was later determined to cause “hepatitis contagiosa 
canis” in dogs (Rubarth, 1947). Furthermore, Parry (1950) indicated that there are 
‘multiple forms’ of ICH in domestic dogs, a spectrum of disease from mild to severe 
(“fulminating” and acute). Although veterinary medical textbooks recognise the 
disease in dogs to have varied clinical signs, it is rarely emphasised that ICH can be 
acutely fatal in other canids (or non-canids), nor that clinical signs in non-domestic 
canids may be vague or non-existent. This is important because veterinary care often 
 




cannot be optimally delivered for free-ranging animals. For example, in the 
presented cases, even though moderate to severe hepatic lesions (and other lesions 
outwith the CNS) were noted on post-mortem examination, clinical signs from these 
lesions did not dominate ante-mortem. The use of the term ‘massive’ hepatic 
necrosis in this study (and hereafter in this thesis) refers to severe panlobular or 
multilobular necrosis (Rothuizen, 2006), which affects all parts of a hepatic lobule or 
acinus. However, there may be some debate on the exact use of this term, since it has 
been ‘adopted’ from use in human hepatic pathology where there are some 
inconsistencies in its usage (Weng et al., 2015). In veterinary pathology, it is noted 
that this term often relates to necrosis of every hepatocyte in a lobule (Maxie, 2016). 
By the latter definition, submassive or ‘severe, multifocal to coalescing’ necrosis 
would have been more appropriate in this study. To avoid inconsistency, the term 
massive, originally used in the published article, will continue to be used by the 
former understanding. 
 
It is possible that the cause of death of some of the foxes was multifocal CNS 
haemorrhages and disturbances as a consequence of CAV-1 proliferation, given the 
history of foxes seizuring or dying without ‘warning’; this is not the ‘classic’ clinical 
picture of ICH. It is also interesting to note that fox 2 had neurological signs ante-
mortem, but did not have significant findings in the CNS upon post-mortem 
examination. It is possible that the section of cortex examined just did not display the 
relevant pathology, or that the CPE was too subtle to be detected. Hepatic 
encephalopathy is also a possibility, but this has not been reported in relation to 
CAV-1 in red foxes. 
 
Therefore, there is a need to systematically compare and assess clinical material from 
red foxes and dogs, which have died following infection with CAV-1, to identify the 
key pathological features of disease in the red fox compared to the domestic dog. A 
‘re-definition’ of so called ‘infectious canine hepatitis’ may be required to better 
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Recent evidence (Chapter 3; Walker et al., 2016a) and historical accounts suggest 
that there could be varying manifestations of ‘ICH’ (Green et al., 1930; Rubarth, 
1947) in foxes and dogs. This contrast between so-called fox encephalitis and ICH 
may explain how infection with CAV-1 was discovered, seemingly independently, in 
two species. It has been introduced that there is a broad spectrum of disease in the 
domestic dog (Chapter 1; Parry, 1950) and this is related to a range of possible 
clinical signs. However, an acutely fatal disease with a limited spectrum of overt 
clinical signs may predominate in CAV-1 infected red foxes (Chapter 2; Walker et 
al., 2016a). 
 
It is notable that Green et al. (1930) stated that “the symptoms of epizootic fox 
encephalitis are so consistently referable to the central nervous system, it appears 
that the microscopic pathology of these tissues has the most significance.” It was 
noted that the general findings were typically multifocal haemorrhages in the CNS 
and round cell infiltration (specifically, perivascular cuffing; Green et al., 1930); 
however, either finding occurred to varying degrees. It is possible that, in these early 
experiments in red foxes, the relatively severe disease observed in the CNS could be 
partly attributable to the experimental, intra-cranial inoculation methods performed 
in some animals (Green et al., 1930). However, Green et al. (1930) also described 
severe CNS lesions in red foxes as a consequence of naturally occurring disease (see 
1.7.4 Histopathology of ICH). Furthermore, ‘modern’ reports of naturally occurring 
ICH in fox species also describe a rapid and fatal course of disease; mild to severe 
neurological symptoms can be evident ante-mortem (Thompson et al., 2010; Choi et 
al, 2014; Walker et al., 2016a). 
 
Thus, there is a lack of evidence to suggest that free-ranging red foxes naturally 
infected by CAV-1 display the wide range of overt clinical signs to the extent 
described in domestic dogs (Parry, 1950; Decaro et al., 2012). Most overt clinical 
signs, if noted at all, appear to be severe neurological symptoms, gastro-intestinal 
(e.g. diarrhoea, vomiting) or non-specific (e.g. apathy, anorexia; Walker et al., 
 




2016a). Pathological findings on post-mortem examination were noted to varying 
degrees in an array of tissues during the outbreaks of ICH reported in Chapter 2. 
However, CNS disease appeared to be ‘more severe’ than one might expect in dogs 
(Innes and Saunders, 1962). 
 
Despite these intermittent accounts of severe CNS disease in infected foxes (‘fox 
encephalitis’), the disease caused by CAV-1 is now widely referred to as only ‘ICH’ 
in all cases and species in which it is reported; possible ICH has also been reported in 
bears and otters (Pursell et al., 1983; Park et al., 2007). It is apparent there is 
insufficient (or poorly disseminated) evidence to confirm the different manifestations 
of disease caused by CAV-1 and the frequencies in which disease occurs in different 
tissues. Specifically, a systematic comparative approach has not been taken to 
compare the disease caused by CAV-1 in red foxes and dogs. Clear research to 
address the hypothesis that CNS disease is more severe in red foxes is thus required 
to fill this knowledge gap. This could aid veterinarians in particular in their diagnosis 
of CAV-1 disease with an acute clinical course, where this may be otherwise 
overlooked. 
 
Therefore, as a follow up to the findings discussed in Chapter 2 (Walker et al., 
2016a) a pilot study was initiated, using a comparative pathology approach, to re-
explore the possibility of varying spectra of disease between red foxes and domestic 
dogs. It was hypothesised that CNS symptoms may predominate in red foxes (albeit 
in combination with other widespread lesions of varying severity) following 
infection with CAV-1, that hepatic lesions may predominate in the dog, and that a re-
definition of ‘ICH’ as a term is required to accommodate a range of intraspecific and 
interspecific lesions. 
 
In this chapter the histopathology of naturally occurring disease caused by CAV-1 is 
described. A subset of tissues from both red foxes and dogs, including liver, kidney 
and brain were utilised. Both standard and immunohistochemical staining have been 
used. Quantitative analysis and semi-quantitative scoring systems were established to 
compare other histological features of the diseased tissue. 
 




3.2 Materials and methods 
 
3.2.1 Study design and selection of cases 
 
Formalin-fixed paraffin-embedded (FFPE) tissues were selected for inclusion from a 
collection of clinical case material collected at the Small Animal Hospital, University 
of Glasgow, UK and the RDSVS, University of Edinburgh, UK. The collection 
included brain, liver, and kidney tissue samples from domestic dogs and free-ranging 
red foxes suspected to have died from adenoviral disease, including foxes which died 
as part of outbreaks of ICH in wildlife rehabilitation centres (Walker et al., 2016a). 
The year of submission of the pathological material in the archive ranged from 1986 
to 2013. 
 
Diagnosis of each case was based on a combination of clinical history, gross 
pathology and preliminary histological findings. Molecular diagnoses of CAV-1 
infection were already made for red foxes in the study by Walker et al. (2016a). A 
total of four fox livers were selected to compare with five dog livers, and three fox 
kidneys with four dog kidneys. The brains (cerebrum) from three foxes and two dogs 
were also compared (the region sampled was not consistent because sections were 
opportunistically obtained from an archive). Spleen and heart from two foxes and a 
mediastinal lymph node from one fox were included for interest. FFPE tissues were 
included in the study based on the range of tissues available, and the subjective 
quality of the tissue sections on standard histological examination using light 
microscopy. Full ‘sets’ of tissues from individual dogs could not be accommodated 
due to the availability of archived tissues (e.g. preserved brain was not available for 
four of the included dogs). Tissues from canids, which had died from causes other 
than ICH, were also selected for use as ‘healthy’ controls. The selected cases are 











Summary of tissues included in the study. All identification numbers (ID) have been 
anonymised for data protection purposes.  
 
ID Species Samples‡ 
Fox 1* Red fox Liver, lung, brain, (heart) 
Fox 2* Red fox Liver, kidney, brain, (spleen) 
Fox 4* Red fox Liver, kidney, brain, (spleen, heart, mediastinal lymph node) 
Fox 5 Red fox Liver, kidney 
Dog 1 Dog Liver, brain 
Dog 2 Dog Brain 
Dog 3 Dog Liver, kidney 
Dog 4 Dog Liver, kidney 
Dog 5 Dog Liver, kidney 
Dog 6 Dog Liver, kidney 
FoxControl1† Red fox Liver, kidney 
FoxControl2† Red fox Brain, spleen 
DogControl1† Dog Liver, kidney, brain 
DogControl2† Dog Liver, brain 
 
* Foxes 1, 2 and 4 originated from the study by Walker et al. (2016a). 
† ‘Healthy’ controls, no ICH present. All other animals showed evidence of ICH on preliminary 
analysis. 










Methods contributions - The immunohistochemistry and histological slide 
preparation was performed by staff in the histopathology laboratory, Easter Bush 
Pathology, RDSVS. 
 




3.2.2 Selection of stains and antibodies 
 
Sections of tissues prepared from each block were stained routinely with 
haematoxylin and eosin (H&E). A CAV-1 type-specific, monoclonal, mouse anti-
CAV-1 antibody (IgG1 isotype; 2E10-H2; Veterinary Medical Research and 
Development, Pullman, Washington, USA) was used to detect cells with CAV-1 
antigen. Specificity of this antibody towards CAV-1 was verified using a whole-virus 
ELISA technique using cultured CAV-1 and CAV-2 adapted from methods 
described by Walker et al. (2016b). In addition, a non-type-specific monoclonal 
mouse anti-adenovirus antibody (clone 2/6 and 20/11 IgG1; MAB805; Merck 
Millipore, Billerica, Massachusetts, USA) was used. It was considered that the use of 
two anti-adenovirus antibodies could allow detection of a greater number of infected 
cells, given that the anti-CAV-1 antibody was not designed for use for IHC and the 
anti-adenovirus antibody was raised against HAds. 
 
Polyclonal rabbit anti-active caspase-3 antibody (ab2302; Abcam, Cambridge, 
Cambridgeshire, UK) was also selected for used as a cell apoptosis marker to 
highlight areas of programmed cell death within sections; this was to evaluate if 
apoptosis correlated with CAV-1 infection. 
 
Mouse IgG1 isotype control (MA5-14453; Thermo Fisher, Rockford, Illinois, USA) 
and rabbit IgG whole molecule control (31235; Thermo Fisher) antibodies were used 
on sections of each tissue type from both species as negative controls. ‘Healthy’ 
control tissues were only stained with H&E and caspase because of the limited 
amount of anti-adenovirus antibodies available. However, all tissues and ‘healthy’ 
controls were stained with both the ‘negative control’ antibodies to ensure the 




Following routine slide preparation, antigen retrieval was performed on the tissue 
sections. For sections to be incubated with anti-active caspase-3 antibody, the 
 




sections were subject to ‘high pH antigen retrieval’ using antigen unmasking solution 
(Vector Laboratories, Burlingame, California, USA) and incubated at 60 °C 
overnight. Sections to be incubated with anti-CAV-1 or anti-adenovirus antibodies 
were pre-treated with proteinase K (‘ready-to-use’ preparation, unspecified dilution; 
Dako) at ambient temperature for 30 min or 20 min respectively. The selected 
antibodies were then applied to the prepared sections. Anti-active caspase-3 antibody 
was incubated with sections for 60 min at a dilution of 1:20, anti-CAV-1 (1:100) was 
incubated with samples at 4 °C overnight and anti-adenovirus (1:500) was incubated 
with sections for 1 h at room temperature. 
 
Mouse or rabbit EnVision kits (Dako) were used as appropriate, utilising the 
Autostainer 360 system (Thermo Fisher Lab Vision, Runcorn, Cheshire, UK), 
followed by staining with 3,3′-diaminobenzidine (DAB) and counterstaining with 
haematoxylin. Where necessary, slides which possessed prominent formalin 
pigments were subject to saturation with alcoholic picric acid diluted 1:1 with 
ethanol for 1 h. Mercuric chloride in older FFPE tissues was treated with Lugol’s 
iodine and sodium thiosulphate.  
 
3.2.4 Analysis of sections 
 
Whole slides were digitised using the NanoZoomer-XR system (Hamamatsu, 
Welwyn Garden City, Hertfordshire, UK) and the associated NDP.scan software 
(Hamamatsu). NDP.view (Hamamatsu) and the Fiji distribution of ImageJ software 
(Schindelin et al., 2012) were used to assess the slides and extract selected fields for 
semi-quantitative scoring. For sections stained with DAB and haematoxylin, whole 
slide image analysis was performed using QuPath (Bankhead et al., 2017); this 
automated the detection and counting of DAB (‘positive’) and haematoxylin 
(‘negative’) stained cells across entire tissue sections (Figure 3.1). Areas of tissues 
were excluded, for example, where there were processing artefacts or tissue 
imperfections. Computation was optimised for each tissue type and antibody to 
minimise false-positive cell detection. 
 
 





Fox 4, renal cortex with CAV-1 antibody; example of a field snapshot from QuPath 
(Bankhead et al., 2017), demonstrating positive detected cells (red and yellow 







For sections stained with H&E, whole sections were manually scored using a 
subjective and relative ‘0 to 3’ scoring system for ‘severity’ (where ‘0’ was normal 
and ‘3’ was the most severe). For the liver and kidney sections, this was judged on a 
number of factors including distribution and extent of necrosis, presence of 
inflammation, presence of haemorrhage and presence of fibrin deposition. Liver 
scores were assigned as: ‘0’ when tissue was normal, ‘1’ when there was individual 
hepatocyte or vascular endothelial cell necrosis/inclusion body presence ranging to 
mild focal/multifocal necrosis (involving less than one third of the section), ‘2’ 
where moderate multifocal hepatocellular necrosis was present (involving 
approximately one third to two thirds of the section) and ‘3’ where marked necrosis 
was present with presence of multifocal haemorrhage or oedema (involving more 
than two thirds of the secton). If inflammatory infiltrates were present, the nature and 
extent of these were described separately. 
 
 




Kidneys were scored as ‘0’ if the section was normal ‘1’ if the section contained only 
1 or 2 glomeruli with intranuclear inclusion bodies or if there was a mild nephrosis, 
‘2’ if rare to several glomeruli in the section contained intranuclear inclusion bodies 
and there was the presence of a mild nephritis and ‘3’ if sections contained 
occasional to frequent glomerular intranuclear inclusion bodies in the presence of a 
more moderate/marked nephritis relative to ‘2’ and interstitial inflammatory 
infiltrates. 
 
The brain was scored on a scale of ‘0 to 3’; this was where ‘0’ was normal, ‘1’ was 
the presence of infrequent vascular endothelial intranuclear inclusion bodies but 
limited pathology, ‘2’ was the presence of perivascular cuffing and/or presence of 
many vascular endothelial inclusions bodies and ‘3’ was the same as the criteria for 2 
but with multifocal haemorrhages and/or neuronal necrosis. 
 
For liver, brain (excluding vessels), renal cortex (excluding glomeruli) and renal 
medulla, ten randomly selected fields at 20x magnification were extracted from each 
section to quantify the number of intranuclear inclusion bodies in these fields. Thirty 
glomeruli from renal sections and 30 blood vessels from brain sections were 
randomly selected to count the number of inclusion bodies separately to the rest of 
the sections; it was assumed inclusion bodies may be more prevalent in these 
features. Random selections were made using a numbered grid system, laid over 
tissue sections, and random number generation using a calculator. Statistical analyses 
were performed, where appropriate, using R version 3.4.0 (R Core Team, 2017). 
Correlations were calculated with the cor.test function using Pearson’s method (stats 
package; R Core Team, 2017). Standard error bars for charts were calculated in 














3.3.1 Manual analysis of sections with H&E stain 
 
Whole-slides were examined manually to assess the severity of CAV-1 infection 
including cytopathology, haemorrhage, oedema and cellular infiltrates 
(inflammation). The histological descriptions from each tissue are given in Table 3.3 
with a score of severity for each tissue. Overall, it was evident that the severity of 
disease in the dog livers was greater than that exhibited by the red foxes (although 
formal statistical comparisons of the semi-quantitative severity scores was not 
conducted due to the low sample size). It was also notable that cellular 
infiltrates/inflammation were not a feature in the livers of any animal examined. The 
liver of ‘FoxControl 1’ showed some mild pathology, but was likely to be a 
consequence of being a sample from a ‘wild animal’; virus specific pathology was 
not evident. Photomicrographs of examples of the key features described in Table 3.3 
are depicted in Figure 3.2. An example of focal neuronal necrosis and haemorrhage 
of a CNS blood vessel in fox 4 can be seen in Figure 2.1c (Chapter 2). The 
histopathological descriptions from most of the tissues sampled from foxes 1, fox 2 




















Summary of the histopathological findings in sections stained with H&E, prepared 
from samples from dogs and foxes with ICH. 
 
ID Tissue Summary description Severity score 
Fox 1 Liver See section 2.5.2 Histopathology 1 
 Brain See section 2.5.2 Histopathology 2 
 Lung, heart See section 2.5.2 Histopathology; heart unremarkable N/A 
Fox 2 Liver See section 2.5.2 Histopathology 1 
 Kidney See section 2.5.2 Histopathology 1 
 Brain Resectioning of the brain from fox 2 revealed infrequent 
intranuclear inclusion bodies in vascular endothelial cells. 
Otherwise the section was unremarkable. 
2 
 Spleen Mild lymphocytolysis was present in the lymphoid follicles in 
the white pulp. Rare intranuclear inclusion bodies were present 
in the red pulp (cell type unidentifiable). Some congestion was 
present. 
N/A 
Fox 4 Liver See section 2.5.2 Histopathology 2 
 Kidney See section 2.5.2 Histopathology 2 
 Brain See section 2.5.2 Histopathology 3 
 Spleen, heart, 
mediastinal 
lymph node 
See section 2.5.2 Histopathology, heart unremarkable N/A 
Fox 5 Liver Multifocal areas of necrosis were present in a 
zonal/centrilobular pattern. Hepatocytes showed swelling, 
vacuolation and fading of nuclei; some nuclei were 
fragmented. Intranuclear inclusion bodies were rare. Minimal 
inflammation was present. 
2 
 Kidney Mild non-suppurative interstitial nephritis was evident, 
characterised by a lymphoplasmacytic infiltrate, mainly at the 
corticomedullary junction – this may have been pre-existing. 
Rare glomerular intranuclear inclusion bodies were present. 
There was moderate nephrosis with tubular degeneration and 
necrosis and interstitial oedema. Some autolysis was present 
3 
Dog 1 Liver Massive3 hepatic necrosis affected the entire section. 
Hepatocytes showed frequent intranuclear inclusion bodies or 
were degenerate, dissociated and or swollen and vacuolated. 
Oedema and haemorrhage surrounded portal areas. 
Intranuclear inclusion bodies were also evident in some 
vascular endothelial cells. 
3 
 Brain Moderate non-suppurative encephalitis was present; there was 
mild perivascular lymphoplasmacytic cuffing of blood vessels; 
infiltrates were 1 to 2 cell layers. Lymphocytes were observed 
in some perivascular spaces of cuffed vessels. 
2 
                                                      
3 The use of ‘massive’ hepatic necrosis here refers to a severe extensive necrosis or cytopathology, 
which is panlobular/multilobular and affects most (but not necessarily all) of the hepatocytes in all 
parts of a hepatic lobule. See Chapter 2.6. 
 




Dog 2 Brain Moderate non-suppurative encephalitis was present, with 
lymphoplasmacytic perivascular cuffing of some blood vessels 
and endothelial reactivity (some swelling of vascular 
endothelial cells present). There was a focal area of mild 
gliosis. 
2 
Dog 3 Liver There was a multifocal pattern of hepatic necrosis; this was 
locally extensive to coalescing, and appeared to be random. 
Inclusion bodies were frequent in hepatocytes. 
2 
 Kidney Mild nephrosis was present and there was a segmental pattern 
of some tubules with degenerating renal tubular epithelial 
cells; some nuclei were pyknotic and some fading. There was 
some fibrovascular hyperplasia at the corticomedullary 
junction, which was likely to be pre-existing. 
1 
Dog 4 Liver There was massive hepatic necrosis; overtly necrotic 
hepatocytes were present, whilst others were dissociated, 
showed intranuclear inclusion bodies, or were severely 
swollen and vacuolated. Haemorrhage, oedema and fibrinous 
deposits were present. No cellular infiltrates were noted. 
3 
 Kidney Some glomeruli showed individual cell necrosis and rare 
intranuclear inclusion bodies (probably in mesangial cells). 
There was moderate nephrosis and renal tubular damage; some 
tubular cells had condensed nuclei and were detaching, others 
had fragmented and faded nuclei. 
2 
Dog 5 Liver There was massive hepatic necrosis with frequent intranuclear 
inclusion bodies. Fibrin was present in blood vessels, which 
was consistent with a state of DIC. 
3 
 Kidney There was a moderate segmental nephrosis and occasional 
intranuclear inclusion bodies in glomerular cells. There was a 
chronic lymphoplasmacytic pyelitis, which was possibly pre-
existing. 
2 
Dog 6 Liver There was massive hepatic necrosis and intranuclear inclusion 
bodies were common in hepatocytes, which also exhibited 
degeneration, dissociation and vacuolation. Occasional 
Kupffer cells exhibited intranuclear inclusion bodies. There 
was severe haemorrhage and congestion. Notable 
inflammatory infiltrates were not observed. 
3 
 Kidney Some glomeruli had single cells with intranuclear inclusion 
bodies (probably in mesangial cells). There was a moderate 
segmental pattern of nephrosis, with some renal tubular cells 
showing pyknotic or faded nuclei and detachment. There were 
two granulomatous foci present, surrounding degenerating 
parasites (possibly Toxocara canis). 
2 
FoxControl1 Liver Rare degenerate hepatocytes were present in the liver; 
hepatocytes were frequently pleomorphic and binucleate.  
1 
 Kidney The kidney was autolysed, but otherwise unremarkable. 0 
FoxControl2 Brain Unremarkable. 0 
 Spleen Some mild lymphocytolysis. N/A 
DogControl1 Liver Unremarkable, but autolysis was present. 0 
 
 Kidney Unremarkable. 0 
 Brain Unremarkable. 0 
DogControl2 Brain Unremarkable. 0 
 





Exemplary fields from sections of tissues from ICH cases in red foxes and dogs. 
Sections are demonstrative of varying severity and features of the disease in the 
displayed tissues. Scale bars are displayed in each field. 
 
a) Fox 5 liver; Centrilobular pattern of hepatocellular necrosis. Vacuolation of 
hepatocytes is present. A hepatocyte on the periphery of the markedly necrotic zone 
demonstrating a fragmented nucleus is marked by a solid arrow. A dissociated 
hepatocyte with a large vacuole is marked by an empty arrow. Some haemorrhage is 





























b) Dog 5 liver; massive hepatocellular necrosis with haemorrhage. This field shows 
hepatocytes displaying frequent inclusion bodies (some highlighted with solid 
arrows). Haemorrhage is evident around the central vein and in the centrilobular 
tissue. The vascular endothelial cells are swollen and some have intranuclear 








c) Dog 4 liver; a field from a liver with massive necrosis. Most hepatocytes display 
intranuclear inclusion bodies and/or cytopathology. Haemorrhage is present. 
 
 
d) Fox 4 liver; Hepatocellular necrosis in a fox with ‘moderate’ random necrosis. 
Intranuclear inclusions bodies are occasionally present in the field (solid arrow). A 









e) Dog 1 brain; moderate perivascular cuffing (mainly lymphocytic), presumed to be 
a consequence of CAV-1 infection. 
 
 
f) Fox 4 brain; Multifocal haemorrhages evident at low power magnification (solid 












g) Fox 4 brain; small vessel demonstrating several swollen vascular endothelial cells, 
one with an intranuclear inclusion body (solid arrow). 
 
 










The number of intranuclear inclusion bodies manually counted in 10 random liver 
fields in dogs compared to foxes was significantly higher (W(7) = 0, p = 0.0139; 
Table 3.4). Formal comparisons of 30 random glomeruli and CNS vessels containing 
intranuclear inclusion bodies were not computed due to the lower number of 
inclusions and replicates; however, more inclusions were evident in fox CNS vessels 
on H&E stained sections (Table 3.5). 
 
Table 3.4 
Summary of the mean number of intranuclear inclusion bodies manually counted 
over 10 random liver fields. 
ID 




Fox 1 0.2 0.8 
Fox 2 0.7 0 
Fox 4 0.8 10.5 
Fox 5 0.7 24.9 
Dog 1 23.9 5.0 
Dog 3 2.9 15.7 
Dog 4 61.5 11.1 
Dog 5 53.2 41.1 
Dog 6 8.2 0.9 
FoxControl1 0 0 
DogControl1 0 0 
 
Table 3.5 
Summary of the number of glomeruli or blood vessels (in kidney and brain sections 
respectively) which contained intranuclear inclusion bodies, which were manually 







Fox 2 Glomeruli 1 Fox 1 CNS blood vessels 4 
Fox 4 Glomeruli 1 Fox 2 CNS blood vessels 6 
Fox 5 Glomeruli 1 Fox 4 CNS blood vessels 11 
Dog 3 Glomeruli 0 Dog 1 CNS blood vessels 1 
Dog 4 Glomeruli 1 Dog 2 CNS blood vessels 1 
Dog 5 Glomeruli 0    








3.3.2 Analysis of sections subject to IHC 
 
Positively staining cells were counted automatically using whole slide analysis 
(QuPath; Bankhead et al., 2017). A summary of the results is shown in Figure 3.3 
(full count results are available in Appendix 2). Because of the small sample sizes 
(see Figure 3.3a), formal statistical analyses were not performed. 
 
Overall, the largest number of positive staining cells (for either adenovirus antibody) 
were in liver and brain; in the liver, the number of cells with positive staining was 
higher in dogs than foxes, while in the brain, the number of cells was higher in foxes 
than dogs. Cortex and medulla were considered as separate units because it was 
noted that inclusion bodies were most frequent in the glomeruli when H&E-stained 
renal tissues were assessed. In foxes, the frequency of CAV-1 in both the renal 
cortex and medulla was low compared to the liver and brain. It is notable that 
positive staining for anti-caspase 3 correlated significantly with both anti-CAV-1 
(t(26) = 7.7405, p < 0.001) and anti-adenovirus (t(26) = 5.5262, p < 0.001) antibodies. 
 
When manually assessing the slides, both the anti-CAV-1 and anti-adenovirus 
antibodies worked well. However, it was noted that with both antibodies that cells 
with intranuclear inclusion bodies inconsistently stained, which was unexpected (see 
Figure 3.4i). The anti-CAV-1 antibody also appeared to be more sensitive than the 
anti-adenovirus based on the number of cells stained (Figure 3.3). 
 
Overall, when assessing all tissues, CAV-1 antigen was detected in many cell types 
in the tissues to which antibody was applied, demonstrating the systemic nature of 
CAV-1 infection. Namely, in the liver, hepatocytes, Kupffer cells and vascular 
endothelial cells were stained. An unexpected staining pattern in the liver was that all 
four foxes showed biliary epithelial staining (see Figure 3.4h), which was not evident 
in any of the dog livers. In the brain, vascular endothelial cells and unidentifiable 
glial cells were stained (although secondary IHC would be required to confirm this 
finding). In the kidney, glomerular cells (mostly mesangial), vascular endothelial 
cells and renal tubular epithelial cells were stained. In the spleen and mediastinal 
 




lymph node some cells in both the red and white pulps were positive (presumably 
including lymphocytes and macrophages; secondary IHC is also required for 
differentiation). A summary of overall staining patterns is provided in Figure 3.3. 










Summary of the whole slide analysis indicating the mean number of cells per mm2 
positive for anti-adenovirus antibody (a), anti-CAV-1 antibody (b) and anti-caspase 3 
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Exemplary fields from tissue sections from foxes and dogs with ICH, which were 
subject to IHC. Each figure caption indicates the animal ID, the tissue section 
displayed and the antibody used respectively. Scale bars are indicated on each 
photomicrograph. 
 
a) Fox 4, brain, anti-adenovirus (blend); a large blood vessel with many positive 
vascular endothelial cells, some with evident intranuclear inclusion bodies. Two 



















b) Fox 4, brain, anti-adenovirus (blend); a blood vessel with infected vascular 
endothelial cells on the entire circumference. The integrity of the vessel wall appears 
to be lost, and haemorrhage is evident surrounding a sloughed, infected endothelial 
cell (although processing artefact cannot be ruled out; solid arrow). A possible glial 
cell infected with CAV-1 is present (empty arrow).  
 
c) Fox 2, brain, anti-adenovirus; likely vascular endothelial cells with intranuclear 










d) Fox 4, mediastinal lymph node, anti-CAV-1; many cells (likely including 
lymphocytes and possibly macrophages) with varying degrees of staining. 
 
 
e) Fox 1, cardiac muscle and vasculature, anti-CAV-1; two infected vascular 











f) Dog 1, liver, anti-CAV-1; staining of hepatocytes observed at high power. 
 
 
g) Fox 1, liver, anti-adenovirus; infrequent positive staining of hepatocytes (solid 













i) Dog 4, liver, anti-adenovirus; weak staining of hepatocytes with intranuclear 
inclusion bodies (examples indicated by solid arrows) and hepatocytes with 











j) Dog 4, liver, anti-caspase 3; extensive staining of hepatocytes 
 
 
k) Fox 4, mediastinal lymph node, anti-caspase 3; marked staining of probable 











A pilot study to investigate the comparative pathology of red foxes and dogs, which 
had died of IHC, was initiated. It is remarkable that Green et al. (1930), who first 
widely reported fox encephalitis in a detailed experimental infection study first 
called the disease caused by CAV-1 ‘fox encephalitis’ due to the predominance of 
encephalitis (or encephalitis-like clinical signs) in red foxes which died (or were 
experimentally infected). Subsequent studies (Rubarth, 1947; Parry, 1950) 
demonstrated the wide ranging clinical signs and pathological changes in dogs, and 
‘hepatitis’ was noted as the predominant pathological finding. However, it is also 
noted that in most of the early ICH studies, a wide-range of pathological findings 
were evident in both species; the difference may lie in the predominance/severity of 
the clinical signs and features. The possible interspecific differences, and increased 
severity of CNS lesions, has been demonstrated by a rapid course of disease and 
clinical signs in recent outbreaks of ICH in temporarily captive free-ranging red 
foxes in wildlife hospitals (see Chapter 2; Walker et al., 2016a). The inadequacy of 
‘infectious canine hepatitis’ as a term has been discussed historically (Innes and 
Saunders, 1962), but has not been investigated further. 
 
The lack of further research may be a consequence of the fact that the availability of 
clinical case material from free-ranging red foxes which have died due to ICH is 
rare; immunohistochemistry as a diagnostic method has not been widely reported in 
samples from free-ranging canids. Furthermore, clinical case material from domestic 
dogs from countries which routinely vaccinate pet dogs (and where stray populations 
are controlled) is now uncommon. Thus, this is the first study to systematically 
compare tissues from both species. This study has revealed that there may be 
differences in the apparent pathology of ICH in red foxes and domestic dogs, among 
the samples assessed, by both standard histological stains and 








Firstly, in the liver there appears to be a difference in the distribution and severity of 
infection between the red fox and dog. The staining of hepatocytes for CAV-1 (as 
determined by both general and specific adenovirus immunostains) in dogs was 
higher than hepatocytes in red foxes, in which staining was rarer. The frequency of 
intranuclear inclusions bodies was also lower in red fox hepatocytes compared to dog 
hepatocytes. The high frequency of staining of hepatocytes in dogs was also 
somewhat ‘proportional’ to the histopathological descriptions (and semi-quantitative 
severity scores). Dogs frequently had massive hepatic necrosis, which could even be 
seen on low-power microscopy; in at least two dogs it was extremely difficult to find 
evidence of ‘normal’ liver tissue. There was also evidence of DIC within the 
sections. Therefore, clearly, hepatic pathology was severe in dogs, and could be 
speculated to be the main contributor to the death of those animals (or requirement 
for euthanasia). However, the sample size was small in this study and so the results 
should be interpreted with caution. 
 
The increased frequency of staining was also significantly correlated with an 
increased staining of hepatocytes for caspase 3, suggesting widespread apoptosis was 
likely to be a direct result of CAV-1 infection. It is possible that manipulation of 
‘programmed cell death’ (PCD) may be a strategy by which viruses maximise 
production of virus (e.g. by first inhibiting apoptotic pathways) and then enhance it 
(i.e. by ‘allowing’ apoptosis); a similar strategy has been suggested for bovine 
herpesvirus-1 (Devireddy and Jones, 1999). An alternative theory is that the host 
cells could induce caspases and PCD to limit viral proliferation, that is, a ‘suicide’ to 
protect uninfected cells in the tissue. However, Bantel et al. (2001) have shown that 
caspase activation contributes significantly to necroinflammatory disease in chronic 
hepatitis C virus infection. It is possible that this may be a consequence of the pro-
inflammatory role of caspase; it has been demonstrated that caspase 1 is crucial in 
the maturation pathway of interleukins during influenza A and Sendai virus 
infections (Pirhonen et al., 1999; Kanneganti et al., 2006). The inclusion of caspase 
in the ‘panel’ of antibodies used in this study was therefore warranted, and has 
produced some intriguing findings, which require further study. 
 
 




Interestingly, in the livers of all foxes there was frequent staining of epithelia in the 
bile ducts with anti-adenovirus, whilst staining in hepatocytes was uncommon; this 
has not been described previously. Frequent staining of biliary epithelia was not 
evident in the dogs. The DAB stain did not appear to be nucleus associated, and the 
staining could be attributed to non-specific staining. However, it was not consistently 
present in all bile ducts. Therefore, this finding is difficult to explain. If it does 
indeed represent the true presence of CAV-1 in these cells, then it may represent an 
ascending infection through the biliary tracts, before replication in the nucleus, but 
this would be a novel finding in the pathogenesis of CAV-1. It is also possible that 
the red foxes died rapidly prior to heavy infection of the liver, and biliary ascension 
represents part of the ‘seeding’ process of the liver, but this is entirely speculative; 
this could be an area for future studies. 
 
Marked differences in IHC staining and scoring were also detected in the brains of 
red foxes compared to dogs. Many vascular endothelial cells in CNS vessels in red 
foxes were detected to contain CAV-1 antigen. In comparison, staining was rarer in 
the dog brains, and intranuclear inclusion bodies were less frequent. In the red foxes, 
microhaemorrhages were evident, and the brain of fox 4 contained many foci of 
haemorrhage. The dogs showed no evidence of haemorrhage, but interestingly both 
the dog brains had evidence of perivascular cuffing. Inflammatory infiltrates were 
not evident in any of the fox brains. 
 
It is also noted that glial cells in the CNS were suspected to be infected with CAV-1 
in red foxes (using both the anti-CAV-1 and anti-adenovirus antibodies). It was not 
possible to determine which glial cells were infected (or to rule out the possibility of 
single-cell vascular endothelial cell staining of ‘microvessels’). Therefore, secondary 
staining with cell markers would be required to confirm this finding, which could not 
be conducted in the current study due to limited finances. However, subsequent 
confirmation of infection of glial cells could be significant; clinically, infection of 
these cells could contribute to CNS disturbances. These cell types have not been 
previously reported to be permissible for CAV-1 in natural infections (or 
experimental infections) and were also not infected in the dogs’ brains. 
 





The CNS findings are therefore very intriguing and may be reflective of two 
hypotheses. Firstly, CAV-1 could have increased tropism for vascular endothelial 
cells in red foxes; secondly, CAV-1 does infect vascular endothelial cells in dogs, 
but this may be to a lesser degree, and that survival times of dogs is increased 
relative to red foxes (which allows for a longer course of disease and time for 
inflammatory infiltrates to accumulate). Thus, foxes may die quickly due to the fatal 
effects of neurological disturbances and multifocal haemorrhages, whereas dogs may 
die from massive haemorrhage, fluid loss and DIC, which could take longer 
(allowing time for the development of perivascular cuffing in the CNS). However, it 
is also noted that the sample size was very low for brain tissues (n = 3 and n = 2 for 
red foxes and dogs respectively); the sample size must be increased to confirm this 
difference statistically. Further studies are therefore required, and warranted, to 
confirm this difference in pathology and to investigate if dogs have increased 
survival times to foxes.  
 
Findings in the kidney of both species were generally less ‘dramatic’. However, 
some moderate nephrosis was present, limited to segmental renal tubular epithelial 
cell degeneration/necrosis and rare-to-infrequent glomerular intranuclear inclusion 
bodies. Some suspected pre-existing pathology was present in some samples and is 
likely to be a consequence of the nature of the sampling. However, despite the low 
sample size and limited pathology it is suspected that there is little clinically 
significant difference in renal pathology between red foxes and dogs. Pathology 
elsewhere (i.e. brain and liver) is likely to predominate. Pathology was mainly 
observed in the renal cortex, rather than the renal medulla, although the sample size 
limits formal statistical comparisons in the current study. 
 
Although not included in formal comparisons, CAV-1 antigen was detected in 
vascular endothelial cells in the cardiac vasculature of a red fox. This would not be 
unexpected given the propensity of CAV-1 to infect vascular endothelial cells.  Of 
the small number of tissues included, a high frequency of cells were demonstrated to 
be infected with CAV-1 in the medulla of lymph nodes and often in the red pulp of 
 




the spleen. It is possible there may have been some non-specific staining, but this 
appeared not to occur in other tissues. If the staining is ‘genuine’ then this is an 
interesting finding and, in further studies, would warrant secondary staining to 
determine the exact cell types infected, which may include lymphocytes and 
macrophages. This is important and intriguing because infection of non-circulating 
lymphocytes has been shown as a site of persistence for HAds, and may be 
maintained as ‘non-lytic’ infections (Assadian et al., 2016). Thus, in surviving 
animals, renal tubular epithelial cells (Poppensiek and Baker, 1951) may not be the 
only potential site of persistence of CAV-1 infection. 
 
The IHC developed may be useful as a diagnostic technique. Using both anti-
adenovirus antibodies, CAV-1 antigen was often detected in the absence of 
intranuclear inclusion bodies, which are often relied on during analysis of H&E 
sections to help identify a viral infection. Theoretically, in red foxes, this could 
identify CAV-1 infection in cases which die peracutely, for example, before 
inclusion bodies can be formed in hepatocytes. In addition, when they are present, 
intranuclear inclusion bodies can often be difficult to identify in vascular endothelial 
cells. Therefore, IHC can be used as an aid to detect and confirm adenoviral infection 
in cases where this is suspected, due to severe clinical signs, and is not obvious using 
standard histological staining techniques. However, because some intranuclear 
inclusion bodies were not detected by the antibodies, there may be a need to optimise 
the IHC staining protocol further, which may include increased antigen retrieval 
times and increased concentration of antibodies. 
 
It is reported that hepatocytes and vascular endothelial cells are considered to be the 
main targets of CAV-1 (Decaro et al., 2012); however, to the authors’ knowledge, 
this is based on the apparent severe hepatic pathology and vascular disruption noted 
in many fatal IHC cases in dogs and not on cell permissibility studies, or molecular 
analyses, using a full panel of cell types. The present study shows that additional cell 
types are infected, beyond what has been reported and expected. In foxes, vascular 
endothelial cells were detected to be positive for CAV-1 infection to a higher degree 
than hepatocytes (in which inclusion bodies and CAV-1 immunopositivity were 
 




rare). There may be differences in the permissibility of cells to CAV-1 between these 
species, and this is likely to require experimental confirmation using primary cell 
lines. The pilot study conducted here warrants expansion to increase the sample size 
to a statistically suitable number of cases. 
 
For the first time, it has been noted that brain parenchymal cells may be infected with 
CAV-1, including glial cells, and this is with increased frequency in the red fox 
compared to the dog. This is a novel finding and would be expected to be associated 
with severe CNS disturbances and to contribute to overt clinical signs. 
 
The observed differences in the pathology caused by CAV-1 in the red fox and dog 
should be interpreted with some caution because of the limited associated clinical 
histories (the time-course cannot be controlled for and is a limitation of the presented 
study). In addition, three of the foxes included were juveniles (one fox’s age is 
unknown) and the ages of all of the dogs is unknown. Therefore, an ‘age-related’ 
difference cannot be ruled out. However, given the high frequency of infection of 
vascular endothelial cells in the CNS of the red foxes in this study, it is possible that 
this cell type is ‘more of a’ primary target for CAV-1 in this species. Infected foxes 
may quickly succumb to fatal, widespread micro-haemorrhages (as a consequent of 
vascular endothelial cell disruption/lysis) and/or CNS disturbances by infection of 
glial cells. This could occur before large numbers of hepatocytes demonstrate the 
typical intranuclear inclusion bodies, as is evident in the dog. Given the additional 
history of a rapid course of disease in foxes 1, 2 and 4 included in this study, this 
theory may be supported. In future studies, the region of the brain sampled should be 
standardised when possible so as to remove any possibility of regional variation in 
lesions. 
 
It is noted that hepatic necrosis is still severe in the fox livers, but relative to the dog, 
is certainly not as widespread and may be less contributory to death. Consequently, 
the reverse situation may occur in the dog. In the cases in this study, the dog livers 
exhibited severe necrosis, with severe haemorrhage and fibrin deposition. It is 
reasonable to assume that DIC occurred in the dogs as a terminal event. 
 





Outwith this current study, it is further noted that the consistency of dogs showing 
predominately ‘liver-based’ clinical signs is not always the case. For example, in 
isolated outbreaks of CAV-1 in puppies, the cases died rapidly from 
‘encephalopathy’ (Caudell et al., 2005). Thus, the findings in this chapter confirm 
the ‘trend’ in most of the literature. It is possible that ‘aggravators’ of disease may 
occur, such as immunosuppression and concurrent disease (Michaels et al., 1992; 
Baldwin et al., 2000), which has been demonstrated in humans. The possibility of 




The results of the pilot study indicate that there may be differences between the 
general manifestation of disease caused by CAV-1 in red foxes compared to 
domestic dogs. However, more subjects are required to be included in future studies 
to confirm this, including knowledge of clinical history, and this is a limitation of the 
present study. 
 
Despite the term ‘infectious canine hepatitis’ now being widely used in veterinary 
text books and case reports of fatal disease in wide-ranging species, it is clear that the 
term is not fully representative of the disease manifestations, particularly in foxes. 
Firstly, and technically, the disease is not only a disease of ‘canines’ (i.e. ‘dog-like’ 
animals, including wolves but not vulpids), but is a disease of many species within 
the canidae genus (i.e. ‘canids’), including the species in which it was first described, 
the red fox (Green et al., 1930). Possible, rare ‘host-switching’ has even been 
suggested, where CAV-1 was suggested to have infected a single Eurasian otter 
(Lutra lutra; Park et al., 2007) and black bears cubs (Ursus americanus; Pursell et 
al., 1983). 
 
Secondly, as is evident in the majority of literature reporting fatal disease, the study 
presented in this chapter and in Chapter 2, the disease caused by CAV-1 is often 
systemic. As is apparent in the red fox, it causes fatal disturbances in vascular 
 




endothelial cell integrity resulting in multifocal haemorrhages in the CNS, and may 
also infect glial cells. It is re-iterated that the disease was first described as ‘fox 
encephalitis’ because of this clinical feature (Green et al., 1930), although 
inflammatory infiltrates were not commonly noted. Green et al. (1930) showed that 
this feature was not consistent, and there is a possibility of disease exacerbation 
through immunosuppression or concurrent disease. Therefore, the disease, in some 
foxes, may be an ‘encephalopathy’ as compared to ‘inflammation’ (cellular). Rubarth 
(1947) and Parry (1950) pioneered the term ‘infectious canine hepatitis’, due to the 
liver disease observed in dogs. However, inflammatory cellular infiltrates were not 
present in any cases (foxes or dogs); it could be argued that it could be ‘acute 
inflammation’ in regard to the presence of haemorrhage, oedema and a possible 
‘cytokine cascade’ (Zachary and McGavin, 2013), but the term ‘hepatitis’ may be 
misleading. ‘Hepatopathy’ may be a more appropriate term. It is re-iterated that 
despite a possible predominance of ‘encephalopathy’ and ‘hepatopathy’ in either 
species, a wide-range of pathology is present, which has been described in a limited 
number of tissues in the current study. 
 
Therefore, the author argues that ‘infectious canine hepatitis’ is a confusing and 
misleading descriptive term, and upon expansion of this pilot study, should be 
discontinued. This is recognised to likely be a ‘controversial’ recommendation; 
however, the disease, at a minimum, should recognise that it is not only a disease of 
canine species (which technically refers to mainly Canis spp.). In addition, ‘hepatitis’ 
is not generally not present and encephalopathy predominates in some animals. A 
term such as ‘systemic canine adenovirus type 1 disease’ (‘SCAD’) could be a more 
intuitive term; it defines the causative agent, that many tissues may be infected 
regardless of the predominating clinical signs and does not limit the disease to the 
species of a single genus. It is recognised this term is broad and relatively non-
descript, however, much like ‘porcine circovirus-associated disease’, the wide-range 
of clinical signs necessitates the recommendation.4 
 
                                                      
4 Infectious canine hepatitis (ICH) will still be used hereafter in this work for continuation and to 
avoid confusion. 
 




Future research is required, not only to expand the present study (which was not 
possible due to limited finances) but to focus on the molecular basis of the apparent 
differences in pathogenesis of CAV-1 in dogs and red foxes. It is evident that a 
broader range of cells in red foxes are infected by CAV-1 than previously thought. It 
is possible that immunosuppression may play a major role in the exacerbation and 
severity of disease; this is particularly evident in immunosuppressed people suffering 
from systemic disease caused by HAds (e.g. (Chakrabarti et al., 2002; Seidemann et 
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4.1 Chapter introduction 
 
The first vaccines to protect canids against CAV-1 were developed in response to 
outbreaks of ICH in domestic dog populations and the continued losses on vulpid fur 
farms (Rubarth, 1947; Parry, 1950; Pay, 1950). Including its earliest form (i.e. 
attenuated CAV-1; Burgher et al., 1958; Cabasso et al., 1958, now attenuated CAV-
2; Appel et al., 1975; Bass et al., 1980), CAV has been recommended for use as part 
of the routine vaccination schedules of pet dogs since their first development, with 
considerable effectiveness. Since then, the uptake of vaccination in ‘developed’ 
countries is high and the incidence of ICH in dogs has reduced so that is now 
considered a rare infectious disease in many countries which routinely vaccinate pet 
dogs (Decaro et al., 2012; PDSA and Yougov, 2016). 
 
However, as has been introduced in Chapter 1, cases of disease caused by CAV-1 are 
occasionally reported in domestic dogs worldwide, often in juvenile animals (e.g. 
Headley et al., 2013; Duarte et al., 2014). Disease is usually associated with a 
clinical history in pet dogs, or in breeding populations, which lack sufficient, or any, 
vaccination protocols (e.g. Pratelli et al., 2001). Moreover, as has been demonstrated 
in Chapter 2, there are occasional reports of outbreaks of ICH in red foxes in the UK, 
specifically in individuals which have previously been free-ranging but are now 
hospitalised or held in captivity for some other reason (such as misadventure, injury, 
displacement etc.). 
 
Although pet dogs with ICH can still rarely be presented to veterinarians in the UK, 
most cases in dogs are not likely to be formally reported (because it is not regarded 
as a novel report itself) and cases in red foxes in wildlife hospitals may go 
unreported or are not identified. Thus, the true incidence of ICH is unknown in the 
UK. However, ICH appears to present more frequently than would be expected given 








Recent limited evidence suggests that some red foxes in Italy may be infected with 
CAV-1, as detected by PCR, and these animals are not suffering from overt ICH 
(Balboni et al. 2013). Further, reports of disease caused by CAV-1 in red foxes in the 
UK (which has developed ‘in the field’ and not whilst captive) are present and 
suggests CAV-1 could indeed be circulating in free-ranging red foxes in the UK 
(Thompson et al., 2010). Such findings could mean that captive red foxes are 
becoming diseased due to the introduction of inapparently infected red foxes (which 
may be shedding infectious CAV-1 but show no signs of ICH) into established 
groups of susceptible individuals. The findings also suggest that red foxes may be a 
source of infection for domestic dogs. 
 
Red foxes are prevalent in the UK and are increasingly urbanised (Webbon et al., 
2004). Therefore, it is important to determine the prevalence of CAV-1 among red 
foxes in the UK to establish if red foxes are a significant wildlife reservoir of CAV-
1, and whether they pose a risk of infection for unvaccinated domestic dogs (which 
may include insufficiently vaccinated animals where owners of domestic dogs have 
not adhered to manufacturers’ recommended vaccination schedules). A degree of 
‘risk’ would ultimately be established if foxes were determined to shed CAV-1 in 
contactable excretions such as urine and faeces. 
 
It has not been previously established that red foxes in the UK are persistently 
infected with CAV-1 in tissues by molecular methods, and there is no evidence that a 
wide-range of tissues continue to be infected with CAV-1 following resolution of 
infection (corresponding to tissues infected in ‘active disease’). There is also no 
current evidence to suggest that foxes maintain a state of viruria following recovery 
from disease caused by CAV-1, which would provide a means for infection of 
susceptible species. Additionally, although Thompson et al. (2010) provided 
evidence of circulating neutralising antibodies in red foxes (19%; 11 of 58), this was 
limited in sample size, sample selection and methodology at the time (e.g. use of 
tissue fluids vs. blood/serum). Furthermore, there is no analysis of the sequence 
variation exhibited by CAV-1 and how this might vary regionally. Determining 
whether foxes remain positive for CAV-1 in the absence of disease validates the 
 




precautionary biosecurity protocols suggested in Chapter 2 and will provide a basis 
for further research into the mechanisms underlying adenoviral persistence in 
mammalian tissues 
 
Therefore, in this chapter a published manuscript is presented which outlines the 
work conducted to determine the epidemiological state of CAV-1 in the UK (by both 
serological and molecular methods), whether red foxes without ICH (based on gross 
findings at post-mortem examination) are positive for CAV-1 and in which 
tissues/samples. This addresses the questions posed in Chapter 2 (regarding a 
possible CAV-1 reservoir in red foxes). The article entitled “Serological and 
molecular epidemiology of canine adenovirus type 1 in red foxes (Vulpes vulpes) in 

























Reproduced from [Serological and molecular epidemiology of canine adenovirus 
type 1 in red foxes (Vulpes vulpes) in the United Kingdom, D. Walker, S. A. Fee, G. 
Hartley, J. Learmount, M. J. H. O’Hagan, A. L. Meredith, B. M. de C. Bronsvoort, T. 
Porphyre, C. P. Sharp, A. W. Philbey, Scientific Reports, 6, 36051, 2016]. 
Permission not required due to a Creative Commons Attribution 4.0 International 
Licence. 
 
Publication contributions – DW wrote the draft manuscript, collected carcases and 
performed post-mortem examinations of foxes from Scotland, processed all samples 
for molecular tests, performed molecular tests, analysed molecular data and 
developed and performed the serological assays. BMdeCB and TP provided the 
advanced coding scripts and guidance in statistical analyses, text for the relevant 
statistical methods (and Table 4.3) and coding to help generate Figure 4.1. CPS 
assisted with the initial design of the detection PCR/qPCR primers. SAF and MO’H 
performed/organised the post-mortem examinations of the red foxes from Northern 
Ireland. GH provided some fox carcasses and tissues from Scotland. AM provided 
some tissues from archived Scottish samples. AWP assisted with collection of foxes 
from wildlife centres and performed some post-mortem examinations. Hannah 
Willetts performed post-mortem examinations on foxes from England. Nor-Abdul 
Azlina Aziz, Eric Morgan and JL provided sera and data from a previous study. 















4.2 “Serological and molecular epidemiology of 
canine adenovirus type 1 in red foxes (Vulpes vulpes) 




Infectious canine hepatitis (ICH) is caused by canine adenovirus type 1 (CAV-1) and 
can cause severe and fatal disease, primarily in domestic dogs and other canids 
(Decaro et al., 2012). The disease first came to prominence in the early 20th century, 
having been described as “epizootic fox encephalitis” in farmed silver foxes, a colour 
variant of the red fox (Vulpes vulpes), in North America (Green et al., 1930). Clinical 
signs of ICH in dogs and foxes include sudden death, neurological signs and 
jaundice. Lesions in dogs and foxes include severe necrotising hepatitis, 
disseminated intravascular coagulation (DIC) and vasculitis, the latter manifesting as 
encephalitis and glomerulonephritis, caused by viral replication in hepatocytes and 
vascular endothelial cells (Decaro et al., 2008; Walker et al., 2016a). Mortality from 
experimental infections is 10-25% in red foxes and 10-30% in dogs (Cabasso, 1962). 
 
Most documented information relating to the clinical course of non-experimental 
ICH is based on reports of natural disease in domestic dogs. However, there have 
been several documented cases of ICH in free-ranging species, including a grey fox 
(Urocyon cinereoargenteus) in Georgia, USA (Gerhold et al., 2007) and three cases 
in red foxes in the UK (Thompson et al., 2010). Furthermore, disease appears not to 
be restricted to canids; fatal ICH has been suspected in hospitalised black bear cubs 
(Ursus americanus) in the USA (Pursell et al., 1983) and a captive Eurasian otter 
(Lutra lutra) in Seoul, South Korea (Park et al., 2007). 
 
CAV-1 is widely distributed geographically and evidence of infection has been 
found amongst canid species worldwide (Thompson et al., 2010; Truyen et al., 
1998). The prevalence of antibodies against untyped canine adenovirus (CAV) can 
be particularly high in free-ranging canid species; for example, 97% of island foxes 
(Urocyon littoralis) in the Californian Channel Islands (Garcelon et al., 1992) and 
 




94.7% of wolves (Canis lupus) in Alaska (Stephenson et al., 1982) had antibodies 
against CAV. In Europe, neutralising antibodies against CAV were detected in sera 
from 17 of 485 (3.5%) red foxes in Germany (Truyen et al., 1998) and in tissue fluid 
extracts from 11 of 58 (19%) red foxes in England and Scotland (Thompson et al., 
2010). However, this seropositivity is not necessarily specific for CAV-1, since there 
is substantial cross-reactivity between CAV-1 and canine adenovirus type 2 (CAV-
2), which is implicated in infectious tracheobronchitis in dogs (Decaro et al., 2012). 
Cross-protection between the two viruses is exploited by the routine use of CAV-2-
based vaccines in veterinary practice to protect dogs against ICH. There is no current 
evidence to suggest that CAV-2 is pathogenic in foxes, although Balboni et al. 
(2013) reported detection of CAV-2 by the polymerase chain reaction (PCR) in the 
faeces of a free-ranging red fox in Italy. 
 
The population of red foxes in the UK is estimated to be approximately 258,000 and 
this species, the only wild canid in the UK, has adapted well to urban environments 
(Webbon et al., 2004). Domestic dogs are therefore likely to come into indirect (or 
rarely direct) contact with foxes via urine, faeces and infected fomites. In active 
infections, CAV-1 is shed in urine, faeces and possibly other secretions (Decaro et 
al., 2012); therefore, concern has been raised that red foxes may be a wildlife 
reservoir of CAV-1 (Thompson et al., 2010; Balboni et al., 2013), as well as other 
pathogens, such as Angiostrongylus vasorum (Taylor et al., 2015). In a study of 
outbreaks of ICH amongst captive juvenile red foxes in wildlife hospitals in the UK, 
an apparently healthy fox, thought to be shedding infectious CAV-1, was the likely 
cause of one outbreak (Walker et al., 2016a). To determine whether foxes are a 
significant reservoir of CAV-1, and thus a source of infection for dogs and other 
susceptible species, it is important to determine the prevalence of infection 
(including inapparent infection) with CAV-1 amongst seemingly healthy foxes in the 
UK and other countries with high densities of foxes. 
 
To date, the impact and prevalence of CAV-1 in wildlife in the UK has not been 
fully assessed. This is due, in part, to the practical difficulty in obtaining large 
sample sizes, an inherent limitation in many wildlife surveys. Furthermore, there is 
 




some evidence suggesting that CAV-1 establishes persistent infections in renal 
tubular epithelial cells in a proportion of domestic dogs and that virus is shed in the 
urine of these animals for up to 9 months (Parry, 1950). Therefore, CAV-1 may 
persist and/or be excreted for varying periods of time at low levels during inapparent 
infections and it is desirable that more sensitive molecular techniques, such as nested 
PCR or quantitative real-time PCR (qPCR), are developed for detecting potentially 
low copy number CAV-1 DNA so as to minimise false negative results in molecular 
surveys. 
 
The aim of this study was to examine the role of red foxes in the UK as a wildlife 
reservoir of CAV-1 and as a potential source of infection for domestic dogs. In this 
survey, the first in the UK to use molecular methods for the detection and sequencing 
of CAV-1, we investigated the epidemiology of CAV-1 in red foxes across the UK, 
comprising Great Britain (GB, which includes England, Scotland and Wales) and 
Northern Ireland (NI); the occurrence of CAV-1 in red foxes in Wales and NI has not 
been assessed previously. The survey combined serology, using an indirect enzyme-
linked immunosorbent assay (ELISA), and molecular investigations, using a nested 
PCR. A probe-based qPCR was also developed to estimate viral loads in CAV-1 
infected samples, including tissues and urine. Viral loads were quantified for the first 
time in urine, which is considered to be one of the primary routes of CAV-1 
transmission in active infections (Decaro et al., 2012). We also examined whether 
red foxes might harbour CAV-2. 
 
 
4.4 Materials and methods 
 
4.4.1 Specimen collection and processing 
 
The project was approved by the Royal (Dick) School of Veterinary Studies 
(RDSVS), University of Edinburgh, Veterinary Ethical Review Committee (VERC; 
approval number 103 14). Methods were performed in accordance with relevant 
guidelines and regulations. All samples in the study were obtained as excess clinical 
 




material or as by-products of other activities and events, unrelated to the study. 
Tissues were obtained from red fox carcasses originating from a variety of sources 
throughout the UK. A number of animals were collected as a result of land and game 
management regimes in the Lothians and Borders, Scotland and in Cumbria, 
England. Carcasses obtained in this manner were refrigerated at 4 °C or frozen at -20 
°C before undergoing post-mortem examination. Foxes were also collected 
opportunistically from incidents of road traffic accidents (RTAs) or from natural 
causes of death in Edinburgh and the Lothians and Borders, Scotland. Tissues which 
had been stored at -80 °C were also utilised from a prior study by Meredith et al. 
(2015). 
 
Other foxes were obtained from wildlife hospitals in Scotland and England, where 
foxes had died as a result of injury or disease, not including clinical cases of ICH, or 
had been euthanased by a lethal injection of barbiturate on humane grounds. 
Carcasses were stored at -20 °C prior to collection for examination. Blood samples 
included in the study were also obtained from Tiggywinkles Wildlife Hospital, 
Haddenham, England. Animals which had been euthanased due to disease or injury 
unrelated to ICH at the RDSVS, were also included in the study. Clinical records 
were interrogated following each post-mortem examination when possible. 
 
The Animal and Plant Health Agency (APHA), England, Science and Advice for 
Scottish Agriculture (SASA), Scotland, and the Agri-Food and Biosciences Institute 
(AFBI), NI, routinely perform post-mortem examinations on fox carcasses for 
disease surveillance (foxes submitted to AFBI were initially collected by the 
Department of Agriculture, Environment and Rural Affairs, NI; DAERA) (Zimmer 
et al., 2009; Learmount et al., 2015). Carcasses are provided to these organisations 
mainly as a result of land and estate management, or sometimes as RTAs or natural 
causes of death. Blood samples from foxes from these large-scale surveys were 
subsequently made available for testing, including samples previously utilised by 
Taylor et al. (2015) in an unrelated study. AFBI and SASA provided tissue samples 
from NI and Scotland respectively.  
 
 




When possible, relevant individual data, such as sex, weight and body condition 
score (BCS) were recorded during post-mortem examination. The age of each fox 
undergoing post-mortem examination at the RDSVS was estimated on the basis of 
size, body weight and dentition. To allow data to be merged with that recorded by 
AFBI and Taylor et al. (2015), foxes were assigned to an estimated age class (1 = 
cub/juvenile, 2 = young adult, 3 = aged adult). Similarly, BCS was scored 
subjectively (1 = poor, 2 = fair or 3 = good), based on a range of factors including 
external and internal fat coverage, and muscle mass. Any significant gross lesions 
were also recorded during the post-mortem examination. The location from where 
carcasses were collected (grid references, geographical coordinates or place name) 
were available for most samples. However, the origin of most red foxes admitted to 
wildlife hospitals could not be traced accurately. Locations, where available, were 
converted and standardised to longitudes and latitudes to account for the multiple 
measurement formats. Foxes were also assigned to larger regions, designated NI, 
Scotland, North England, Midlands and Wales (Central), South East England or 
South West England. 
 
A range of tissues and samples were collected from foxes in Scotland. The tissues 
collected, when full sets could be obtained, were blood, liver, kidney, spleen, small 
intestine, brain, lung, urine and faeces. When the full array of tissues could not be 
collected, for example due to carcass damage or scavenging, a subset was collected. 
Only blood, liver and kidney samples were collected from foxes from NI. Samples 
were collected into polypropylene containers and stored at -20 °C prior to further 
processing. After collection, blood samples were centrifuged to remove debris and 
stored at -20 °C. DNA from tissues and urine samples was extracted using the DNA 
Blood and Tissue Kit (Qiagen, Hilden, Germany), whilst DNA from faecal samples 
was extracted using the E.Z.N.A Stool DNA Kit (Omega Bio-tek, Norcross, Georgia, 
USA), then stored at -20 °C prior to further testing. 
 
A total of 154 foxes from across the UK were included in the molecular survey, and 
a total of 469 foxes were included in the serological survey. 
 
 




4.4.2 CAV-1/CAV-2 specific PCR protocol 
 
Liver and kidney were classified as the ‘sentinel’ organs for CAV-1 infection in this 
study; liver is one of the main organs infected during the acute stages of ICH in dogs 
(Decaro et al., 2012), and the kidney is considered to be a sentinel organ for ‘chronic’ 
infection (although it is also infected early in infection) when animals may be shedding 
virus in their urine (Baker et al., 1954). Therefore, only foxes where both liver and 
kidney were collected were included in the study; DNA extracted from these organs 
was screened for CAV-1 in all foxes. PCR was performed to screen for both CAV-1 
and CAV-2 in the urine and faeces of animals from which these samples were 
collected, to detect animals which were shedding virus. When a positive result was 
obtained in DNA extracts from liver and/or kidney, DNA extracts from all other 
samples collected during the post-mortem examination of the positive animals were 
tested. 
 
We hypothesised that a low copy number of CAV-1 DNA, particularly in animals 
without clinical signs or gross lesions typical of ICH, would be present in infected 
tissues. Therefore, we developed a nested PCR protocol specific for CAV-1 using the 
CAV-1 reference sequence (EMBL AC_000003.1) (Table 4.1). An alternative set of 
nested primers was also developed to detect CAV-2 (EMBL AC_000020.1) (Table 
4.1). The primer sets were designed against a region of the genome to allow 

















Summary of the detection primers specific for canine adenovirus type 1 (CAV-1) and 




Description Nucleotide sequence (5’-3’) a,b Nucleotide position on 
CAV-1/CAV-2 genome a,b 
CAV_F 
 
CAV-1 and CAV-2, 
forward, 1st round 
TAYTCATACATTTCATTGGAG 6184 – 6204 (CAV-1) 
6272 – 6292 (CAV-2) 
CAV_R 
 
CAV-1 and CAV-2, 
reverse 1st  round 
GCAGAAATMCCACCCGTG 6840 – 6857 (CAV-1) 1 










AGGATGGTACTTAGGTGGTGTGT 6302 – 6324 
CAV-1_R 
 
CAV-1, reverse, 1st 
round 
TACGTGCCTAGCAAAGATTACAGA 6735 – 6758 
CAV-2_R 
 
CAV-2, reverse, 1st 
round 
TACGTGCCTGCCAAGAGTTACGAG 6823 – 6846 
CAV-1_2R 
 
CAV-1, reverse, 2nd 
round 
GTAACAGCCCAGCTAGTTAACAAG 6378 – 6401 
CAV-2_2R 
 
CAV-2, reverse, 2nd 
round 
GTAACAGCCCAGTTGGTAAACAAA 6466 – 6489 
CAV_probe Probe, CAV-1 and 
CAV-2 
FAM-GAGCTGATGGTTGGACGCTGGAAGAC-TAM 6289 – 6314 (CAV-1) 
6377 – 6402 (CAV-2) 
 
a EMBL AC_000003.1 





















The PCR first-round reaction mixture for CAV-1 consisted of 35.8 µL H2O, 0.2 µL 
(1 U) GoTaq G2 DNA polymerase (Promega, Madison, Wisconsin, USA), 10 µL 5x 
Green GoTaq reaction buffer (Promega), 1 µL deoxynucleotide triphosphates 
(dNTPs; final concentration 200 µM each dNTP), 1 µL CAV_F forward primer 
(final concentration 200 nM), 1 µL CAV-1_R reverse primer (final concentration 
200 nM) and 1 µL DNA. Product (1 µL) from the first round PCR was used as a 
template for the second round using the second round primer set CAV-1_2F and 
CAV-1_2R. The CAV-2 reaction was identical except that the first round used the 
primers CAV_F and CAV-2_R, while the second round used CAV-2_2F and CAV-
2_2R (Table 4.1). The reaction conditions were 94 °C for 18 s, 50 °C for 21 s and 72 
°C for 1 min, repeated for 40 cycles, followed by one cycle of 72 °C for 5 min. 
 
The specificity of the PCRs using primers designed for each CAV type was verified 
using clinical case material from fatal ICH cases in foxes (Walker et al., 2016a) and 
a commercial vaccine containing CAV-2 (Nobivac DHPPi, MSD Animal Health, 
Walton, UK). PCR products from these control samples, as well as selected positive 
study samples, were also sequenced to confirm specificity (Edinburgh Genomics, 
Edinburgh, UK). The sensitivities of the PCRs for detecting CAV-1 and CAV-2 were 
assessed using dilutions of plasmid controls containing a CAV-1 or CAV-2 insert 
(see ‘Quantitative PCR’) and was determined to be less than 10 copies. 
 
Each DNA sample in this study was tested in triplicate, in an attempt to increase 
rates of detection of very low copy number samples and to negate possible false 
positive results from contamination. PCR products were loaded on agarose gel 
stained with SYBR safe DNA stain (Invitrogen, Paisley, UK) and separated by 
electrophoresis. Amplicons were observed using a G:Box gel viewing system 
(Syngene, Cambridge, UK). The expected amplicon size of the second round product 
was 188 base pairs (bp) for both CAV-1 and CAV-2 primer sets. Positive amplicons 
were confirmed by sequencing (Edinburgh Genomics).5 
                                                      
5 Addendum – DNA samples were tested in triplicate as a trade-off method to minimise false negative 
results in an economical manner. This was based on informal sensitivity tests of the nested PCR using 
diluted plasmid DNA (section 4.4), suggesting the CAV-1 PCR could detect between 1-10 copies of 
DNA per µL. A single positive result in a triplicate was repeated to negate false positive results. 
 




4.4.3 Additional CAV-1 sequence data 
 
An additional four sets of nested primers, based on genes or transcriptional units 
(including hexon, fiber, E3 and E4) (Morrison et al., 1997), were designed using the 
reference CAV-1 genome (EMBL: AC_000003.1) (Table 4.2). The purpose of these 
primers was to amplify and analyse sequences in addition to those provided by the 
CAV-1 detection primer set in positive animals, allowing for comparison of different 
genomic regions among detected sequences from different locations in the UK. The 
PCR reaction mixture and amplification conditions were the same as those used for 
screening for CAV-1, except that 2 µL DNA was used (and H2O reduced 
accordingly to 34.8 µL). PCR products were confirmed to be a match for CAV-1 by 
direct Sanger sequencing (Edinburgh Genomics) using the internal primers. In the 
case of faint bands on agarose gels, DNA was extracted using the QIAquick Gel 
Extraction Kit (Qiagen) and cloned using the pGEM-T Easy Vector System 
(Promega) and DH5α Escherichia coli competent cells, before sequencing. 
 
4.4.4 Quantitative PCR (qPCR) 
 
A CAV-1 specific probe based qPCR protocol was developed to estimate the viral 
load of tissues positive for CAV-1 by conventional nested PCR. A dual labelled 
oligonucleotide probe was used (CAV_probe); this was labelled at the 5’ end with 6-
carboxyfluorescein (FAM) and at the 3’ end with 6-carboxytetramethylrhodamine 
(TAM) (Table 4.1). The protocol utilised the second round forward and reverse 
primers designed for the nested PCR protocol (Table 4.1). DNA (2 µL) was added to 
a reaction mixture containing 10 µL Brilliant III Ultra Fast qPCR Master Mix 
(Agilent Technologies, Wokingham, UK), 5 µL H2O, 1µL CAV_probe dual labelled 
probe (final concentration 500 nM), 1 µL CAV-1_2F forward primer and 1 µL CAV-
1_2R reverse primer (each final concentration 500 nM). A CAV-2 specific probe-
based qPCR protocol was created using the same conditions and reaction mixture, 
substituting the CAV-1 second round primers for the CAV-2 primers, CAV-2_2F 
and CAV-2_2R (Table 4.1). 
 
 









Description Nucleotide sequence (5’-3’) b Target(s) a, b Nucleotide position 
on CAV-1 genome b 
CAV-1_hex_F 
 
Forward, 1st round CATGGCACACAACACAGC Hexon [partial] 18475 – 18492 
CAV-1_hex_2F 
 
Forward, 2nd round GTAAATGACCAGTCCTTTGC Hexon [partial] 18524 - 18543 
CAV-1_hex_R 
 
Reverse, 1st round GAATTGTTATGCTGGTGACC Hexon [partial] 19070 - 19089 
CAV-1_hex_2R 
 
Reverse 2nd round AAGTGGTAGCCTTGATAGC Hexon [partial] 18942 - 18960 
CAV-1_E3_F 
 
Forward, 1st round CTCTGTCTCTCCAATGGC Putative orf 23/Early E3 22.1 
kDA glycoprotein Q96688 
[partial], orf 24, orf 25 [partial]  
25293 - 25310 
CAV-1_E3_2F 
 
Forward, 2nd round ACTATCATGCCGCTGAAC Putative orf 23,/Early E3 22.1 
kDA glycoprotein Q96688 
[partial], orf 24, orf 25 [partial] 
25396 - 25413 
CAV-1_E3_R 
 
Reverse, 1st round GAGGCGAGATATTCACAGC Putative orf 23/Early E3 22.1 
kDA glycoprotein Q96688 
[partial], orf 24, orf 25 [partial] 
26019 - 26037 
CAV-1_E3_2R 
 
Reverse, 2nd round GGGGCGTCATATGGATACAC Putative orf 23/Early E3 22.1 
kDA glycoprotein Q96688 
[partial], orf 24, orf 25 [partial] 
25929 - 25948 
CAV-1_fib_F 
 
Forward, 1st round CCGTGTATCCATATGACGC Fiber [partial] 25927 - 25945 
CAV-1_fib_2F 
 
Forward, 2nd round CTCTGGCTGTGAATATCTCG Fiber [partial] 26014 - 26033 
CAV-1_fib_R 
 
Reverse, 1st round TTGCTGGAGGTTGAACTGC Fiber [partial] 26490 - 26508 
CAV-1_fib_2R 
 
Reverse, 2nd round TAGTACGGTGAGACCCGGAC Fiber [partial] 26455 - 26474 
CAV-1_E4_F 
 
Forward, 1st round GCCCACTGTGACTAGAAAGC Putative orf29 Q96692 [partial] 
and orf30 Q96693 
29544 - 29563 
CAV-1_E4_2F 
 
Forward, 2nd round CGACACAAATCTGTCTCGC Putative orf29 Q96692 [partial] 
and orf30 Q96693 
29615 - 29633 
CAV-1_E4_R 
 
Reverse, 1st round GCTGATTTCCTGAGACGC Putative orf29 Q96692 [partial] 
and orf30 Q96693 
30283 - 30300 
CAV-1_E4_2R 
 
Reverse, 2nd round GAGACTTCATTCTCGACAGC Putative orf29 Q96692 [partial] 
and orf30 Q96693 
30207 - 30226 
 
a Morrison et al., 1997 
b EMBL: AC_000003.1, GenBank Y07760.1  
 




DNA samples were repeated within each run in triplicate. Plasmids containing CAV-
1 or CAV-2 DNA inserts were used as positive controls for the CAV-1 and CAV-2 
qPCR protocols, respectively. Plasmid constructs were created using DH5α E. coli 
competent cells and the pGEM-T Easy Vector System (Promega). The insert DNA 
was the 674 bp amplicon created a single round of PCR using the CAV_F and 
CAV_R primers (Table 4.1). The DNA templates for both CAV-1 and CAV-2 
vectors were from field strains of virus, originating from an outbreak of ICH in foxes 
in Scotland (Walker et al., 2016a), and a cultured laboratory stock (University of 
Glasgow, Scotland, UK), respectively. Plasmid concentrations were estimated using 
a spectrophotometer (NanoDrop, Thermo Scientific, Wilmington, Delaware, USA). 
Sonified salmon sperm DNA (50 ng/µL; AppliChem, Darmstadt, Germany) was 
used to dilute plasmids to their intended calculated dilutions. Control plasmid 
samples were used within each qPCR run in triplicate and in 10-fold dilutions 
ranging from 106 to 101 estimated plasmid copy numbers. ‘No template’ control 
(NTC) samples were also loaded in triplicate. 
 
The qPCR reaction conditions followed a two-step cycle consisting of 95 °C for 10 
min, then 45 cycles of 95 °C for 15 s and 60 °C for 60 s. The qPCR cycler (Rotor-
Gene, Corbett Life Science, Mortlake, Australia) was set to acquire FAM 
fluorescence signals during amplification. The resulting data were analysed using 
Rotor-Gene Q Series software (Qiagen). A threshold value for quantification was 
determined by automated calculation, requested within the software, which was 















4.4.5 Indirect enzyme-linked immunosorbent assay 
 
An indirect ELISA was developed to assess the anti-CAV antibody status of red 
foxes in the UK by detection of immunoglobulin G (IgG) in sera or blood from 469 
red foxes. The ELISA was optimised on 96-well, flat bottomed, high binding 
microplates (Greiner Bio-One, Stonehouse, UK) using a chequerboard assay 
following methods adapted from Crowther (2000). The antigens were prepared as 
separate supernatants containing whole virus, CAV-1 (ATCC VR-293) or CAV-2 
(field strain, University of Glasgow), which were propagated in Madin-Darby canine 
kidney (MDCK) cell cultures. Virus-free supernatant was prepared for use in 
negative control wells. The preparations were used to coat alternate wells of a 
microplate at a dilution of 1:80 in carbonate/bicarbonate buffer (Sigma-Aldrich, St 
Louis, Missouri, USA) in a volume of 100 µL, at 4 °C overnight or at ambient 
temperature for up to 4 h. 
 
Each well was then washed twice with 250 µL phosphate buffered saline (PBS) 
containing 0.05% by volume Tween 20 detergent (Sigma-Aldrich) (PBS/0.05% 
Tween) using an automated microplate washer (Ays Atlantis, Biochrom, Cambridge, 
UK). The wells were subsequently blocked with 2% bovine serum albumin (BSA; 
Sigma-Aldrich) diluted in PBS (2% BSA/PBS) at ambient temperature for at least 2 
h. Following aspiration of the blocking agent, each serum sample was applied at a 
dilution of 1:80 in a volume of 100 µL, which was tested in duplicate against the 
three wells: (1) ‘CAV-1’, (2) ‘CAV-2’ and (3) ‘virus-free’ negative control. Each 
microplate included CAV-antibody positive and negative control fox sera, which 
were verified for antibody status with a virus neutralisation test (VNT; see below). 
 
Wells were then aspirated and washed six times over a 1 h period. Horseradish 
peroxidase (HRP) conjugated goat anti-dog IgG (Abcam, Cambridge, UK) was 
diluted to 1:1600 in 100 µL 2% BSA/PBS and applied to wells for 30 min. 
Following four washes over 30 min and aspiration of liquid, secondary antibody was 
detected using 2,2-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) substrate 
(Sigma-Aldrich). The optical density (OD) of each well was measured using a 
 




microplate reader (Multiskan Ascent, Thermo Scientific, Waltham, Massachusetts, 
USA) at a wavelength of 405 nm (OD405).  
 
The mean OD405 reading for all samples was corrected for background reactivity by 
subtraction of the mean OD405 recorded from the virus-free control wells for each 
sample, and also corrected by a calculated ‘inter-plate variability factor’. This was 
calculated as the percentage difference between the OD405 of the positive control 
serum against CAV-1 or CAV-2 on the designated reference plate (arbitrarily 
assigned as the first test plate) compared to the positive control sample on the current 
test plate. 
 
An animal was declared as positive for antibodies reactive against CAV-1 or CAV-2 
based on OD405 cut-off values calculated separately for CAV-1 and CAV-2. The cut-
off values for IgG positivity were estimated using receiver operating characteristic 
(ROC) curves to provide an objective method of ELISA cut-off estimation. Data 
used for the ROC curves were OD405 values recorded from a sub-population of 
CAV-1 and CAV-2 antibody positive and negative control sera determined by a 
CAV VNT (see below). The ROC curves were computed using the pROC package 
(Robin et al., 2011) within R Studio version 0.99, running R version 3.2.4 (R Studio, 
Boston, Massachusetts, USA) (R Core Team, 2016). The OD405 cut-off values for 
CAV-1 (0.2475) and CAV-2 (0.2500) were estimated from the ROC curves using the 
‘ROC01’ method implemented by the OptimalCutpoints package (Metz, 1978; 
Lopéz-Ratón et al., 2014). A binary value was assigned to the final OD405 of each 














4.4.6 Virus neutralisation test 
 
A CAV VNT was developed using non-haemolysed control sera, which consisted of 
canine sera obtained from the RDSVS and fox sera obtained from Tiggywinkles 
Wildlife Hospital. These sera were suggestive of being negative or positive for CAV 
IgG in the CAV ELISA (i.e. subjectively very low or moderate-to-high OD405) prior 
to the determination of the estimated absolute cut-off OD405 for the CAV ELISA 
(Appendix 2). 
 
The VNT was optimised following methods adapted from those described by 
Loeffen et al. (2012). Serum was diluted two-fold on 96-well tissue culture plates, 
from a dilution of 1:5 to a final dilution of 1:5120. Sera were tested in duplicate 
against both CAV-1 and CAV-2 at 100 50% tissue culture infectious doses 
(TCID50)/50 µL. Sera were incubated with virus for 1 h at 37 °C before the addition 
of ~8 x 104 MDCK cells in 100 µL cell culture medium. The virus load was verified 
by back titration of 100 TCID50 CAV-1 or CAV-2 in 10-fold dilutions ranging from 
10-1 to 10-5. Plates were read on day five post-infection; wells in the plates were 
assigned as positive or negative for cytopathic effect (CPE). The antibody titre 
against CAV-1 or CAV-2 for each serum sample was calculated as the average titre 
within each duplicate. Absolute negative sera (titre = 0) were distinguished from 
CAV-1/CAV-2 positive sera to identify control sera for calculation of the cut-off 
OD405. The cut-off was then verified by ‘back-analysis’ of the ELISA binary result 
for the VNT controls. 
 
4.4.7 Statistical analyses 
 
A generalised linear model (GLM) was used to evaluate the association of the CAV 
IgG status (positive or negative) of the sampled red foxes with both demographic and 
environmental variables. The CAV IgG status used in the model was based on the 
estimated cut-off value applied to the mean OD405 against CAV-1 in the ELISA. 
Individual descriptors included sex, age class, BCS and region of capture/collection. 
On the basis of the spatial location of the foxes, we extracted information for several 
 




habitat and environmental variables, considered to be potentially influential in the 
likelihood of CAV-1 infection, from freely available digital environmental data 
(Table 4.3). We considered that human population density and land cover may be 
associated with the population density of red foxes and the likelihood of contact 
between individuals, whereas maximum and minimum temperature, relative 
humidity and precipitation may also be associated with individual immune status. 









Additional explanatory variables used in the regression model development with data 
source. 
 
Variable Unit Year Spatial 
resolution 
Name and source of data Reference 
Human population density km-1 2011 1 km UK gridded population, CEAH Reis et al. (2016) 
Relative humidity % 2011 5 km Gridded observation data (UKCP09), Met 
Office 
Perry and Hollis (2005) 
Total annual rainfall mm 2011 5 km Gridded observation data (UKCP09), Met 
Office 
Perry and Hollis (2005) 
Mean monthly maximum 
temperature 
oC 2011 5 km Gridded observation data (UKCP09), Met 
Office 
Perry and Hollis (2005) 
Mean monthly minimum 
temperature 
oC 2011 5 km Gridded observation data (UKCP09), Met 
Office 
Perry and Hollis (2005) 
Altitude m - 1 km The Shuttle Radar Topographic Mission 
(SRTM) digital elevation data, CGIAR-
CSI 
Jarvis et al. (2008) 
Land cover class - 2012 250 m Corine Land Cover European database, 
















All explanatory variables were screened for missing values, so that foxes were only 
included in the model if all variables were known, and then evaluated for strong 
collinearity using bivariable plots for all continuous variables. Several of the 
environmental variables were strongly correlated with each other and with ‘region’. 
A backward stepwise elimination process was used to retain covariates (along with 
biologically plausible two-way interactions) in the multivariate logistic regression 
model. Variables were retained in the multivariate model if they confounded other 
variables or if they significantly improved model fit at an -level < 0.05 using the 
likelihood ratio test (LRT). Akaike’s information criterion (AIC) was used to 
determine which combination of variables best explained the data with the minimal 
number of covariates (i.e. the most parsimonious model). The coefficient estimates 
and standard errors were monitored during model selection for evidence of 
instability. Evidence of overfitting of the model was evaluated using a bootstrapping 
approach, as suggested by Harrell et al. (1996), and examination of shrinkage of the 
slope and intercept parameters. An automated stepwise selection based on 
minimising the AIC was also run for comparison. 
 
 
Goodness-of-fit was ensured by the calculation and plotting of several diagnostic 
measures (including deviance ΔD, Pearson’s chi-square Δχ2 and influence Δβ) 
against the predicted probabilities as suggested by Hosmer and Lemeshow (2000). 
The goodness-of-fit of the overall model was further assessed using the area under 
the curve (AUC) of the ROC curve created from the model. Model sensitivity and 
specificity were estimated at the proposed thresholds and their 95% confidence 
intervals were computed using 2000 bootstrap iterations.  
 
To identify the presence of residual spatial autocorrelation in the data, a binned 
omni-directional semi-variogram (Isaaks and Srivastava, 1989) was constructed over 
the model’s residuals. Semi-variance was computed over distances of up to 10 km 
and compared to those obtained from a series of 999 Monte Carlo simulations. 
 
 




Analyses were carried out in R (R Core Team, 2016). The R packages ggplot2 
(Wickham, 2009) and rgdal (Bivand et al., 2016a) were used to visualise the 
distribution and IgG status of foxes tested by the CAV ELISA (Figure 4.1), using a 
map of the UK obtained from the Database of Global Administrative Areas version 
2.8 (GADM, 2015). Other mapping and environmental data extraction procedures 
were carried out using the maptools (Bivand et al., 2016b) and raster (Hijmans et al., 
2015) packages respectively. Final model selection was verified by computing AICc 
and ΔAIC using the R package AICcmodavg (Mazerolle, 2016). Goodness-of-fit 
procedures were carried out with the pROC (Robin et al., 2011) and LogisticDx 
(Dardis, 2015) packages, whereas the binned omni-directional semi-variogram was 


















6 Addendum - In the published manuscript, statistical analyses were largely performed in R (R Core 
Team, 2016) or R Studio (R Studio, Boston, Massachusetts, USA). The specific packages used for 
most statistical tests are outlined in the manuscript results section. Detailed methods for each 
statistical test are available in the referenced texts. Confidence intervals for prevalences (section 4.5.3) 
were calculated using a method for a single proportion (stats package; Newcombe, 1998). The 
regional differences in CAV-1 positivity and the age structure of red foxes (section 4.5.3) were 
initially compared using Pearson’s Chi-squared tests (stats package). Sample code from the statistical 
analyses are provided in Appendix 2. 
 





Spatial distribution of red foxes sampled in the United Kingdom (n = 387), according 
to canine adenovirus (CAV) IgG status. Jittering of data points was applied to 
improve the differentiation of overlapping data points. The map was created in R (R 































4.5.1 Prevalence of CAV-1 and CAV-2 by PCR  
 
CAV-1 DNA was detected by nested PCR in tissue DNA extracts from 29 of 154 
(18.8%, 95% confidence interval, CI 13.2-26.1%) foxes across the UK. One 
additional fox was negative for CAV-1 by PCR in DNA extracts from liver and 
kidney, but was positive in the spleen, which was tested non-routinely prior to 
confirmation of liver and kidney negativity. Urine and faeces from all foxes, when 
available, were tested for both CAV-1 and CAV-2. Three of 17 (17.6%, 95% CI 4.7-
44.2%) urine samples available for testing were positive for CAV-1 by PCR. All 
foxes with positive results in urine were also positive for CAV-1 by PCR in liver and 
kidney. None of 19 foxes were positive for CAV-1 by PCR in faeces and no animals 
were positive for CAV-2 in either faeces or urine. 
 
4.5.2 Distribution and viral load of CAV-1 in fox samples 
 
No animals had gross lesions suggestive of ICH at post-mortem examination. 
However, because of the nature of the samples, tissues from most foxes were not 
suitable for histological processing and examination. Two foxes exhibited mild 
jaundice at post-mortem examination, but both were negative by PCR for CAV-1.  
For positive animals, all the available collected samples were screened for the 
presence of detectable CAV-1 (PCR results for individual positive animals are 
summarised in Supplementary Table 4.1). The tissue distribution of CAV-1 and 













Supplementary Table 4.1 
Summary of CAV-1 PCR screening results of samples from red foxes determined to 
be positive for CAV-1 in liver and/or kidney. All other foxes subjected to molecular 
testing were negative for CAV-1 in liver and kidney by PCR. 
 
 
Fox ID Liver Kidney Blood Spleen Brain Lung GIT Urine Faeces 
061014/2 1 0 0 0 0 - - 0 - 
111114/1 1 0 1 - 1 0 - 0 - 
201114/1 1 1 1 - 1 - - - 0 
201114/2 1 1 1 1 1 1 - - 0 
120115/1 1 0 - - - - - - - 
120115/3 1 0 - - - - - - - 
300115/1 1 0 0 - - 0 - - - 
300115/2 1 1 0 - - 1 - 1 - 
300115/3 0 1 - - - - - - - 
020215/1 0 0 0 1 1 0 0 - 0 
090315/1 1 1 0 1 0 0 0 1 0 
090315/2 1 1 1 - - 0 - 1 - 
030415/1 1 0 0 1 1 0 0 0 0 
010515/5 0 1 0 - - - - - - 
220515/1 1 0 1 1 0 1 0 - 0 
15195 1 0 - - - - - - - 
15346 0 1 0 - - - - - - 
15620 1 1 0 - - - - - - 
15622 1 0 0 - - - - - - 
15703 0 1 0 - - - - - - 
15705 0 1 0 - - - - - - 
16036 1 0 - - - - - - - 
16137 0 1 - - - - - - - 
16185 1 0 - - - - - - - 
16432 0 1 0 - - - - - - 
16606 1 0 0 - - - - - - 
17066 1 1 0 - - - - - - 
17154 1 1 1 - - - - - - 
17157 1 0 0 - - - - - - 
 









Distribution of CAV-1 infection among tissues/samples in foxes positive for CAV-1 
by PCR, and estimation of viral load (genome copies per μL) by qPCR. GIT, 









4.5.3 Prevalence of IgG antibodies against CAV-1 
 
Across the UK, the sera of 302 of 469 (64.4%, 95% CI 59.8-68.7%) red foxes were 
estimated to be positive for IgG antibodies reactive against CAV-1 by ELISA. 
Amongst CAV-1 PCR positive foxes subjected to serological testing, 20 of 25 (80%, 
95% CI 58.7-92.4%) foxes with blood available for serology had IgG reactive 
against CAV-1 by ELISA. Among CAV-1 PCR negative foxes 48 of 103 (46.6%, 
95% CI 36.8-56.7%) were positive for IgG reactive against CAV-1. IgG antibodies 
reactive against CAV-2 by ELISA were detected in 264 of 469 (56.3%, 95% CI 
51.7-60.8%) foxes. The cross-reactivity between CAV-1 and CAV-2 was high 
(84.1%, 95% CI 79.4-87.8%). Of foxes positive for CAV IgG, 254 were estimated to 
have IgG reactive to both CAV-1 and CAV-2, whereas 48 animals had IgG reactive 
to only to CAV-1. Only 10 animals had antibodies which were reactive only to 
CAV-2. 
 Liver Kidney Blood Spleen Brain Lung GIT Urine Faeces 
Percentage (%) of CAV-1 
PCR positive foxes 
85 
(n = 29) 
61.9 
(n = 29) 
27.3 
(n = 22) 
83.3 
(n = 6) 
62.5 
(n = 8) 
33.3 
(n = 9) 
0 
(n = 4) 
50 
(n = 6) 
0 
(n = 6) 
Mean CAV-1 genome 
copies/µL 
1.15 x 103 6.50 x 103 1.14 x 101 5.45 x 102 BLD 1.43 x 101 - 1.42 x 104 - 
Standard deviation 2.66 x 103 2.30 x 104 2.27 x 101 1.06 x 103 - 1.69 x 101 - 2.41 x 104 - 
 





Amongst the subset of red foxes with associated spatial data, included in the 
multivariate model, 257 of 387 (66.4%, 95% CI 61.4-71.1%) foxes were seropositive 
for CAV. Initial plotting of the spatial distribution suggested a possible north/south 
trend in prevalence with a higher prevalence in the south of the UK (Figure 4.1). 
Looking at the regional differences, 37 of 72 (51.4%, 95% CI 39.4-63.2%) in NI 
were CAV seropositive, compared to 220 of 315 (69.8%, 95% CI 64.4-74.8%) in 
GB; this difference was statistically significant (χ2 = 8.14, df = 1, p = 0.004). This 
initial difference was largely explained by a significant difference in the age structure 
of the foxes in the samples from NI and GB (χ2 = 19.89, df = 2, p < 0.001). 
 
In total, 11 variables were tested for association with the odds of foxes being CAV 
seropositive, including region, age, sex, BCS and the seven environment and habitat 
variables (Table 4.3). The final model included the age and sex of the sampled foxes 
as well as the mean monthly maximum temperature recorded at the 
capture/collection site. Compared to being a juvenile fox, being an aged adult fox 
significantly increased the odds of being CAV seropositive by a factor of 2.75 (95% 
CI 1.11-6.93), whereas young adult foxes were not significantly more likely to be 
CAV seropositive (odds ratio (OR) 1.51, 95% CI 0.67-3.46). 
 
There was no statistically significant difference between male and female foxes in 
the likelihood of being CAV seropositive (OR for male compared to female foxes 
0.70, 95% CI 0.45-1.10), but this variable was retained in the model to adjust for 
potential confounding. The mean monthly maximum temperature was the most 
influential variable in the model, accounting for 60% of the deviance explained. For 
each degree increase in the mean monthly maximum temperature, the odds of being 
CAV seropositive increased with a factor of 1.45 (CI 1.23-1.71). Adding the variable 
‘region’ with or without the temperature variable did not improve the fit of the 
model, confirming that the effect of temperature was not related to the spatial 
location of the foxes. 
 
 




The AUC of the final model was 0.68 (95% CI 0.62-0.73) and the index corrected 
shrinkage for the intercept and slope were 0.047 and 0.922 respectively. There were 
no overly influential covariate patterns observed in subsequent model diagnostic 
plots and there was no residual spatial clustering detected when semivariance was 
evaluated. This suggests that the model has reasonable explanatory power and little 
of evidence of overfitting. 
 
4.5.4 CAV-1 sequence analysis 
 
Sequences obtained using the additional sequence primers (Table 4.2) were 
submitted to GenBank under accession numbers KU755693 to KU755761. 
Sequences obtained using the detection primer set were not submitted due to their 
relatively short length (< 200 bp). The sequences obtained using all primer sets 
shared 99-100% identity with the reference genome (EMBL AC_000003.1). 
However, all sequences obtained from the hexon region, using the CAV-1_hex 
primer set (n = 17), were identical to the reference genome in all foxes (GenBank 
accession numbers KU755693 to KU755701). 
 
Single nucleotide changes which were unique to foxes from GB or NI were 
identified in other amplified genomic regions, in addition to several single nucleotide 
changes which were present mostly, but not solely, in one of the populations; these 
are summarised in Figure 4.2. These changes may represent single nucleotide 
polymorphisms (SNPs). Single nucleotide changes in relation to the CAV-1 
reference genome, which were present in two or less foxes from which sequences 
were obtained were also identified (Figure 4.2); these were verified by repeat 













Summary of the common, single nucleotide changes among sequences obtained from 
foxes in Great Britain (England and Scotland) and Northern Ireland, and the 
associated GenBank accession numbers. 
 
 
* In relation to CAV-1 sequence EMBL: AC_00003.1 
+ Indicates that a nucleotide change was present in the sequence; - nucleotide change absent. 
A blank cell indicates that no sequence was obtained for that fox at that genomic region. 
The sequence from fox 111114/1 with a nucleotide change at position 6279 (in relation to EMBL AC_000003.1) was not 




































































































Fox ID Origin Accession number(s)
111114/1 England + - - - - - - - - - - + - - + + - KU755715 KU755752 KU755734
061014/2 Scotland - - - - - - - - - + + - + - + + - KU755718 KU755754 KU755735
201114/1 Scotland - - - - - - - - - + + + - - + + - KU755714 KU755746 KU755733




300115/2 Scotland - - + - - - + + - - - + - - + + - KU755711 KU755750 KU755730
300115/3 Scotland - - - - - - - - KU755710
020215/1 Scotland - - - - + + - - + - KU755753 KU755737
090315/1 Scotland - - - - - + - - - - - KU755717 KU755751
090315/2 Scotland - - - - - - - - - - - - + - + + - KU755716 KU755748 KU755736
030415/1 Scotland - + - - + - - - - + + KU755719 KU755749
010515/5 Scotland - - + - - - - - KU755720
220515/1 Scotland - - - - - + - - + - - + - - KU755712 KU755731
15195 N. Ireland - - + + - - + + + - - + - + - + + KU755723 KU755760 KU755739
15346 N. Ireland - - + - - - + + + - - + - - - + + KU755727 KU755755 KU755744
15620 N. Ireland - - + - - - + + + - - + - - - + + KU755725 KU755761 KU755741
15622 N. Ireland - - + - - - + + KU755728
15703 N. Ireland -
15705 N. Ireland - + - - KU755759
16036 N. Ireland - - + - - - + + - - - - + + KU755726 KU755740
16137 N. Ireland -
16185 N. Ireland -
16432 N. Ireland -
16606 N. Ireland - - + - - - + + + - - - + + KU755729 KU755738
17066 N. Ireland - - + - - - + + + - - + - - - + + KU755724 KU755756 KU755745
17154 N. Ireland - - + - - - + + + - - + - - - + + KU755722 KU755757 KU755742
17157 N. Ireland - - + - - - + + + - - + - - - + + KU755721 KU755758 KU755743
 






This study has shown that 18.8% of red foxes from across the UK, all of which were 
free from gross evidence of ICH on post-mortem examination, were positive for 
CAV-1 sequences by PCR, consistent with inapparent infection. A range of tissues 
were infected and 50% of urine samples from CAV-1 infected foxes were also 
positive for CAV-1 by PCR. The majority of foxes with detectable CAV-1 DNA also 
had antibodies against CAV, which strongly suggests that CAV-1 may establish 
persistent infections in foxes. The majority (64.4%) of red foxes from across the UK 
had antibodies against CAV, indicating that the red fox is likely to be a significant 
wildlife reservoir for CAV-1 in the UK. 
 
It is not possible to estimate how many CAV-1 infections in free-ranging foxes 
actually result in clinical ICH and how many foxes will die from the disease, despite 
mortality being reported to be up to 25% in experimental infections in captive foxes 
(Cabasso, 1962). Most cases of ICH are likely to go unnoticed (or undiagnosed) in 
free-ranging animals and many affected foxes are likely to die underground in their 
dens, so that the carcasses are never found and examined. In the present study, all of 
the CAV-1 infections were inapparent, suggesting that a proportion of red foxes do 
not develop fatal ICH, but instead become persistently infected. Given the high 
number of red foxes which were estimated by ELISA and PCR to have been exposed 
to CAV-1, it appears that many animals are subclinically infected or develop only 
mild ICH, from which they recover. It is possible that some foxes are protected from 
CAV-1 by maternal antibodies when young and subsequently develop acquired 
immunity through intermittent exposure to CAV-1 from infected conspecifics. 
 
Aged adult foxes were significantly more likely to have antibodies against CAV than 
juveniles, consistent with a longer period of potential exposure to CAV-1. Given that 
protective antibody titres towards CAV appear to be maintained in most dogs which 
have not been vaccinated for more than 3 years (Böhm et al., 2004), and that the 
mean lifespan of free-ranging, urban red foxes in the UK was as low as 2.1 years for 
subordinate individuals in one study (Baker et al., 1998), it is likely that infection 
 




and exposure to CAV-1 promotes lifelong persistence of antibodies against CAV in 
most foxes. CAV-1 appears to be highly prevalent in the UK. Therefore, initial 
infection may occur early in life following the waning of any maternal immunity and 
these surviving juvenile animals then progress to adulthood. In the present study, 
20% of foxes were positive for CAV-1 by PCR, but did not possess detectable 
antibodies against CAV. These may have been only recently exposed to CAV-1, and 
thus may not yet have developed IgG, or this could be a consequence of the high 
ELISA cut-off value in this study. It is notable that 80% of foxes which were PCR 
positive for CAV-1 possessed detectable antibodies against CAV; this suggests that 
CAV-1 possesses effective mechanisms to evade the immune system and persist in 
the foxes. However, it should be noted that cell-mediated immunity was not 
measured in this study. 
 
The seropositivity in this study (64.4%) is higher than has been previously estimated 
in the UK (Thompson et al., 2010). This finding is likely to be a result of the large 
sample size, a more sensitive serological diagnostic test and the use of blood instead 
of tissue fluids, rather than a temporal increase in seroprevalence since the time of 
the survey by Thompson et al. (2010). The relatively high CAV seroprevalence in 
the present study should not be viewed as an unusual finding, since it is consistent 
with a seroprevalence of 59.7% reported in red foxes in Norway (Åkerstedt et al., 
2010); furthermore, considerably higher estimates of seroprevalence of CAV have 
been estimated in other species (Garcelon et al., 1992; Almberg et al., 2010). 
 
Geographical differences in CAV seroprevalence were observed, with red foxes from 
southern regions of GB being more likely to be seropositive than those from the 
north; this association was related to mean monthly maximum temperature. Such an 
association is most likely to be related to an unobserved variable, such as fox 
density; fox populations and thus densities are estimated to be higher in the south of 
GB (Webbon et al., 2004). Together with the effect of temperature and longitude 
(possibly related to an unobserved variable such as population density), the 
difference in the age structure of the sampled fox populations between NI and GB 
may account for the observed lower seroprevalence of CAV in red foxes in NI. The 
 




study population was largely obtained through convenience sampling and, although 
it represents a relatively large sample of foxes from across the UK, inferences from 
the analyses may be biased. However, it is unlikely that biases through convenience 
sampling are associated with CAV infection, so can be controlled for in the 
modelling process. Alternatively, it is possible that the population structure and 
dynamics of red foxes in Ireland (NI and the Republic of Ireland) are different to 
those in GB. However, detailed studies on the structure of the Irish red fox 
population have not been published to date. 
 
The high serological cross-reactivity between CAV-1 and CAV-2 is somewhat, but 
not wholly, addressed using inferences from the associated molecular survey and 
from clinical evidence. We found that numerous foxes in the UK had evidence of 
infection with CAV-1 by PCR. However, CAV-2 was not detected in the urine or 
faeces of any red foxes tested. In addition, although there is a single report of a 
CAV-2 sequence being detected by PCR in the faeces of a red fox (Balboni et al., 
2013), there is no definitive evidence to suggest that CAV-2 is a frequent infection or 
causes disease in this species. Therefore, red foxes are unlikely to be a major 
transmitter of CAV-2 in the UK. 
 
Although persistent excretion of virus in urine has been observed in dogs which have 
recovered from clinical disease after experimental infection with CAV-1 (Parry, 
1950), it has not been demonstrated previously that free-ranging foxes with 
molecular evidence of inapparent infection with CAV-1 in tissues also shed CAV-1 
in urine. Despite the low sample size, it should be noted that the viral load of CAV-1 
was relatively high in urine (Table 4.4), suggesting that this may be an important 
sample to screen in epidemiological studies of CAV-1 and possibly as a monitoring 
tool in wildlife hospitals which regularly admit red foxes. Adenoviruses are 
considered to be moderately resistant in the environment (Decaro et al., 2012). 
Therefore, a susceptible red fox, dog or other susceptible species which comes into 








Although Balboni et al. (2013) found that 2 of 32 (6.3%) red foxes in Italy excreted 
CAV-1 in faeces, there was no evidence of excretion of CAV-1 in faeces from red 
foxes in our study. Faeces generally are not considered to be a primary route of 
excretion of CAV-1 in animals which have recovered from ICH (Decaro et al., 
2012). However, it is possible that the detection of CAV-1 may have been limited as 
a consequence of the small number of samples screened. Although faeces can 
contain PCR inhibitors, adenoviruses have been successfully detected in faecal 
samples in other studies (Balboni et al., 2013; Fox et al., 1977; Roy et al., 2009) and 
the faecal DNA extraction kit selected was chosen to improve the removal of PCR 
inhibitors. 
 
In addition to liver and kidney, the spleen, lung and brain were shown to be infected 
with CAV-1 in some red foxes in the present study. Therefore, CAV-1 appears to 
establish possibly persistent infections in a range of tissues corresponding to those 
most often affected during the clinical course of severe ICH (Walker et al., 2016a). 
There would be value in testing gastrointestinal and oral lymphoid tissues for 
evidence of CAV-1, particularly since oral lymphoid tissues have been shown to be 
sites of adenovirus persistence in humans, associated with intermittent excretion in 
faeces in humans and non-human primates (Fox et al., 1977; Roy et al., 2009). 
 
Some differences in viral load were found between sample types by qPCR; for 
example, relatively high loads were observed in urine, kidney and liver compared to 
the brain, in which viral loads were too low to be quantified. However, due to the 
small number of samples tested from these sites, it was not possible to apply 
statistical analysis to the data. In view of the low viral loads in some tissues, a highly 
sensitive molecular assay, such as nested PCR, is necessary to estimate the true 
prevalence of inapparent infections with CAV-1. 
 
Since the present study has provided evidence for inapparent infections in red foxes, 
further molecular experimental studies are required to investigate the pathogenesis of 
persistent CAV-1 infections and the viral or host mechanisms which underlie this. 
Some similarities are evident between inapparent CAV-1 infections in red foxes and 
 




human adenoviruses (Fox et al., 1977; Rowe et al., 1953; Garnett et al., 2002). 
However, it is notable that in this study CAV-1 DNA was detected in a range of 
functionally distinct lymphoid and non-lymphoid tissues, in otherwise healthy 
animals. Moreover, in humans, it is unclear whether, in some cases, systemic disease 
is a result of recrudescence of a persistent infection or as a result of infection in 
transplanted tissues (e.g. in transplant recipients) (Kojaoghlanian et al., 2003). 
Whether similar recrudescence events can occur in persistently infected non-human 
species is not known, but would be of particular importance when, for example, a 
free-ranging animal is brought into captivity (i.e. hospitalised), which may result in 
considerable individual stress. Some CAV-1 proteins in the early expressed (E) 
regions have low similarity to E gene products of human adenoviruses (Morrison et 
al., 1997), so CAV-1 may possess unique evasion mechanisms. 
 
It was not possible to determine the duration of CAV-1 persistence in red foxes, or 
the cell type(s) that support persistence. Suitable in vitro models using canine or 
vulpine cell lines could be used to investigate the pathogenesis of CAV-1 
persistence. It is unclear whether CAV-1 detected by PCR in the organs of carrier 
foxes is viable and capable of lytic infections in permissible cell lines; this could be 
investigated using freshly harvested tissues. 
 
This study also presents evidence of genetic variation in the sequences of CAV-1 in 
foxes from different regions in the UK. This manifests as single nucleotides changes 
(or possible SNPs) in different regions of the CAV-1 genome, with some nucleotide 
variants appearing to be unique to foxes from GB or NI. Genetic variation may be a 
result of genetic drift caused by the disruption of gene flow between GB and Ireland, 
which are geographically separated by the Irish Sea. Such spatial variation in the 
CAV-1 genome has not been reported previously. There may be a variable rate of 
divergence in different regions of the CAV-1 genome, since sequences obtained from 
the hexon region were invariant whereas others were more variable. The sequences 
from the possible multiple CAV-1 field strains circulating in red foxes in the UK are 
different to those which historically have been detected in dogs in the UK and 
Europe. The reference genome for CAV-1 was sequenced from a field strain isolated 
 




from a dog in the UK in 1996 (Morrison et al., 1997). Two CAV-1 sequences 
reported in dogs from Italy from 2012 were identical to this reference sequence, 
although only the CAV-1 E3 region was sequenced in these cases (Balboni et al., 
2014). CAV-1 molecular epidemiological studies should be extended to dogs and red 
foxes in other countries, and other genomic regions should be sequenced to allow 






ICH is now generally considered to be a relatively uncommon disease in domestic 
dogs in areas where vaccination is performed routinely. However, because a high 
proportion of red foxes in the UK are inapparently infected with CAV-1 and, in some 
cases, CAV-1 is shed in the urine, it is recommended that all dogs continue to be 
routinely vaccinated against ICH (using CAV-2-based vaccines). Consideration of 
current wildlife reservoirs of disease should also be strongly considered in the 
planned or potential reintroductions of susceptible free-ranging carnivores to 
historical habitats, for example the debated reintroduction of wolves into Scotland 
(Nilsen et al., 2007; Wilson, 2004), which may become an additional reservoir of 
CAV-1 in the UK. Consideration should also be given to the management and 
vaccination of red foxes in wildlife rescue centres to prevent outbreaks of ICH 
(Walker et al., 2016a). Small animal veterinarians should be aware that there is a risk 
of infection in unvaccinated animals, and ICH should be suitably considered in the 
differential diagnoses of critically unwell, unvaccinated dogs and other susceptible 
species with supporting clinical history. It is likely to be both practically and 
financially unfeasible to attempt a disease eradication programme for CAV-1 in red 
foxes in the UK.  
  
As the only free-ranging canid species in the UK, the red fox is deemed to be the 
primary wildlife reservoir of CAV-1. Other canid species may be the primary, or an 
additional reservoir, of the virus in other countries, and sensitive molecular methods 
 




should be employed to investigate this. Further molecular studies investigating the 
pathogenesis of CAV-1 should specifically aim to identify the viral mechanism(s) 
which may permit CAV-1 to persist in the tissues of infected hosts. 
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4.8 Chapter conclusion 
 
In summary, the manuscript has demonstrated that a large proportion of red foxes in 
the UK have been infected with CAV during their lifetime, as detected by the 
presence of IgG in sera. Additionally, a proportion of red foxes proved to test 
positive for CAV-1 DNA by PCR, when DNA was extracted from selected tissue 
samples. Two fundamental points regarding the epidemiology and pathogenesis of 
CAV-1 are therefore highlighted. 
 
Firstly, the study shows that CAV-1 is prevalent in the free-ranging populations of 
red foxes in the UK. As the only free-ranging canid on the mainland of the UK, the 
red fox is likely to be the major reservoir (a ‘wildlife reservoir’) of infection for 
domestic dogs, and other susceptible species. The prevalence of CAV-1 in free-
ranging red foxes (and suggestion that there may be a systemic persistent infection in 
some animals) explains the occasional outbreaks of ICH observed in this species in 
wildlife rehabilitation centres in the UK (see Chapter 2). A proportion of the infected 
foxes are likely to suffer from ICH and may die ‘in the wild’. The mortality rate 
caused by ICH in free-ranging foxes cannot be accurately determined with the 
presented data, and this is considered a limitation of the study. 
 
Because of the high uptake of vaccination in the dog population in the UK, this 
domestic species is unlikely to maintain a CAV-1 reservoir alone (and demonstrates 
a ‘herd immunity’ effect). Therefore, free-ranging foxes could be the main source of 
infection for the majority of cases of ICH involving individual, unvaccinated, 
domestic dogs, which present to veterinarians. The study emphasises that domestic 
dogs need to be vaccinated regularly, according to the manufacturers’ stated 
intervals. Veterinarians should be prepared to defend this stance with clients. 
Because, theoretically, any lapse in vaccination schedules, and a resulting loss of 
neutralising antibody titre, is likely to put pet dogs at risk of severe disease. This is 
based on the demonstrated molecular evidence of high-titre shedding of CAV-1 
directly into the environment via urine. A limitation of the study is that, although 
there is clearly a risk of infection, the true ‘risk’ of infection cannot be quantified 
 




statistically; it is infeasible to objectively quantify and model all possible direct and 
indirect interactions which unvaccinated dogs and foxes may have in the UK. 
However, arguably, this is likely not necessary because ‘risk’ per se should not be a 
factor in responsible pet ownership (i.e. vaccinating pets).  
 
Other non-canid species exist in the UK, which may be capable of infection with 
CAV-1, such as the Eurasian otter (Park et al., 2007). Closely related mustelids such 
as pine martens (Martes martes), polecats (Mustela putorius) and ferrets (Mustela 
putorius furo; including polecat-ferret hybrids) also exist. It is therefore important to 
establish if additional reservoirs of CAV-1 are maintained; this will be investigated 
in Chapter 5. It is possible that multiple reservoirs of infection may exist in other 
parts of the world such as North America, mainland Europe and Australia, where 
there are several species of free-ranging canids, or where there are large populations 
of unvaccinated feral dogs, capable of infection with CAV-1. The dynamics of 
infection between multiple canid species needs to be investigated further in other 
regions, but is beyond the scope of the current project. 
 
The presented study is important in regards to the discussed, and controversial, re-
introduction of wolves to Scotland (Arts et al., 2016). Figure 4.1 highlights that 
many red foxes were detected to be CAV seropositive, and that a red fox was 
seropositive in a northerly region of Scotland. Wolves appear to be susceptible to 
ICH (Pursell et al., 1983) and therefore this needs to be factored into reintroduction 
modelling. It is assumed that this species would receive a standard course of DHPPi, 
if bred in captivity, and before release. This immunity would eventually wane in any 
wild-born offspring, and they will subsequently be susceptible to fatal CAV-1. If 
free-ranging wolves were to be translocated from abroad and re-introduced into the 
UK, then these animals need to be screened for CAV-1, since they may also be 
inapparently infected and shed CAV-1, and thus become an additional CAV-1 








Secondly, as was discussed in the conclusions of the published manuscript (see 
section 4.7 Conclusion and mentioned above) the molecular findings highlight an 
important aspect of CAV-1 pathogenesis: that is, the possible persistence of CAV-1 
infection in some individuals. This has not been adequately explored since the early 
experiments on, and intermittent interest in, CAV-1 (e.g. Green 1930; Rubarth 1947; 
Wright et al., 1981) and there are still many questions which remain unanswered 
regarding the persistence of adenoviruses in all host species.  
 
It has been previously stated that renal tubular epithelial cells are the site of viral 
persistence and this can continue for up to 6 months post-infection, primarily based 
on the presence of infectious virions in urine (Poppensiek and Baker, 1951). 
However, in this chapter, it was shown that CAV-1 was detected in a variety of 
organs, some of which are not capable of directly disseminating/shedding virus to the 
external environment (e.g. brain, liver and spleen). This suggests that renal tubular 
epithelial cells are not the only cell type which remains infected with CAV-1 
following recovery from the acute stages of ICH. Given the immunohistochemical 
evidence in Chapter 3, in which it was shown that many cell types can be infected by 
CAV-1 (in overt ICH cases), there is no reason to suggest that other cell types are 
less likely to be sites of viral persistence. Moreover, ‘persistence’ does not 
necessarily cease when virions are no longer detected in excrement/urine (i.e. ‘after 6 
months’; Poppensiek and Baker, 1951). It is not known whether CAV-1 and other 
mastadenoviruses persist by a low-level transcription of regulated genes, or whether 
they enter a state of ‘true latency’ (depending on one’s definition of latency) such as 
in the strategies employed by herpesviruses (Minarovits et al., 2007). 
 
CAV-1 was detected in many tissue-types tested. Given this evidence that there 
could be a ‘systemic persistent infection’ in some animals, in future studies it would 
be useful to sample spleen and other lymphoid tissues (including tonsillar tissue and 
gastrointestinal lymph nodes) because lymphoid tissues in humans have been shown 
to be persistently infected with HAds (Garnett et al., 2009). This study was 
financially and practically limited to screen a subset of tissues by molecular methods, 
which were selected pragmatically based on tissues which can show severe 
 




pathology during ICH or tissues suggested to become persistently infected with 
CAV-1 (i.e. kidney; Parry, 1950; Thompson et al., 2010). Moreover, although no 
signs of ICH were noted on any post-mortem examination, most tissues were not 
suitable for histological examination due to the varying degrees of autolysis and 
physical destruction of tissue (as a consequence of the sampling of foxes which were 
involved with RTAs or were shot, and which are not submitted in a timely fashion). 
This could have allowed assessment of the possibility of any residual, chronic 
pathology. As a result, there is no current evidence of chronic disease in infected 
tissues of free-ranging species following resolution of the acute stages of ICH. 
Following this study, more tissues from foxes were collected and formed part of a 
study on ‘residual pathology’ in PCR positive foxes (see Chapter 7). 
 
Regarding the possibility of infection of foxes with CAV-2, it is also important to 
mention that CAV-2 was not detected in any of the faeces screened in this study by 
PCR, despite detection in a single faecal sample from a red fox in Italy (Balboni et 
al., 2013). This could be a result of the small number of samples screened. 
Furthermore, other tissues were not sampled specifically for CAV-2 screening, 
which may have been more appropriate, such as upper respiratory tract (URT) and 
tonsillar tissues which it is thought to predominantly infect; it is possible that CAV-2 
could be detected here. However, to the author’s knowledge CAV-2 has not been 
known to cause URT disease in red foxes and this, along with financial and time 
constraints, was the reason for omitting these samples from the study which was 
primarily focused on CAV-1. Based on current clinical evidence, the disease caused 
by CAV-2 is thus presently regarded as primarily a disease of Canis lupus. Based on 
this assumption, we regarded most of the ‘untyped-CAV’ antibodies, detected by 
ELISA, to be antibodies formed as a result of historical/current CAV-1 infection. 
This will be investigated further in Chapter 6 by the attempted development of a 









So far, in Chapters 2 and 3 the acute disease caused by CAV-1 has been explored. 
These chapters revealed that severe and multiple manifestations of disease may occur 
as result of infection with CAV-1. This chapter has explored the serological and 
molecular prevalence of CAV-1 in the UK and has confirmed that CAV-1 can persist 
as an inapparent and systemic infection in a proportion of animals which were 
initially infected. Therefore, the evidence emphasises that veterinarians not only 
should be mindful of the clinical features caused by CAV-1 in red foxes and dogs 
(which may be subtle and varied), but also that red foxes may be persistently infected 
with CAV-1 and pose a risk of infection to susceptible conspecifics and dogs. 
Wildlife centres and veterinary hospitals which treat canids should therefore take this 
into account in biosecurity policies. It is also important to investigate whether CAV-
1, or other novel mastadenoviruses, could be present and cause disease in other 
British wildlife. This would determine whether adenoviruses need to be considered 
by veterinarians and conservationists in mustelid projects, and also will demonstrate 
if other species are capable of exhibiting a ‘systemic persistent infection’. This is 
imperative given mustelid recent translocation events (Veterinary Record, 2015) and 
will be explored in Chapter 5. 
 
It is also concluded that, because CAV-1 is suggested to establish persistent 
infections, the mechanisms which CAV-1 employ to persist in host tissues, in theory, 
could be similar to the mechanisms which may be employed by HAds to infect 
human lymphoid tissue/blood lymphocytes (Ornelles et al., 2015; Assadian et al., 
2016), due to the high degree of homology among the putative gene products of the 
annotated genomes (Davison et al., 2003). However, CAV-1 is detected in many 
tissue types (in assumingly immunocompetent red foxes), and such a wide range of 
tissues in individuals which may be persistently infected has not been reported in 
immunocompetent humans. Therefore, CAV-1 may be unusually ‘virulent’ 









The mechanisms of persistence of infection of adenoviruses have not been widely 
studied. However, given the increasing literature regarding severe, systemic disease 
caused by HAds in immunocompromised human patients (e.g. Lion, 2014), this is an 
increasingly important area of research. CAV-1 persistence is an area of research 
which could provide a comparative framework to model HAd persistence. It would 
also aid in understanding why foxes become persistently infected, whether this 





























Adapted to a full-length article from a short communication article [Novel 
adenoviruses detected in British mustelids, including a unique Aviadenovirus in the 
tissues of pine martens (Martes martes), D. Walker, W. F. Gregory, D. Turnbull, M. 
Rocchi, A. L. Meredith, A. W. Philbey, C. P. Sharp, Journal of Medical 
Microbiology, 66, 1177-1182, 2017]. Creative Commons Attribution 3.0 (free to 
share and adapt). 
 
Publication contributions - AWP performed the otter post-mortem examinations as 
part of an unrelated project. Pine marten post-mortem examinations were conducted 
jointly by DW, AWP, ALM and Gidona Goodman, RDSVS as part of additional 
projects with these specimens. The Centre for Genomic Research, University of 
Liverpool performed the Illumina sequencing and provided the initial consensus 

























Most of the published literature concerning adenoviruses, and the diseases which 
they may cause, involves the study of HAds. Adenoviruses in non-human primates 
are also well studied, particularly in terms of epidemiology (including serology and 
molecular screening; Fox et al., 1977; Schmitz et al., 1983; Nkogue et al., 2016). 
The relative abundance of adenovirus research in non-human primates is likely to be 
a result of the concern of zoonoses in these animals and the good availability of 
material. 
 
CAV-1, which infects mainly canids, has already been discussed as a significant 
infectious cause of morbidity and mortality, prior to the introduction of an effective 
vaccination (see Chapters 1 to 3; Green et al., 1930; Kummeneje, 1971). However, 
compared to adenoviruses in free-ranging species, CAV-1 has been relatively well 
studied among canids, and this is partly due to the commercial and medical benefits 
that knowledge of the pathogenesis of this virus brings (historically in terms of 
protecting against losses at fox fur farms and the development of an effective 
vaccine) and the level of interest for both the scientific and non-scientific 
communities (dogs are popular pets that are routinely treated by veterinarians).  
 
Publications regarding diseases caused by non-primate adenoviruses have 
occasionally been reported in other veterinary species, mainly of commercial 
interest, such as in fowl (e.g. Toro et al., 1999; Shivachandra et al., 2004; 
Meulemans et al., 2004), cattle (e.g. Darbyshire et al., 1965; Lehmkuhl et al., 1975) 
and free-ranging deer in the USA, which can be hunted (Woods et al., 1996, 
Lehmkuhl et al., 2001). Some research has also been conducted on agamid 
adenovirus type 1 (Moormann et al., 2009; Kubiak, 2013), likely due to the 
increasing popularity of bearded dragons (Pogona vitticeps) as a household pet and 
the commercial interest of captive breeding populations. In other non-domestic 
species, the frequency of research concerning adenoviruses is low or non-existent, 
particularly in free-ranging species with no perceived commercial benefit. 
 
 





It is important to extend the current study to other free-ranging wildlife in the UK. 
This is pertinent given the knowledge of inapparent CAV-1 infections in free-
ranging red foxes and that this species is likely to be a major reservoir of infection of 
CAV-1 in mainland Britain (Chapter 4; Walker et al., 2016b). There is also some 
evidence to suggest that adenoviruses, particularly CAV-1, have a broader host-range 
than would normally be expected. For example, a Eurasian otter (Lutra lutra) 
specimen in Seoul Grand Park Zoo, South Korea, was determined by the authors to 
be infected with CAV-1 and died from ‘ICH’ (Park et al., 2007). Cases have been 
reported in black bear cubs (Pursell et al., 1983; Whetstone et al., 1988), although 
this was before the ready availability of affordable Sanger sequencing to confirm the 
presence of CAV-1 specifically. Other free-ranging species may therefore be capable 
of becoming infected with CAV-1 and could be a source of CAV-1 ‘spillover’ (and 
other novel adenoviruses) into domestic animals themselves. 
 
A recent translocation project in the UK has seen pine martens (Martes martes) 
moved from Scotland to Wales (Veterinary Record, 2015). The potential for novel, 
unidentified pathogens (including adenoviruses) in translocation projects has not 
been explored. The home ranges of different mustelid species in the UK are likely to 
overlap (Harrington and Macdonald, 2008), and there is likely to be a degree of 
overlap with other free-ranging wildlife such as red foxes (Vulpes vulpes), which are 
widespread in the UK (Webbon et al., 2004). Moreover, pine martens which have 
been translocated are likely to migrate at least locally during the establishment of 
new territories and during foraging and hunting sessions. This may allow for 
potential cross-infection among species through indirect exposure to adenoviruses 
via infected faeces, urine and infected fomites. Closely related Eurasian otters, which 
frequent the coasts and rivers of the UK, may also be capable of CAV-1 infection 
(Park et al., 2007) and of being a source of infection to other mustelids. This species 
is also particularly important to study, due to its recovering (and expanding) 
population in some parts of the country (Hobbs et al., 2011), and its isolated and 
possibly vulnerable populations (e.g. Shetland, UK; Kruuk et al., 1989). Free-
ranging mustelids in the UK are also closely related to the domestic ferret (Mustela 
 





putorius furo), an increasingly popular pet, which could also be infected by closely 
related species. 
 
There have been no published studies to date investigating the molecular presence of 
adenoviruses in free-ranging mustelids in the UK, nor have there been serological 
surveys. However, skunk adenovirus type 1 (SkAdV-1) has been detected in a striped 
skunk (Mephitis mephitis), which is a member of the family Mephitidae, in Guelph, 
Canada (Kozak et al., 2015). Furthermore, in South-West, France, it was determined 
that 5-33% of Mustela spp. and Martes spp. possessed antibodies against CAV 
(Philippa et al., 2008). It cannot be determined if these were specific for CAV given 
the cross-reactivity of antibodies among adenoviruses in serological assays (Calnek 
et al., 1982; Smith et al., 1998). Although CAV-1 has not been previously detected 
in a free-ranging mustelid by molecular methods, serological evidence suggests that 
mustelids on mainland Europe are likely to harbour ‘cross-reactive’ adenoviruses, 
which may include novel adenoviruses. 
 
Although research that is only serological in nature can generally offer recent or 
historical evidence of exposure to adenoviruses in populations, it cannot determine if 
host tissues are still infected or if the host is shedding virus. However, molecular 
adenovirus studies in many host species cannot definitively conclude that detection 
of adenoviruses in faecal samples (a commonly tested sample) alone represent a 
persistent infection (e.g. Roy et al., 2009) or that the host species are indeed the 
definitive host for those particular adenoviruses, especially in animals which eat a 
broad diet (e.g. rodents; Zheng et al. 2016). It can be argued that adenoviruses may 
be present in faeces due to the ingestion of adenovirus-infected dietary material, with 
the subsequent excretion of DNA or intact adenovirus capsids (i.e. transient); this 
does not necessarily demonstrate a persistent infection without further evidence of 
virus also being present in tissue samples. Therefore, when conducting molecular 









The aim of this study was to extend the survey already conducted in red foxes, to 
determine whether CAV-1 and/or other novel adenoviruses play a role in free-
ranging mustelids in the UK, and if screening for novel pathogens should also be 
considered in national conservation projects. This would also determine if 
adenoviruses need to be considered by veterinarians when treating these animals and 
whether mustelids may be an additional source of infection for domestic species, 
including dogs and ferrets. Therefore, in this study, mustelid specimens from the UK 
(namely, pine martens and Eurasian otters) were screened for adenoviruses 
(including CAV-1 and novel adenoviruses) by PCR using suitable samples. 
Additionally, if the sampled animals were deemed to be infected, whether this was 
associated with gross pathological evidence of disease or if there was suggestion of 
inapparent persistent infections. 
 
 
5.2 Materials and methods 
 
5.2.1 Post mortem examinations and extraction of DNA 
 
The carcasses from 14 pine martens were sourced from Scotland, primarily from the 
county of Aberdeenshire. Carcasses from nine Eurasian otters were sourced from 
Shetland, Scotland, collected by Natural Heritage Scotland, as part of an ongoing 
study on the health of Eurasian otters in the region (Philbey, 2016). Animals had died 
as a result of ‘natural’ or inapparent reasons or were killed in road traffic accidents 
(RTAs). 
 
Carcasses underwent post-mortem examinations and a range of tissue samples and 
faeces were collected during the procedures (Table 5.1), which were stored at -20 °C. 
During the post-mortem examinations there was no gross pathological evidence of 
acute or chronic viral disease to be noted in any of the animals. Histopathological 
examination was not routinely performed on the mustelid tissues because the 
samples had been subjected to freeze-thaw and the carcasses were autolytic to 
varying degrees, due to the nature of the sample selection. 
 





DNA was extracted from the tissue samples using the DNeasy Blood and Tissue Kit 
(Qiagen, Hilden, Germany) following the manufacturer’s protocol. DNA from the 
faeces of the pine martens was extracted using the E.Z.N.A. Stool DNA Kit (Omega 
Bio-tek, Norcross, Georgia, USA). DNA from faeces and tissues were extracted 
separately, and equipment/surfaces cleaned thoroughly between extractions, to 
minimise PCR cross-contamination. 
 
5.2.2 PCR protocols for the initial detection of adenoviruses 
 
Screening was performed by the use of the adenovirus consensus PCR previously 
adapted in Chapter 2 (Wellehan et al., 2004; Walker et al., 2016a). This would allow 
the detection of the DNA from CAV-1 and any other novel adenoviruses, if present. 
DNA extracted from the livers of pine martens and the livers of otters were screened 
and positive samples (as determined by gel electrophoresis) were directly sequenced 
(Edinburgh Genomics, University of Edinburgh), following sample preparation by 




















Summary of the mustelid samples included in the study. The table includes 
information on the geographic source of the animal, where available (Adapted from 




Location (Scotland, UK) Samples† Samples not available 
Pine marten 01 Portlethen, Aberdeenshire Liver, kidney, lung, faeces - 
Pine marten 02 Black Isle, Ross and Cromarty Liver, kidney, lung, faeces - 
Pine marten 03 Not recorded Liver, kidney, lung, faeces - 
Pine marten 04 Helmsdale, Highland Liver, kidney, lung, faeces - 
Pine marten 05 Not recorded Liver, kidney, lung, faeces - 
Pine marten 06 Not recorded Liver, kidney, lung, faeces - 
Pine marten 07 Achvaich, Highland Liver, kidney, lung, faeces - 
Pine marten 08 Dornoch, Highland Liver, kidney, lung, faeces - 
Pine marten 09 Tarlogie, Highland Liver, kidney, lung, faeces - 
Pine marten 10 Not recorded Liver, kidney, lung, faeces - 
Pine marten 11 Not recorded Liver, kidney, lung, faeces - 
Pine marten 12 Not recorded Liver, kidney, lung Faeces 
Pine marten 13 Not recorded Liver, kidney, lung, faeces - 
Pine marten 14 Not recorded Liver, lung Kidney, faeces 
Otter 01 Shetland Liver, kidney - 
Otter 02 Shetland Liver, kidney - 
Otter 03 Shetland Liver, kidney - 
Otter 04 Shetland Liver, kidney - 
Otter 05 Shetland Liver, kidney - 
Otter 06 Shetland Liver, kidney - 
Otter 07 Shetland Liver, kidney - 
Otter 08 Shetland Liver, kidney - 
Otter 09 Shetland Liver, kidney - 
 
* Pine marten (Martes martes), Eurasian otter (Lutra lutra) 


















5.2.3 Virus isolation by cell culture inoculation 
 
MDCK cells were cultured in a ‘maintenance medium’, differing from that described 
in Appendix 1. This consisted of Dulbecco’s modified Eagle’s medium (DMEM; 
Sigma-Aldrich) containing 10% FBS (Gibco Life Technologies, Inchinnan, Paisley) 
2mM L-glutamine (Gibco Life Technologies), 100 U/mL penicillin streptomycin 
(Gibco Life Technologies), 0.5 µg/mL gentamicin, 100 U/mL polymixin B, 1.25 
µg/mL amphotericin B. The ‘test medium’ was identical to the maintenance medium 
except the FBS content of the cell culture medium was reduced from 10% to 5%. 
 
Approximately 1 cm3 sections of tissues (from adenovirus PCR positive tissues: liver 
from pine marten 10, livers from otters 01, 04, 07, 08 and 09) were homogenised 
with 4 mL of test medium using gentleMACS M Tubes (Miltenyi Biotec, Surrey, 
UK) loaded into the Dispomix Drive (Medic Tools AG, Zug, Switzerland). After 
homogenisation for approximately 45 s, tubes were centrifuged at 2000 x g for 10 
min at 4 °C. The supernatant was filtered using a 0.45 µm syringe filter (Minisart, 
Sartorius, Surrey, UK) and the filtrate was diluted to 1:10 and 1:100 using test 
medium in a volume of 4 mL 
 
25 cm3 flasks of confluent MDCK cells were washed with PBS before inoculation 
with 4 mL of tissue homogenate filtrate from each liver sample, diluted 1:10 and 
1:100 in PBS. This was removed after 1 h and cells were then washed with FBS. Test 
medium was then added to each tissue culture flask and observed daily for CPE for 1 
week. After 1 week, cell cultures were frozen to -20 °C and thawed (freeze-thaw) for 
three cycles, and the flask contents centrifuged. The supernatant (~4 mL) was then 
used to inoculate an uninfected 25 cm3 MDCK flask following the previous methods. 
Passage 2 was observed for a further week post-infection, before the initiation of 











5.2.4 Preparation of tissues for high throughput sequencing (HTS) 
 
DNA was extracted directly from samples of mustelid tissues for high throughput 
sequencing (HTS). Due to the limited amount of material available, only relatively 
small weights of tissue could be used; 500 mg of kidney from otter 08 and 288 mg of 
liver from pine marten 10. These tissues were initially macerated using disposable 
scalpels. Samples were added to microcentrifuge tubes with 500 µL PBS and 
glass/ceramic beads. The tubes were fixed to a vortex with a custom horizontal 
adaptor (Mo Bio, Carlsbad, California, USA), which was used to aid further 
maceration of the tissues. The tissues were centrifuged for 5 min at 12,100 x g, 
before supernatant was filtered through a syringe with a Millex-HA 0.45 µm 
membrane attachment (Merck, Millipore, Carrigtwohill, County Cork, Ireland). 
 
An attempt to increase the ratio of viral DNA (encapsidated) to DNA from the host 
were made by addition of deoxyribonuclease (DNase) treatment to the samples (to 
degrade unprotected host DNA). To each 600 µL tissue filtrate a mixture of 15 µL 
TURBO DNase (Life Technologies, Carlsbad, California, USA), 60 µL 10x TURBO 
DNase buffer and 15 µL RNase A (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) was added. The final mixture was heated to a temperature of 
37 °C for a duration of 90 min. ‘Buffer AL’ (Qiagen) and 100% ethanol were then 
added at equal volumes to the mixture, and centrifuged through DNeasy mini spin 
columns (Qiagen). Multiple centrifugations, followed by the discard of the contents 
of collection tubes, were required due to the final volumes of the tissue preparations. 
The protocol then proceeded according to the DNeasy Blood and Tissue Kit 
instructions, provided by the manufacturer (Qiagen). 
 
The modified consensus adenovirus PCR (Wellehan et al., 2004; Walker et al., 
2016a) was utilized to confirm that adenovirus was present in the DNA extractions 
following the above protocol. The Qubit 3.0 flourometric quantitation system 
(Thermo Fisher Scientific) was used to quantify the DNA in the preparations, which 
was required for HTS. 
 
 





5.2.5 High throughput sequencing (HTS) 
 
DNA library preparation, HTS and the initial bioinformatics ‘pipelines’ of the 
resulting reads were performed by the Centre for Genomic Research (CGR), 
University of Liverpool, UK. DNA libraries from the DNA preparations were 
created using the Tru-seq Nextera platform (Illumina, San Diego, California, USA). 
250 bp paired-end (PE) reads were recorded from these libraries by the MiSeq 
System sequencing platform (Illumina). Paired reads were then aligned to the 
genome of the ferret (GenBank GCA_000215625.1), because the complete genome 
sequences of the pine marten and Eurasian otter were not available. This process 
removed reads determined to be host genomic DNA by alignment. The CGR 
‘pipeline’ process used the Burrows-Wheeler Aligner (BWA) software package (Li 
and Durbin, 2010) and the resulting ‘un-mapped’ reads were separated using 
SAMtools (Li et al., 2009), which were assembled with MEGAHIT (Li et al., 2015). 
 
Following the initial bioinformatics, the reads which were unassembled by CGR 
were re-processed using Geneious 9.1.6 software (Biomatters, Auckland, New 
Zealand). Specific adenovirus sequences were identified by the use of BLAST 
(Johnson et al., 2008). Sequences determined to be from an adenovirus were then 
aligned to appropriate reference adenovirus genomes in SSE (Simmonds, 2012) and 
MEGA6 (Tamura et al., 2013). 
 
5.2.6 Sequencing the full coding sequence of MAdV-1 hexon and DNA 
polymerase 
 
Following HTS, additional primer sets were designed in order to obtain the complete 
coding sequence of the detected novel adenovirus, marten adenovirus type 1 
(MAdV-1; see section 5.3.4 Detection of novel adenoviruses by HTS)  hexon and 
DNA polymerase. Hexon and DNA polymerase were selected due to the amount of 
data available on NCBI GenBank for comparison with other adenoviruses, and 
because of their importance in antigenicity and pathogenesis (see Chapter 1). 
 
 





In order to populate the large coding sequence gaps (in the order of 103 bp) between 
contigs a specialized long-range Taq DNA polymerase was selected for use. The 
reaction mixture to amplify long sequences was 2 µL (5 U) LongAmp Taq DNA 
polymerase (New England Biolabs, Ipswich, Massachusetts, USA), 10 µL 5x 
LongAmp Taq reaction buffer (New England Biolabs), 2 µL dNTPs (200 µM for 
each dNTP), 2 μL forward primer (200 nM), 2 μL reverse primer (200 nM), 3 µL 
DNA and 29 µL H2O. The PCR primers and protocols are summarised in Table 5.2 
and Table 5.3 respectively. Products for Sanger sequencing (Edinburgh Genomics) 
were prepared using BigDye Terminator v3.1 (Thermo Fisher). 
 
Following the sequencing of nucleotides within the inter-contig ‘gaps’, additional 
‘short-range’ sequencing was performed. The reaction mixture consisted of 0.2 µL (1 
U) GoTaq G2 DNA polymerase (Promega), 10 µL 5x Green GoTaq buffer 
(Promega), 1 µL dNTPs (200 µM for each dNTP), 1 µL forward primer (200 nM), 1 
µL reverse primer (200 nM), 2 to 4 µL DNA and H2O (to attain a final volume of 50 
µL). The PCR primers and protocols are also summarised in Table 5.2 and Table 5.3 
respectively. Where possible, PCR products were sequenced by direct Sanger 
sequencing (Edinburgh Genomics). The amplicon of one primer set was sequenced 
following cloning of DNA (indicated in Table 5.1) using the pGEM-T Easy Vector 




















Primer sets used to sequence DNA polymerase and hexon of marten adenovirus type 
1 (MAdV-1; table from Walker et al., 2017). 
 
Primer name Sense/Antisense Sequence (5'-3') Target 
k87_5383_pol_F Sense TCTACCGTGAGGGAAAGGTC DNA Polymerase 
k87_5383_pol_R Antisense GGTTAGTGTGGACAAACGAGA DNA Polymerase 
k87_4084_5009_F Sense CCCCACTGGTGAGCTGTAGA DNA Polymerase 
k87_4084_5009_R Antisense ATCGGGAGTTTAGGCGCTAT DNA Polymerase 
PM_pol1_AS Antisense ACAAGGAGTGTGGGCATGTT DNA Polymerase 
PM_pol1_S Sense AACATGCCCACACTCCTTGT DNA Polymerase 
PM_pol2_AS Antisense GATATTGCATCCTCGGATCG DNA Polymerase 
PM_pol2_S Sense CGATCCGAGGATGCAATATC DNA Polymerase 
PM_pol3_AS Antisense AGCAACTCGTTGTATGGTGCT DNA Polymerase 
PM_pol4_S Sense CAGCGAACCTCTTGACTAAGTTT DNA Polymerase 
PM_pol4_AS Antisense AAACTTAGTCAAGAGGTTCGCTG DNA Polymerase 
PM_pol5_S Sense CTTGACCCTGAAGCTAATGTCA DNA Polymerase 
PM_pol5_AS Antisense TGACATTAGCTTCAGGGTCAAG DNA Polymerase 
PM_pol6_AS Antisense GATGCCACTCCTGATGCTCT DNA Polymerase 
PM_pol7_S Sense GCCCTTGAAGGTGTAGATGC DNA Polymerase 
k87_5634_4643_F Sense AGCTGCAGGCGCTTATACA Hexon 
k87_5634_4643_R Antisense GGTCTCACGTAGGCACCGTA Hexon 
k87_3902_961_F Sense CTTTATGGGCGCCAAGTC Hexon 
k87_3902_961_R Antisense CATGACACCCTTCAAGCTGAG Hexon 
k87_5634_4643_F Sense AGCTGCAGGCGCTTATACA Hexon 
PM_hex1_F Sense AATGGCACCAAGTTCCTCTC Hexon 
PM_hex1_R Antisense AACTGGGAGCGGTATTTCAA Hexon 
PM_hex1_R_S Sense TTGAAATACCGCTCCCAGTT Hexon 
PM_hex1_R_outer Antisense ACGCTGTACAGAGCGGACTT Hexon 
PM_hex2_AS Antisense GGGCTTGTACATGTCCTCGT Hexon 
PM_hex3_S Sense GTGCCGTTCAGCTCAGACTT Hexon 
PM_hex4_S Sense GCAACCCCATCATAGACATCT Hexon 
PM_hex5_F Sense AAAGTTCCTCTGTGACAACTACCTC Hexon 
PM_hex5_R Antisense TGTTGTCGAAGACACCCAGA Hexon 
PM_hex6_AS Antisense TAGTTGGTACGGGTCAGGCT Hexon 
PM_hex7_AS Antisense GTAGTGGTGCCTGCTCATCA Hexon 
PM_hex8_F Sense AGCCCAGATCCAATTCACTG Hexon 
PM_hex8_R Antisense TGACTTTGAGCCGTGTGAAG Hexon 
PM_hex9_F Sense GAGGAATTTTGACCCCATGA Hexon 
PM_hex9_R Antisense TGGTGTACATGGGGTTCTGC Hexon 
  
 






The PCR reaction conditions for each primer set for sequencing DNA polymerase 
and hexon MAdV-1 are summarised, including the Taq polymerase used (Table from 
Walker et al., 2017). 
 
Forward primer Reverse primer Taq 
polymerase 
Reaction conditions 
k87_5383_pol_F k87_5383_pol_R LongAmp 94 °C for 30 s, 35 x (94 °C for 30 s, 57 °C for 30 s, 65 °C for 1 min 40 
s), 65 °C for 10 min 
k87_4084_5009_F k87_4084_5009_R LongAmp 94 °C for 30s, 35 x (94 °C for 30 s, 57 °C for 30 s, 65 °C for 1 min 40 
s), 65 °C for 10 min 
k87_5634_4643_F k87_5634_4643_R LongAmp 94 °C for 30 s, 35 x (94 °C for 30s, 57 °C for 30s, 65 °C for 1 min 40 
s), 65 °C for 10 min 
k87_3902_961_F k87_3902_961_R LongAmp 94 °C for 30 s, 35 x (94 °C for 30 s, 57 °C for 30 s, 65 °C for 2 min), 
65 °C for 10 min 
k87_5634_4643_F k87_3902_961_R LongAmp 94 °C for 30 s, 35 x (94 °C for 30 s, 57 °C for 30 s, 65 °C for 4 min), 
65 °C for 10 min 
k87_5383_pol_F PM_pol1_AS GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 
PM_pol1_S PM_pol2_AS GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 
PM_pol2_S PM_pol3_AS GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 
k87_4084_5009_F PM_pol2_AS GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min, 
72 °C for 5 min 
PM_pol4_S PM_pol5_AS GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min 
30 s), 72 °C for 5 min 
PM_pol5_S k87_4084_5009_R GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 
PM_hex1_F PM_hex1_R GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 
PM_hex1_R_S PM_hex1_R_outer GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 
k87_3902_961_F PM_hex2_AS GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30s, 72 °C for 1 min 30 
s), 72 °C for 5 min 
PM_hex3_S PM_hex2_AS GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 
PM_hex4_S k87_3902_961_R GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 
k87_5383_pol_F PM_pol2_AS GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 
PM_pol1_S PM_pol6_AS GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 
PM_pol7_S PM_pol5_AS GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 
PM_hex5_F PM_hex5_R GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 57 °C for 30 s, 72 °C for 45 s), 
72 °C for 5 min 
PM_hex1_F PM_hex7_AS GoTaq 95 °C for 2 min, 35 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 
k87_5634_4643_F PM_hex6_AS GoTaq 95 °C for 2 min, 40 x (95 °C for 30 s, 54 °C for 30 s, 72 °C for 1 min 
40 s), 72 °C for 5 min * 
PM_hex8_F PM_hex8_R GoTaq 95 °C for 2 min, 40 x (95 °C for 30 s, 54 °C for 30 s, 72 °C for 1 m 40 
s), 72 °C for 5 min 
PM_hex9_F PM_hex9_R GoTaq 95 °C for 2 min, 40 x (95 °C for 30 s, 52 °C for 30 s, 72 °C for 1 min), 
72 °C for 5 min 











5.2.7 Screening of pine marten tissues for marten adenovirus type 1 
(MAdV-1) using a specific nested PCR 
 
To estimate the frequency of MAdV-1 in all of the samples collected from the pine 
martens (see section 5.3.2 Initial detection of novel adenoviruses by consensus 
adenovirus DNA polymerase nested PCR) a more specific nested PCR was designed 
using the complete cds of MAdV-1 DNA polymerase. 
 
For the nested MAdV-1 DNA polymerase PCR, the primers were PMPolFouter (first 
round, forward; 5’-GCTGATGTCTGGATGGTCCT-3’), PMPolRouter (first round, 
reverse; 5’-ATACCGAGCAATACCCATGC-3’), PMPolFinner (second round, 
forward; 5’-TGCAGTGTTGGCAGGATCTA-3’), PMPolRinner (second round, 
reverse; 5’-CCGCACAGAGAGATGTTCAA-3’). The reaction mixture was 0.2 µL 
(1 U) GoTaq G2 DNA polymerase (Promega), 10 µL 5x Green GoTaq buffer 
(Promega), 1 µL dNTPs (200 µM for each dNTP), 1 µL of each primer (forward and 
reverse; first or second round; 200 nM each primer), 5 µL DNA (DNA in first round 
or PCR product in second round) and H2O to 50 µL. The PCR mixture was heated to 
95 °C for 1 min, then 95 °C for 1 min, 50 °C for 1 min, 72 °C for 45 s for 45 cycles, 
and a final extension by continued heating to 72 °C for 5 min. Samples which were 
determined to be positive for MAdV-1 DNA were confirmed by a repeated PCR to 


















5.3.1 Prevalence of canine adenoviruses in mustelid samples 
 
CAV-1 was not detected in mustelid samples using the consensus nested PCR. All 
liver and kidney samples were negative for CAV-1 by the specific PCR developed in 
section 4.4.2 (CAV-1 specific PCR protocol). 
 
5.3.2 Initial detection of novel adenoviruses by consensus adenovirus 
DNA polymerase nested PCR 
 
The initial screening of mustelid livers, by the consensus adenovirus DNA 
polymerase nested PCR, revealed two distinct and novel adenovirus sequences in 
two of the pine martens, pine marten 10 and pine marten 11, which were tentatively 
called marten adenovirus type 1 (MAdV-1) and marten adenovirus type 2 (MAdV-2) 
respectively. The nucleotide sequence corresponding to MAdV-1 DNA polymerase 
shared 71% identity with fowl adenovirus type 3 (GenBank KT862807.1) on BLAST 
analysis, which was unexpected because fowl adenovirus type 3 is an Aviadenovirus. 
This sequence was also detected in the DNA extracted from the kidney and faeces 
from the same pine marten, and the faeces of a second pine marten (with the initial 
consensus adenovirus PCR protocol). 
 
The tentatively named MAdV-2 was detected in the DNA extracted from the liver of 
a single pine marten and shared most identity with the Mastadenovirus, 
vespertilionid adenovirus type 1 (75%; GenBank KM043089.1). The single MAdV-2 
sequence was submitted to GenBank (KY753134; Appendix 2). 
 
DNA extractions from faecal samples taken from five pine martens were positive for 
additional novel sequences, which shared most identity with adenoviruses on 
BLAST with avian, reptilian and mammalian hosts (not shown). Unlike MAdV-1 
and MAdV-2 these sequences were not detectable in the DNA extracted from the 
liver, kidney or lung samples of the pine martens. Therefore, an assumption was 
 





made that these probable novel adenoviruses were detectable in faeces as a 
consequence of digestion of infected prey species, and may contribute to part of a 
mixed population of adenoviruses in the faecal samples. Sequences detectable in 
faeces alone were not investigated further for this reason. 
 
A novel adenovirus sequence, which was tentatively called lutrine adenovirus type 1 
(LAdV-1) was detected in a DNA sample from otter livers (pooled from otters 07, 08 
and 09). The LAdV-1 DNA polymerase sequence shared 81% identity with the 
Mastadenovirus, Indian flying fox adenovirus type 5 (GenBank KC692421.1). 
 
The initial MAdV-1 and LAdV-1 sequences were not submitted to the GenBank 
database because further sequences were obtained, which later received accession 
numbers (section 5.3.6 Prevalence of the detected adenoviruses in mustelid samples). 
The sequences are displayed in FASTA format below (the isolate descriptor refers to 
the individual animal source and tissue). 
 
























5.3.3 Virus isolation by cell culture inoculation 
 
Attempts to isolate and purify detected adenoviruses from the liver of pine marten 10 
(for which there was sufficient tissue available) and the livers of otters 01, 04, 07, 08 
and 09 by cell culture inoculation were unsuccessful. 
 
5.3.4 Detection of novel adenoviruses by HTS 
 
HTS was conducted to detect further sequences from MAdV-1 from pine marten 10 
and LAdV-1 from otter 8; this was conducted in the absence of a successful cell 
culture isolation. From the pine marten DNA library preparation, a total of 18 contigs 
were assembled from the MiSeq System reads and were determined to be part of the 
MAdV-1 genome. The contigs determined to share identity with an adenovirus, 
when analysed with BLAST, were most closely related to aviadenoviruses. 
 
The full cds of the putative MAdV-1 DNA polymerase and hexon genes were 
sequenced following additional PCR design (see 5.2.6 Sequencing full coding 
sequence of MAdV-1 hexon and DNA polymerase) to span the ‘gaps’ among contigs, 
which were assembled following analysis of HTS reads (CGR, University of 
Liverpool). Following assembly of the partial consensus sequences the complete 
coding sequence of the putative hexon and DNA polymerase genes of MAdV-1 were 
determined. The sequences of the putative genes of MAdV-1, which were submitted 
to GenBank, are summarised in Table 5.4 (sequences from Table 5.4 are available in 
Appendix 2). Other sequences assembled from HTS data, pertaining to other genes 
or non cds, were submitted to GenBank under accession numbers KY705359 to 
KY705373. 
 
No adenovirus contigs were assembled from the otter DNA library preparation and 
subsequent HTS. However, three single (unassembled) sequences were detected in 
the kidney of otter 08 by HTS, which were determined to be part of the tentatively 
named LAdV-1 genome. The reads were unpaired and 250 bp in length, but were not 
submitted to GenBank because the unpaired reads did not assemble into a contig 
 





(thus, they were not suitable to be submitted to the NCBI Sequence Read Archive; 
SRA; Leinonen et al., 2011). The LAdV-1 reads, in FASTA format below, display 
the putative gene in the descriptor. These sequences shared 72-81% identity with bat 
adenovirus (WIV13 isolate; GenBank KT698852.1) hexon, DNA polymerase and 
52K cds upon BLAST analysis. 
 




































MAdV-1 sequences submitted to GenBank. Sequences are available in Appendix 2 
(Walker et al., 2017). 
 
Sequence name* Accession number 
Marten adenovirus type 1 hexon complete cds KY705357 
Marten adenovirus type 1 DNA polymerase complete cds KY705358 
Marten adenovirus type 1 IVa2 partial cds KY705359 
Marten adenovirus type 1 IVa2 partial cds KY705360 
Marten adenovirus type 1 pTP partial cds KY705361 
Marten adenovirus type 1 52K partial cds KY705362 
Marten adenovirus type 1 pIIIa partial cds KY705363 
Marten adenovirus type 1 pIIIa partial cds KY705364 
Marten adenovirus type 1 pIIIa partial cds KY705365 
Marten adenovirus type 1 penton partial cds KY705366 
Marten adenovirus type 1 penton partial cds KY705367 
Marten adenovirus type 1 pVI partial cds KY705368 
Marten adenovirus type 1 DNA-binding protein partial cds KY705369 
Marten adenovirus type 1 100K partial cds KY705370 
Marten adenovirus type 1 100K partial cds KY705371 
Marten adenovirus type 1 pVIII partial cds KY705372 
Marten adenovirus type 1 pVIII partial cds KY705373 
 





5.3.5 Phylogenetic reconstruction 
 
Upon phylogenetic reconstruction using MEGA6 (Tamura et al., 2013), both the 
complete hexon and DNA polymerase genes (putative) of MAdV-1 were found to be 
most related to aviadenoviruses (Figure 5.1). 
 
Phylogenetic reconstruction for LAdV-1 was not formally performed due to the short 
length of the available sequences. However, as expected, all sequences shared most 











Phylogenetic reconstruction was performed using MEGA6; the amino acids 
sequences of MAdV-1 (a) DNA polymerase (KY705358) and (b) hexon (KY705357) 
were aligned to other adenovirus amino acid sequences with the ClustalW 
methodology (Larkin et al., 2007). Modelling was performed by best maximum 
likelihood (Le and Gascuel, 2008) with 500 bootstrap replicates. MAdV-1 sequences 





























5.3.6 Prevalence of the detected adenoviruses in mustelid samples 
 
The pine marten samples were re-screened following design of a specific nested 
PCR. MAdV-1 DNA was detectable in samples from pine martens in 2 of 14 (14.3%, 
95% CI 2.5-43.8%) livers (Table 5.5). The kidneys and faeces of the same animals 
were also positive for MAdV-1. Two additional faecal samples were MAdV-1 
positive (overall, 4 of 12 (33.3%, 95% CI 11.3-64.6%) faeces were positive). In total, 
the MAdV-1 prevalence among all pine martens (taking into account all sample 
types) was 28.6% (4 of 14, 95% CI 9.6-60.0%; Table 5.5). 
 
A specific LAdV-1 PCR could not be effectively designed because of the short cds 
obtained from the LAdV-1 genome. Therefore, the consensus adenovirus DNA 
polymerase PCR (Wellehan et al., 2004; Walker et al., 2016a) was used to estimate 
the frequency of LAdV-1 amongst all otter samples. DNA from LAdV-1, using the 
consensus nested PCR, was determined to be present in 8 of 9 (88.9%, 95% CI 50.7-
99.4%) Eurasian otters; 6 of 9 (66.6%, 95% CI 30.9-91.0%) livers and 5 of 9 (55.6%, 
95% CI 22.7-84.7%) kidneys were positive for LAdV-1 (Table 5.5; LAdV-1 






















Summary of the PCR result of each tissue. The pine marten PCR result is for MAdV-
1 (using the specific method designed in section 5.2.7). The Eurasian otter PCR 





Samples positive Samples negative 
Pine marten 01 - Liver, kidney, lung, faeces 
Pine marten 02 - Liver, kidney, lung, faeces 
Pine marten 03 - Liver, kidney, lung, faeces 
Pine marten 04 - Liver, kidney, lung, faeces 
Pine marten 05 Faeces Liver, kidney, lung 
Pine marten 06 - Liver, kidney, lung, faeces 
Pine marten 07 - Liver, kidney, lung, faeces 
Pine marten 08 - Liver, kidney, lung, faeces 
Pine marten 09 Faeces Liver, kidney, lung 
Pine marten 10 Liver, kidney, lung, faeces - 
Pine marten 11 - Liver, kidney, lung, faeces 
Pine marten 12 - Liver, kidney, lung 
Pine marten 13 Liver, kidney, faeces Lung 
Pine marten 14 - Liver, lung 
Otter 01 - Liver, kidney 
Otter 02 Kidney Liver 
Otter 03 Kidney Liver 
Otter 04 Liver, kidney - 
Otter 05 Liver Kidney 
Otter 06 Liver Kidney 
Otter 07 Liver, kidney - 
Otter 08 Liver, kidney - 





















Multiple contigs determined to assemble part of the putative MAdV-1 genome were 
detected. A second putative marten adenovirus, MAdV-2, was detected in the liver of 
a single animal, but was not investigated further for this reason. DNA polymerase 
from the putative LAdV-1 was detected in multiple Eurasian otters. Both MAdV-1 
and LAdV-1 were prevalent among samples, and LAdV-1 was present in the 
majority of otters (88.9%). CAV-1 was not detected in the tested samples. However, 
the sample size was relatively small (and the samples were from a small 
geographical area) and CAV-1 may not have been detected for this reason. 
 
The fully sequenced hexon and DNA polymerase genes of MAdV-1 appear to group 
with the Aviadenovirus clade, based on the phylogenetic reconstructions. According 
to this evidence, MAdV-1 could be a contemporary of the common ancestor of the 
fowl adenovirus grouping. This finding is unexpected and novel; every 
Aviadenovirus which has been previously sequenced has only been isolated or 
detected from avian host tissues/faeces. The sequences from LAdV-1 grouped with 
the mastadenoviruses on phylogenetic reconstruction, but this reconstruction was not 
analysed further due to the limited sequence data obtained (length of sequence). 
However, upon BLAST analysis, the sequences mostly resemble mastadenoviruses. 
This was expected because up until the present study all mastadenoviruses 
discovered have only been detected in hosts which are mammalian. 
 
The presence of the Aviadenovirus MAdV-1 in pine martens could possibly mean 
that there has been a cross-species transmission between hosts which are very 
divergent, as a result of predation of an infected prey species (which was the 
previous host). Members of the Atadenovirus branch have been suggested to have 
resulted from possible host-switch events, on the basis of the very divergent hosts 
within this clade (including cattle; Bos taurus, Tokay geckos; Gecko gecko, and 
chickens; Gallus gallus domesticus; Wellehan et al., 2004). However, MAdV-1 
clearly does not group within the Atadenovirus clade on phylogenetic reconstruction 
and is unique. 
 





More closely related host species have also effectively demonstrated interspecies 
transmission events. For example, interspecies transmission (and interspecies 
recombination) of adenoviruses from chimpanzee hosts to human hosts has also been 
suggested (Wevers et al., 2011). Serological evidence of historical exposure to non-
human primate adenoviruses in humans (and vice versa) is occasionally reported 
(Ersching et al., 2010, Chiu et al., 2013), although some of this may be accounted for 
by immunological cross reactivity. 
 
Zoonotic transmission of adenoviruses have been reported in other outbreaks of 
respiratory disease. For example, a titi monkey (Callicebus cupreus) research colony 
at the California National Primate Research Center, University of California, Davis 
was shown to be the source of an outbreak of fulminant pneumonia in researchers 
and some contact family members. Titi monkey adenovirus (TMAdV) was identified 
as the causative agent (Chen et al., 2011). Outbreaks have also been reported from 
contact with baboons in research facilities (Chiu et al., 2013). Additionally, non-
primate adenoviruses have been detected, and have caused mortalities in hosts, in 
hosts other than the named host. For example, a Eurasian otter, part of the zoological 
garden collection in Seoul Grand Park Zoo, South Korea was suggested to have died 
from ICH as a result of infection of CAV-1 (Park et al., 2007). Recently, SkAdV-1 
has been detected in a single captive African pygmy hedgehog (Atelerix albiventris) 
and was attributed to the respiratory tract disease in this individual (Madarame et al., 
2016). These discussed cases are likely to have occurred from opportunistic 
transmission of adenovirus. However, establishment of the adenoviruses in cases 
demonstrating a host-switch has not been demonstrated; most appear to be ‘dead-
end’ hosts. 
 
Therefore, MAdV-1 could represent the first demonstration of an established host 
switch, because it is present in multiple pine martens and as inapparent infections. 
Theoretically, MAdV-1 could have become ‘established’ in the new host as a result 
of the predation of an infected prey species, likely avian. Following this, given the 
estimated prevalence of MAdV-1 in Scottish pine martens, the virus could have 
adapted in the host to be infectious for conspecifics. It is acknowledged that further 
 





experimental work is required, including experimental infections, to investigate this 
further. If isolation is successful, it should be determined if MAdV-1 can directly 
infect other pine martens or mustelids (including pet ferrets). It would also be 
important to establish if MAdV-1 can re-infect avian cells/hosts.  
 
The two viruses MAdV-2 and LAdV-1 resemble mastadenoviruses, and probably 
evolved from a Mastadenovirus ancestor through co-speciation (Davison et al., 
2003). However, given the presented increasing evidence for host-switching of 
adenoviruses, these viruses could also be investigated further due to potential 
transmission of these viruses to other mustelids. 
 
Detection of these adenoviruses highlights that free-ranging species in the UK, other 
than red foxes, are infected with adenoviruses, and that unidentified adenoviruses are 
present within these populations. These mustelid species have home ranges which 
overlap with other mammals and may come into direct or indirect contact (via urine 
and faeces) with domestic dogs. Although it is unlikely that dogs are at risk of 
disease from contact with adenovirus-infected excrement or fomites, the unusual 
scenario of an Aviadenovirus being present in pine martens, means that ‘host-
switching’ is not an impossibility. It was therefore justified to have screened 
mustelids for CAV-1 also (given previous evidence of host-switching from canids to 
non-canids), although this was not present in any samples. 
 
It is important to highlight that there has been a recent pine marten translocation 
project in the UK (Veterinary Record, 2015). To the author’s knowledge the pine 
martens, and conspecifics from the same population, had not been screened by 
molecular methods for novel adenoviruses using consensus PCR protocols. Although 
pine martens were not present in the new location, there is a possibility that a new 
adenovirus could be introduced to other English/Welsh pine marten populations if 
further migration of translocated individuals occur. The marten adenoviruses could 
also be transmitted to other susceptible species, including other mustelids, and this 
may warrant further investigation. However, it is yet to be determined if MAdV-1, 
MAdV-2 or LAdV-1 can cause overt disease even in the host species. Serious viral 
 





pathology in free ranging pine martens and Eurasian otters has not previously been 
reported in the UK, but this can now be considered if cases are reported. Thus, it is 
hypothesised that these adenoviruses, if they indeed truly infect the host species, 
could be subclinical in nature (as is the case with most HAds) and are unlikely to 
cause serious population declines. However, this would need to be confirmed 
experimentally. 
 
The additional benefit of this study is that many published studies which determine 
adenovirus prevalence in free-ranging species populations are based on extractions of 
DNA from faecal samples. As has been highlighted in this study, the results 
presented by analysis of faeces alone should be considered with a degree of caution 
because it is possible that DNA from adenoviruses is present in faeces because of 
digestion of adenovirus-infected prey tissues. In the present study, care has been 
taken to only designate an adenovirus as a new adenovirus of the host if it was 




Three novel adenoviruses (MAdV-1, MAdV-2 and LAdV-1) were detected in the 
tissues of pine martens and otters from Scotland, UK. Two of these viruses, MAdV-1 
and LAdV-1, were also determined to be capable of being disseminated to 
susceptible individuals because they were detected in the faeces. Due to the absence 
of gross pathological changes in the tissues, it is suggested that these infections are 
inapparent and may be indicative of a persistent infection, similar to that exhibited by 
CAV-1 in red foxes (Walker et al., 2016b). The mustelids in this study were not 
positive for CAV-1 and are thus likely not to be an additional reservoir for this virus. 
However, it is noted that the sample size was relatively low and that the samples 
were sourced from geographically restricted areas. 
 
This study presents evidence to suggest that a major host switch of an adenovirus has 
occurred, and it may be warranted to monitor for this adenovirus in other host 
species from where the pine martens were located if further samples become 
 





available. Although the tissues used in this study were not useful for successfully 
isolating the novel adenoviruses (possibly due to variable degrees of autolysis or 
because the selected MDCKs were not permissive for infection) further attempts 
with fresh tissues (if available) and an array of cultured cell types is warranted. The 
suggestion that further mastadenoviruses are capable of establishing persistent 
infections in their hosts, and that an Aviadenovirus may be capable of establishing a 
persistent infection in a mammal, adds to the need to understand the mechanism of 
persistence of adenoviruses in mammalian tissues. 
 
Thus, it is emphasised that a major lack of knowledge (particularly in wildlife, but 
applicable to all adenoviruses) results from the mechanisms permitting possible 
persistence of infections. The current knowledge of adenovirus persistence lies 
mainly with HAds detected in lymphoid tissues (Garnett et al., 2009), HAds which 
are shed in human faeces (Roy et al., 2009) and HAds which ‘re-activate’ in 
immunosuppressed solid-organ and bone marrow transplant patients (e.g. Shields et 
al., 1985; Ison, 2006). The current study has suggested that further adenoviruses in 
free-ranging mammals are capable of persistence, and in a broad range of tissues.  It 
is hypothesised that common mechanisms of persistence may exist amongst them. It 
is important to investigate this further because it will allow us to understand how so 
many red foxes appear to be persistently infected with CAV-1 and become a wildlife 
reservoir. Transfer of knowledge, using CAV-1 as a model adenovirus, may also aid 
our understanding of how adenoviruses reactivate in human patients to cause severe, 




Development of a peptide ELISA 
























For the large-scale screening of fox sera, an indirect ELISA was developed in 
Chapter 4. This ELISA detected antibodies (IgG) against CAV-1 and CAV-2, but 
was indiscriminate in doing so because of the high cross-reactivity of antibodies to 
these viruses (Bass et al., 1980). However, it effectively addressed the need for a 
high-throughput, efficient and economically viable screening method for sera from 
free-ranging red foxes. 
 
There is a high degree of inference that, at least in red foxes in the UK, an untyped 
CAV antibody is assumed to be more likely a response to infection with CAV-1. 
This stance is based on the clinical evidence of disease caused by CAV-1 in red 
foxes (Chapter 2; Walker et al., 2016a), and the molecular prevalence of CAV-1 in 
the UK (Chapter 4; Walker et al., 2016b). Moreover, disease caused by CAV-2 has 
never been reported in a non-domestic canid and CAV-2 was not detected by 
molecular methods in red foxes in the UK in the samples which were tested. 
Therefore, there is some evidence to provide support to the argument that an untyped 
CAV antibody in a fox in the UK is more likely to have been a response to challenge 
with CAV-1. Thus, a degree of serological uncertainty is arguably acceptable for 
some studies, including the one conducted in Chapter 4, when there is corroborating 
molecular and clinical evidence. 
 
However, the issue of whether CAV-2 can cause disease in canids (other than dogs) 
is increasingly controversial. Despite there being no evidence of disease caused by 
CAV-2 in non-domestic canids, it has been reported that faeces from a single fox in 
Italy was positive for CAV-2 by PCR (Balboni et al., 2013). To the author’s 
knowledge this is the only detection of CAV-2 in the faeces of a fox which has been 
reported and is an unusual finding if it is indicative of a true infection; CAV-2 was 
not detected in faeces from foxes in the UK (Walker et al., 2016b). As has been 
discussed in Chapter 5, and has been demonstrated elsewhere (Baker et al., 2013; 
Chiappetta et al., 2016; Sukmak et al., 2017), adenoviral DNA can be frequently 
detected in the urine/faeces of animals, yet may not indicate an active infection 
 




without additional evidence of PCR positivity in tissue samples. In theory, CAV-2 
DNA could have been present in faeces due to contact with infected dog faeces/urine 
or contaminated foodstuffs. Therefore, there is a need for a discriminatory CAV 
ELISA, which can distinguish CAV-1 and CAV-2 specific antibodies. It is important 
to establish the epidemiological role of CAV-2 in red foxes emphatically; this would 
allow a true estimation of the prevalence of CAV-1 exposure compared to CAV-2, 
and whether red foxes in the UK are exposed to the latter at all. 
 
Furthermore, since the publication of Chapter 4, it has been demonstrated that CAV-
2 was detected by PCR in the spleens of two Iberian wolves (Canis lupus signatus) 
in northern Spain (Millán et al., 2016). This would indeed indicate a true infection 
with CAV-2 in non-domestic canines and it was suggested that this could have been 
a ‘spillover’ from domestic dogs in the region (Millán et al., 2016). Although disease 
in the Iberian wolves was not reported as a consequence of this infection, it raises 
questions on the epidemiological role of CAV-2 in Canis lupus subspecies. It is 
possible that CAV-2 is a virus which mainly infects Canis lupus spp., and primarily 
causes ITB in dogs, but there may be rare spillover into non-Canis spp. (i.e. Vulpes 
spp.), as detected by PCR and in the absence of disease. 
 
Outwith the UK, in ‘developing countries’ there is more often contact between 
wildlife (i.e. free-ranging canids) and domestic dogs (feral or owned; Belsare and 
Gompper, 2015). In countries where feral dogs are common, it is possible that these 
populations may be the ‘reservoir’ of viral disease; a reverse of the situation in the 
UK in regard to CAV-1. In situations where there is a less clear divide between free-
ranging wildlife and feral dogs, it is difficult to establish which population is the 
reservoir of CAVs because of the serological cross reactivity of CAV antibodies. 
Given that it is hypothesised that CAV-2 may be ‘a disease of dogs’, it is both 
interesting and important to find out which CAV is most prevalent where 
vaccinations of feral dogs are not, or are only intermittently, performed. This is 
important because CAV-1 can cause fatal disease and could cause serious declines in 
vulnerable and susceptible populations. Whereas, it can be argued that CAV-2 is 
often not serious and would not cause significant declines (based on the assumption 
 




that CAV-2-related disease is less severe than CAV-1); a feral dog shedding CAV 
could be a source of infection for susceptible species. 
 
For example, in Bolivia, feral dogs are rife in and around the Madidi National Park, 
which is also home to threatened free-ranging canids, including bush dogs (Speothos 
venaticus) and crab-eating foxes (Cerdocyon thous; Fiorello et al. 2004). Between 56 
and 100% of dogs in various towns surrounding Madidi National Park, were 
determined to have been exposed to CAV (Fiorello et al. 2004). Evidence of CAV 
exposure has also been documented in ‘communal dogs’ in north-western Zimbabwe 
in land surrounding Victoria Falls and Zambezi National Park; African wild dogs 
(Lycaon pictus) may be present in these parks (McRee et al., 2014). The free-ranging 
non-domestic canids in these studies are threatened or endangered. However, it was 
not addressed whether CAV seroprevalence in feral dogs was more likely to be the 
presence of antibodies against CAV-1 or CAV-2. Given the current serological 
assays available, it is impossible to address this beyond reasoned theory. If the 
seroprevalence was high because of exposure to, and the possible persistent infection 
with, CAV-1, then this needs to be ascertained; CAV-1 could be a threat to 
susceptible free-ranging canid species. Focused resources and efforts could then be 
directed to these populations to vaccinate dogs and possibly the free-ranging species. 
On the other hand, if it was determined that it was CAV-2 which was most prevalent 
in dogs (causing less severe disease), then conservation efforts could be re-directed 
elsewhere. 
 
Disease ‘spillover’, if it occurs, is often not possible to demonstrate because of the 
rarity of samples from endangered canids. However, some evidence of a spillover of 
CAV between species was provided by Belsare et al. (2014). It was shown that in 
and around the Great Indian Bustard Wildlife Sanctuary, Maharashtra, central India, 
that 71% of dogs were seropositive for CAV and that 52% of Bengal foxes (Vulpes 
bengalensis) were also seropositive; the home ranges of these species overlap 
(Belsare et al., 2014). The mechanism of infection between these two species is 
likely to be indirect contact. Because of the CAV assay used, which cannot 
distinguish CAV antibody types, it is unclear which CAV is circulating. One of 
 




several scenarios is therefore possible, including: i) that dogs are a reservoir of CAV-
1, which can spillover into Bengal foxes; ii) dogs are a reservoir of CAV-1 and 
CAV-2, which both spillover into Bengal foxes; iii) dogs are a reservoir of CAV-2, 
which can spillover into Bengal foxes; iv) dogs are a reservoir or CAV-2, but Bengal 
foxes are a reservoir of CAV-1 and are not (or rarely) infected by CAV-2; or v) that 
both species maintain each virus independently. 
 
In addition, spotted hyenas (Crocuta crocuta), albeit an animal of ‘least concern’ 
according to the International Union for Conservation of Nature (IUCN), have been 
known to predate on domestic dogs (Butler et al., 2004), which could be infected 
with CAV-1/CAV-2. It would not be unreasonable to consider other such ‘direct’ 
contact amongst other wild canids. Although it is noted that there is no current 
evidence of disease caused by CAV-1 in many free-ranging canid species in which 
populations were deemed to be seropositive (for untyped CAV; e.g. Belsare et al., 
2014; McRee et al., 2014), there is no reason to suspect that they are not susceptible 
to developing fatal disease, given evidence of CAV-1 infection in diverse hosts (see 
Chapter 1). Chapter 5 demonstrates that, in theory, a possible adenovirus host-switch 
occurred between a bird and a mammal (likely through predation of infected tissue), 
and such a host switch event may be considered less unusual than between the more 
closely related canid host species. 
 
A further use for a CAV discriminatory ELISA is highlighted by the studies 
demonstrating that untyped CAV antibodies were detected in European mink 
(Mustelia lutreola; Philippa et al., 2008), Wolverines (Gulo gulo; Dalerum et al., 
2005) and North American river otters (Lontra canadensis; Kimber et al., 2000). 
Although the authors of these publications reason that this demonstrates exposure to 
CAV (implied CAV-1), this may not necessarily be the case because novel 
mastadenoviruses (LAdV-1 and MAdV-2) have now been detected in mustelids by 
molecular methods (Chapter 5). Thus, alternatively, the seropositivity in these 
studies could be demonstrative of the cross-reactivity of adenovirus antibodies with 
closely related mastadenoviruses. For example, the antibodies detected in mustelids 
in south-west France (Philippa et al., 2008) were assumed to be towards CAV. It is 
 




possible that these may actually be MAdV-2 (another Mastadenovirus) antibodies 
which are cross-reactive with CAV. A discriminatory CAV ELISA could 
demonstrate whether these untyped adenovirus antibodies are indeed reactive to 
CAV-1, CAV-2 or neither. 
 
Finally, there is an additional requirement for a discriminatory serological assay 
because, although molecular methods (i.e. PCR) have been established to distinguish 
between CAV-1 and CAV-2, it is economically and practically infeasible to screen 
an adequate number of samples from wildlife by this method (taking into account 
required sample size calculations; Thrusfield, 2007). PCR on tissue samples can only 
practically be performed on deceased animals following post-mortem examinations 
and the collection and processing of samples. A molecular survey on threatened and 
endangered free-ranging species could not be conducted in this way, because 
sufficient tissue samples could not be obtained. The majority of red fox samples 
available for screening in the molecular survey in Chapter 4 were only available due 
to the surveillance network already established by governmental organisations (e.g. 
APHA, DAERA etc.). Such a network is likely not to exist for vulnerable or 
endangered species, which are not culled or killed on roads. PCR also does not 
demonstrate ‘historical’ exposure if an animal is PCR negative, unlike the presence 
of IgG. Haematological samples are arguably easier to obtain and are more practical 
to obtain a large sample size, and this can be effectively exploited by a high-
throughput ELISA. 
 
Development of a high-throughput, cheap, serological test to distinguish the 
antibodies towards CAV-1 and CAV-2 would solve these highlighted issues, and in 
relation to the current study, would seek to clarify the role of CAV-2 in free-ranging 
red foxes. One approach is the development of a new ELISA based on the use of 
synthetic peptides as antigen (as linear epitopes for antibodies), as compared to 
‘whole’ virus. 
 
Peptides can be designed to possess an amino acid sequence specific for a desired 
organism by knowledge of genomic sequence. Peptide ELISAs have been 
 




successfully employed to detect antibodies in otherwise non-differentiable 
organisms. For example, Shen et al. (1999) developed a peptide ELISA which could 
distinguish between the sera of animals vaccinated with foot-and-mouth disease virus 
(FMDV) and those which are naturally infected with FMDV. This was based on an 
ELISA containing antigenic peptide sequences specific for wild-type FMDV only 
(Shen et al., 1999). Similarly, a peptide ELISA was successfully developed by 
Kannangai et al. (2001), which was capable of distinguishing between antibodies 
against human immunodeficiency virus type 1 (HIV-1) and human 
immunodeficiency virus type 2 (HIV-2). Velumani et al. (2011) demonstrated the 
use of peptide ELISA to distinguish exposure to a specific H5N1 avian influenza 
antigen in chickens and humans. In addition to their successful employment in other 
diseases, peptide ELISAs are beneficial due to the ease of production of peptides and 
that there is no need to produce infectious virus (Shen et al., 1999). 
 
Therefore, the aim of this chapter is to develop a ‘proof of concept’ indirect ELISA, 
based on a similar approach to the aforementioned studies, using candidate peptides 
potentially capable of distinguishing between the antibodies against CAV-1 and 
CAV-2. Sera used in this study was selected based on the assumption that CAV-
positive dogs were likely to have been vaccinated with CAV-2 and CAV-positive 
foxes were likely to have been exposed to CAV-1. 
 
6.2 Materials and methods 
 
6.2.1 Analysis of CAV-1 and CAV-2 genomes and selection of peptides 
 
The structure and annotation of the CAV-1 and CAV-2 genomes have been detailed 
and annotated previously (Morrison et al., 1997; Davison et al., 2003). The entire 
reference genomes of CAV-1 (EMBL AC_000003.1) and CAV-2 (EMBL 
AC_000020.1) shared 86% nucleotide identity when compared using BLAST 
(Johnson et al., 2008). Practically this equates to two viruses which are highly related 
and contributes to the considerable cross-reactivity exhibited by these adenoviruses, 
which cannot be reliably distinguished using conventional serological techniques. 
 





The genomes of CAV-1 and CAV-2 were downloaded from the National Center for 
Biotechnology Information (NCBI; https://www.ncbi.nlm.nih.gov) and imported into 
SSE (Simmonds, 2012) for sequence and alignment and to visualise the 
nucleotide/amino acid differences between the genomes. 
 
The sequence analysis results (see section 6.3.1 Results of CAV-1 and CAV-2 genome 
analysis and selection of peptides) encompass non-synonymous nucleotide variation 
(to varying degrees) between CAV-1 and CAV-2, including unique nucleotide 
insertions/deletions within the selected genes.  
 
The potential for the existence of linear epitopes was confirmed, and many candidate 
peptide sequences identified, from the amino acid sequences using a linear epitope 
prediction program, Support Vector Machine with Tri-peptide Similarity and 
Propensity scores (SVMTriP; Yao et al., 2012). Because linear epitopes may not 
necessarily reflect the antigenicity of a three-dimensional protein structure (i.e. they 
are predictions based on, for example, surface accessibility and hydrophilicity), 
many of the identified peptide candidates would have to be screened to confirm their 
antigenicity in practice (Van Regenmortel and Pelleguer, 1994). Therefore, it was 
decided that the most efficient approach to screening numerous peptides was to 
create an overlapping peptide library of the entire amino acid sequences of the 
selected key genes (or partial genes; see section 6.3.1 Mapping of antigenic sites in 
CAV-1 and CAV-2) which showed some variation between CAV-1 and CAV-2: 
hexon (partial), fiber, E3 ORFA, pV (partial) and pVI (partial). Peptides were 
selected to be 15 amino acids in length (15-mer) with a 14 amino acid overlap. The 












6.2.2 Ultrahigh-density peptide microarray 
 
The screening of thousands of peptides provides technical and economic difficulties. 
Thus, an approach devised by Buus et al. (2012) was employed, which uses 
ultrahigh-density peptide microarrays to map linear epitopes, after application of 
primary antibodies, using high resolution imaging (this was performed by Schafer-N, 
Copenhagen, Denmark). Peptides were synthesised directly onto BSA-coated slides, 
in defined 2x2 arrays, using methods detailed in Buus et al. (2012). The approach 
allowed for the screening of 24 identical microarrays containing 2,857 15-mer 
peptides in duplicate. Briefly, 24 sera from dogs and foxes were screened (sera 
diluted to 1:100). Sera included positive and negative controls as determined by the 
VNT described in Chapter 4 (Table 6.1). At this stage, positive sera were selected 
assuming that vaccinated dogs would possess CAV-2 antibodies and red foxes would 
have been exposed to CAV-1 only. 
 
Peptide-bound fox and dog IgG was then detected using antibody tagged with 
indocarbocyanine (Cy3) fluorescent dye, Cy3-Affinipure Rabbit Anti-Dog IgG (1 
µg/mL; Jackson ImmunoResearch, West Grove, Philadelphia, USA). The secondary 
antibody was first validated for use with fox sera using a standard direct ELISA 
approach (by omission of the incubation of CAV-1 from the methods described in 
Chapter 4.4.5) and the Cy3 signal was detected by the Typhoon FLA 7000 laser 
scanner (General Electric Healthcare, Little Chalfont, Buckinghamshire, UK). 
Images of the ultrahigh-density peptide microarrays were captured using a 
florescence microscope and digital camera (Olympus, Ballerup, Denmark; Buus et 
al., 2012) and the signal quantified with PepArray (Schafer-N). A representative 













Summary of the sera selected for use with each sector of the ultrahigh-density 
peptide microarray. The animal identification (ID) is anonymised for clinical record 
data protection. The microarray ID refers to the ID of each microarray sector 
(Appendix 2). Dog sera originated from Easter Bush Pathology, RDSVS unless 
otherwise indicated. Fox sera originated from Tiggywinkles Wildlife Hospital, unless 
otherwise indicated. 
 
Animal ID Microarray ID Species CAV IgG status 
AnonDog1 Dog 1 Dog Positive 
AnonDog2 Dog 2 Dog Positive 
AnonDog3 Dog 3 Dog Negative 
AnonDog4 Dog 4 Dog Positive 
AnonDog5 Dog 5 Dog Positive 
AnonDog6 Dog 6 Dog Positive 
AnonDog7 Dog 7 Dog Positive 
AnonDog8 Dog 8 Dog Positive 
AnonDog9 Dog 9 Dog Positive 
AnonDog10 Dog 10 Dog Positive 
AnonDog11 Dog 11 Dog Positive 
AnonDog12 Dog 12 Dog Negative 
NormalDog* Dog 13 Dog Positive 
AnonFox1 Fox 1 Red fox Negative 
AnonFox2 Fox 2 Red fox Positive 
AnonFox3 Fox 3 Red fox Positive 
AnonFox4 Fox 4 Red fox Negative 
AnonFox5 Fox 5 Red fox Negative 
AnonFox6 Fox 6 Red fox Positive 
AnonFox7 Fox 7 Red fox Positive 
AnonFox8 Fox 8 Red fox Positive 
AnonFox9 Fox 9 Red fox Positive 
AnonFox10 Fox 10 Red fox Positive 
180516/1† Fox 11 Red fox Positive 
 
* Commercial ’dog control serum’ (Alpha Diagnostic International, San Antonio, Texas, USA). Marketed as a 
non-immunised control, but was actually positive for CAV IgG in the untyped CAV ELISA (i.e. used as a 
positive control for CAV). 
† Red fox underwent post-mortem examination at RDSVS on this date and did not have a clinical record ID. 
 
 





Representative sector from the ultrahigh-density peptide microarray; Sector 6, dog 6. 
Each peptide is printed in a ‘2 x 2 mirror’ in the grid (10 µm2 per mirror; Buus et al., 
2012). More positively antigenic peptides appear as brighter areas within the grid 
(contrast has been enhanced to improve print visibility).  
 
 




6.2.3 Epitope mapping 
 
The dataset obtained from the ultrahigh-density microarray was imported into 
Microsoft Excel to be analysed. A mean reading for each duplicated 15-mer peptide 
was obtained for each sera. A positive signal (i.e. an ‘antigenic peptide’) was 






μ	all	peptide	signals	in	sector	 	 3σx̅ lowest 10%	signals	in	sector
 
 
In order to easily visualise the most antigenic sites (as 15-mer linear epitopes) in the 
CAV-1 and CAV-2 peptide libraries tested, the corrected peptide signals were 
plotted on line graphs. The signals from sera of dogs and foxes could be grouped 
together (as a mean signal for dogs vs. foxes) according to positivity and negativity 
(in regards to untyped CAV IgG status) and individual sera could be analysed by 












7 The use of the mean + 3x(standard deviations of the mean) of the lowest 10% signals in sector 
was suggested by Claus Schafer (Schafer-N), personal communication, 14 July 2016). Mean + 
3x(standard deviations of the mean) of control samples is an accepted, subjective calculation to 
determine the positive/negative cut off value in ELISAs (e.g. Wirtz et al., 1987; Beier et al., 
1988) in the absence of a standard curve. 
 




6.2.4 Peptide selection for proof of concept peptide ELISA 
 
Following analysis of the ultrahigh-density peptide microarrays, eight candidate 15-
mer peptides were selected to carry forward for use in a proof of concept peptide 
ELISA to discriminate IgG against CAV-1 and CAV-2 (only eight were selected due 
to financial restrictions; see section 6.3.3). The selected peptides were synthesised in 
5-9 mg quantities at >70% purity with unmodified (free) N- and C-termini 
(ProImmune, Oxford, UK). 
 
6.2.5 Trial peptide ELISA protocol 
 
There are inherent difficulties associated with binding peptides to microplates 
because of their very small molecular weight compared to a whole virion, 
incompatibility with the pH of buffers used and/or masking of epitopes/signal by 
BSA (Cuccuru et al., 2012). A peptide ELISA was first performed using the same 
method described in Chapter 4 for the ‘whole virus’ ELISA (except substituting 
CAV-1/CAV-2 for the peptides). However, it was determined that the peptides did 
not bind to the plate, and were removed during the washing steps. Therefore, a 
specialised Nunc Covalink NH microplate (Thermo Fisher Scientific, Langenselbold, 
Germany) was utilised. 
 
The binding of synthesized peptides to the Nunc Covalink NH microplate is based on 
the formation of amide bonds between the free carboxyl groups (-COOH) of the 
peptides and a polystyrene microplate with modules coated with amine groups (-
NH). The chemical reaction was initiated by the use of 1-ethyl-3(3-
dimethylaminopropyl)carbodiimide (EDC) to generate O-acylurea compounds. 
These compounds are hydrolysed readily without the use of N-
hydroxysulfosuccinimide (sulfo-NHS), which is considered to enhance the EDC-
mediated coupling reaction (Staros et al., 1986; Andersen, 2012). The protocol is 
summarised below and was adapted from the one described in section 4.4.5 (Indirect 
enzyme-linked immunosorbent assay) and the recommended protocol of the 
microplate manufacturer (Andersen, 2012). The microplate incubation and wash 
 




steps differed from the manufacturer’s because omission of protein for blocking 
empty binding sites in the microplate wells was deemed to be unsuitable for an 
indirect ELISA as compared to a direct ELISA, for which it was developed. 
 
1.84 mg sulfo-NHS (Abcam, Cambridge, UK) was dissolved in 10 mL dH2O and 
12.3 mg of EDC was (Sigma-Aldrich, Gillingham, Dorset, UK) dissolved in 10 mL 
dH2O. 1 mg of each peptide was dissolved in 1 mL of H2O (molecular grade; 
Qiagen), except peptides 3 and 5 which were dissolved in 970 µL H2O and 30 µL 
NH4OH due to insolubility.  
 
Peptides were diluted in sulfo-NHS to a working concentration of 200 µg/mL. 100 
µL peptide (200 µg/mL) was added to the microplate wells (Nunc Covalink NH). 
100 µL EDC was added to each well to activate the coupling reaction and incubated 
for 2 h at ambient temperature. Each well in the microplate was then washed twice 
using 250 µL PBS/0.05% Tween (Sigma-Aldrich), dispensed by an automated 
microplate washer (Ays Atlantis, Biochrom). The wells were then blocked with 150 
µL dried skimmed milk (Marvel, Premier Foods, St. Albans, Hertfordshire, UK) 
dissolved in PBS to 1% weight/volume (PBS/1% skimmed milk), for 1 h at ambient 
temperature. Wells were then aspirated and sera applied, diluted 1:10 in PBS/1% 
skimmed milk, in a volume of 100 µL for 1 h. Wells were aspirated and soaked with 
PBS/0.05% Tween six times over 40 min. Secondary antibody, HRP conjugated goat 
anti-dog IgG (Abcam) diluted to 1:1600 in PBS/1% skimmed milk, was applied to 
aspirated wells in a volume of 100 µL for 30 min. Wells were then washed four 
times over 30 min and aspirated. 70 µL azino-bis (Sigma-Aldrich) was applied to 
wells for 15 min to detect the secondary antibody. OD405 was then measured using 
the Synergy HT microplate scanner (BioTek, Swindon, Wiltshire, UK). 
 
All eight peptides (Table 6.2) were included in a trial microplate to test the 
antigenicity of peptides in this application against various sera. Two peptides were 
chosen to carry forward into a proof of concept screening ELISA (limited to two 
because of the results and limited sera stocks; see section 6.3.4 Trial peptide ELISA 
results). 
 




6.2.6 Screening peptide ELISA protocol 
 
The same protocol for ELISA preparation was followed to that described in section 
6.2.5 (Trial peptide ELISA protocol). For each sera, the two peptides were added to 
the microplates in duplicate and included negative control wells. The negative 
control (‘irrelevant’) peptide was also prepared in the same manner as the test 
peptides; this was a 15 amino acid long peptide fragment (>95% purity) based on 
human amyloid beta (single letter amino acid sequence: DAEFRHDSGYEVHHQ; 
Eurogentec, Southampton, Hampshire, UK). 
 
6.2.7 Analysis of peptide ELISA results 
 
A similar approach to ELISA analysis to that described in Chapter 4 was not 
employed (i.e. calculation of a ROC curve and objective cut off; see section 4.4.5 
Indirect enzyme-linked immunosorbent assay) because the number of positive and 
negative controls was not sufficient to calculate a cut off with a suitably narrow 
confidence interval. Therefore, a positive/negative cut off value was estimated by 
calculation of the mean value of the negative control wells plus three standard 
deviations of the mean. Background signal (calculated from the irrelevant peptide) 
was subtracted from the mean OD405 of negative control peptide signals. The cut off 
value of three standard deviations of this corrected OD405 mean was subtracted for 




6.3.1 Results of CAV-1 and CAV-2 genome analysis and selection of 
peptides 
 
Hexon and fiber were selected for further analytical processing since they are 
expected to be highly antigenic. Core proteins including pV and pVI were also 
selected because these showed some variation between CAV-1 and CAV-2. 
However, most proteins shared high identity (as expected by overall nucleotide 
 




identity), which limited the number of potential candidates for peptides offering 
specific antigenicity. Alignments are displayed in Figure 6.2. 
 
The most significant difference between CAV-1 and CAV-2 is the presence of an 
approximately 500 bp nucleotide sequence within the coding sequence of the E3 
gene of CAV-2, which shares 0% identity with CAV-1 (Figure 6.2). It has been 
previously suggested that this is a result of an insertion event due to insertion of host 
or viral DNA (Linné, 1992). However, on BLAST analysis, homologous amino acid 
sequence (approximately 174 amino acids, relating to the CAV-2 E3 nucleotide 
‘insertion’) was present in the E3 ORFA cds of bat adenovirus strain TJM 
(YP_005271198.1), SkAdV-1 (YP_009162604.1) and equine adenovirus type 1 
(ANG08573.1). This unique CAV-2 sequence was identified as an important target 
of peptide selection for the discriminatory ELISA; any antigenicity in this region 
should be CAV-2 specific because there is no CAV-1 homologous sequence due to 
this possible deletion event. 
 
Figure 6.2 
Full and partial amino acids sequences of selected CAV-1 genes aligned with 
corresponding sequences from CAV-2. Identical amino acids are displayed with dark 
backgrounds and different amino acids are displayed with white backgrounds. The 
relevant protein name and NCBI protein identification numbers are indicated above 
each alignment. Alignments were imported into the web-based program, Multiple 
Align Show, for display purposes (http://www.bioinformatics.org/sms/multi_align.html). 
 
Hexon [partial 1] (AP_000059.1, AP_000622.1) 
CAV-1 - F K P Y S G T A Y N A L A P R A G A N N C L F N G S G A N I N T L A Q V P F A G - 40 
CAV-2 - F K P Y S G T A Y N A L A P K A G A N N C L F N G Q G A N I N T L A Q V P S A G - 40 
I                      
CAV-1 - A I T V N G Q A A V T D N T Y Q P E P Q L G P E S W V D G T L A D L G D A S G R - 80 
CAV-2 - A I T V N G Q A A V T N N T Y Q P E P Q L G P E S W V D G S L A E L G D A S G R - 80 
I                      
CAV-1 - A L K A S T P R M P C Y G S Y A P P T N E N G G Q A T G A V E R K F Y K V T A N - 120
CAV-2 - A L K A S T P R M P C Y G S Y A P P T N E N G G Q A T G P V E S R F Y K V T T N - 120
I                      
CAV-1 - N N N E A D A L L Y T E D V N L Q T P D T H L V H Q V S D D Q V T G V Q G L G Q - 160
CAV-2 - N N N E A D A M L Y T E D V N L Q A P D T H L V H Q V P E G Q V T G V Q G L G Q - 160
I                      
CAV-1 - Q A A P               - 164
CAV-2 - Q A A P               - 164
 





Hexon [partial 2] (AP_000059.1, AP_000622.1) 
CAV-1 - I D N H G V E D D M P N Y C F P L S G M G P L T N M T A M K V N N Q N F Q T D N - 40 
CAV-2 - I D N H G V E D D M P N Y C Y P L S G M G P L T N M T T M K V N N Q N F Q A E N - 40 
I                      
CAV-1 - T N V G P I Q K I G F G N V E A M E I N L N A N L F K G F L Y S N V A L Y L P D - 80 
CAV-2 - T N V G P I Q K I G F G N V E A M E I N L N A N L F K S F L Y S N V A L Y L P D - 80 
I                      
CAV-1 - A Y K Y T P D N I V A P A N A N T Y A Y M N V R L P A A N       - 109 
CAV-2 - A F K Y T P E N I V A P A N V N T Y A Y M N V R L P A A N       - 109 
 
Hexon [partial 3] (AP_000059.1, AP_000622.1) 
CAV-1 - G Y N V A Q S N M T K D W F L V Q M L A H Y N I G Y Q G Y H L P E S Y K D R M Y - 40
CAV-2 - G Y N V A Q S N M T K D W F M V Q M L A H Y N I G Y Q G Y H L P E S Y K D R M Y - 40
I                      
CAV-1 - S F L R N F E P M C R Q L V D V T N Y A T Y Q S V T V G H Q H N N S G Y A S A L - 80
CAV-2 - S F L R N F E P M C R Q L V D V A N Y A A Y Q P V T V G H Q H N N S G Y A S A L - 80
I                      
CAV-1 - S T F N P R E G H P Y P A N W P Y P L I G V N A V P T V T Q K K F L C D R T L W - 120
CAV-2 - S A F N P R E G H P Y P A N W P Y P L I G A N A V P T V T Q K K F L C D R S L W - 120
I                      
CAV-1 - R I P F S S N F M S M G        - 132
CAV-2 - R I P F S S N F M S M G        - 132
 
Fiber (AP_000069.1, AP_000632.1) 
CAV-1 - M K R T R S A L P A N F D P V Y P Y D A P K P S T Q P P F F N D R K G L T E S S - 40 
CAV-2 - M K R T R R A L P A N Y D P V Y P Y D A P G S S T Q P P F F N N K Q G L T E S P - 40 
I                     
CAV-1 - P G T L A V N I S P P L T F S N L G A I K L S T G A G L I L K E G K L E A N I G - 80 
CAV-2 - P G T L A V N V S P P L T F S T L G A I K L S T G P G L T L N E G K L Q A S L G - 80 
I                     
CAV-1 - P G L T T N Q E G Q I T V E K D S D G L T F T S P L H K I E N T V S L S I G E G - 120
CAV-2 - P G L I T N T E G Q I T V E N V N K V L S F T S P L H K N E N T V S L A L G D G - 120
I                     
CAV-1 - L E D E S G T L K V N F P S P P P P L L F S P P L A E A G G T V S L P L Q E S M - 160
CAV-2 - L E D E N G T L K V T F P T P P P P L Q F S P P L T K T G G T V S L P L Q D S M - 160
I                     
CAV-1 - Q V T E G K L G V K P T T Y S P P L Q K T D Q Q V S L R V G P G L T V L N G Q L - 200
CAV-2 - Q V T N G K L G V K P T T Y A P P L K K T D Q Q V S L Q V G S G L T V I N E Q L - 200
I                     
CAV-1 - Q A V Q P P A T T Y K E P L L E T E N S V S L K V G A G L A V Q D G A L V A T P - 240
CAV-2 - Q A V Q P P A T T Y N E P L S K T D N S V S L Q V G A G L A V Q S G A L V A T P - 240
I                     
CAV-1 - - P N V T F S A P L E K N G N A V S V R V G A G L S I Q G N A L V A T T S P T L - 279
CAV-2 - P P P L T F T S P L E K N E N T V S L Q V G A G L S V Q N N A L V A T P P P P L - 280
I                     
CAV-1 - T F A Y P L I K N N N H I T L S A G S G L R V S G G S L T V A T G P G L S H I N - 319
CAV-2 - T F A Y P L V K N D N H V A L S A G S G L R I S G G S L T V A T G P G L S H Q N - 320
I                     
CAV-1 - G T I A A V I G A G L K F E N N A I L A K L G N G L T I R D G A I E A V A P Q P - 359
CAV-2 - G T I G A V V G A G L K F E N N A I L A K L G N G L T I R D G A I E A - - T Q P - 358
I                     
CAV-1 - S F T P V T L W T G P D P N V N T S I N G T P V I R S F I S L T R D S N L V T V - 399
CAV-2 - P A A P I T L W T G P G P S I N G F I N D T P V I R C F I C L T R D S N L V T V - 398
 




I                     
CAV-1 - N A S F T G E G S Y Q S V S P T Q S Q F S L I L E F N Q F G Q L M S T G N L N S - 439
CAV-2 - N A S F V G E G G Y R I V S P T Q S Q F S L I M E F D Q F G Q L M S T G N I N S - 438
I                     
CAV-1 - T T T W G E K P W G N N T V Q V Q P S H T W K L C M P N R E V Y S T P A A T L T - 479
CAV-2 - T T T W G E K P W G N N T V Q P R P S H T W K L C M P N R E V Y S T P A A T I S - 478
I                     
CAV-1 - S C G L N S I A H D G A P N R S I D C M L I I N K L A G A A T Y T L T F R F L N - 519
CAV-2 - R C G L D S I A V D G A P S R S I D C M L I I N K P K G V A T Y T L T F R F L N - 518
I                     
CAV-1 - F N K L S S S T V F K T D V L T F T Y V G E N Q         - 542
CAV-2 - F N R L S G G T L F K T D V L T F T Y V G E N Q         - 541
E3 ORFA (AP_000067.1, AP_000630.1) 
CAV-1 - M R F C F F F C F T A S I F C T T G N S S D I V F C C A H T P C L L H L E V D Q - 40 
CAV-2 - M R F S F F I A - - A V L F C T T G A S N D I V T C C A H T P C L L H L E V G L - 38 
I                     
CAV-1 - E T S V T W I D S N T G Q I P L C L S N G T C H I S E K G L H F S A N F S K D G - 80 
CAV-2 - G A N V S W I N S D T G Q A P I C L S N G M C N A T Q Q G L Q F S A N F S E D G - 78 
I                     
CAV-1 - L Y I A I I N E T N Y H A A E H Y Y L V Y I Y E N C H Q M P Y D S - - - - - - - - 112
CAV-2 - L Y I A L I K E S N Y E G A E H Y Y L V Y I Y G D C Y Q T A N E S A H G P I S R - 118
I                     
CAV-1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 112
CAV-2 - P L N E M P L P S V T I N A S L F Y P A F L E L P P Q Y S N D L S N V R W Y K V - 158
I                     
CAV-1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 112
CAV-2 - D P S G F Q A Q K I S K V R S G G R K E N L H P N W A L V T Y T G D L L V L H V - 198
I                     
CAV-1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 112
CAV-2 - S P N T L G L W L A A V Q H R G G R T N F I T F N I T V P N W Q Q N L V T I F N - 238
I                     
CAV-1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 112
CAV-2 - Q H E P P K K G D N Y E D S F M E W T L F K K L K K G L F R V T C R A K S I F P - 278
I                     
CAV-1 - - - - - - - - P R H T G H K G T S F N W S M G L W L V K C S H N K T F F L P F V - 146
CAV-2 - E C V L N I T R D G T F L L I G D S K K T P Y V I L L P F F A N P K E D T P I L - 318
I                     
CAV-1 - L D S A K S A P I I M T E T A I T I Y I S M I F L I V S L L T F L N V L I T L N - 186
CAV-2 - M A L S H S M P V A I P D T A M P I Y I S I M F F I V A M L A T L S L L M G L N - 358
I                     
CAV-1 - N K Y K H Y G V             - 194














pV [partial] (AP_000056.1, AP_000619.1) 
CAV-1 - K S E V E D E I L K R A K M - - E P F E T T V K M E Y S E Q P Q V E V F D T G V - 38 
CAV-2 - K G D A E D E I I K R V K M E L E P Y E T T M K M E Y S E E P Q V E A F D T G I - 40 
I                       
CAV-1 - E P S S F F E V R S Q A R P I A V A R K R R - - - - - V P T V E V M E V Q Q S D - 73 
CAV-2 - E P S S F F E V R S Q A R P I A V A R K R R T A A A S A P A V E V M E V Q Q S N - 80 
I                       
CAV-1 - H T A P T A S A A P V A N V I V G P H L S R R P S R W G P A N A I Y P D Y V Y H - 113
CAV-2 - P A T P A T A A A R T A T A L - G P R L A R R P S R W G P A N A I F P D Y K Y H - 119
I                       
CAV-1 - P S I S A K K T M G P R P T G R V S R W G P A N S I F P E V R L H P S M V S A V - 153
CAV-2 - P S I T A R K M R G P K P T G K I S R W G P A N S I L P E V R L H P S M V S A V - 159
I                       
CAV-1 - T R A A P R K S T K S R R R R R V R T R R A F V L P A G T K T G V M L P Q N I R - 193
CAV-2 - T R A A P R R V T K T R R R R R A R T R Q A F V L P A R T K T G A L L S Q N V R - 199
I                       
CAV-1 - Y H P S I - L F R R           - 202




pVI [partial] (AP_000058.1, AP_000621.1) 
CAV-1 - E R R L E R Q Q P L E P - - E V E E E T V E T K S E A K A P L V V E M P L K R P - 38 
CAV-2 - E R R L E R Q Q P L E P E V E V E E E V V D I K P E A Q A P L V V Q I P K K R P - 40 
I                     
CAV-1 - R D E D L V I T A D E P P S Y E E T I K T M A P L V P M T R P H P S M A R P V I - 78 
CAV-2 - R D E D L L I T A D E P P S Y E E S I K T M A P L M P M T R P H P S M A K P V L - 80 
I                     
CAV-1 - A D R P T T L E L K P S D Q P P P Y S P Q S - - - - - - - - - S N M P V T A P V - 109
CAV-2 - V D R P T T L E L K P S D Q P P A Y S P P A P S A V R V T V P S N I P V V T P A - 120
I                     
CAV-1 - R S R G W Q G T L A N I V G V G L S N V K R R R C F       - 135

















6.3.2 Mapping of antigenic sites in CAV-1 and CAV-2 
 
Readings from all 24 scanned sectors of the ultrahigh-density peptide microarray are 
available in Appendix 2 (see Figure 6.1 for the appearance of a representative 
sector). Some sera samples were subject to high background, but this was corrected 
somewhat by normalisation of values by calculating the corrected signal (see section 
6.2.3 Epitope mapping). 
 
When corrected, and the Cy3 signals were plotted, there was evidence of high 
antigenicity in some regions in all of the selected peptide libraries. Some of the 
individual peptides along the library show different levels of antigenicity between 
red foxes, dogs and intraspecifically. Therefore, many possible antigenic sites were 
possible to select for further testing in a peptide ELISA; representative plots are 
displayed in Figure 6.3. However, and unfortunately, in general it was difficult to 
discern differences between foxes and dogs (and often the negative control sera). 
Therefore some subjectivity was applied in the selection of peptides to take forward 
into the peptide ELISA development, based on differences between individual sera, 
not averages of species (see Table 6.2 for the selected peptides; Appendix 2 for all 
microarray readings). Peptides were heavily selected from the E3 region of CAV-2, 
where there was antigenicity, particularly to encompass novel sequence with 
no/minimal homology to CAV-1 which might provide specificity. 
 
Full readings from the 2,857 peptides tested with 24 sera are available in Appendix 
2. It is notable that the average reading for negative sera (i.e. sera considered to be 
negative for untyped CAV IgG; Table 6.1) was very high for some peptides (Figure 
6.3; Appendix 2). This may be because some negative control sera may have had low 
levels of CAV IgG, which was not detected using the calculated cut off for the 
untyped CAV ELISA; in this study, because the signal is a ‘relative’ signal, this 










Representative plots of linear epitopes, based on serological reactivity to 15mer 
peptides. The peptide number refers to the identity of the 15mer peptide sequence 
(Appendix 2). The signal is the corrected signal recording from the ultrahigh-density 
peptide microarray (section 6.2.3 Epitope mapping). The linear epitopes are shown 
for the first 200 15mer peptides from CAV-1 fiber (a) and CAV2 fiber (b), then the 
last 200 15mer peptides from CAV-1 fiber (c) and CAV-2 (fiber). The mean signal 
for all the foxes positive for CAV IgG in the untyped ELISA and all the positive 
dogs are shown. The mean for all negative control sera (both foxes and dogs) is also 
shown, which showed high ‘relative reactivity’ when plotted. 
 
a) Fiber, CAV-1: peptides 491 to 690 
 







































































































































































































































































c) Fiber, CAV-1: peptides 820 to 1019 
 
 







































































































































































































































































6.3.3 Selection of peptides for use in the trial peptide ELISA 
 
The peptides were selected on the basis that the 15-mer peptide sequences possessed 
i) amino acid variations between the corresponding CAV-1 and CAV-2 sequences 
(see Figure 6.2), ii) a large antigenic response in multiple canids, and iii) an antigenic 
response difference between red foxes and dogs. The peptides are summarised in 
Table 6.2. Because of the large numbers of peptides analysed by the ultrahigh-
density peptide microarray some degree of subjectivity was applied when selecting 
the final peptides. Subjectivity in peptide selection was exacerbated because of the 
high intraspecific variability in peptide signal, meaning an objective algorithm to 






Summary of the selected peptides for use with the proof of concept peptide ELISA to 
discriminate CAV-1 and CAV-2 IgG. The peptide sequences are displayed in single 
letter amino acid form. N- and C- termini were unmodified (free). 
 
Peptide name Peptide library 
number* 




Peptide 1 1463 EKPWGNNTVQPRPSH Fiber CAV-2 
Peptide 2 2050 HSMPVAIPDTAMPIY E3 (ORFA) CAV-2 
Peptide 3 2335 PAVEVMEVQQSNPAT pV CAV-2 
Peptide 4 1964 FNQHEPPKKGDNYED E3 (ORFA) CAV-2 
Peptide 5 1918 GDLLVLHVSPNTLGL E3 (ORFA) CAV-2 
Peptide 6 1650 YENCHQMPYDSPRHT E3 (ORFA) CAV-1 
Peptide 7 1828 YGDCYQTANESAHGP E3 (ORFA) CAV-2 
Peptide 8 566 EANIGPGLTTNQEGQ Fiber CAV-1 
 
* In the relation to the peptide library subject to testing in the ultrahigh-density peptide microarray; 








6.3.4 Trial peptide ELISA results 
 
Sera used in the trial ELISA (indicated in Table 6.3) were tested in duplicate against 
the eight selected peptides, produced on the basis of the results from section 6.3.2 




Several fox and dog sera known to be positive or negative to CAV (by the untyped 
CAV ELISA developed in Chapter 4) were selected to trial with each peptide. A 
negative control fox serum and a negative control dog serum was included. The 
numbers displayed are the mean corrected OD405 readings (after subtracting 
‘background OD405’ based on wells with no antigen). Sera identification numbers are 
not shown to hide clinical case numbers. The sum of all the corrected OD405 is shown 
under each column to indicate the most ‘reactive’ peptides across all sera. The 





















Fox Positive 0.07 0.19 0.01 0.23 0.08 0.30 0.98 0.20 
Dog Positive 0.03 0.07 0.01 0.06 0.01 0.03 0.01 0.04 
Fox Low positive 0.04 0.10 0.03 0.04 0.01 0.10 0.05 0.04 
Fox Positive 0.10 0.21 0.18 0.17 0.10 0.36 0.69 0.13 
Fox Positive 0.01 0.08 0.30 0.42 0.06 0.53 1.21 0.10 
Dog Low positive 0.06 0.14 0.03 0.09 0.02 0.06 0.02 0.06 
Dog Low positive 0.07 0.16 0.16 0.31 0.05 0.05 0.03 0.10 
Fox Negative 0.02 0.03 0.01 0.04 0.01 0.04 0.02 0.04 
Dog Negative 0.02 0.02 -0.06 0.09 0.00 -0.01 0.39 -0.07 
Dog Negative 0.03 0.07 -0.01 0.01 0.01 0.02 -0.01 0.01 
 Sum of corrected 
OD405 
0.44 1.06 0.66 1.46 0.35 1.48 3.37 0.66 
 
*IgG status based on testing against the CAV-1 antigen in the untyped CAV ELISA (see section 4.4.5 









Subsequently, peptides 6 and 7 were selected to screen against a larger number of 
sera because they were among the most reactive and designed against CAV-1 and 
CAV-2 respectively; peptide 7 encompassed the start of the unique CAV-2 E3 amino 
acid sequence (Figure 6.2). Thus, these peptides were selected as interesting 
candidates for a screening peptide ELISA, which may distinguish between the 
antibodies against CAV-1 and CAV-2, and were included in the final ELISA (More 
than two peptides could not be tested due to restrictions on the volumes of sera and 
equipment available). 
 
6.3.4 Proof of concept peptide ELISA 
 
The selected peptides (peptides 6 and 7) used in the final screening ELISA appeared 
to show moderate corrected OD405 readings for some sera. One serum showed 
unusually high background OD405 and was excluded on this basis. Sera with positive 
results against the peptides are indicated in Table 6.4, based on the calculated cut off 
values. Although one serum, previously regarded as negative in the ‘whole virus’ 
ELISA, showed a positive value for peptide 7, this was a low OD405. One serum, 
AnonFox14, showed a high signal for peptide 7, but was negative for peptide 6, 
indicated in Table 6.4. The majority of sera showed ‘similar’ OD405 for both 
peptides, except the positive control (from a red fox), which showed 


















Results from the proof of concept peptide ELISA, which ‘screened’ fox and dog 
sera. The sera were tested over two plates (plate number for each serum is indicated), 
which both had a negative and positive control. The negative control on each plate 
was used to calculate a threshold for a positive/negative result by calculating ‘three 
standard deviations of the mean’ of the mean peptide OD405 for negative control after 
subtracting the irrelevant peptide (i.e. background OD405). Peptide 6 is predicted to 
be specific for CAV-1 and peptide 7 is predicted to be specific for CAV-2. 
 





















AnonDog2 Positive 1 0.09 0.07 0.08 -0.08 -0.07 0 0 
AnonDog10 Positive 1 0.2 0.15 0.13 -0.02 -0.05 0 0 
AnonDog12 Negative 2 0.13 0.13 0.11 -0.09 -0.09 0 0 
AnonDog14 Positive 1 0.13 0.11 0.09 -0.04 -0.04 0 0 
AnonDog15 Positive 1 0.15 0.13 0.11 -0.06 -0.04 0 0 
AnonDog16 Positive 1 0.76 0.58 0.26 0.4 0.25 1 1 
AnonDog17 Positive 1 0.2 0.18 0.12 -0.02 -0.01 0 0 
AnonDog18 Positive 1 0.13 0.11 0.08 -0.05 -0.03 0 0 
AnonDog19 Positive 2 0.21 0.16 0.13 -0.04 -0.08 0 0 
AnonDog20 Positive 2 0.33 0.32 0.16 0.06 0.06 1 1 
AnonDog21 Positive 2 0.37 0.29 0.17 0.09 0.01 1 1 
AnonDog22 Positive 2 0.16 0.13 0.11 -0.07 -0.09 0 0 
AnonFox2 Positive 1 0.38 0.29 0.1 0.19 0.12 1 1 
AnonFox3* Positive 2 0.27 0.85 0.22 -0.07 0.53 0 1 
AnonFox4 Negative 2 0.17 0.17 0.1 -0.04 -0.04 0 0 
AnonFox5 Negative 2 0.13 0.12 0.07 -0.06 -0.07 0 0 
AnonFox6 Positive 1 0.19 0.14 0.11 0 -0.03 0 0 
AnonFox12 Negative 1 0.09 0.08 0.07 -0.08 -0.06 0 0 
AnonFox13 Positive 2 0.1 0.1 0.09 -0.1 -0.1 0 0 
AnonFox14 Negative 2 0.2 0.22 0.1 -0.02 0 0 1 
AnonFox9 Control 
positive 
1 0.4 0.26 0.14 0.16 0.05 1 1 
AnonFox9 Control 
positive 
2 0.72 0.38 0.17 0.44 0.1 1 1 
AnonFox11 Control 
negative 
1 0.15 0.16 0.11 -0.05 -0.02 0 0 
AnonFox11 Control 
negative 
2 0.2 0.18 0.11 -0.02 -0.03 0 0 
 
* High background; results regarded as invalidated. 
 






The ultrahigh-density peptide microarray revealed that the genomes of CAV-1 and 
CAV-2 possessed highly antigenic sites when screened with CAV (untyped) IgG 
positive sera; this has not been previously investigated in any adenovirus. It is noted 
that all possible antigenic targets may not have been detected, due to the linear 
epitopic structure of the 15-mer peptides, and may not reflect the antigenicity of the 
three-dimensional structure. However, it has been revealed that that many sites are 
possible targets for IgG (when presented as a linear epitope in this system), including 
capsid proteins and core proteins. This could reflect the important role these genes 
play in the pathogenesis of CAV-1 (and CAV-2) infection and the subsequent host 
immune response. 
 
The ultrahigh-density peptide microarray shows some variation in antigenicity 
among individuals. This heterogeneity would be expected as part of individual 
immune responses (Poland et al., 2007). When all sera are averaged and analysed as 
‘red fox vs dog’, the immune response between the species to the two viruses 
becomes very similar. This may represent the cross-reactivity of CAV antibodies, 
even at homologous sites with amino acid changes. Alternatively, it may actually 
mean that some dogs are exposed to CAV-1 (which is not unlikely, given the 
prevalence of CAV-1 in red foxes in the UK; Walker et al., 2016b), and that some 
red foxes are exposed to CAV-2, which was not expected given the initial 
assumptions on interspecific differences of exposure. Therefore, when mean readings 
are calculated for each species, the individual variability is likely lost (i.e. the 
average reading from either species could represent a mixed population of both 
CAV-1 and CAV-2 IgG). However, even when combined, some differences in 
antigenicity still exist for some peptides. This may be a result of immune challenge 
(a high-titre vaccine-based immune response may induce a different immune 
response in dogs than in natural infection) or may be due to vaccine and field strain 
sequence variation. There is no vaccine strain sequence information available to 
assess this.  
 
 




It is a great limitation of the study that ‘ideal’ control sera could not be tested. The 
control sera used (both positive and negative) could not be assured to be true controls 
since, for example, the fox serum was used as a CAV-1 control based on assumption 
of exposure alone. In addition, negative control serum was based on the results of the 
previously developed ELISA/VNT; the negative control may actually contain ‘very 
low’ levels of IgG not detected due to artificially high cut off values in those assays. 
It is therefore important to note that signal was present in the negative control sera at 
some of the most antigenic sites. It is also hard to ascertain whether this is non-
specific signal (not due to CAV-1/CAV-2) or whether, in fact, these animals have 
been historically exposed to CAV-1/CAV-2, and have retained some IgG to the most 
antigenic sites, which is just not detectable in the untyped CAV ELISA. 
 
Due to financial restrictions, it was not possible to obtain specific-pathogen-free 
(SPF) negative control serum (i.e. from laboratory beagles known to be not exposed 
to both CAV-1 and CAV-2). Additionally, it was not possible to obtain positive 
control SPF sera (i.e. canids exposed only to a CAV-1, and those exposed only to a 
CAV-2). SPF sera would be absolutely required to confirm the absence/presence of 
IgG and thus the specificity of peptides. Therefore, it is not possible to fully interpret 
and verify the results with absolute certainty unless SPF/control serum can be 
obtained and tested. As such, analysis of readings across the entire library of 2,587 
peptides was extremely difficult to interpret.  
 
It is important to highlight that, although not directly related to the development of a 
peptide ELISA, when analysing the genomes the ~500 bp difference in nucleotide 
sequence between CAV-1 and CAV-2 E3 is more likely to be a deletion of 
nucleotides in CAV-1 rather than an insertion of CAV-2, contrary to that stated by 
Linné (1992). This sequence may have appeared as a nucleotide insertion in a 
common ancestor of these mastadenoviruses, and was later lost in CAV-1. This is an 
important finding and may reflect the modern evolution of CAV-1, which was first 
widely reported in silver foxes (Vulpes vulpes) in 1930 (Green et al., 1930). 
Theoretically, CAV-2 may have existed in wolves and domestic dogs as the more 
‘ancient’ pathogen, and the emergence of CAV-1 represented an opportunistic host 
 




switch (during the period when large groups of canids (foxes) were farmed for fur; 
Green et al., 1930; Sompolinsky, 1949), with the deletion within E3 (and subsequent 
or concurrent mutations) theoretically allowing for increased pathogenicity and host 
range, and its discovery as widespread outbreaks of fatal disease in foxes. CAV-1 
could then have spread back into dogs from infected foxes, allowing for its discovery 
as ‘infectious canine hepatitis’ in 1947 (Rubarth, 1947). It wasn’t until the 1960s that 
CAV-2 was molecularly detected as a cause of respiratory disease (Ditchfield et al., 
1962), but had not been the cause of major, fatal outbreaks of disease to warrant 
characterisation prior to this. However, in relation to the current study, this unique 
CAV-2 sequence was identified as an important target of peptide selection for the 
discriminatory ELISA; any antigenicity in this region should be CAV-2 specific 
because there is no CAV-1 homologous sequence due to this likely deletion event. 
Thus, in the absence of ‘true’ control sera, the peptides based on this gene should 
have helped to clarify proceedings. 
 
The peptide ELISA which included peptides 6 and 7 (based on CAV-1 and CAV-2 
E3 respectively), in theory should discriminate between CAV-1 IgG and CAV-2 IgG 
because of their low homology; cross-reactivity should be unlikely. Thus, it is 
interesting to note that some of the dogs and red foxes were reactive to both. The 
control red fox serum appeared to show a higher signal for peptide 6 (CAV-1-based 
peptide) than peptide 7 (despite also being very weakly positive for peptide 7). 
‘AnonFox14’ was only positive for peptide 7 (CAV-2-based peptide). This can be 
interpreted in two ways: firstly that the peptides are indeed specific for either virus, 
or secondly, that the peptides are not specific and there is cross-reactivity of the 
selected peptides. 
 
However, extreme caution is taken in committing to an interpretation of this result, 
due to the absence of SPF control sera. If CAV-2 IgG is present in red foxes, then it 
has implications for the epidemiology of CAV IgG in the UK. Although it was noted 
in Chapter 4 that the presence of CAV IgG in 302 of 469 (64.4%) foxes, was more 
likely to be CAV-1, this was not definitively stated (hence, part of the reason for 
developing a specific peptide ELISA) and was based on reasonable inference and 
 




molecular evidence of CAV-1 and absence of CAV-2. It should be noted that both 
the positive control fox and AnonFox14 originated from Tiggywinkles Wildlife 
Hospital. It is possible that they were exposed to CAV-2 in captivity, and thus free-
ranging foxes may not be exposed to CAV-2 under normal circumstances ‘in the 
wild’. 
 
It is also noted that most of the dogs were not positive to either peptide, despite being 
known to have been vaccinated, and thus the sensitivity of the assay may have been 
low in detecting specific CAV-1/CAV-2 IgG. This could be, in part, due to poor 
binding of small peptides to the microplates, allowing only high titre sera to be 
detected as positive in the ELISA. Alternatively, this peptide may not represent an 
important antigen in vaccine-induced immunity. 
 
Furthermore, it is unfortunate that more of the peptides were not antigenic in the trial 
peptide ELISA (which included all eight of the peptides), despite their antigenicity in 
the ultrahigh-density peptide microarray. This could be a result of continued poor 
binding of peptides to a microplate (despite the use of a specialised microplate), 
masking of antigen by milk proteins in the blocking solution, in addition to the 
medium-purity of the peptides used (>70%). However, the financial restrictions 
prevented the synthesis of near-pure peptides. An improved approach would be to 
conjugate the peptide to a larger protein such as BSA (Gómez et al., 1988) or 
keyhole limpet heamocyanin (KLH; Casal et al., 1995). Coupling requires a 
substantially larger amount of peptide, but could improve the binding efficiency to 
high-binding microplates and could also reduce the masking of specific antigen by 
larger proteins in the blocking steps. 
 
Some false-negative results may have been created due to an artificially high OD405 
cut off value for the ELISA, however, without SPF sera from sufficient animals, an 
objective cut off value cannot be calculated. Additional peptides are also likely to be 
required to be included in the panel to increase the sensitivity of the assay, based on 
individual immune response. It is expected that two peptides would not be sufficient 
 









It has been established that there is a need for a CAV-1 and CAV-2 discriminatory 
ELISA. Thus, it was investigated whether it was possible to produce such a 
diagnostic assay by i) investigation of the sites of antigenicity of key CAV-1/CAV-2 
genes and ii) production of a proof of concept peptide ELISA. Although no 
functional discriminatory ELISA was produced, it is concluded the project was 
partially successful in its goals. 
 
A large number of antigenic sites on the genome of CAV-1 and CAV-2 have been 
detected using a high throughput peptide screening method. Thus, for future 
research, additional candidate discriminatory peptides have been revealed. However, 
the follow-up experiments in the current study were financially restricted to 
subsequently screen a ‘handful’ of peptides in ELISA format, and so a suitably large 
sample of peptides could not be investigated further. In addition, SPF control sera 
(i.e. absolute confidence that animals, both red foxes and dogs, had been exposed to 
one or the other virus, or neither) could not be obtained, and these are absolutely 
required to validate the ELISA and continue development of the discriminatory 
ELISA. It is difficult to fully interpret results in the absence of SPF sera. Such 
controls can only be obtained by additional funding and this was a limitation of the 
study. 
 
Some positivity is drawn from the fact that several sera did show reactivity towards 
the peptides. Whether discriminate/indiscriminate in nature, it highlights, in 
principal, that linear epitopes (in the form of short peptides) could be useful in 
detecting CAV-1/CAV-2 IgG, much like previously successful peptide-based ELISA 
for other pathogens (e.g. Shen et al., 1999; Kannangai et al., 2001; Velumani et al., 
2011). As a ‘proof of concept’, therefore, some success was gained, despite the 
failings in providing sensitivity. There are also some intriguing results which could 
 




suggest that at least one fox serum sample was reactive to the CAV-2 peptides, 
which warrants expansion of the study. However, further research is required to 
develop the ELISA, and this may require a switch to a more efficient binding method 
(perhaps by coupling of peptides to carrier proteins), or the use of larger quantities of 
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7.1 Chapter introduction 
 
In Chapter 3 it was shown that the pathology caused by CAV-1 appears to be 
distinctive in the red foxes and domestic dogs which were examined; a new IHC 
technique to visualise the sites of viral replication was described. This was deemed to 
be useful for describing the pathology in clinically affected animals during the acute 
phases of ICH. As a consequence of the findings, it was proposed that the disease 
caused by CAV-1, ICH, be re-named to a more appropriate term to encompass the 
pathological differences between red foxes and dogs. 
 
Furthermore, an estimated 29 of 154 (18.8%) of red foxes in the UK were detected to 
be infected with CAV-1, as determined by PCR (Chapter 4; Walker et al., 2016b). 
The tissues infected in these animals included liver, kidney, spleen, brain and lung. 
Urine was also demonstrated to contain high titres of CAV-1 in some animals. The 
PCR positive tissues were declared as ‘inapparent infections’; during the post-
mortem examination of these animals, no grossly evident signs of acute viral 
pathology were noted. This may suggest that the virus is not replicating prolifically 
(and may not necessarily undergo transcription), and is highly suggestive of a 
persistent infection in the CAV-1 PCR positive foxes. However, it was not possible 
to examine tissues from most of these foxes histologically due to the scarcity of 
suitable tissues (most possessed a degree of autolysis). It was deemed important to 
obtain histologically suitable materials because the possibility of ‘chronic’ disease in 
animals recovering from ICH exists. 
 
At an early stage in adenoviral research, it was shown that dogs, experimentally 
infected with CAV-1, can also shed virus for up to 161 days following recovery from 
ICH (Poppensiek and Baker, 1951). This was thought to be a result of persistently 
infected renal tubular epithelial cells, and contributed to a prolonged focal interstitial 
nephritis in some experimentally infected animals (‘peaking’ 15-25 days post 
infection; Poppensiek and Baker, 1951; Wright et al., 1971). Previous to the research 
presented in the current study, it has not been demonstrated that such a wide-range of 
cells can be infected (Chapter 3) and that a similarly wide-range of tissues are 
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inapparently infected (Chapter 4; Walker et al. 2016b), and sometimes in the 
presence of anti-CAV IgG. Therefore, it is now clear that renal tubular epithelial 
cells may not be the only cells likely to be capable of being persistent infected 
following ‘overt stages’ of ICH. This evidence raises several important aspects of 
CAV-1 pathobiology which remain unclear. 
 
Firstly, although it is shown that many tissues appear to remain infected by CAV-1, 
it is not known which cell types remain infected in such cases and if this corresponds 
to the same cells infected during the acute stages of disease. Although it has been 
suggested that the persistently infected cells could be the renal tubular epithelial cells 
in dogs (Poppensiek and Baker, 1951), this has not been demonstrated in naturally 
infected animals which have recovered from ICH, and appears to be based only on a 
reasonable assumption. Wright et al. (1971) demonstrated a ‘spontaneous CAV 
nephritis’ in experimentally infected dogs, occurring from eight days post infection. 
However, this may not be representative of natural systemic infections; the localised 
infection does not appear to persist beyond several weeks and has not been 
demonstrated in red foxes (Wright et al., 1971). Determining the cell types which 
remain infected in inapparently infected tissues in naturally occurring disease is 
important. This information will highlight the cell types which are capable of 
‘harbouring’ CAV-1 in the long-term in free-ranging animals (and pet dogs), and 
which should be the targets of further studies on the mechanisms of CAV-1 
persistence. 
 
Therefore, and secondly, these cells could be targeted to study the transcription and 
interaction between CAV-1 and host cells. This is important to investigate because 
the mechanisms employed by adenoviruses, in any host species, to evade host 
immune defences is unclear. As introduced in Chapter 1, it has been demonstrated 
that HAds can be detected in human lymphoid tissues, which are not infectious and 
appear not to proliferate (Garnett et al., 2002; Garnett et al., 2009). It has also been 
demonstrated in cell cultures, infected with HAds, that HAds may exist as a 
monomeric episome in infected cells and that viral transcription is notably reduced 
(Zhang et al., 2010). Thus, HAds may exist in a ‘latent’ or ‘quiescent’ state within 
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the host cell. The transcriptome of adenoviruses (if indeed transcription occurs at all) 
in this possible state is not fully understood. CAV-1 has not been studied at all, 
despite its seemingly unusual systemic and severe infection pattern in otherwise 
immunocompetent canids. A recent study by Zheng et al. (2016) indicate that IFNs 
may play a role in promoting persistence of HAd5, since IFNα and IFNγ block 
replication in primary human bronchial epithelial cell cultures by binding at the E1A 
enhancer domain, thus preventing E1 expression (Zheng et al., 2016). It is not 
unreasonable to predict that similar mechanisms may exist in other mastadenoviruses 
and that key genes required for a ‘lytic infection’ to ensue may not be transcribed in 
persistent infections. 
 
Thirdly, the histological features (if any) associated with ‘inapparent infections’ 
(regardless of time post-infection) have not been fully explored. Partly, in free-
ranging species, this is because of the lack of suitable samples. It is possible that 
continued infection may produce chronic disease which is ‘mild’, limited and only 
visible histologically. During ICH in dogs, type III hypersensitivity often occurs in 
the kidney, a result of deposition of immune complexes in glomeruli, causing a 
glomerulonephritis. However, this is not known to lead to chronic or permanent renal 
disease (Wright, 1976). This has also not been demonstrated in non-canine species. 
Another particular sequela of ICH is ‘blue eye’ (Curtis and Barnett, 1983). ‘Blue 
eye’ is thought to occur in a fifth of recovered dogs up to 3 weeks post infection, as a 
result of type III hypersensitivity, but is normally transient (Carmichael et al., 1975; 
Wright, 1976). Eyes were not a focus of the current study because they were often 
damaged, poorly preserved and not sampled. 
 
Type III hypersensitivity reactions occur in the time during resolution of severe 
disease. However, little is known of the longer-term effect in PCR positive tissues 
(although it is not possible to determine the length of time post-infection in the red 
fox samples obtained in the present study), and whether CPE is still present 
following resolution of type III hypersensitivity (which only occurs in ~20% of dogs; 
Wright et al., 1976). In humans, HAds can be detectable for long periods (i.e. months 
to years) in lymphoid tissues and faeces (Fox et al., 1977; Adrian et al., 1988; 
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Garnett et al., 2002); however, histopathology of HAd-infected tissues is rarely 
performed. 
 
Therefore, there is a need to explore the pathological features, if any, associated with 
inapparent infections in CAV-1-infected red fox tissues. Such evidence would also 
be useful to highlight possible chronic disease which may occur in other 
Mastadenovirus-infected tissues. The absence of disease (if this is shown to be the 
case) could suggest CAV-1 exists in a ‘latent’ state if there is supporting 
transcriptional evidence (i.e. absence of transcription). 
 
Thus, in this chapter the aim was to develop a novel in situ hybridisation (ISH) 
technique to identify, in situ, the individual cells which are suspected to be 
persistently infected with CAV-1 using tissues from red foxes determined to be 
positive for CAV-1 DNA by PCR. Standard histological techniques were utilised to 
describe the key pathological features (if any) of CAV-1-infected red fox tissues 
which have no grossly evident ICH lesions on post-mortem examination. In such 
tissues, another aim was to determine the transcriptional activity of CAV-1; 
specifically, whether key CAV-1 transcripts in inapparently infected tissues were 
reduced relative to transcripts expected from ‘active’ or lytic infections in clinically 
diseased tissues and CAV-1-infected cell cultures. This involved development of a 
panel of primers for key CAV-1 transcripts, deployed in a reverse transcription real-
time quantitative PCR (RT-qPCR), as a cost-effective way of analysing temporal 
viral transcription. 
 
The aims of this chapter could determine whether CAV-1 does, by definition, 
establish a persistent or ‘latent’ infection in the tissues it infects, by identification of 
the cell-types which permit this and whether there is detectable transcription. The 
developed assays could also provide a platform for future research in the 
pathogenesis of CAV-1 and establishment of persistent infections with adenoviruses 
in other host species, based on the significant conservation of genes between 
mastadenoviruses (Davison et al., 2003). 
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7.2 Materials and methods 
 
7.2.1 Selected red fox samples for in situ hybridisation 
 
Tissues from fatal infections of CAV-1 in red foxes (Chapter 2) were used for 
positive control tissues to develop the ISH technique and are indicative of ‘classic’ 
ICH. Negative control samples were obtained from red foxes which were CAV-1 
PCR negative (Chapter 4), selected from the small number of carcasses with the least 
autolytic degradation of those collected during the epidemiological survey. 
 
Additional samples from red foxes, submitted after the conclusion of the 
epidemiological survey, were taken during post-mortem examination; liver, lung, 
kidney and brain were collected. Additional lymphoid tissues (tonsil and spleen) 
were also collected when possible. These tissues showed little or no signs of 
autolysis, which was evident on gross examination, and had not been previously 
frozen. DNA was extracted using the DNeasy Blood and Tissue and AllPrep 
DNA/RNA Mini Kits (Qiagen). PCR was conducted using the method described by 
Walker et al. (2016b) to confirm whether the red foxes were positive or negative for 
CAV-1 DNA. The negative control tissues and additionally collected tissues showed 
no evidence of obvious gross pathological signs of acute ICH, regardless of PCR 

















Summary of the red fox samples used for the development of the CAV-1 ISH 
technique. The identification numbers (IDs) of ‘fox 1’ and ‘fox 4’ (Chapter 2) were 
anonymised to hide clinical record numbers. Other fox IDs are named by the date of 
the post-mortem examination and collection of samples. CAV-1 status refers to PCR 
result using the methods described by Walker et al. (2016b). Foxes with ‘fatal 
disease’ were PCR positive and had overt ICH. Foxes without fatal disease died for 
reasons unrelated to infection with CAV-1 and had no obvious signs of ICH. A 
negative control was included for each tissue type except tonsils and the mediastinal 
lymph node. 
 
Fox ID CAV-1 status CAV IgG status† Samples 
‘Fox 1’ Fatal disease Not tested Liver, lung 
‘Fox 4’ Fatal disease Not tested Liver, brain, spleen, mediastinal lymph node 
161214/1 PCR negative 0 Liver, kidney 
191214/2 PCR negative 0 Spleen, brain 
201114/1 PCR positive 0 Liver, kidney, spleen, brain 
201114/2 PCR positive 1 Liver, kidney, spleen, brain 
160816/1* PCR positive Not tested Liver, kidney, spleen, lung, brain, tonsil 
120916/1* PCR positive Not tested Liver, kidney, spleen, lung, brain, tonsil 
121216/1* PCR positive Not tested Liver, kidney, spleen, lung, brain, tonsil 
 
*Included in the RT-qPCR transcript panel, see section 7.2.6 Selection and preparation of samples for 
RT-qPCR. 
†Presence of IgG determined by the untyped CAV ELISA (Chapter 4). Some foxes not tested because 
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The selected tissues were fixed in 10% buffered formal saline. After saturation with 
the fixative (several weeks), the tissues were trimmed using scalpel blades and 
embedded in paraffin wax. Sections of tissues were cut at a thickness of 6 µm (brain) 
or 4 µm (all other tissues) using a microtome. Sections were adhered to SuperFrost 
Ultra Plus slides (Thermo Scientific Menzel, Braunschweig, Germany) by heating at 
40 °C for 15 min, followed by 50 °C for 25 min. Sections were either stained 
routinely with H&E for histological examination, or left unstained for further 
processing in the ISH protocol (see 7.2.3 CAV-1 ISH protocol). Unstained slides 
were stored in an airtight container at ambient temperature before ISH commenced. 
Slides were prepared by the histopathology section, RDSVS. 
 
7.2.2 CAV-1 ISH probe design 
 
Theoretically, it is possible that the capsid proteins of persistently infectious 
adenoviruses are not produced in sufficient abundance (or at all) and therefore the 
number of antigenic sites are reduced. If this is the case, then the IHC developed in 
Chapter 3 may not be useful in detecting persistently infected cells because antigenic 
targets may not be available for the anti-adenovirus antibodies which were used (see 
section 3.2.2 Selection of stains and antibodies). This would render the antibodies 
insensitive or useless for identification of individual infected cells. Therefore, it was 
decided that a specific CAV-1 ISH protocol should be developed in order to detect 
CAV-1 in inapparently infected tissues. This method would be used in addition to 
regular histological techniques (i.e. H&E staining) to determine if there was any 
residual or chronic pathological changes in red foxes as a result of inapparent CAV-1 
infection. 
 
An oligonucleotide probe was designed to target viral DNA. A DNA probe was 
chosen for use over an RNA probe because it was hypothesised that transcription 
may be low (or not occurring) in cells which were persistently infected with CAV-1 
and, therefore, the abundance of RNA in the tissue sections would be minimal. 
Moreover, the use of an RNA probe would make it imperative that tissues were 
preserved and fixed quickly following the death of the animal. Given that the 
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majority of red foxes which have been sampled during this study did not undergo 
post-mortem examination immediately following death, the RNA would be subject 
to time-dependent degradation (Fleige and Pfaffl, 2006). Similarly, RNA in FFPE 
preserved tissues is not as stable as DNA, particularly if stored at room temperature 
for extended periods, as was the case in the current study (Von Ahlfen et al., 2007). 
An RNA-probe based ISH technique could be subject to more variation based on 
RNA-quality (e.g. endogenous and contamination digestion), rendering the technique 
less repeatable and less useful for other potential users for use on preserved tissue 
archives. Therefore, a DNA probe was deemed to be more useful in this study, where 
tissues had been preserved but where RNA preservation specifically was not an 
immediate consideration. 
 
The oligonucleotide probe was designed against a region of the CAV-1 genome 
which was relatively invariant amongst all samples infected with CAV-1 from red 
foxes across the UK (see section 4.6.4 CAV-1 sequence analysis; Table 7.2). Prior to 
the epidemiological study conducted in Chapter 4 (Walker et al., 2016b), nucleotide 
variation in HAds was thought to mainly be focussed in ‘hypervariable regions’ 
based largely in the hexon gene (Robinson et al., 2013), but there is little evidence 
available which assesses geographical variation in sequences. Thus, given the 
knowledge that likely SNPs were identified in CAV-1 (see section 4.6.4 CAV-1 
sequence analysis), then selection of the invariant site, located on ORF7 should 
ensure specificity and sensitivity towards CAV-1 regardless of the geographic origin 
of the samples. The probe was labelled at the three prime terminus (3’) with 
digoxigenin (DIG) for detection and targeted the sense strand (Table 7.2). The short 
oligonucleotide probe should also be less hindered in the penetration of tissues 
compared to longer probes (Sterchi and Astbury, 2013). The probe was synthesised 











Summary of the oligonucleotide probe used in the CAV-1 ISH. 
Probe name Nucleotide sequence (5’-3’) * Target(s) * Nucleotide position on 







6318 - 6284 
 
* Based on GenBank Y07760.1 
 
 
7.2.3 CAV-1 ISH protocol 
 
ISH was conducted using the IsHyb ISH kit (BioChain, Newark, California, USA). 
The protocol was adapted from that provided by the manufacturer. Deparaffinisation 
and rehydration of the selected slides was performed by immersion in xylene for 15 
min, followed by immersion in xylene in a second receptacle for an additional 15 
min. Slides were then soaked in sequential ethanol dips, with decreasing 
concentration, for 5 min at each concentration; slides were soaked in 100% ethanol 
twice, then 95%, 90%, 80% and 70% ethanol dips. The sections were then 
rehydrated in distilled H2O (dH2O) for 5 min. 
 
The sections were fixed by soaking in 4% paraformaldehyde in PBS (4% PFA; 
VWR, Lutterworth, Leicestershire, UK) for 5 min at ambient temperature. Slides 
were briefly rinsed in dH2O and excess liquid removed. Proteinase K solution (10 
µg/mL) was pipetted onto the surface of the slides in a volume enough to cover the 
tissue sections. The slides were heated to 37 °C for 7 min, before being immersed in 
4% PFA for an additional 5 min. Slides were then briefly rinsed in dH2O. 
 
The tissue sections were air dried before application of HybriWell (Grace Bio-Labs, 
Bend, Oregon, USA) adhesive chambers directly over the tissues of interest. 40 µL 
of ‘pre-hybridisation solution’ (supplied with the IsHyb kit; BioChain) was 
introduced into a port of the HybriWell, which diffused through the chamber. The 
two ports were then sealed with adhesive tabs. Slides were incubated in an airtight 
polystyrene container in an incubator at 50 °C for 3 h. 
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An adhesive tab was removed from one HybriWell port, and 20 µL of the pre-
hybridisation solution was extracted by gentle manual pressure and pipetting of 
solution at the port. The second adhesive tab was then removed. 20 µL of 
‘hybridisation solution’ (BioChain), containing CAV-1_ISH probe at a concentration 
of 20 ng/µL, was pipetted into a port and allowed to diffuse throughout the chamber, 
before resealing of both ports. Hybridisation with this solution (final probe 
concentration 10 ng/µL) took place at 44 °C for 14 h (in an air-tight container). To 
control for background staining a duplicate ‘internal negative control’ slide was 
processed for each tissue section of interest; this was identical except the probe was 
omitted from the hybridisation solution. 
 
The HybriWells were then removed from the slides and the sections were washed in 
2x concentrated saline-sodium citrate (SSC) buffer (BioChain) at 45 °C for 10 min. 
Following this, the slides were washed once in 1.5x SSC at 45 °C for 10 min and 
finally washed twice in 0.2x SSC at 37 °C for 20 min. 1x ‘blocking solution’ 
(BioChain) was pipetted directly onto the tissue sections, which was left at ambient 
temperature for 1 h. Slides were briefly washed in dH2O before the addition of 40 µL 
anti-DIG antibody (BioChain) at a dilution of 1:100. A HybriSlip (Grace Bio-Labs) 
was placed over each tissue section and remained at ambient temperature in a sealed 
container for 7 h. Slides were then washed three times in PBS for 5 min, followed by 
two washes in alkaline phosphatase (AP) buffer (BioChain) for 5 min. 
 
6.6 µL nitro-blue tetrazolium (NBT) and 3.3 µL 5-bromo-4-chloro-3'-
indolyphosphate (BCIP; BioChain) were added to 1 mL AP buffer. The NBT-BCIP 
substrate solution was added to tissue sections at a volume to completely cover the 
tissue sections and left in a sealed container in the dark for ~7 h (and checked at 1-2 
h intervals). After microscopic confirmation of an adequate colour change in the 
positive control slides, the slides were rinsed with dH2O. The tissue section was 
counterstained with nuclear fast red (Vector Laboratories. Burlingame, California, 
USA) for 10 min, washed briefly with H2O and then air dried. Finally, slides were 
mounted and coverslips applied using the Microm CTM 6 automated glass coverslip 
applicator (Thermo Scientific). 
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7.2.4 Analysis of sections following ISH 
 
Slides were scanned using the NanoZoomer-XR (Hamamatsu) system and the 
associated NDP.scan software. Slides were viewed, and the fields of interest 
extracted, with NDP.view software. 
 
7.2.5 Design of qPCR transcript panel 
 
The synthesis of double stranded complementary DNA (cDNA) from RNA extracted 
from CAV-1 infected MDCKs (i.e. viral transcripts) at specified time points could 
allow the evaluation of how the CAV-1 transcriptome temporally varies during the 
course of infection. This could provide a model to evaluate transcription in an acute 
infection, compared to transcription in tissues deemed to be persistently infected with 
CAV-1. If the transcription of certain genes were found to be altered (regulated) then 
this could help to identify whether CAV-1 exists as a ‘non-lytic’ infectious agent 
(demonstrating latency) in persistently infected tissues, and highlight the possible 
mechanisms allowing it. 
 
Due to financial considerations, it was not possible to evaluate the full transcriptome 
of CAV-1 and the MDCKs (or tissues) which were infected, requiring an approach 
such as total RNA sequencing (RNA-seq) using next generation sequencing (NGS) 
technology. Therefore, a panel of transcripts were selected to provide a ‘proof of 
concept’ to test the hypothesis that the transcription of certain genes during CAV-1 
infection may vary temporally, and that the relative transcription of CAV-1 genes in 
persistently infected tissue are altered to that in an acute infection (e.g. in a cell 
culture model). A panel of two early expressed ‘E’ genes and two late expressed ‘L’ 
genes were selected with various expected functions based on inference from studies 
with HAds (Table 7.3; Maclachlan and Dubovi, 2011). If these were key targets to 
regulate adenovirus replication (e.g. by the host immune response) then the genes 
could be expected to show altered levels of transcription. It was hypothesised that the 
transcription levels of late genes may be reduced or not detectable if, for example, 
transcription cannot progress due to the binding/blocking of a regulatory site. 
 
Chapter 7 – Investigating inapparent CAV-1 infections 
 
217
The exact functions of many proteins encoded by adenoviral genes are as of yet 
unknown (the functions of some genes are discussed in sections 1.4 Physical and 
genomic structure of adenoviruses and 1.5 Molecular pathogenesis). However, of the 
genes selected in the panel, the E1A proteins are thought to activate subsequent viral 
transcription by activation of adenoviral transcription initiation promoters, and also 
may effect cellular gene expression; mutations of E1A show reduced concentrations 
of early viral mRNA (Flint and Shenk, 1989; Frisch and Mymryk, 2002). 
 
In HAds there are several E3 proteins which are immunoregulatory (Burgert et al., 
1987) but they appear not to be essential factors for replication (in cell cultures; 
Horwitz, 2004). Tollefson et al. (1996) first described the ‘E3 11.6 kDa’ protein of 
HAd2 and HAd5, also known as the ‘adenovirus death protein’ (ADP). It was shown 
that this protein, although not required for HAd replication, increased the efficiency 
of cell lysis at the late stages of infection (despite being an ‘early’ gene; Tollefson et 
al., 1996). On BLAST analysis, this protein appears to have no homologues in other 
mastadenoviruses and appears to be unique to HAds. However, in CAV-1 two E3 
proteins were predicted by Morrison et al. (1997), 13.3 kDa and 22.2 kDA. The 
primer set designed in Table 7.3 is intended to amplify the E3 13.3 kDa protein 
(ORF 22; Morrison et al., 1997). On BLAST analysis, the E3 13.3 kDa protein 
appears to be the homolog of adenovirus 12.5 kDa protein, which is present in many 
annotated Mastadenovirus genomes, including CAV-2 and also HAds (Figure 7.1). 
The E3 12.5 kDa homolog appears to be the only E3 protein in the murine 
adenovirus type 1 gene and suggests this protein could be vital for adenovirus 
function (Fauquet et al., 2005). The exact function(s) of these putative proteins 
remains unknown. 
 
Of the L genes, fiber is a key structural protein and is critically involved with various 
functions including the initial binding to the cell’s adenovirus receptor (CAR; as 
determined for HAds), for viral entry to the cell (Chroboczek et al., 1995) and 
paracellular movement allowing escape of progeny virus following replication 
(Walters et al., 2002). Hexon, the second selected L gene, is the major structural 
protein of the adenoviral capsid, comprising the faces of the icosahedral virion 
(Toogood et al., 1992; Russell, 2009). 
 




Multiple alignment of CAV-1 E3 13.3 kDa and homologous sequences from other 
Mastadenoviruses. GenBank accession numbers are displayed below the alignment. 
Black highlighting indicates where the amino acid is identical in all sequences in the 
alignment. Alignments were imported into the web-based program, Multiple Align 
Show, for display purposes (http://www.bioinformatics.org/sms/multi_align.html). 
 
CAV-1 - M A M T E E S - - V D Q V E V N C L C V Q H G Q S C N N T R C F V K E G L R A N - 38
CAV-2 - M A M T E E S - - M D Q V E V N C L C A Q H A Q T C T R P R C F A K E G L C A N - 38
Bat Ad 2 - M A T T N T C - - - - Q V E V D C L C L V H E K T C T Y P R C F V R Q - - - - - - 31
SkAdV-1 - M A M I N R Q - E A A Q E L I K E L C Q S H A T V C D Y P R C F V K D - - - - - - 34
Titi monkey Ad - - - M T D G D L E A E V E K A R - - - L R H L V H C R R P R C Y A R D - - - - - - 30
HAdE - - - M S H G - - - G A A D L A R - - - L R H L D H C R R F R C F A R D - - - - - - 27
I                     
CAV-1 - W F Y N P V L - - E E F A I P - - - - - - - - - - D S Y Q E G - - H G V N V K I - 64
CAV-2 - W F Y N P A L A F E G F D I P - - - - - - - - - - D S Y Q E G - - H G V D I E V - 66
Bat Ad 2 - - - - - - N L K P V W F H N P P L D N N E C V V I D S Y Q E G - - H G L S L S V - 64
SkAdV-1 - - - - - - K H E A A W F H V E L P K F G D - - V P D S L Q E G - - H G V R V R L - 65
Titi monkey Ad - - - - - - L L L L E G F - - - - - - - - F - - Y P P N H P E G P A H G L R L T V - 55
HAdE - - - - - - L A E F T Y F - - - - - - - - E - - L S E E H P Q G P A H G V R I V V - 52
I                     
CAV-1 - T F S H R S R N L - - R H N G H D V I C S Y S H L G S H I S I R C T C N K P R P - 102
CAV-2 - K C S H H S S K L - - C H N G H D M I C S Y S R L G S H I N I R C I C N K P R P - 104
Bat Ad 2 - K C F H H S T K L - - - G K Q S T L L C S K T H S G S E I L I R C E C K K P A P - 101
SkAdV-1 - K S C Y S S H C Y G R E I T G K S L - - - - - H H G S E I T I T C H C L H P E P - 100
Titi monkey Ad - P E T Q R S R L D - N F F T G R P L L V E T T H G P V T L S V T C I C A A T Q L - 94
HAdE - E G G L D S H L L - R I F S Q R P I L V Q R Q Q G N T L L T L Y C I C N H P G L - 91
I                     
CAV-1 - H L S L I E A A C S M Y N L D - - - - -         - 117
CAV-2 - H M S L I E A A C S M Y N L N - - - - -         - 119
Bat Ad 2 - H K E M I Q A L C H M Y N L N - - - - -         - 116
SkAdV-1 - H L A L I N A A C D M Y N L H - - - - -         - 115
Titi monkey Ad - H E E L F E R L C T I F N T S T C P Q Q         - 114
HAdE - H E S L C C L L C T E Y N K S - - - - -         - 10
 
 
CAV-1, GenBank NP_044204.1; 
CAV-2, GenBank AP_000629.1; 
Bat adenovirus type 2, GenBank YP_003782116.1; 
SkAdV-1, GenBank YP_009162603.1; 
Titi monkey adenovirus, GenBank YP_00751838711; 
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Because there was a requirement to run an array of primers sets in a single qPCR run 
with one set of reaction temperatures, the online primer design program Primer3Plus 
(Untergasser et al., 2007) was used to design optimal primers. This ensured that the 
primer sets had similar melting points and product sizes. A summary of the panel of 
primer sets used is displayed in Table 7.3. 
 
The aim of the qPCR was to quantify CAV-1 transcripts relative to one another (i.e. 
not absolute quantification). Therefore, a plasmid system was not established for the 
qPCR, which would have increased the risk of the introduction of contamination. 
Instead, primers for housekeeping genes (HKG) were selected to allow normalisation 
of each primer set to the amplified HKG sequence. HKGs should be endogenous 
genes in the cell lines experimented with, and their transcription is expected to 
remain stable and be independent of experimental stimuli and variations (Hruz et al., 
2011). This permits comparison of genes at different time points, and helps to control 
for variations among samples in terms of the quantity of RNA isolation from 
extraction kits and the production of cDNA from RNA, both of which are not 100% 
efficient. 
 
It was important to verify HKGs for the system being used; many are designed for 
human cell lines and previous research by others has demonstrated that commonly 
selected HKGs are often not as stable as thought (e.g. glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and β-actin), and that more than one HKG should be used 
(Dheda et al., 2004; Radonić et al., 2004). Therefore, two HKGs, which have already 
been evaluated and verified as relatively stable in canine cell line systems, were 
selected (Brinkhof et al., 2006) to ensure normalised results are similar for either 
HKG. Both the HKGs, hypoxanthine phosphoribosyltransferase (HPRT) and 
ribosomal protein S5 (RPS5), designed by Brinkhof et al. (2006) specifically for use 
with canine cell lines, appeared stable when preliminarily evaluated with MDCKs 
infected with CAV-1 and were deemed to be appropriate for use in the current 








Panel of primers used in the RT-qPCR for CAV-1 transcripts and the primers to 
detect the reference housekeeping genes (HKGs) of infected MDCKs/canid tissues. 
Oligonucleotide 
name 
Description Nucleotide sequence (5’-3’) Nucleotide position 

















































































* Primers from Brinkhof et al. (2006) 
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7.2.6 Selection and preparation of samples for RT-qPCR 
 
Because of the rarity of freshly collected tissues from CAV-1 infected canids 
(compared to archived FFPE tissues), a cell culture model of CAV-1 lytic infection 
was established in order to extract minimally degraded RNA. MDCK cells were 
cultured to confluency in six-well Nunc tissue culture multidishes with lids (Thermo 
Fisher Scientific, Rochester, New York, USA) grown in non-FBS containing DMEM 
(Appendix 1). 
 
One well was sacrificed to estimate the number of cells present per well using a 
modified Neubauer cell-counting chamber. Wells were infected with 10 multiplicity 
of infection (MOI; the average number of virus particles infecting each host cell) of 
CAV-1 (strain ATCC VR-293; LGC Standards, Teddington, Middlesex, UK). A 
mock infected well (to which virus-free supernatant from an uninfected cell culture 
was added) was trypsinised immediately and this acted as the mock/0 h time point in 
the time course. MDCK cells in trypsin were pelleted in a 15 mL Falcon tube by 
centrifugation at 3000 x g for 3 min. The 6-well tissue culture multidishes were 
placed in an incubator (at 37 °C and 5% CO2 atmosphere) and the wells were 
sampled sequentially at 3 h, 6 h, 9 h, 12 h, 18 h, 24 h, and 48 h post infection (when 
CPE is evident); sampling was by trypsinisation and pelleting of cells. RNA was 
extracted from cell pellets using QIAshredder homogeniser spin columns (Qiagen) 
and the RNeasy Mini kit (Qiagen) following the manufacturer’s instructions. 
 
In addition, RNA was preserved from the tissues sampled from three red foxes, 
which were collected during the post-mortem examinations and were CAV-1 PCR 
positive (identifications of red foxes indicated in Table 7.1; summary of tissues used 
in RT-qPCR are summarised in Table 7.4). These foxes were allocated as 
representatives of red foxes with inapparent CAV-1 infections (and likely 
represented persistent infections) and possessed no obvious pathological ICH-related 
lesions on gross examination. Following the manufacturer’s instructions, samples of 
tissues (<0.5 cm3) were placed in at least 5 volumes of RNA stabilisation solution 
(RNAlater; Ambion, Carlsbad, California, USA) and chilled at 4 °C overnight, 
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before storage at -20 °C until RNA was required to be extracted. Brain, liver, kidney, 
spleen and tonsil from the red foxes were selected for extraction. 
 
Tissues were also collected during a post-mortem examination of one dog 
(‘DogAnon_RT’; clinical case ID anonymised) which underwent post-mortem 
examination at RDSVS and was diagnosed with ICH. Liver and kidney samples were 
utilised for the RT-qPCR, but these were frozen at -20 °C without RNAlater. This 
dog was designated as a control to represent the tissues (in terms of CAV-1 
transcription) of a canid with ‘overt ICH’ to compare with the cell culture model of 
CAV-1 infected cells and inapparently infected red fox tissues. ~30 µg of the frozen 
tissues were macerated using glass beads and disposable pestles in 600 µL tissue 
lysis buffer (Buffer RLT Plus, Qiagen). The lysates were then homogenised using 
QIAshredder homogeniser spin columns. RNA was extracted using the AllPrep 






Tissues from which RNA was extracted and tested for RT-qPCR. The red foxes are 
those described in Table 7.1 for ISH (The dog was not used in the ISH). 
 
Fox ID Samples subject to RT-qPCR 
DogAnon_RT Liver, kidney 
160816/1* Liver, kidney spleen 
120916/1* Liver, kidney, spleen, brain 
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7.2.7 Removing complementary DNA contamination from RNA 
 
During the optimisation of the procedure it was determined that the RNA extraction 
kit (RNeasy Mini Kit, Qiagen) was not successful in eliminating genomic DNA 
(gDNA) contamination in the RNA elution; gDNA contamination provides 
misleading results for low-copy number transcripts. To aid the elimination of gDNA, 
the optional DNase step (in the manufacturer’s instructions) was followed, which 
involved use of the RNase-Free DNase set (Qiagen) prior to the ‘wash steps’ of the 
RNeasy Mini Kit/AllPrep Mini kit protocols. A second round of DNase treatment 
was also performed to ensure the complete elimination of detectable gDNA. 8 µL of 
eluted RNA from each sample was incubated with 3 µL DNase I amplification grade 
(1 U/µL Sigma-Aldrich) and 3 µL 10x Reaction Buffer (Sigma-Aldrich) at 37 °C for 
30 min. 3 µL of Stop Solution (50 mM ethylenediaminetetraacetic acid; EDTA; 
Sigma-Aldrich) was added and the solution heated to 70 °C for 10 min. 
 
7.2.8 RT-qPCR protocol to detect CAV-1 transcripts 
 
To synthesise first-strand cDNA for each sample by reverse transcription (RT), 5 µL 
RNA (DNase treated) was added to a mixture of 1 µL random hexamers (10 mM), 1 
µL dNTP (10 mM) and 6 µL nuclease-free H2O (Qiagen). This mixture was heated 
to 65 °C for 5 min, immediately followed by incubation on ice for 1 min. To this, 1 
µL SuperScript III reverse transcriptase (200 U/µL; Invitrogen, Carlsbad, California, 
USA), 4 µL 5x First-Strand Buffer (Invitrogen), 1 µL dithiothreitol (DTT; 0.1M; 
Invitrogen) and 1 µL RNaseOUT recombinant ribonuclease inhibitor (40 U/µL; 
Invitrogen) was added (following the manufacturer’s instructions for the SuperScript 
III reaction mixture; Invitrogen). This solution was incubated at 25 °C for 10 min 
then 50 °C for 50 min. The reaction was terminated by heating to 70 °C for 15 min. 
 
A duplicate control sample was prepared in parallel for each test sample, but 
substituting 1 µL SuperScript III reverse transcriptase for 1 µL nuclease-free H2O; 
this was designated as the minus RT (-RT) control. 
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For the qPCR reaction mixture, 1 µL of cDNA was added to 10 µL 2x Takyon No 
Rox SYBR MasterMix dTTP blue (Eurogentec, Liège, Belgium), 1 µL forward 
primer, 1 µL reverse primer (each primer final concentration 500 nM) and 7 µL H2O. 
Using the Rotor-Gene Q real-time PCR cycler (Qiagen), this mixture was heated to 
95 °C for 5 min, then underwent 40 cycles of denaturation at 95 °C for 10 s, and a 
combined annealing/extension stage at 60 °C for 40 s. The cycler was set to acquire 
‘green’ channel data on the annealing/extension stage. Following cycling, ‘melting’ 
of the qPCR products took place. The cycler was set to increase from 72 °C (with 90 
s of pre-melt conditioning) to 95 °C, rising by 1 °C (for a duration of 5 s) at each 
step, whilst acquiring ‘green’ channel data. The production of non-specific signals 
were verified to be absent by melt curve analysis. 
 
For RT-qPCR of samples from MDCK infections, the samples included in each run 
were the cDNA from each time sampling point in combination with each primer set 
(including HKG primers for normalisation). Each sample was duplicated, and each 
run included a negative control (substituting 1 µL cDNA for 1 µL H2O) and the -RT 
control for each primer set. Fluorescence was required to be detected in both samples 
(with specific peaks on the melt curve analysis) in a duplicate to be classified as 
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7.2.9 Analysis of qPCR results 
 
The analysis was based on relative quantification, not an absolute quantification, 
which does not require normalisation to a standard curve (i.e. using samples with a 
known concentration of specific DNA, such as plasmids with DNA inserts). The 
mean cycle threshold (CT) and standard deviation of the mean was calculated for 
each duplicate sample. The mean CT of the gene of interest (GOI) samples were then 
normalised using the mean CT of both HKG genes (HPRT and RPS5) at each time 
point. This was calculated using the following formula (adapted from Schmittgen 
and Livak, 2008): 
	
ΔCT 	CT GOI 	‐	CT HKGs;	CT	 HPRT ,	CT	 RPS5 	
 
This corrected for any variation in CT of the HKGs between samples and showed the 
relative expression of each GOI at each sampled time point during the course of 
infection. ΔCT is often used to calculate 2-ΔΔCT, which is then used to analyse qPCR 
results as a ‘fold change’ (Schmittgen and Livak, 2008). However, computation of 2-
ΔΔCT relies on the presence of detectable genes in a reference sample (e.g. at time 
point 0 h) to compare with the GOI at another time point. Because only viral genes 
are the GOIs in the current study, this rendered the method unhelpful (i.e. viral genes 
were not expressed in uninfected cells or at time point 0 h and thus cannot be 
expressed as a fold increase). Therefore, analysis of the ΔCT values was a method to 
analyse the data in the current study where there was no reference ΔCT of the GOI to 















7.3.1 Histological descriptions of tissues inapparently infected with 
CAV-1 
 
For tissues which were PCR positive for CAV-1, but showed no obvious lesions on 
gross examination, the following main findings were noted on slides stained with 
H&E. Most findings were non-specific in all the examined red foxes, except the 
kidney of fox 201114/2 (see below). 
 
Fox 201114/1 
In the liver, binucleate hepatocytes were common. Some individual hepatocyte 
necrosis/degeneration was present (Figure 7.1a). In the spleen, there was mild 
lymphocytolysis and replacement with small amounts of proteinaceous material and 
erythrocytes. Renal tissue was unremarkable. The brain was unremarkable. 
 
Fox 201114/2 
On histological examination of the liver, some pleomorphism of hepatocyte nuclei 
was observed with occasional binucleate cells. There were several dissociated and 
degenerating hepatocytes. Other random hepatocytes possessed fading nuclei 
(possibly due to autolysis). Overall, there was a generalised hepatopathy with 
individual cell necrosis. Some mild splenic changes were observed; including mild 
lymphocytolysis in the white pulp/germinal centre and evidence of some 
proteinaceous deposits (the findings in the spleen were largely non-specific). In the 
kidney, there was mild interstitial nephritis. The renal pelvis showed an ‘active-
chronic’ lymphoplasmacytic inflammation. A small number of neutrophils and 
mononuclear cells were present within renal medullary blood vessels, which could 
have been from a haemodynamic effect. Some renal tubular epithelial cells showed 
intranuclear inclusion bodies and these were evident as clusters within single tubules 
(Figure 7.2b) The intranuclear inclusion bodies in the renal tubules were assumed to 
be a consequence of CAV-1 infection. The brain was unremarkable. 
 
 




Most tissues showed evidence of autolysis. The liver demonstrated areas of focal 
necrosis surrounding several central veins and portal areas. Within the areas of 
hepatocellular necrosis was haemorrhage and fibrin deposits (Figure 7.1c). 
Hepatocytes surrounding the focal necrosis were vacuolated and there were some 
autolytic changes. There was a granuloma evident in the liver parenchyma 
surrounding a degenerating parasite (unidentifiable species). The necrosis evident in 
the liver could possibly be a result of recently migrating parasite larvae.  The lung 
exhibited chronic fibrotic changes, including thickening of alveolar septa and a 
lymphoplasmacytic infiltrate with eosinophils, and was likely a consequence of 
infection with ‘lung worm’ (probably either Crenosoma vulpis or Angiostrongylus 
vasorum). The kidney showed advanced autolysis and could not be evaluated. Other 
tissues were autolytic or otherwise unremarkable. 
 
Fox 120916/1 
On examination of the liver section, the hepatocytes demonstrated moderate 
floccular vacuolation and there were some mild lymphoplasmacytic infiltrates 
surrounding several central veins. In the lung, eosinophils and plasma cells were 
present, and a marked inflammatory response surrounding nematodes (unidentified; 
possibly C. vulpis) was evident. Mild lymphocytolysis was evident in the spleen. The 
kidney and tonsillar tissues were unremarkable. 
 
Fox 121216/1 
The kidney showed microvesicular to macrovesicular vacuolation in segments of 
nephrons; although this was suspected to be of little significance to CAV-1, it could 
have been a metabolic or physiological response. However, the clinical history of the 
fox was unknown. The liver showed mild anisokaryosis and mild floccular vesicular 
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Fox 161214/1 – PCR negative control 
Rare degenerate hepatocytes were present in the liver; hepatocytes had evidence of 
anisokaryosis and were often binucleate. The kidney was autolytic, but was 
otherwise unremarkable.  
 
Fox 191214/1 – PCR negative control 































Photomicrographs of histological findings in two CAV-1 PCR positive red foxes, 
from sections stained with H&E. Scale bars are defined on the captured fields. 
 
a) Fox 201114/1 liver; occasional binucleate cells (solid arrows) and individual cell 
degeneration of a probable binucleate cell (empty arrow) 
 
b) Fox 201114/2 renal medulla; multiple intranuclear inclusion bodies within a 
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c) Fox 160816/1 liver; focal necrosis surrounding a blood vessel, with deposition of 
















Chapter 7 – Investigating inapparent CAV-1 infections 
 
231
7.3.2 Detection of CAV-1 positive cells by ISH in tissues from red foxes 
with ICH 
 
Tissues from the ‘positive control’ sections (fox 1 and fox 4; PCR positive and 
demonstrative of grossly/histologically evident ICH) were positive for CAV-1 by 
ISH. The distribution of CAV-1 was similar to that expected from the IHC conducted 
in Chapter 3, but was reduced in frequency, possibly as a result of decreased 
sensitivity. Representative fields from the positive control sections are displayed in 
Figure 7.3. Using the protocol described, positive cells with intranuclear inclusion 
bodies stained well with the substrate; cells without intranuclear inclusion bodies 
demonstrated lighter staining. This could be a consequence of lower concentration of 


























Photomicrographs of exemplary fields which were positive for CAV-1 DNA by ISH 
in positive control fox tissues (tissues from fatal ‘ICH’ cases). Purple staining 
represents CAV-1 positive cells (NBT-BCIP substrate). Tissues are counterstained 
with nuclear fast red. Scale bars = 50 μm. 
 
a) Fox 4 spleen; staining of many cells in the red pulp (exact cell type cannot be 
determined; possibly include macrophages). Inclusion bodies are evident in several 
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b) Fox 4 liver; hepatocyte nuclei from fox 4 demonstrating intranuclear inclusion 
bodies (solid arrows), and one hepatocyte nucleus demonstrating ‘light staining’ 
without an intranuclear inclusion body (empty arrow).
 
c) Fox 1 liver; a Kupffer or endothelial cell (solid arrow) and hepatocyte (empty 
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d) Fox 4 brain, multiple infected blood vessels (vascular endothelial cells; solid 
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7.3.3 Detection of CAV-1 positive cells by ISH in tissues from red foxes 
without gross evidence of ICH 
 
Of the CAV-1 PCR positive tissues, inapparently infected with CAV-1 (on gross 
examination), some tissues demonstrated very rare staining of cells for CAV-1 by 
ISH. Positive cells were detected in the kidney of fox 201114/2 (Figure 7.4a). 
Despite no immediately evident pathology on gross examination, the kidney of this 
fox also demonstrated pathology which was evident on H&E staining (described in 
section 7.3.1 Histological descriptions of tissues persistently infected with CAV-1); 
the ISH positive cells corresponded to the same location of cells (renal medulla) 
where intranuclear inclusions were evident on H&E stained sections (Figure 7.3). 
The cells detected to be positive for CAV-1 DNA by ISH appear to be renal tubular 
epithelial cells, likely in collecting ducts, and some contained intranuclear inclusion 
bodies; some positive cells did not appear to have intranuclear inclusion bodies 
(Figure 7.5). No cells were positive for CAV-1 by ISH in other tissues from the same 
fox. 
 
In fox 121216/1, a nucleus of a hepatocyte appeared to be positive for CAV-1 DNA 
by ISH (Figure 7.4b). The staining was weak and other tissues from the same fox 
showed no positive cells. No specific liver pathology was noted on the H&E stained 
section, beyond a mild floccular vesicular change in hepatocytes. 
 
Other tissues did not show definite evidence of CAV-1 positive cells in the other 
foxes. However one ‘suspect’ positive cell was noted in the brain of fox 201114/1 
(Figure 7.4c). This appears to be faint, and it is unclear whether it was cell 
associated; if so, it could have been within a glial cell (possibly an astrocyte). 
Astrocytes have not been reported to be permissive for CAV-1 before and would be 










Fields displaying the positive cells in CAV-1 PCR positive tissues by ISH, which 
were deemed to be ‘inapparently infected’. Scale bars = 50 μm. 
 
a) Fox 201114/2, renal medulla; clusters of CAV-1 positive renal tubular epithelial 
cells. Three clusters of positive cells are indicated by solid arrows. 
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c) Fox 201114/1 brain; a weakly staining ‘focus’ (solid arrow); it is unclear if it is 
cell associated but is typical of the correct colour stain expected from the devleoped 
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7.3.4 Transcription profile of a lytic CAV-1 infection in MDCK cells 
 
The transcription profile of the CAV-1 genes E1A, E3, fiber and hexon were 
monitored at intermittent time points in the 48 h infection period. Following RT-
qPCR and normalisation of the GOIs to the HKGs it was shown that fiber and hexon 
were not expressed until the 9 h sampling point and the 18 h sampling point 
respectively (Figure 7.5); this was expected. It was also found that E1A was 
expressed first in a higher relative quantity to E3 at 3 h, but by 18 h was overtaken in 
expression by E3 and at 24 h by all genes; this was also as expected. Expression of 
E1A then remained constant in the last 24 h period (until 48 h; Figure 7.5). E3 was 
expressed by 3 h post infection and was most expressed (relative to the other genes 
in the panel) at all time points, and continued to be heavily expressed at 48 h, more 
so than hexon and fiber; this was an unexpected finding (Figure 7.5). 
 
No viral genes were detected in the mock control (not shown). Expression was very 
similar when GOIs were normalised to either HPRT or RPS5 HKGs (Figure 7.5a and 





















Comparative expression of four selected CAV-1 transcripts during a 48 h course of 
MDCK infection. The y-axis represents the expression normalised to the HPRT 
HKG (a) and RPS5 HKG (b). Negative values means that the expression was less 
than that detected to be present by the HKG. Fiber was not detected until the 9 h 
sampling point and hexon not until the 18 h sampling point. No transcripts were 
detected in the mock/0 h controls, except the HKGs (not shown). Standard error bars 
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7.3.5 Transcription of selected CAV-1 genes in infected canid tissues 
 
RNA was extracted from canid tissues as described in section 7.2.6 (Selection and 
preparation of samples for RT-qPCR). Transcripts were detected in the liver, kidney 
and spleen of DogAnon_RT. Transcripts were not detected in samples other than the 
kidney of fox 121216/1. Because transcripts were not analysed as a time course, the 
results are displayed as a proportion of overall comparative expression (after 






Relative expression of CAV-1 E1A, E3, hexon and fiber following RNA extraction 
from the tissues indicated in the chart (normalised to HPRT). E3 and fiber expression 
were similar in 121216/1 kidney (points overlain). Hexon and E1A expression were 
similar (points overlain). Standard error bars are not shown because points were the 
















































This is the first study to date investigating the histological features of tissues from 
free-ranging red foxes which were PCR positive for CAV-1, but possessed no 
evidence of the typical gross pathological features of ICH. These tissues were 
investigated as ‘inapparently infected’ tissues, which may have represented persistent 
infections. The aim of the final study in this thesis was to define the histopathology 
of such tissues, determine the specific cell types which might remain infected, and 
interpret this in regards to the underlying molecular mechanisms of pathogenesis. 
 
The ISH technique developed appeared to be specific within the tissues examined, 
and the negative control slides had none-to-minimal artefactual staining; when 
artefacts were present, they were obviously unassociated with cells. Dark 
yellow/brown haemosiderin in some sections was easily distinguished from positive 
cells because the NBT-BCIP preparation which was used produced a colour ranging 
from light grey/purple to a dark purple colour. Formal quantification of the number 
of staining cells was not performed because of the rarity of positively staining cells 
among persistently infected tissues. However, it was deemed likely that the 
sensitivity of the ISH technique was not adequate in detecting all infected cells 
because not all tissues positive for CAV-1 PCR appeared to have any positive cells 
by ISH. Although PCR false positivity must be considered, this is unlikely to be the 
case because the foxes were positive by PCR in multiple tissues and regular 
procedures to minimise PCR contamination were taken. A more likely explanation is 
that the copy number of CAV-1 DNA in persistently infected cells could be too low 
to be detected by this technique, thus further optimisation may be required. In 
addition, the ISH was less sensitive when compared to tissues from foxes with ICH 
which were subject to IHC (Chapter 3). 
 
To correct for this it may be possible to optimise the procedure by increasing the 
concentration of the probe in the hybridisation solution. However, this would be an 
expensive optimisation and would be expected to increase the risk of false-positive 
background staining. Alternatively, it may be possible to develop the ISH further by 
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increasing the CAV-1 DNA copy number in situ. This would involve PCR on tissue 
sections, followed by ISH (in situ PCR; Bagasra, 2007). In situ PCR may be more 
useful to detect cells persistently infected with CAV-1 because it is already shown 
that the developed ISH was successful in detecting cells in clinically affected tissue 
(i.e. high copy number inclusion bodies), albeit with less sensitivity than the IHC 
techniques developed. The procedure could not be optimised in the current study 
because of the limitation of materials (both reagents and tissues) and funding. 
 
However, the CAV-1 ISH developed does provide a successful proof of concept. For 
the first time it has been shown that, in the absence of ‘classic’ ICH in surrounding 
tissue, cells infected with CAV-1 can be detected. To the author’s knowledge, 
persistently infectious adenovirus has only ever been detected in situ once; in human 
GIT biopsies which were infected with HAd (using a HAd5 probe; infected in lamina 
propria lymphoid cells and GIT epithelial cells; Kosulin et al., 2016). The current 
study is therefore significant, because it demonstrates that several possible cell types 
which are non-lymphoid, are positive for CAV-1 DNA by ISH and these were thus 
deemed to be persistently infected. The cell types permissive for CAV-1 are likely to 
be different from other mastadenoviruses, given the systemic nature of CAV-1 
infection during overt disease. 
 
Several renal tubular epithelial cells were detected to be positive in clusters within 
tubules in the kidney of fox 201114/2. This provides firm evidence, as initially 
suggested by the early experimental infections of Poppensiek and Baker (1951), that 
renal tubular epithelial cells do remain persistently infected with CAV-1. This can 
explain how the DNA extracted from urine (in Chapter 4) was shown to possess a 
relatively high copy number of CAV-1, as determined by qPCR, and is likely to be a 
result of shedding of virus from these renal cells into the urine. However, it is noted 
that it is not possible to determine when the fox was infected with CAV-1 and 
exactly how long these cells have been infected. This may be demonstrative of the 
‘spontaneous CAV nephritis’ demonstrated by Wright et al. (1971). Although it can 
be argued that this may be the initial acute stages of an infection, or a ‘re-infection’, 
this would not be expected because, given the systemic nature of CAV-1; lesions in 
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the CNS and liver would have been expected to also be present if inclusions were 
already present in the renal medulla. The infection is unlikely to have been ‘very’ 
recent because fox 201114/2 possessed CAV IgG (Table 7.1). 
 
Some of the ISH-detected cells in the renal medulla of fox 201114/2 demonstrated 
intranuclear inclusion bodies (and in the H&E stained sections), whereas some cells 
were positive for CAV-1 in the absence of intranuclear inclusion bodies. This is 
similar to what was found by use of IHC in other foxes (Chapter 3), where CAV-1 
positive cells can be found in the absence of intranuclear inclusion bodies. Again, it 
is also important to note that this fox was positive for (untyped) CAV antibody in the 
ELISA (Chapter 4; Walker et al., 2016b). Thus, this is likely to represent a true 
persistent infection, although may not represent ‘latency’ because inclusion bodies 
are present, which is indicative of viral proliferation and impending lysis. The 
observation that some infected cells contained intranuclear inclusion bodies and 
some infected cells did not could indicate that they are at different stages of the 
CAV-1 replication cycle. The process behind this can only be speculated. It is 
possible that lysed renal tubular epithelial cells infect cells in neighbouring tubules, 
or it may represent infection from elsewhere which has been ‘deposited’ in the 
medulla.  
 
It is interesting that no other cells in other tissues were detected to be positive for 
CAV-1 in fox 201114/2. This may be a result of the low sensitivity of the ISH (and 
low copy number of CAV-1 outwith the renal tubules). This could mean that virus 
concentrates in the renal medulla, that this site is constantly seeded from elsewhere, 
that CAV-1 has adapted to persistently infect renal tubular epithelial cells, and/or 
there may be an immunoprotective mechanism at this site. This can only be 
speculated at the current stage and is an important area for future research; 
specifically, the molecular mechanisms underlying this (including analysis of 
host/viral transcripts). 
 
It was also shown that a hepatocyte was positive for CAV-1 in 121216/1. This is an 
unusual finding, and may demonstrate for the first time in situ that CAV-1, in tissues 
 
Chapter 7 – Investigating inapparent CAV-1 infections 
 
244
other than the kidney, can be persistently infected. However, it is a limitation that it 
cannot be determined at what time post-infection this tissue is representative of (i.e. 
when the fox was infected with CAV-1). It is unfortunate that concurrent serological 
evidence (ELISA) is not available for this fox to determine the presence of CAV 
IgG, which would have given some suggestion of ‘chronicity’. Thus, an ‘early 
infection’ cannot be ruled out in this individual fox, prior to the development of ICH. 
However, one might speculate that many more positive cells (and in other tissues) 
would be detected if this were the case. The nuclei appears to be partially stained in 
the positive hepatocyte and thus suggests that the CAV-1 DNA exists within the 
nuclei itself (if this is a true representation of persistence and not a ‘recent 
infection’), and not the cytoplasm. Within the renal tubular epithelial cells of fox 
201114/2 (Figure 1.5), the CAV-1 DNA also appears to be nucleus associated, 
although the presence of intranuclear inclusion bodies suggests CAV-1 may be 
actively replicating. An intranuclear inclusion body is not evident in the positive 
hepatocyte in fox 121216/1, this therefore may suggest that CAV-1 could be latent. 
Zhang et al. (2010) presented evidence that HAds may persist as monomeric 
episomes, and this could be representative of this in situ. However, experimental 
work would be required to confirm that CAV-1 had not integrated into the genome 
(e.g. with restriction endonucleases; Zhang et al., 2010).  
 
The staining present in the CNS (Figure 7.4c; possibly an astrocyte, although 
secondary IHC is required to confirm the cell type) is less clear and may represent 
false positivity. However, if this is true staining then it adds to the evidence that cells 
other than vascular endothelial cells can be infected in the CNS (see Chapter 3). 
 
It is difficult to speculate the consequence of the presence of CAV-1 DNA in the 
nuclei in possibly persistently infected tissues without further experimental evidence. 
The study by Zhang et al. (2010) may not represent a ‘real world’ situation since T-
cells and B-cells were experimentally infected with HAd and, although the authors 
suggest that ‘latency’ was ‘modelled’, infectious virus was still produced to a lesser 
degree. However, Zheng et al. (2016a) demonstrate that HAd5 E1A transcription is 
repressed by the presence of IFNs in cell cultures. Therefore, where transcription is 
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hindered, the virus may still remain in the cell nuclei until transcription can ensue 
and whole virions can be produced; this would provide one mechanism of 
persistence. 
 
Of the inapparently infected CAV-1 PCR positive tissues subject to RT-qPCR, only 
the kidney of fox 121216/1 demonstrated detectable transcripts. This is interesting 
because positive cells were not detected by ISH in the kidney of this fox and could 
further suggest that the ISH is indeed low in sensitivity in its current form. If this 
tissue is truly representative of a persistently infected tissue (possible in a ‘later’ 
stage of infection than the kidney of fox 201114/2) then it suggests CAV-1 is not 
latent in renal tissue because transcripts from both E and L genes would not be 
expected to be detectable, and theoretically could ‘exist’ by infection with a low 
copy number and a low replication rate. However, the results must be interpreted 
with caution, because again it cannot be determined at what point post-infection the 
tissue represents (it is a sample from a naturally infected red fox with no clinical 
history available). When comparing the relative expression of the transcripts from 
the kidney of fox 121216/1 (Figure 7.6) it matches the relative expression of 
transcripts shown in an active CAV-1 infection of MDCK cells at 24 h (Figure 7.5). 
This evidence therefore may be in favour of the ‘recent infection’ theory. 
 
In the tissue sections examined histologically in other red foxes, which were deemed 
to possess CAV-1 by PCR, the findings were also inconclusive. Therefore, it is hard 
to determine whether detection of CAV-1 in inapparently infected tissues is related 
to any specific pathology. In some tissues autolysis made interpretation difficult. 
Binucleate cells were more common than one might expect to find in a normal dog, 
for example, but this may be a ‘normal’ finding in wild red foxes, which are likely 
exposed to many pathogens, parasites and other physical and environmental 
‘hardships’. However, the brains were invariably unremarkable.  
 
The CAV-1 infection model of MDCK cells (Figure 7.5) was successful in 
demonstrating the transience of relative gene expression of the four selected 
transcripts. It is interesting to analyse this comparative expression in the absence of 
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any other transcript profiles detected in ‘real tissues’ to compare it with.  As 
expected, E1A was expressed first, by the first sampling point at 3 h. Fiber was 
detectable by the 9 h sampling point and hexon was detectable by the 12 h sampling 
point, as would be expected from L genes. However, although E3 (13.3 kDA) was 
expressed early, its expression was sustained throughout infection, and was still most 
highly expressed at 48 h onwards, as cells progress to lysis. This suggests that this 
could be an important gene for CAV-1 proliferation. However, it can only be 
speculated as to the function of this gene, because its orthologs in HAds and other 
mastadenoviruses have not been studied at all and its expression was not manipulated 
in the current study. It is possible that it has immunoregulatory functions (Horwitz, 
2004). Thus, CAV-1 E3 (13.3 kDA) would be an interesting transcript to evaluate in 




Although full interpretations of the findings presented in the chapter are difficult due 
to the lack of clinical history and controlled time course of infection of the tissues 
utilised, some important findings have been revealed. For the first time the findings 
likely demonstrate that red foxes can possess a ‘chronic’ form of ICH, at least in the 
renal medulla. This is based on ISH and concurrent serological evidence in fox 
201114/2. The fact that actively replicating CAV-1 is present in renal tubular 
epithelial cells (based on the presence of intranuclear inclusion bodies), this provides 
a means by which urine can be detected to contain CAV-1 for several months post-
infection (in the absence of overt clinical signs of ICH; Poppensiek and Baker, 1951) 
and how CAV-1 can be detected by PCR in the urine of several foxes during the 
epidemiological survey in the UK (Chapter 4; Walker et al., 2016b). It is difficult to 
interpret whether this infection (of unknown duration of time post-infection) results 
in a definable residual pathology (other than evidence of intranuclear inclusion 
bodies) because there may have been concurrent renal disease in this fox; again, the 
lack of clinical history, as a consequence of sampling ‘wild animals’ is therefore a 
limitation. The solution to this may be to increase the sample size, however, this 
would take some time to collect enough suitable (and non-autolytic) samples; the 
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problem of a lack of clinical history would still exist, but this is an inherent difficulty 
in working with samples from free-ranging animals. 
 
It is inconclusive whether CAV-1 causes disease in other tissues in foxes suspected 
to be persistently infected. As discussed, in some foxes, there may be little pathology 
because infections could be recently acquired (rather than be persistent). In others, a 
low-grade chronic pathology may be difficult to interpret because, for example, 
parasites and other pathogens are present. The fact that fox 201114/2 demonstrated 
renal medulla infection justifies a continuation of the study into the possibility of a 
chronic or ‘occult’ form of CAV-1-infecton, with mild associated disease, as 
opposed to the ‘overt’, predominately neurological form in red foxes observed in 
recent infections (Chapter 3). In tissues of foxes where some pathology was detected 
then this was usually associated with pre-existing disease and likely not to be 
attributable to CAV-1. However, because this somewhat masks the interpretations, 
the hypothesis that infection with CAV-1 in other tissues is usually ‘inapparent’ or 
causes minimal disease, as is usually the case with persistently infectious HAds in 
human lymphoid tissues (Garnett et al. 2002), cannot be proven definitively. 
 
In regard to the molecular mechanisms of persistence in the present study, what is 
(and isn’t) being detected in situ may still represent ‘repressed’ virus, for example, 
by a mechanism similar to that suggested by Zheng et al. (2016a) or a combination 
of unknown mechanisms. It is speculated that CAV-1 may then be occasionally 
stimulated to replicate in persistently infected cells, and shed virus into the urine (for 
renal tubular epithelial cells; Wright et al., 2016) or haematogenously (for 
hepatocytes, for example). It is likely that there is a constant low-level shedding of 
virus (into urine) following recovery, which then becomes undetectable, for example, 
after ‘6 months’ post infection (Poppensiek and Baker, 1951). This study could 
represent the first evidence of this in situ in red foxes. However, the molecular 
mechanism underlying this could not be revealed in this current study. Whether 
transcription is regulated or not in the inapparently infected tissues could not be 
determined because transcripts were not detected.  
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It was unfortunate that CAV-1 transcripts could not be detected by RT-qPCR in 
more tissues, despite its effectiveness at detecting transcripts in a cell culture 
infection. It was not possible to determine whether this lack of detection of 
transcripts in other inapparently infected tissues was due to low sensitivity of the 
assay and/or a low copy number of CAV-1 transcripts, or whether CAV-1 was just 
not transcribing (i.e. is latent). However, given that transcripts were present in one 
sample, it is possible that RNA (through detection of cDNA) was just not detected 
due to low copy number (given the rarity of positive cells by ISH) and possibly due 
to poor quality of samples (compared to cell culture extractions). The RNA quality of 
the extractions was not formally quantified in this study, but this would be useful to 
determine in any future work. Thus, the assay likely requires further optimisation to 
increase the sensitivity. It may be more fruitful to develop a CAV-1 model of 
persistent infection (e.g. by the use IFNs; Zheng et al., 2016a) where transcript 
abundance (and RNA quality) is likely to be much higher than RNA extraction from 
tissues of free-ranging red foxes. 
 
In conclusion, despite the mixture of success attained in the study presented in this 
chapter, it provides a ‘proof of concept’. The ISH was successful in detecting a 
limited number of cells with CAV-1 DNA in situ. Further work to optimise this to 
achieve a sensitivity whereby more cells infected with CAV-1 can be detected in 
persistently infected tissues would provide greater confidence in the theory that 
CAV-1 can be persistently infectious. 
 
Although further efforts in future studies could be made to optimise the RT-qPCR to 
detect a panel of key CAV-1 transcripts, it may be more rewarding to follow an 
RNA-seq approach, if funding can be secured. The ISH has highlighted that certain 
cells were infected with CAV-1 DNA, particularly renal epithelial tubular cells. A 
cell targeted RNA-seq approach would allow an analysis of the full transcript of 
CAV-1, and also of the host cell to fully assess the transcriptome of virus and host. 
The RT-qPCR panel may be best placed to evaluate transcripts following further 
RNA-seq (to confirm the selection of the primers chosen) in cell culture 




























8.1 Thesis overview and further research 
 
The disease caused be CAV-1 was arguably the first adenovirus-associated disease to 
be described, following the widely reported mass mortalities on fox fur farms in N. 
America (Green et al., 1930). Despite this, the ‘agent’ itself was not recognized to be 
an adenovirus until Kapsenberg (1959) described its serological relationship to the 
recently discovered human adenoviruses; it was later imaged by Davies et al. (1961). 
The disease was first referred to as ‘epizootic fox encephalitis’ (Green et al., 1930), 
but was later re-characterised in dogs as ‘infectious canine hepatitis’ (Rubarth, 
1947), despite the wide range of other symptoms which CAV-1 infection was 
reported to cause. This early research on CAV-1 highlighted that there may be 
interspecific differences in the pathology caused by CAV-1. The inconsistency was 
noted by Innes and Saunders (1962) and Cabasso (1962), although the concerns in 
terminology has not been ‘followed up’ until the present study. 
 
It is highlighted that, for an adenovirus, CAV-1 causes unusually severe disease in a 
range of tissues, even in immunocompetent canids. Usually, adenoviruses in humans 
cause only mild respiratory and gastrointestinal disease, and several HAds are highly 
prevalent (Brandt et al., 1969; Ison et al., 2002). However, it has been noticed that 
HAd disease can be exacerbated in high-density populations (e.g. military recruits; 
Hendrix et al., 1999) and is increasingly reported to cause severe, systemic disease in 
immunocompromised patients including humans with HIV and recipients of solid 
organ and haematopoietic stem cell transplants (e.g. Michaels et al., 1992; Baldwin 
et al., 2000). 
 
In this thesis, outbreaks of naturally occurring CAV-1 in red foxes, which were 
temporarily captive in wildlife rehabilitation centres in the UK, were investigated 
(Walker et al., 2016a). It was noted that disease was rapidly fatal in the cases 
described and a hypothesis was made that disease could have been exacerbated by 
immunosuppression (e.g. some other disease process or psychological stress), which 
often occurs in immunosuppressed human patients (e.g. Chakrabarti et al., 2002; 
Seidemann et al., 2004). This suspicion could not be confirmed due to the lack of 
 





clinical histories and further clinical evidence. However, the CNS disease noted 
during the outbreaks was typical of the lesions and course of disease described in 
historical fox fur farm outbreaks (Green et al., 1930; Sompolinsky, 1949) and so the 
disease caused by CAV-1 in red foxes may be particularly acute and distinct from 
that in dogs, in which ‘hepatitis’ and other systemic disease is more apparent, 
regardless of immunocompetency. The outbreaks of ICH amongst juvenile red foxes 
described in Chapter 2 also suggest that a single fox at one of the wildlife 
rehabilitation centres could have been ‘inapparently’ infected with CAV-1; That is, 
the fox was likely persistently infected with, and shedding, CAV-1 without showing 
clinical signs of ICH. Therefore, there was a suggestion that there may be distinct 
differences in the disease between red foxes and dogs, and that some red foxes may 
become persistently infected following recovery from disease. 
 
Thus, a comparative pathology study was initiated to systematically compare the 
disease between tissues from clinically affected red foxes and dogs. It was suggested 
that the CNS was indeed more severely affected by CAV-1 than in dogs and many 
vascular endothelial cells were found to be infected using immunohistochemical 
techniques. It was also noted that hepatic disease (mainly hepatic necrosis and 
haemorrhage) was more severe and usually affected the entire tissue section in dogs 
as compared to foxes (though hepatic disease was also often moderate-to-severe in 
foxes, by definition). Therefore, based on this re-characterisation of the detailed 
histopathological features of ‘ICH’, it was suggested that the disease could be 
renamed to encompass the broad range of features in multiple species. 
 
It is important to note that during the comparative pathology of CAV-1 in dogs and 
foxes, cellular inflammation was a minimal feature in the liver sections examined, 
and was non-existent in the CNS of foxes. However, some perivascular cuffing was 
noted in the dog brains examined, and this could be reflective of an increased 
chronicity of disease in the dogs (i.e. several days in dogs rather than a day or less in 
foxes; Walker et al., 2016a). It is argued that the terms ‘hepatitis’ and ‘encephalitis’ 
are inappropriate, because cellular inflammation in the liver was not a feature and 
encephalitis (and specifically ‘vasculitis’ within the CNS) was inconsistent between 
 





red foxes and dogs. For example, in some CNS sections, CAV-1 was evident in 
vascular endothelial cells in the absence of perivascular cuffing with inflammatory 
cells. In reality ‘ICH’ exhibits a wide-range of ‘-opathies’, and this may be a more 
appropriate ‘non-specific’ suffix to use than ‘–itis’. Specifically, in the liver a 
hepatopathy characterised by moderate-to-severe necrosis of hepatocytes, with a 
distribution ranging from multi-focal/coalescing-to-massive is evident. The CNS of 
foxes showed many vessels infected with CAV-1. One can argue that what is being 
observed in the liver, for example, is early-acute inflammation; a result of 
haemorrhage in combination with oedema and fibrin accumulation (Zachary and 
McGavin, 2013). Although haemorrhage, congestion and oedema are severe in some 
dogs, it is not consistent interspecifically, subtle in some animals and, in the absence 
of cellular infiltrate, inflammation is hard to describe histologically. 
 
The findings presented in this study further suggest that CAV-1 might have a 
particular propensity to infect vulpine vascular endothelial cells in the CNS. In the 
dog, CAV-1 may have tropism for hepatocytes (although both cell types, and many 
others, are infected to different degrees in both species). There is an argument to be 
made that the more severe hepatic disease in dogs may simply be because the disease 
had a longer-course. This could only be controlled for by knowledge of when the 
animals were infected, which was not possible in this study. However, the findings 
do highlight that the course of disease was likely to be rapid in red foxes (regardless 
of control samples). Firstly, there was none-to-minimal inflammation in the red fox 
brains and livers, and CAV-1 highly infected the CNS (as determined by IHC). The 
appearance of intranuclear inclusions in the dogs and the presence of perivascular 
inflammation in the CNS suggests a longer course of disease. In addition, if dog 
vascular endothelial cells were ‘as susceptible’ as hepatocytes, then one would have 
expected many cells to have been infected by IHC by the time perivascular 
inflammation was histologically visible; this was not the case. There is therefore a 
strength in the evidence for an interspecific difference in CAV-1 tropism, which may 
influence the time from infection to death. Further experimentation is required to 
confirm that CAV-1 may have different ‘tropism’ for particular cells among species. 
 





This is likely to require extension of the research into culturing primary vulpine and 
canine cells, which may be challenging. 
 
Furthermore, it is noted that the sample size of the comparative study was relatively 
low (this was a limitation of the funding and materials available) and the findings 
discussed would be controversial to enforce as definitive evidence of interspecific 
differences without further studies. Specifically, the sample size requires to be 
increased, but this is hindered by the scarcity of non-autolytic or freeze-thaw 
damaged samples. Even when samples can be obtained from red foxes, the full 
clinical history of those animals cannot be obtained and that is an inherent difficulty 
with working with samples from ‘wild’ animals. Furthermore, concurrent and 
chronic disease was observed in some of the red fox samples examined, which 
somewhat masked the interpretation of the clinical importance of inapparent CAV-1 
infections. 
 
CAV-1 is well controlled among dog populations in countries where the vaccine is 
widely distributed as part of a the ‘core vaccination’ strategy of pet dogs (Day et al. 
2016). However, occasional incidences occur in pet dogs in the UK, which suggests 
that there is a wildlife reservoir of disease (if dogs were the only susceptible species, 
then a herd immunity could contribute to its eradication, since the majority of pet 
dogs in the UK are vaccinated; PDSA and YouGov, 2016). In Chapter 2 of the thesis, 
it was speculated that the likely cause of outbreaks of ICH in red foxes was the 
introduction of an inapparently infected red fox to a group of susceptible juveniles 
(Walker et al., 2016a). Subsequently, a UK-wide study of samples from red foxes 
revealed that 29 of 154 (18.8%) red foxes were infected with CAV-1 and none of the 
foxes possessed gross pathological evidence of ICH upon post-mortem examination. 
In addition, 302 of 469 (64.4%) red foxes were estimated to be seropositive for CAV 
(untyped). This revealed not only that most red foxes in the UK have been exposed 
to a CAV, but that around a fifth are inapparently infected with CAV-1, with some 
shedding high quantities of CAV-1 in urine. Therefore, it was determined that red 
foxes could be a significant source of CAV-1 infection for pet dogs in the UK, given 
that they are the only free-ranging canid in the UK. 
 






The prevalence of CAV-1 in red foxes in the UK has implications for disease control 
and biosecurity protocols in veterinary practices and wildlife hospitals. It is strongly 
recommended that ‘incoming’ red foxes to veterinary facilities be quarantined 
routinely, since they may be infected with (and shed) CAV-1 (Walker et al., 2016b). 
In addition, it is emphasised that CAV-1 was shown to cause a rapid course of 
disease, with minimal clinical signs. Veterinarians should be aware of the subtleness 
and rapidness the disease may present with, particularly in red foxes. Specific control 
measures to limit the disease in red fox populations are not recommended, given that 
vaccination is wholly effective against the disease in dogs and this should not be 
neglected in place of any other control measure. Because the vaccine for CAV-1 
(based on the use of CAV-2) is part of a combined multivalent vaccine for other 
significant diseases of dogs, the author regards that vaccination should be regarded 
as part of responsible pet ownership (since it also encourages regular ‘health check 
ups’). Additionally, vaccination of red foxes directly and by oral bait is likely to be 
ineffective (Baker et al., 2001), and red fox culling (and other predator species 
culling) is very controversial in terms of ‘social conflict’ (Woodroffe and Redpath, 
2015); it has also has been shown not to significantly reduce population sizes (due to 
constant immigration from neighbouring areas; Baker and Harris, 2005). 
 
This study also highlighted an important aspect of adenovirus pathogenesis which 
has been poorly studied, that of persistence of infection following resolution of 
disease. This was highlighted as a feature of adenoviruses as early as 1954 (Huebner 
et al., 1954). In dogs, it was also shown that CAV-1 was shed for prolonged periods 
following experimental infections (Poppensiek and Baker, 1951) but this was before 
the virus was characterised. It was particularly remarkable that such a wide range of 
samples were determined to be positive for CAV-1 during the molecular screening of 
tissues from red foxes (Walker et al., 2016b). 
 
The molecular mechanisms which allow the possible persistence of infection  
(of HAds) have more recently received attention from a limited number of research 
groups. However, it is deemed important to investigate this further because systemic 
 





adenovirus-associated disease in immunosuppressed human patients is often severe 
and fatal (Chakrabarti et al., 2002; Seidemann et al., 2004). In transplant patients, it 
is unclear whether HAds ‘re-activate’ within the recipient tissues, or is introduced 
with donor tissues (Flomenberg et al., 1994). Thus, veterinarians should also be 
aware that seemingly healthy or ‘clinically stable’ red foxes which are presented to 
veterinary hospitals (and even dogs in countries where they are not routinely 
vaccinated) could be harbouring CAV-1, which theoretically could recrudesce (as a 
result of immunosuppression or stress) to cause fatal disease. The molecular 
mechanisms employed by CAV-1 specifically, in any aspect of its pathogenesis, 
have never been studied. Therefore, this was important to investigate further in the 
current study because red foxes may be a wildlife reservoir of CAV-1. It was 
important to determine which cell types remain infected with CAV-1 in a ‘persistent 
infection’. This is a key piece of information to ascertain because it would allow cell-
targeted approaches to investigate the interaction of virus and host by 
transcriptomics. 
 
Thus, an in situ hybridisation technique was developed for CAV-1, which 
highlighted some cell types in tissues which were deemed to be persistently infected 
with CAV-1, in the absence of overt ICH. It was a limitation of the study that the 
sensitivity of the technique at the current time is likely to be low. However, further 
optimisation was not possible due to limited funds and exhaustion of suitable tissue 
archives. Despite this, it does highlight an important proof of concept, that 
adenoviruses can be detected in situ where DNA has been detected in tissues by 
PCR. The technique could be easily adapted to other adenoviruses; this would be a 
useful tool, particularly in human transplant medicine, which could highlight if donor 
tissues are infected with a HAd and the exact cells which are infected. 
 
The tissues, though very limited in number, made available during this project gave a 
unique opportunity to investigate the residual pathology of ICH in persistently 
infected tissues and the mechanisms underlying CAV-1 persistence. This has only 
been once studied, in which Wright et al. (1971) identified that CAV-1 may 
spontaneously ‘recur’ in renal tubular epithelial cells in dogs several weeks post-
 





infection. This has not been demonstrated in free-ranging species, nor has ‘chronic’ 
disease been demonstrated in other tissues in any species. In the current study, renal 
tubular epithelial cells were determined to be infected with CAV-1 in situ, overt ICH 
was not observed in other tissues, and the fox had circulating CAV IgG present (as 
determined by the untyped CAV ELISA). This could represent a fox which is 
recovering from overt ICH, but the length of time post-infection is not known; other 
tissues were not definitively affected by viral CPE. The possibility is therefore raised 
that there are acute and occult forms of ICH, and somewhat confirms the work of 
Wright et al. (1971). Thus, in future studies, it would be useful to try to determine 
the length of time CAV-1 can remain persistent in tissues and whether CAV-1 can 
re-activate under immunosuppression. This would require investigation in animals 
when the time of infection was known. Ultimately, identifying specific mechanisms 
could highlight possible pathways for therapeutics to target to prevent persistence of 
CAV-1 in canids. 
 
In general, the RT-qPCR was not successful in detecting transcripts from most of the 
tissues of inapparently infected red foxes, to try and determine whether certain genes 
were regulated. It was not possible to say whether the lack of detection of CAV-1 
transcripts was a consequence of poor RNA preservation and/or insensitivity of the 
assay, or there were truly no transcripts present (i.e. CAV-1 was latent). The lack of 
knowledge of when the red foxes were infected (as a consequence of ‘sampling from 
the wild’) was again a problem in interpretation of the finding of transcript detections 
in a single red fox kidney; this could have represented a ‘recent infection’ rather than 
a persistent infection. However, some positivity is drawn from the fact that the ISH 
could be further optimised, or developed into an in situ PCR detection system, to aid 
cell-targeted transcript analysis of adenovirus infected cells which could reveal 
mechanisms of persistence (e.g. if particular transcripts were detected to be 
downregulated or absent). For example, by knowing that renal tubular epithelial cells 
may remain persistently infected, these could be targeted for transcriptional analyses; 
RNA from other cells would then not ‘dilute’ the transcripts of interest. Although 
renal tubular epithelial cells were detected to be infected in a fox thought not to have 
‘overt’ ICH, many other tissues were detected to be positive for CAV-1 including an 
 





array of tissues from 29 of 154 (18.8%) red foxes screened for CAV-1 DNA in the 
epidemiological survey (Chapter 4). Therefore, renal tubular epithelial cells are 
likely to not be the only cell to remain persistently infected. 
 
Although the RT-qPCR developed in this study may provide a platform for further 
cell culture transcriptional analysis, it may still not be optimised enough to allow 
adequate sensitivity to detect transcripts from a small number of cells in an entire 
tissue. It is also limited to ‘survey’ a small number of transcripts included in the 
panel. The ideal advancement would be to seek to employ an RNA-seq approach to 
transcriptional analysis. This would also highlight the host cells’ response to 
infection and allow a full assessment of the viral transcriptome. Even if such an 
approach was employed, time-controlled samples would still be required, that is, 
knowledge of when the cells were infected. Thus, in the absence of this, a more 
viable approach may be to develop a cell culture model of CAV-1 persistence (such 
as one developed for HAds by Zheng et al. 2016, using IFNs). This would require a 
panel of vulpid/canine cell lines (including primary cell cultures) which would take 
some time to establish. However, MDCK cells are renal epithelial cells in origin and 
morphology (Rindler et al., 1979) and new approaches to culture primary canine 
hepatocytes (which are difficult to culture) have been recently described (Gow, 
2014); these cell lines could provide a meaningful first step. 
 
The severe and systemic nature of CAV-1 disease is also important to investigate 
further. It was earlier referred to that CAV-1, unusually, appears to be highly 
‘virulent’ and pathogenic even in immunocompetent hosts, compared to any other 
known Mastadenovirus, including CAV-2, which is generally limited to the URT 
(although has rarely been detected in the faeces of dogs with enteric disease; 
Macartney et al., 1988). Many cells were determined to be infected by IHC when 
investigating the comparative pathology of CAV-1 in red foxes and dogs. Thus, the 
molecular mechanisms which underlie this require to be investigated further, 
including the determinants of tropism. Given the severe nature of disease caused by 
CAV-1, it may therefore be a suitable model to study systemic and fatal disease of 
HAds in immunocompromised humans. 
 






Overall, the thesis has provided a comprehensive epidemiological study of CAV-1 in 
the UK. It has also emphasised that adenoviruses (including the discovery of novel 
adenoviruses) can persist in a wide range of tissues and the pathology of disease 
caused in red foxes and dogs has been re-explored (albeit with a relatively small 
sample set), the findings of which could aid the veterinary care of these animals. 
Although some limitations arose as a result of the nature of work (i.e. sampling 
wildlife) some useful data were obtained. It is also suggested that CAV-1 could be an 
ideal and useful model to study systemic adenoviral disease, which would be useful 
from a comparative pathology and molecular approach. If the suggested future work 
is successful then it may reveal the molecular mechanisms employed by CAV-1 to 
persist in a large array of tissues (in canids which have circulating anti-CAV IgG). 
This may highlight pathways which could lead to therapeutics to prevent adenovirus 
re-activation in immunosuppressed people, but also aid in our understanding and 
treatment of infected free-ranging canids, which occasionally present to veterinary 
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Appendix 1 – Additional materials and methods 
 
A1.1 Calculation of sample size for CAV-1 serological and molecular 
survey; Chapter 4 
 
The sample size required, with a 95% confidence interval and assuming random 
sampling, was based on the formula (Thrusfield, 2007): 
1.96 	 	 1 	 	 	
n	 	sample	size	required	for	the	survey;	Pexp	 	prevalence	 expected ;	d	 	precision	 desired 	
 
The expected prevalence of CAV antibodies in the UK has previously been estimated 
to be approximately 19% based on a small sample size of 58 animals (Thompson et 
al., 2010), and this was therefore the prevalence which should be expected in the UK 
based on the currently available data. The population of red foxes in the UK is large, 
and estimated to be around 258,000 (Webbon and Harris, 2004). Therefore, the 
sample size required for the serological survey was calculated to be 236 red foxes. 
 
The estimated proportion of individuals carrying detectable virus is expected to be 
very low, and so an expected prevalence of 0.5 (a figure often used when the 
expected prevalence is unknown) seemed unreasonable (Thrusfield, 2007). A 
previous estimate of the proportion of individuals carrying detectable CAV-1 was 
around 6.25% in a sample size of 32 Italian foxes (Balboni et al., 2013). Previous 
studies on other viral burdens have estimated, for example, detectable canine 
parvovirus in red foxes to be 3.9% (Truyen et al., 1998). Therefore it was deemed 
reasonable to estimate the prevalence of detectable adenovirus DNA to be 
approximately 6% in a large population. For the molecular survey of fox tissues, this 
gave a required sample size, with a 95% confidence interval, of 87 red foxes. In 
practice, the study area and sample size was limited by the availability of material, 
which was mainly hindered by the logistical and financial constraints. This is 
characteristic of many wildlife surveys, where studies can be limited by 
practicalities. However, in the final study, the required sample size for the 





A1.2 Madin-Darby canine kidney (MDCK) cell culturing 
 
Madin-Darby canine kidney (MDCK) cells were routinely cultured in Nunc tissue 
culture flasks (Thermo Fisher Scientific, Wilmington, Delaware, USA) by incubation 
in the following medium (volume varied depending on flask size): 500 mL 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) to which 50 mL 
sterile-filtered foetal bovine serum (FBS; Gibco Life Technologies, Inchinnan, 
Paisley), 5 mL penicillin-streptomycin solution (10,000 U/mL penicillin, 10,000 
µg/mL streptomycin; Gibco Life Technologies) and 5 mL 200mM L-glutamine 
(Gibco Life Technologies) was added (referred to as DMEM+FBS+P/S+L-glut). 
 
MDCK cells were sub-cultured at approximately four day intervals. Cells were 
depleted of DMEM+FBS+P/S+L-glut, and washed with PBS. Trypsin-
ethylenediaminetetraacetic acid (trypsin-EDTA) solution was used to remove the 
monolayer of MDCK cells from the flask. Following trypsinisation, the cells were 
diluted in DMEM+FBS+P/S+L-glut and then pelleted in a 50 mL Falcon tube by 
centrifugation at 1200 rpm for 2 min. The pellet was re-suspended in 
DMEM+FBS+P/S+L-glut, and re-suspended cells were added to ‘fresh’ 
DMEM+FBS+P/S+L-glut in a Nunc tissue culture flask. MDCKs in flasks were 
incubated at 37°C in a 5% CO2 atmosphere. 
 
All cell culture work was performed in a sterile fashion. Media were warmed to 37 
°C prior to use and equipment sterilised with 2% Decon 90 (Decon Laboratories 
Limited, Hove, East Sussex) and 70% ethanol. MDCK cells were intermittently 
screened for Mycoplasma contamination using the MycoAlert Mycoplasma detection 
kit (Lonza, Slough, Berkshire). 
 
A1.3 Propagation of CAV-1 and CAV-2 in MDCKs 
 
CAV-1 (commercial strain; ATCC VR-293) viral suspension was thawed on ice 
from a storage temperature of -80 °C. 1 mL of viral suspension was added to a 





in 5% CO2 atmosphere and observed daily for CPE. The supernatant was pipetted 
into aliquots at four days post infection, following centrifugation to pellet cellular 
debris from lysed MDCK cells. The virus was then titred using the method outlined 
in A1.4 Calculation of CAV titres using TCID50. 
 
An unknown titre of CAV-2 (field strain) from the supernatant of infected MDCK 
cells (University of Glasgow; Thompson et al., 2010) was used to infect a sub-
culture of MDCK at near confluence. The infected cells were incubated at 37 °C in 
5% CO2 atmosphere and observed daily for signs of cytopathic effect (CPE). Cellular 
debris was pelleted at five days post infection and the supernatant was collected and 
labelled in aliquots before being stored at -20 °C until titred. 
 
In following infections of MDCK cell cultures, MDCKs were depleted of medium 
and washed with PBS prior to replacement of medium containing no FBS. The 
medium was identical to that to culture MDCK cells except FBS was not added. 
CAV-1/CAV-2 was then added with a known titre. 
 
A1.4 Calculation of CAV titres using TCID50 
 
CAVs do not form plaques, and so the widely used viral plaque assay, which 
estimates viral titres from the number of plaque forming units (pfu), cannot be easily 
utilised. As an alternative, the 50% tissue culture infectious dose (TCID50) assay was 
employed (Hemminki et al., 2003). This measures the viral titre by determining the 
dilution of virus which infects (e.g. by visualisation of CPE) 50% of tissue cultures 
(e.g. 50% of the tissue culture wells infected with a set dilution of virus in replicate; 
Reed and Meunch, 1938; Burleson et al., 1992). 
 
A 96-well Nunc™ tissue culture plate with 0.2 mL wells (Thermo Fisher Scientific) 
was seeded with approximately 4 x 104 MDCK cells/100 µL per well. The density of 
MDCK cells was estimated manually using a Neubauer chamber cell counter 
following routine sub-culture. At one day post seeding of the MDCK cells, a serial 





viral supernatant into nine volumes of cell culture medium. The dilutions were added 
in 50 µL volumes to 11 columns of the cell culture plate, in eight replicates, starting 
from ‘neat’ to 10-10. Row 12 was a negative control column, containing uninfected 
cell culture medium (Figure A.1). 
 
Recordings of the 50% endpoint were performed at four to five days post infection 
for both viruses. Singles wells were recorded as either ‘+’ (the well contains CPE) or 
‘-’ (the well does not contain CPE). Other methods have been employed which 
define a threshold percentage of cells within a well to display CPE before a well can 
be recorded as positive or negative for infection (Loeffen et al., 2012). However, the 
simplicity of a ‘positive or not’ was more intuitive.  
 
Figure A.1 
Typical layout of a standard 96-well plate cell culture system to estimate the TCID50 
of CAV-1 and CAV-2, which do not form plaques (Reed and Muench, 1938; 
Burleson et al., 1992). 
 
 
The 50% endpoint index was calculated using the method of Reed and Muench 
(1938), when there was not a dilution that gave an equal number of visibly infected 







Using this factor, the viral copy number per mL was calculated (Food and 
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A1.5 Development of an indirect enzyme-linked immunosorbent assay 
(ELISA) to detect antibodies to CAV in serum 
 
For large-scale screening of fox sera, an indirect enzyme-linked immunosorbent 
assay (ELISA) was developed to detect antibodies against CAV-1 and CAV-2. In 
order to optimise the assay, a ‘checkerboard titration’ (CBT) was established 
(Crowther, 2000). In brief, the CBT allowed the optimisation of two reagents at one 
time, serially diluted, and observation of the interaction by means of the resulting 
OD405 value. The aim of CBTs are to specify a certain combination of concentrations 
of reagents that provide an OD405 value which can be reliably defined, which is 
usually an OD405 of ≤1.8, or where OD405 values ‘plateau’ (Crowther, 2000). In the 
present study CBTs allowed the identification of i) the optimal dilution of CAV-1 
and CAV-2 infected cell culture supernatant to coat wells = 1:80, ii) the optimal 
dilution of sera containing antibodies to bind to virus coated wells = 1:80 and iii) the 
concentration of conjugated secondary antibody to bind to the ‘primary’ antibodies, 
1:1,600. The layout of the final ELISA is outlined in Figure A.2. 
 
Figure A.2 
Set-up of a standard CAV ELISA microplate. The serum of each individual animal 
was tested on wells known containing i) CAV-1, ii) CAV-2 (both viruses as ‘whole 
virus’) and iii) a negative control (virus-free cell culture supernatant). 14 test sera 







A1.6 Development of a virus neutralisation test (VNT) to quantify 
neutralising antibody titres 
 
The indirect-ELISA was considered incapable of quantifying the antibody titres to 
CAV-1 and CAV-2 antigens in its current form. Therefore, a virus neutralisation test 
(VNT) was designed for the purpose of i) verifying the results of the sera screening 
for CAV antibodies based on ELISA OD405 results and ii) determining approximate 
OD405 cut-off values that one can assign a cut-off neutralising antibody titre to (by 
calculation of a ROC curve; see Chapter 4.4.7). In most forms, a VNT is able to 
estimate the antibody titre for a particular virus, using serial dilutions of antibody or 
serum, typically in replicates, with a fixed amount of virus and permissive cells. 
Because the antibody titre is usually quantified as equal to or below a dilution that 
neutralises the viral dose, it is classed as semi-quantitative (Horsfall, 1957). A VNT 
was designed by adapting an optimisation procedure as described by Loeffen et al. 
(2012) for the development of a Schmallenberg virus assay and for CAV-1 by 
Thompson et al. (2010). 
 
One issue posed by VNTs is the amount of serum that is required. For the current 
study many samples of fox sera were in small quantities (<50 µL), whereas a typical 
starting dilution for a VNT is 1:4 or 1:5, using 20 µL or 25 µL respectively. The 
volume used is multiplied by the number of replicates required, increasing the 
required volume beyond the volume available in the current study. Therefore, the 
VNT was restricted to samples with volumes of at least 100 µL, allowing for 
sufficient replicates. Serum (and FBS used in the cell cultures) also requires to be 
heat inactivated, to restrict interference of virus neutralisation by complement. This 
is typically performed by heating the volume of serum to be tested at 56 °C for 30 
min (Horsfall, 1957; Loeffen et al., 2012). The VNT was initiated using two-fold 
dilutions of sera in duplicate and was laid out as displayed in Figure A.3. An ‘all or 
nothing’ approach (Horsfall 1957) was taken during analysis of the VNT assays. A 
well was recorded as being positive (1) or negative (0), that is, the well had CPE or 
not, regardless of the amount of CPE in a well. The VNT was performed in parallel 






Layout of an example VNT with a two-fold dilution series, at a starting dilution of 
1:5. Positive and negative wells (based on CPE presence) was marked green (0) or 
red (1). Each serum sample was duplicated. A positive and negative control was 
tested in each VNT round of testing. The final row of the plates contains replicates of 
‘internal controls’; CC: cell control (no virus or serum) to ensure uninfected cells are 




















































A1.7 Production of vector controls for CAV-1 qPCR; Chapter 4 
 
Vectors with CAV-1 inserts were produced as standard controls for use in qPCR. 
The DNA insert was a CAV-1 positive sample which had undergone a single round 
of PCR using the CAV-1 primers. A ligation reaction was initiated using the 
following mixture (adapted from the manufacturer’s): 0.5 µL pGEM-T Easy Vector 
(Promega), 5 µL 2X Rapid Ligation Buffer (Promega), 0.5 µL T4 DNA Ligase 
(Promega), 2.5 µL CAV-1 PCR product and 4 µL H2O. The reaction mixture was 
incubated overnight at 4 °C. 
 
Escherichia coli DH5α cells were thawed from their -80 °C storage temperature on 
ice. 2 µL of the ligation reaction was added to 50 µL E. coli DH5α suspension. This 
mixture was incubated on ice for 20 min, after which the cells were heat shocked for 
50 s at 42 °C. The mixture was then chilled on ice for an additional 2 min. 950 µL 
super optimal broth (SOB) was added to the E. coli DH5α ligation reaction mixture 
and incubated at 37 °C, on a 200 rpm shaking cycle for 90 min. The incubated cells 
were plated on lysogeny broth (LB) agar plates, to which 200 µL ampicillin, 100 µL 
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) and 250 µL isopropyl β-
D-1-thiogalactopyranoside (IPTG) had been added. The plates were placed in an 
incubator at 37 °C overnight. 
 
‘White colonies’ were selected from the plate, and the presence of CAV-1 confirmed 
by sequencing (Edinburgh Genomics). Colonies containing CAV-1 DNA were 
incubated in 5 mL SOB overnight at 37 °C. The cellular contents of the broth was 
pelleted by centrifugation. The cell pellet was extracted using the QIAprep Spin 
Miniprep Kit (Qiagen) following the manufacturer’s instructions. To estimate the 
DNA concentration of pGEM-T Easy-CAV-1 extracted from the bacterial colonies, 
the Nanodrop 1000 (Thermo Fisher Scientific, Wilmington, Delaware, USA) 
spectrophotometer was utilised. A known concentration of pGEM-T Easy-CAV-1 
was added to carrier DNA, sonified salmon sperm DNA (50 ng/µL; AppliChem, 
Darmstadt, Germany) to create 10-fold dilutions for use as qPCR standards. An NTC 





Appendix 2 – Digital data 
 
Supplementary data have been included in the printed version of the thesis on digital 
optical disc storage. The contents of the disc are summarised below. 
 
Chapter 3 
A2.1 Immunohistochemistry cell counts 
 
Chapter 4 
A2.2.1 Full serological dataset 
A2.2.2 VNT results to calculate ELISA positive/negative cut off value 
A2.2.3 Sample R code to produce a GLM and a ROC curve 
 
Chapter 5 
A.2.3 FASTA sequences of PMAdV-1, PMAdV-2 and LAdV-1 
 
Chapter 6 
A2.4.1 List of peptides subject to the ultrahigh-density peptide microarray 
A2.4.2 Full peptide signal dataset 
 
Chapter 7 
A2.5 RT-qPCR results for CAV-1 infected MDCK cells and tissue extractions 
